UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 1 of 255PROTOCOL AS0006 (C -AXSPAND) AMENDMENT 5  
PHASE 3, MULTICENTER, RANDOMIZED, 
PLACEBO -CONTROLLED, DOUBLE -BLIND STUDY TO 
EVALUATE EFFICACY AND SAFETY OF CERTOLIZUMAB 
PEGOL IN SUBJECTS WITH ACTIVE AXIAL 
SPONDYLOARTHRITIS (AXSPA) WITHOUT X -RAY EVIDENCE 
OF ANKYLOSING SPONDYLITIS (AS) AND OBJECTIVE 
SIGNS OF INFLAMMATION  
PHASE 3  
EudraCT Number: 2015-001894-41 
IND Number: 9,869 
UCB BIOSCIENCES GmbH
Alfred-Nobel-Strasse 10
40789 Monheim
GERMANY
Protocol/Amendment number Date Type of 
amendment
Final Protocol 01 Jun 2015 Not applicable
Protocol Amendment 0.1 (Taiwan) 02 Sep 2015 Substantial
Protocol Amendment 1 15 Dec 2015 Substantial
Protocol Amendment 1.1 (Taiwan) 12 Jan 2016 Substantial
Protocol Amendment 2 14 Mar 2016 Substantial
Protocol Amendment 2.1 (Taiwan) 22 Apr 2016 Substantial
Protocol Amendment 3 13 Feb 2017 Substantial
Protocol Amendment 3.1 (Taiwan) 24 Mar 2017 Substantial
Protocol Amendment 3.2 (Australia) 28 Apr 2017 Substantial
Protocol Amendment 4 19 Dec 2017 Substantial
Protocol Amendment 4.1 (Taiwan) 08 Jan 2018 Substantial
Protocol Amendment 4.2 (Australia) 08 Jan 2018 Substantial
Protocol Amendment 5 17 Dec 2018 Substantial
Confidential Material
Confidential
This document is the property of UCB and may not –in full or in part –be passed on, 
reproduced, published, or otherwise used without the express pe rmission of UCB.REDACTED IEIE
NobelNobe
0789 0789
GG
berberRECOPY ENCENC
This document cannotrotocoto
ProtoProtoot
PPncaccbeocol Aol 
cocobeusedAmendmenddd
l AmeAmeed
AAutdtondmendmtosupport1.1 (Ta1 (Tt
nt 2t 2po
ment 2.ment 2upp
ensanyiwanwany
iamarketing g
ark
n)n)mauthorization CES GES G
--StrasStra
MonhMon
ERMERMaapplication 44--414and 11any extensionsCTIVTIVorENEN
Vvariations NCNCthereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 2of 255STUDY CONTACT INFORMATION  
Sponsor  
UCB BIOSCIENCES GmbH
Alfred -Nobel -Strasse 1 0
40789 Monheim
GERMANY
Sponsor Study Physician  
Name: , MD
Address: Alfred-Nobel-Str 10
40789 MonheimGermany
Phone:
Fax:
Clinical Project Manager  
Name: , PhD
Address: Alfred -Nobel -Str 10
40789 Monheim  
Germany
Phone:
Fax:
Clinical Trial Biostatistician  
Name: , PhD
Address: Alfred -Nobel -Str 10
40789 Monheim  
Germany 
Phone:
Fax:REDAbelbel--SSEDACTED CT
DACCOPY Y
CO
This document cannot d
anbedresdresused d
utoiosossupppp
statstapport any marketing tr 10r 10
heimheim
yymauthorization n
, PhD, PhDor
00auapplication tio
pland any yextensions teneor variations thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 3 of 255Clinical Monitoring Contract Research Organization 
Name: PRA Health Sciences
Address: 500 South Oak Way,  
Green Park, Reading, Berkshire RG2 6AD, UK
Phone: +44 (118) 918 1000
Fax: +44 (118) 918 1001
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions on
tenor rorrrvariations vthereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 4 of 255SERIOUS ADVERSE EVENT REPORTING 
Serious Adverse Event reportin g (24h) and safety related issues
Fax Europe and Rest of the World: +32 2 386 24 21
USA and Canada: +1 800 880 6949 or +1 866 890 3175
E-Mail DS_ICT@ucb.com
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or orvariations vathereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 5 of 255TABLE OF CONTENTS 
LIST OF ABBREVIATIONS.......................................... ........................................................11  
1 SUMMARY........................................................ .............................................................16  
2 INTRODUCTION ................................................... ........................................................19  
2.1 Natural history of axial spondyloarthritis ..................... ...............................................19  
2.2 Burden of disease in axSpA..................................... ....................................................20  
2.3 Diagnosing axSpA in clinical practice.......................... ...............................................20  
2.4 Current management of axial spondyloarthritis.................. .........................................21  
2.5 Rationale ...................................................... ............................................................... .22 
3 STUDY OBJECTIVES............................................... .....................................................23  
3.1 Primary objective.............................................. ...........................................................23  
3.2 Secondary objectives ........................................... ........................................................23  
3.3 Other objectives ............................................... ............................................................23  
4 STUDY VARIABLES................................................ .....................................................24  
4.1 Efficacy variables............................................. ............................................................24  
4.1.1  Primary efficacy variable...................................... ...............................................24  
4.1.2  Secondary efficacy variables ................................... ............................................24  
4.1.3  Other efficacy variables....................................... ................................................25  
4.2 Pharmacokinetic, exploratory biomarker, and pharmacogenomic var iables ...............27  
4.2.1  Primary pharmacokinetic variables .............................. .......................................27  
4.2.2  Exploratory biomarkers variables............................... .........................................27  
4.2.3  Pharmacogenomic variables ...................................... ..........................................27  
4.3 Immunological variables........................................ ......................................................27  
4.4 Safety variables............................................... .............................................................28  
5 STUDY DESIGN................................................... ..........................................................28  
5.1 Study description .............................................. ...........................................................28  
5.1.1  Study periods .................................................. .....................................................28  
5.1.2  Study duration per subject ..................................... ..............................................30  
5.1.3  Planned number of subjects and site(s) ......................... ......................................30  
5.1.4  Anticipated regions and countries .............................. .........................................30  
5.2 Schedule of study assessments.................................. ...................................................31  
5.3 Schematic diagram.............................................. .........................................................48  
5.4 Rationale for study desi gn and selection of dose............... ..........................................51  
6 SELECTION AND WITHDRAWAL OF SUBJECTS........................... ........................51  
6.1 Inclusion criteria ............................................. .............................................................51  
6.2 Exclusion criteria ............................................. ............................................................52  
6.3 Withdrawal criteria ............................................ ..........................................................55  
6.4 Eligibility for the SFE Period ................................. .....................................................56  REDACTED ........
arker,arker,
variablvariab
s varias varia
bbCOPY .....
...........
This document 5.45.4
66cannot ScheSche
SSbeAnAnuseddy dy d
lannelanneto er
durdursupport ........
n........
riodsiodsany .........
.marketingablesable
blesbles..
............authorization ....
..........
, and pand p
bleses..
esesapplication .......
...........
............
.....and ..........any ...........extensions ..........
..........
.........or ........variations .2020
2thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 6 of 2557 STUDY TREATMENTS............................................... ..................................................56  
7.1 Description of investigational medicinal product(s)............ ........................................56  
7.2 Treatment(s) to be administered ................................ ..................................................57  
7.2.1  Treatment administration....................................... ..............................................57  
7.2.2  Study AS0006 injection schedule................................ ........................................58  
7.3 Packaging...................................................... ............................................................... 60 
7.4 Labeling ....................................................... ............................................................... .60 
7.5 Handling and storage requirements .............................. ...............................................60  
7.6 Drug accountability............................................ ..........................................................60  
7.7 Procedures for monitoring subject compliance................... .........................................61  
7.8 Concomitant medication(s)/treatment(s) ......................... ............................................61  
7.8.1  Permitted concomitant treatmen ts for axSpA (medications and the rapies).........65  
7.8.2  Prohibited concomitant and rescue  treatments (medications and t herapies) .......66  
7.8.3  Concomitant medication(s)/treatments during the SFE Period ..... ......................67  
7.9 Blinding....................................................... ............................................................... ..67  
7.9.1  Maintenance of study treatment blind ........................... ......................................67  
7.9.2  Breaking the treatment blind in an emergency situation ......... ............................68  
7.10  Randomization and numbering of subjects........................ ..........................................69  
7.10.1  Interactive Response System .................................... ...........................................69  
7.10.2  Randomization.................................................. ...................................................69  
8 STUDY PROCEDURES BY VISIT ...................................... .........................................70  
8.1 Screening visit (Week -6 to Day -1) ............................ ................................................70  
8.2 Baseline visit (Week 0)........................................ ........................................................71  
8.3 Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 , 32, 34, 36, 38, 40, 42, 
44, 46, 48, and 50 (all visits ±3 days relative to Baseline) ... .......................................72  
8.4 Every 4 weeks (± 3 days) during home injection period from Week  14 to Week 46 
(Weeks 14, 18, 22, 26, 30, 34, 38, 42, and 46) ................. ...........................................74  
8.5 Week 52/WD (±3 days) ............................................ ...................................................74  
8.6 SFE Period (Week 52 to Week 156)............................... .............................................75  
8.7 FU visit (8 weeks after the Week 52/WD visit [±3 days]) ......... .................................76  
8.8 Unscheduled visits ............................................. ..........................................................76  
8.9 Alternative visit schedules aft er subject discontinuation of th e double-blind study 
treatment ...................................................... ............................................................... .77 
9 ASSESSMENT OF EFFICACY......................................... .............................................78  
9.1 Assessment of efficacy variables ............................... ..................................................79  
9.1.1  ASDAS .......................................................... ......................................................79  
9.1.2  ASAS20, 40, ASAS 5/6 response, and ASAS partial remission ...... ...................79  
9.1.3  ASAS-NSAID score ............................................... .............................................80  
9.1.4  ASQoL.......................................................... .......................................................81  REDACTED ct
............
...........
ISITSIT
DayDaCOPY ergencergen
ss.....
This document 99
99cannot Unsns
AltAltbe visi
scheschusedriod (od (
sit (8it (8toWD (D (
Wsupport3 day3 day
 22, 2622, 2
(±3(±any 2, 2,
visitsvisitmarketing ..
y y--1)1)
...........
, 14, 14authorization ............
..........
...........
....application P
............
............
y situy situandns ans a
Perioerioanyd thed th
and andextensions ..........
.........
..........
herheror ......variations 6060
606thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 7 of 2559.1.5  BASDAI ......................................................... .....................................................81  
9.1.6  BASFI .......................................................... ........................................................82  
9.1.7  BASMI.......................................................... .......................................................82  
9.1.8  Enthesitis (MASES)............................................. ................................................82  
9.1.9  Extra-articular assessments.................................... ..............................................83  
9.1.10  Health status (EQ-5D) .......................................... ...............................................83  
9.1.11  MOS Sleep Scale ................................................ .................................................83  
9.1.12  MRI assessments ................................................ .................................................83  
9.1.13  PGADA (NRS) .................................................... ................................................84  
9.1.14  PhGADA......................................................... .....................................................84  
9.1.15  Productivity measures (Work Productivity Survey)............... .............................84  
9.1.16  Resources utilization.......................................... ..................................................85  
9.1.17  SF-36.......................................................... ..........................................................85  
9.1.18  Spinal mobility................................................ .....................................................85  
9.1.19  Swollen and tender joint counts (44 joints evaluation)......... ...............................85  
9.1.20  Total and nocturnal spinal pain NRS............................. ......................................86  
10 ASSESSMENT OF PHARMACOKINETICS, EXPLORATORY BIOMARKERS, 
AND PHARMACOGENOMICS VARIABLES.................................. ...........................86  
11 ASSESSMENT OF IMMUNOGENICITY VARIABLES ......................... ....................87  
12 ASSESSMENT OF SAFETY........................................... ...............................................87  
12.1  Adverse events................................................. ............................................................88  
12.1.1  Definition of adverse event.................................... ..............................................88  
12.1.2  Procedures for reporting and recording adverse events.......... .............................88  
12.1.3  Description of adverse events.................................. ............................................88  
12.1.4  Follow up of adverse events .................................... ............................................89  
12.1.5  Rule for repetition of an adverse event........................ ........................................89  
12.1.6  Pregnancy ...................................................... ......................................................89  
12.1.7  Overdose of investigational medicinal product .................. .................................90  
12.1.8  Safety signal detection........................................ .................................................90  
12.2  Serious adverse events ......................................... ........................................................90  
12.2.1  Definition of serious adverse event ............................ .........................................90  
12.2.2  Procedures for reporting serious adverse events ................ .................................92  
12.2.3  Follow up of serious adverse events............................ ........................................92  
12.3  Adverse events of interest..................................... .......................................................92  
12.4  Immediate reporting of adverse events .......................... ..............................................93  
12.5  Laboratory measurements........................................ ....................................................93  
12.6  Other safety measurements...................................... ....................................................95  
12.6.1  Pregnancy testing.............................................. ...................................................95  REDACTEDTY VTY V
..........
............
ventventCOPY , EXP, EXP
LESLES
This document 1212
12.12cannot .2.22.2
2222be ousus
DDusedafety sfety s
sa dsatoose ose supportetitiontition
yy........
ofany erse eerse marketing ...........
g and rg and
se evee evauthorization ............
ARIAARIA
............
........application ..
on)n).....
............
LORALORAand .......
.....any .........
..extensions ..........
.........
..........or ......variations 8383
838thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 8 of 25512.6.2  Physical assessments ........................................... ................................................95  
12.6.3  Assessment and management of TB and TB risk factors ............ ........................96  
12.6.3.1  Tuberculosis assessments ....................................... ...................................98  
12.6.3.2  Chest x-ray .................................................... ............................................98  
12.6.3.3  QuantiFERON or Elispot testing................................. ..............................98  
12.6.3.4  Tuberculosis questionnaire..................................... ...................................98  
12.6.3.5  Tuberculosis management........................................ .................................99  
12.6.4  Vital signs .................................................... ......................................................100  
13 STUDY MANAGEMENT AND ADMINISTRATION ............................. ..................100  
13.1  Adherence to protocol.......................................... ......................................................100  
13.2  Monitoring ..................................................... ............................................................100  
13.2.1  Definition of source data ...................................... .............................................101  
13.2.2  Source data verification ....................................... ..............................................101  
13.3  Data handling.................................................. ...........................................................101  
13.3.1  Case report completion ......................................... .............................................101  
13.4  Electronic reporting outcome................................... ..................................................102  
13.5  Database entry and reconciliation.............................. ................................................102  
13.6  Termination of the study....................................... .....................................................102  
13.7  Archiving and data retention................................... ...................................................103  
13.8  Audit and inspection ........................................... .......................................................103  
13.9  Good Clinical Practice ......................................... ......................................................104  
14 STATISTICS ..................................................... ............................................................104  
14.1  Definition of analysis sets.................................... ......................................................104  
14.2  General statistical considerations............................. ..................................................104  
14.3  Planned efficacy analyses ...................................... ....................................................105  
14.4  Secondary efficacy analyses .................................... ..................................................106  
14.5  Other efficacy analyses ........................................ ......................................................107  
14.6  Planned safety and other analyses.............................. ................................................108  
14.6.1  Safety analyses................................................ ...................................................108  
14.6.2  Pharmacokinetic and immunogenicity variable analysis............ .......................109  
14.7  Handling of protocol deviations................................ .................................................109  
14.8  Handling of dropouts or missing data........................... .............................................109  
14.9  Planned interim analysis and data monitoring ................... ........................................111  
14.10  Determination of sample size................................... ..................................................111  
15 ETHICS AND REGULATORY REQUIREMENTS............................. .......................111  
15.1  Informed consent ............................................... ........................................................111  
15.2  Subject identification cards................................... .....................................................112  
15.3  Institutional Review Boards and Independent Ethics Committees.. ..........................112  REDACTED .
............
...........
............COPY ..........
.......
This document 14.94.9
1414cannotHandHan
HHbePhPh
ddused afeaf
afety afety a
hahtofety ety support lyy
cy analy an
y analyanalyany ere
ysessesmarketing ..
............
...........
ratioratiauthorization ............
..........
..........
....application ..
............
............
...........and .......
.....any .........
..extensions ..........
.........
.........or ...1variations 9999
10010thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 9 of 25515.4  Subject privacy................................................ ...........................................................113  
15.5  Protocol amendments............................................ .....................................................113  
16 FINANCE, INSURANCE, AND PUBLICATION ............................ ...........................113  
17 REFERENCES ..................................................... .........................................................114  
18 APPENDICES ..................................................... ..........................................................120  
18.1  ASAS classification criteria for axial SpA ..................... ...........................................120  
18.2  Modified NY criteria for ankylosing spondylitis................ .......................................121  
18.3  Table of corticoster oid equivalent doses....................... .............................................122  
18.4  ASQoL .......................................................... .............................................................12 3 
18.5  Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).... .........................125  
18.6  Bath Ankylosing Spondylitis Functional Index (BASFI)........... ...............................126  
18.7  EuroQoL (EQ 5D) Questionnaire .................................. ............................................128  
18.8  MOS Sleep Scale Questionnaire.................................. ..............................................130  
18.9  PGADA (NRS) .................................................... ......................................................134  
18.10  Short-Form (SF-36) Questionnaire............................... .............................................135  
18.11  Total spinal pain NRS and nocturnal spinal pain NRS............ ..................................141  
18.12  Tuberculosis Sample Worksheet.................................. ..............................................142  
18.13  Protocol Amendment 1 ........................................... ...................................................143  
18.14  Protocol Amendment 2 ........................................... ...................................................199  
18.15  Protocol Amendment 3 ........................................... ...................................................207  
18.16  Protocol Amendment 4 ........................................... ...................................................229  
18.17  Protocol Amendment 5 ........................................... ...................................................244  
19 DECLARATION AND SIGNATURE OF INVESTIGATOR ...................... ...............254  
20 SPONSOR DECLARATION ............................................ ............................................255  
LIST OF TABLES 
Table 5‒1:  Schedule of study assessments –Screening through Week 52 and FU...........32  
Table 5‒2:  Schedule of alternative study a ssessment with CZP - after subjec t 
discontinuation of the double-blind study treatment ............ ...........................37  
Table 5‒3:  Schedule of alternative study a ssessment with other treatment ( including 
biologics) - after subject discontinuation of the double-blind s tudy 
treatment ...................................................... ....................................................41  
Table 5‒4:  Schedule of study assessments –additional assessments for wdt 0 visit 
required for subjects transitioning to open-label CZP .......... ...........................44  
Table 5‒5:  Schedule of study assessments –additional assessments for wdt 0 visit 
required for subjects transitioning to alternative treatment ... ..........................46  
Table 5‒6:  Schedule of study assessments - Safety Follow-Up Extension Perio d............47  REDACTED .
............
...........
............COPY ..........
.......
This document TabTabcannot ‒3:3:be used SchedSched
disdistoeduledusupport ule oleany NNmarketing ..
............
ATURATUR
NN....authorization ............
.........
...........
....application ..
............
SS..........
...........and .......
.....any .........
..extensions ..........
.........
..........or ...1variations 2121
12212thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 10 of 255Table 7‒1:  Concomitant Medications (prior to Baseline and Study Visits) ... ...................61  
Table 9‒1:  Swelling and tenderness grading ................................ .....................................86  
Table 12‒1: Laboratory measurements up to Week 52 (including the FU visit ( 8 weeks 
after the Week 52/WD visit).................................... ........................................93  
LIST OF FIGURES 
Figure 2‒1:  ASAS Classification Criteria for axSpA......................... .................................21  
Figure 5‒1:  Schematic diagram for subjects completing the double-blind stud y 
treatment ...................................................... ....................................................48  
Figure 5‒2:  Schematic diagram for subjects discontinued from the double-bli nd study 
treatment ...................................................... ....................................................49  
Figure 5‒3:  Schematic diagram for subjects completing the double-blind stud y 
treatment and rolling over to the SFE Period................... ................................50  
Figure 7‒1:  Injection schedule through Week 52............................. ...................................58  
Figure 7‒2:  Injection schedule for the SFE Period .......................... ...................................59  
REDACTED COPY .......
This document cannot be used to support any marketing authorization application ..
............
..........andblinblin
.....any ........
ndndextensions ..........
blindblindor ....variations 2121thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 11 of 255LIST OF ABBREVIATIONS 
ABA abatacept
ACR American College of Rheumatology
ADA adalimumab
ADAb anti-drug antibody (also called anti-CZP antibody)
AE adverse event
AESI adverse event of special interest
ANCOVA analysis of covariance
Anti-CZP Ab  anti-CZP antibody  
Apo apolipoprotein
AS ankylosing spondylitis
ASAS Assessment of SpondyloArthritis International Society 
ASAS20, 40 Assessment of SpondyloArthritis International Society 20%, 40% 
response criteria
ASAS5/6 Assessment of SpondyloArthritis International Society 20% 
improvement in 5 of 6 domains
ASDAS Ankylosing Spondylitis Disease Activity Score
ASDAS-CII Ankylosing Spondylitis Disease Activity Score clinically import ant 
improvement
ASDAS-HD Ankylosing Spondylitis Disease Activity Score high disease acti vity
ASDAS-ID Ankylosing Spondylitis Disease Activity Score inactive disease
ASDAS-LD Ankylosing Spondylitis Disease Activity Score low disease
ASDAS-MI Ankylosing Spondylitis Disease Activity Score major improvement
ASDAS-vHD Ankylosing Spondylitis Disease Activity Score very high disease  activity
ASQoL Ankylosing Spondylitis Quality of Life
ASspiMRI-a Ankylosing spine MRI acuity
AU anterior uveitis
axSpA axial spondyloarthritis 
BASDAI Bath Ankylosing Spondylitis Disease Activity Index
BASFI Bath Ankylosing Spondylitis Functional Index
BASMI Bath Ankylosing Spondylitis Metrology Index
BMO bone marrow oedema
BMP bone morphogenetic protein
BOCF Baseline observation carried forward
CDMS clinical data monitoring systemREDACTEDitis Dtis D
ndylitindyliti
ng Spong SpoCOPYhritishriti
mainsmain
DisDi
This document Bcannot SDAIDA
BASBASbe used to supportAnkyAnk
AAanykylosikylosmarketing ondylndy
g SpondSpon
sing Spsing Sauthorization sease Aease 
s DiseDise
ylitliapplicationtional tional
Internanternandal Socil Socany extensions or variations thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 12 of 255CI confidence interval
CKD-EPI Chronic Kidney Disease Epidemiology Collaboration
COX-2 cyclooxygenase 2
CPM Clinical Project Manager
CPMP Committee for Proprietary Medicinal Products
CRF case report form
CRO Contract Research Organization
CRP C-reactive protein
CSF-1 colony-stimulating factor-1
CZP certolizumab pegol
Dhh Dessert hedgehog
DKK1 Dickkopf-related protein 1
DMARD disease-modifying antirheumatic drug
DS Drug Safety
ECG electrocardiogram
eCRF electronic Case Report Form
ePRO electronic patient reported outcome
EQ-5D EuroQoL Health Status Questionnaire (5 dimensions)
ES Enrolled Set
ETN etanercept
EU European Union
FAS Full Analysis Set
FU Follow-Up
GCP Good Clinical Practice
GM-CSF granulocyte macrophage colony-stimulating factor
GMP Good Manufacturing Practice
GOL golimumab
HbA1c Hemoglobin A1c
HCQ hydroxychloroquine
HIV human immunodeficiency virus
HLA-B27 human leukocyte antigen B27 
HRQoL health-related quality of life
ia intra-articular
IB Investigator BrochureREDACTED eportedeporte
th Stath Sta
etetCOPY FormForm
This document HHcannot A1c1c
HCQHCQbe used to support Follooll
GoGanyAnalAna
owmarketing an Union Uni
lylauthorization d outcd outc
tus Quus Quapplication and any extensions or variations thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 13 of 255IBD inflammatory bowel disease  
ICH International Council for Harmonisation
IEC Independent Ethics Committee
IFX infliximab
IGRA Interferon-Gamma Release Assay
Ihh Indian hedgehog
IL interleukin
IMP investigational medicinal product
IP interphalangeal
IRB Institutional Review Board
iv Intravenous(ly)
IXRS interactive response system
LOCF last observation carried forward
LTB latent tuberculosis
M-CSF Macrophage colony-stimulating factors
MAR missing at random
MASES Maastricht Ankylosis Spondylitis Enthesitis Score
MCID minimal clinically important difference
MCMC Markov Chain Monte Carlo
MCP metacarpophalangeal
MCS Mental Component Summary
MedDRA®Medical Dictionary for Regulatory Activities®
MI multiple imputation
MMP-3 matrix metalloproteinase-3
MMRM mixed model for repeated measures
MOS Medical Outcomes Study
MRI magnetic resonance imaging
mNY Modified New York (criteria)
MTX methotrexate
nr-axSpA nonradiographic axSpA
NRS Numerical Rating Scale
NSAID nonsteroidal anti-inflammatory drug
NTMB nontuberculous mycobacteria
NYHA New York Heart AssociationREDACTED sis Sposis Sp
ally imlly im
hain Mhain M
hhCOPYating ating
This document nncannot Y
MTXMTXbe used to supportmultmult
mamanyical Dical 
tiptimarketing Monon
halangealang
CompoComp
DDauthorization ondyliondyli
mportaporta
nte nteapplication factorsactorsand any extensions or variations thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 14 of 255OMERACT Outcome Measures in Rheum atology Clinical Trials
PCS Physical Component Summary
PFS prefilled syringe
PhGADA Physician’s Global Assessment of Disease Activity
PGADA Patient’s Global Assessment of Disease Activity
PIP Proximal IP
PK pharmacokinetics
PPS Per Protocol Set
prn as needed
PsA psoriatic arthritis 
Q2W every 2 weeks (every other week)
Q12W every 12 weeks
QoL Quality of Life
RA rheumatoid arthritis
RDC remote data capture
RS Randomized Set
SAA Spondylitis Association of America
SAARD slow-acting antirheumatic drug
SAE serious adverse event
SAP Statistical Analysis Plan
sc subcutaneous(ly)
sCSF1r soluble colony-stimulating factor-1 receptor
SD standard deviation
SF-36 Short-Form 36-Item Health Survey
SFE Safety Follow-Up Extension 
SFE-FAS Safety Follow-Up Full Analysis Set
SFE-SS Safety Follow-Up Extension Safety Set
Shh Sonic hedgehog
SI sacroiliac
SIJ sacroiliac joint injection
SOP standard operating procedure
SpA spondyloarthritis
SPARCC Spondyloarthritis Researc h Consortium of Canada
SPARTAN Spondyloarthritis Research and Treatment NetworkREDACTED ation oation o
tirheumirheu
verse eerse e
AACOPY 
This document SScannot SIIbe used to support standtan
ShSanyble coble c
dadmarketing veve
nalysisnalys
neous(leous(
olauthorization of Amf Am
matic matic 
entntapplication and any extensions or variations thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 15 of 255SPC Summary of Product Characteristics
SS Safety Set
SSCM Single Safety Case Management
SSZ sulfasalazine
STIR short-tau-inversion recovery
TEAE treatment-emergent adverse event
TB tuberculosis
TGF transforming growth factor
TNF tumor necrosis factor
TNFi tumor necrosis factor-alpha inhibitor
ULN upper limit of normal (for CRP the ULN defined as the upper lim it of 
normal value indicative for inflammatory disease)
USA United States of America
VAS visual analog scale
VEGF vascular endothelial growth factor
VU vertebral units
WBC white blood cell
WD Withdrawal
wdt withdrawal treatment
WISP wingless-related mouse mammary tumor virus integration site pro tein 
(WNT1) -inducible signaling pathway proteins
WNT1 wingless-related mouse mammary tumor virus integration site pro tein
WPS Work Productivity Surveyreatmreatm
elatelatCOPY factofac
This document cannot be used to support any rk Prork Prmarketing ted moued mo
nduciblducib
ss--relarelauthorization entntapplication and se)e)any the uthe extensions or variations thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 16 of 2551 SUMMARY 
The C-axSpAnd study (AS0006) is a randomized, double-blind, par allel-group, placebo-
controlled study, consisting of 52 weeks of treatment with certo lizumab pegol (CZP) and a 
Follow-Up (FU) Period of 8 weeks after the Week 52 Visit. The stu dy population is subjects 
with active axial spondyloarthritis (axSpA) without x-ray evide nce of ankylosing spondylitis 
(AS), but either with sacroiliiti s on magnetic resonance imagin g (MRI) or C-reactive protein 
(CRP) levels indicative of inflammatory disease or both, who ha ve had an inadequate response 
to, have a contraindication to, or are intolerant to nonsteroid al anti-inflammatory drugs 
(NSAIDs). 
The study population will be subjects (≥18 years), with a docum ented diagnosis of adult -onset 
axSpA and who meet the Assessment of SpondyloArthritis Internat ional Society ([ASAS], 
Sieper et al, 2009) criteria for  axSpA, who have had back pain of at least 12 months’ symptom 
duration, and with active disease defined by a Bath Ankylosing Spondylitis Disease Activity 
Index (BASDAI ) ≥4, and spinal pain ≥4 on a 0 to 10 Numerical Rating Scale (NRS). At 
Baseline, evidence of inflammatory disease will be confirmed ei ther by presence of sacroiliitis 
on MRI (according to ASAS/Outcome Measures in Rheumatology Clin ical Trials [OMERACT] 
criteria) or by elevated CRP or by presence of both.
Additionally, subjects must have had an inadequate response to,  have a contraindication to, or 
have been intolerant to at least  2 NSAIDs. Inadequate response t o a NSAID is defined as lack of 
response to at least 14 days of continuous NSAID therapy at the  highest tolerated dose of the 
administered NSAID. Eligible subjects will be allocated to the following double-blind study 
treatments in a 1:1 ratio:
x CZP administered subcutaneously (sc) at the dose of CZP 400mg a t Weeks 0, 2, and 4 
followed by CZP 200mg every 2 weeks (every other week; Q2W) sc  (starting at Week 6)
x Placebo
At on-site visit days (at Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 2 4, 28, 32, 36, 40, 44, 48, and 50), the 
double-blind study treatments will  be administered sc at the st udy site. At the Week 0, 2, 4, 6, 
and 8 visits, the administration must be done by dedicated, unb linded, and adequately trained site 
personnel. At the Week 10 and 12 visits, the subject will recei ve training on self-injection and
the study treatment will be self-administered under the supervi sion of the unblinded study 
personnel. At Weeks 16, 20, 24, 28, 32, 36, 40, 44, 48, and 50,  the study treatment administration 
should preferably be done by the unblinded study personnel, or alternatively by self-injection of 
the subject under the supervision of the unblinded study person nel. The double-blind study 
treatment will be self-injected at home at Weeks 14, 18, 22, 26 , 30, 34, 38, 42, and 46.
The study will be placebo controlled for 52 weeks and will allow  changes in background 
medications as required to control disease activity according t o the judgment of the Investigator. 
Subjects whose disease activity cannot be controlled by study m edication and changes in 
background therapy (including and not limited to analgesics, NS AIDs, and slow-acting 
antirheumatic drugs [SAARDs]) will be permitted to withdraw fro m the double-blind study drug. 
Subjects will either transition to open-label CZP treatment off ered by UCB or to other treatment 
(including biologics) at the  discretion of the Investigator unt il the assessment of the primary REDACTEDq
SAIDSAID
ill be all be a
ly (sly (sCOPY e respe resp
quatequate
This documentThe he 
medmedcannotect uct u
ment went w
stustubeferabferab
ununusedent wnt w
WeekWeek
blyblyto Wee
wilwisupportments wnts w
istratiostrati
ek 10k 10anyssny 0, 20, 2marketingsc) at tsc) at 
weeks weekauthorizationpo
e respe resp
theraptherap
allocaallocaapplicationher ber b
ogy Clogy C
onse tonse tandng Scg Sc
bybyany 2 m2 m
tis Ditis D
caextensions of aduof adu
ety ([Aty ([A
monmonor variations onse nse thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 17 of 255endpoint at Week 52. At the comp letion of the Week 52 visit ass essments, subjects on double-
blind study treatment may receive open-label CZP treatment for an additional 2 years in an open-
label, Safety Follow-Up Extension (SFE) Period. Subjects who wi thdrew from double-blind 
study treatment and transitioned to open-label CZP treatment ar e also eligible to participate in 
the SFE Period after completing the Week 52 visit assessments. Subjects on alternative 
treatments are not eligible to participate in the SFE Period.
All subjects not participating in the SFE Period after study co mpletion at Week 52, including 
those withdrawn from the study prematurely, will have a FU visi t 8 weeks after their Week 52
Visit. 
If the Investigator chooses to withdraw subjects on the other t reatments (including biologics), the 
local guidelines on initiation and monitoring of the particular  treatment should be followed.
The primary objective of the study is to demonstrate the efficac y of CZP administered at the dose 
of CZP 200mg Q2W, after a loading dose of CZP 400mg at Weeks 0,  2, and 4, on the signs and 
symptoms of active axSpA in subjects without x-ray evidence of AS.
The secondary objectives of the study are to assess efficacy, s afety, and tolerability and to 
demonstrate the effect of CZP on health outcomes, disease activ ity, sacroiliac (SI) joint 
inflammation through MRI, and chan ges in concomitant and backgr ound medications.
Other objectives are to evaluate the effects of CZP on spinal m obility, total and nocturnal spinal 
pain (NRS), spinal inflammation, S I joint structural changes, t reatment response over time, 
additional signs and symptoms of the disease, subject’s health status, acute phase reactant (CRP), 
health-related quality of life (HRQoL), work and household prod uctivity, pharmacokinetics (PK) 
and immunogenicity, gene and pro tein expression and to explore the relationship between 
genomic biomarkers and disease biology, drug treatment and infl ammatory and immune 
responses (for those subjects who consent to the genomics subst udy). 
The primary efficacy variable is Ankylosing Spondylitis Disease  Activity Score major 
improvement (ASDAS-MI) response at Week 52. The secondary effica cy variables are 
ASAS 40% (ASAS40) response at Weeks 12 and 52, change from Baselin e in Bath Ankylosing 
Spondylitis Functional Index (BASFI) at Weeks 12 and 52, change  from Baseline in BASDAI at 
Weeks 12 and 52, change from Baseline in SI joint Spondyloarthr itis Research Consortium of 
Canada (SPARCC) score at W eek 12, the number of subjects without  relevant changes to 
background medication, change from Baseline in Ankylosing Spond ylitis Quality of Life 
(ASQoL ) at Week 52, change from Baseline in nocturnal spinal p ain (NRS) at Week 52, and the 
number of subjects with anterior uveitis (AU) or new AU flares through Week 52.
For Canada (and any other country where applicable or where req uested by Regulatory 
Authorities), the primary efficacy variable is the ASAS40 respo nse at Week 12. The secondary 
efficacy variables are ASAS40 response at Week 52, ASDAS-MI at W eek 52, change from 
Baseline in BASFI at Weeks 12 and 52, change from Baseline in B ASDAI at Weeks 12 and 52, 
change from Baseline in SI joint SPARCC score at Week 12, the num ber of subjects without 
relevant changes to background medication, change from Baseline  in ASQoL at Week 52, 
change from Baseline in nocturna l spinal pain (NRS) at Week 52,  and the number of subjects 
with AU or new AU flares through Week 52.
Other efficacy variables are listed in Section 4.1.3 ., subj, sub
ork andrk and
expresexpres
logy, logy, 
nsenseCOPY on spion sp
ral chral c
j
This document fficfic
BaseBas
ccannotnada nada 
horitieoritie
cacycacybesubjubj
((used icatca
Week 5Week 5
bjecjectosc
ationatiosupportdex (Bex (
nge fromge fro
core aore aany onon
nse at se at
BAmarketing drudru
ent to tent to 
nkylosnkylo
nse anseauthorizationp
hanghang
ect’s hect’s h
d houhou
ssion sion 
rug tug tapplication y, a
vity, saity, s
backgbackg
nal mnal mand and andanynd 4nd 4extensionsbiologiolog
e follofollo
ministminist
44or variations 5252thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 18 of 255Pharmacokinetic, exploratory biomarker, and pharmacogenomic var iables are listed in 
Section 4.2and immunogenicity variables are listed in Section 4.3.
Safety variables to be assessed are adverse events (AEs), vital  signs, physical examination, and 
measurements of laboratory parameters. In addition, subjects wi ll be evaluated at Screening, 
Baseline, and at every 12 wee ks thereafter up to Week 36 and inc luding Week 52/Withdrawal 
(WD) (for subjects not participating in the SFE Period) for sig ns and symptoms of latent or 
active tuberculosis (TB) infection and risk factors for exposur e to TB using the TB 
questionnaire.
Approximately 1200 subjects will be screened in order to have 3 00 subjects (150 subjects per 
treatment group) randomized into the study. Randomization will be stratified by presence of 
sacroiliitis on MRI and elevated CR P to ensure balanced treatme nt allocation across 
3 subgroups: MRI+/CRP+; MRI+/CRP-; MRI-/CRP+. 
For each subject, the study will consist of 3 periods and will l ast a maximum of 66 weeks: 
x Screening Period lasting up to 6 weeks
x Double-Blind, Placebo-Controlled Period for 52 weeks
x FU Period 8 weeks after the Week 52/WD visit (for subjects not p articipating in the SFE 
Period).
For subjects participating in the SFE Period, the study will ex tend up to a maximum of 
104 additional weeks.
The estimated recruitment period is up to 15 months. The first s ubject first visit is planned in 
Quarter 3 2015. The end of the study  will be defined as the dat e of the last subject’s last visit, 
defined as the FU visit 8 weeks after the Week 52/WD visit for subjects not participating in the 
SFE Period, or the last visit of the SFE Period. 
 REDACTED o 15 m15 m
will bewill be
r the r the COPY studystudy
This document cannot be used to support any marketingWeeWee
E PerioPerauthorizationy willy will
monthsmonth
e defindefin
kkapplication ects noects nand anyum oum extensionsec
esencesence
oss oss 
offorts pts pvariations thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 19 of 2552 INTRODUCTION 
2.1 Natural history of axial spondyloarthritis 
Spondyloarthritis (SpA) is an um brella term applied to a family  of rheumatic diseases that have 
features in common with and distinct from other inflammatory ar thritides, particularly 
rheumatoid arthritis (RA).  
Recently, the ASAS working group established classification cri teria to distinguish 2 broad 
categories of SpA: peripheral and axial SpA (axSpA) (Rudwaleit et al, 2011; Rudwaleit, 2010; 
Rudwaleit et al, 2009b). This division is based on the body par t predominantly involved in the 
inflammatory process and those areas of the body that may respo nd similarly well to medication. 
Therefore, peripheral SpA includes diseases affecting mainly pe ripheral joints, such as reactive 
arthritis and psoriatic arthritis (PsA), whereas axSpA comprise s those diseases with mainly axial 
involvement (SI joints and spine), including AS and nonradiogra phic axSpA (nr-axSpA). 
Patients with AS have definitive e vidence of structural changes  in the SI joint (sacroiliitis) on 
x-ray, fulfilling the Modified New York classification criteria  (mNY-positive) (van der Linden et 
al, 1984a), whereas those with nr-axSpA have no definitive stru ctural changes on conventional 
radiographs (mNY-negative) (Rudwaleit et al, 2005; Dougados et a l, 1991). 
Axial SpA is a chronic inflammatory disease that impacts a subs tantial proportion of the 
population. Limited evidence exists regarding the exact prevale nce of axSpA; however, recent 
data suggest that the prevalence is similar to that of RA in th e United States of America (USA) 
(axSpA: 0.7% to 1.4%; RA: 0.5% to 1.0%) (Reveille et al, 2012; Myasoedova et al, 2010; 
Helmick et al, 2008).  
The majority of patients with axSpA have inflammatory back pain . The disease typically
originates in the SI joints, then progresses to the spine. In t he SI joints and the spine, active 
inflammation results in erosions, sclerosis, and fatty lesions.  However, the most characteristic 
feature is new bone formation leading to ankylosis of the SI jo ints and syndesmophytes attached 
to the vertebral bodies. As a result of extended syndesmophyte formation, the spine may become 
fused over time. Objective signs of inflammation, such as enthe sitis, dactylitis, peripheral 
arthritis, or uveitis; genetic features, such as the presence o f human leukocyte antigen B27 
(HLA-B27); and laboratory parame ters, such as elevated CRP, may  also be present (Braun, 
2012; Rudwaleit et al, 2009a; Braun and Sieper, 2007). Disabili ty in axSpA is related to both the 
degree of inflammatory activity, causing pain, stiffness, fatig ue, and poor quality of sleep, and to 
the degree of bony ankylosis, causing loss of spinal mobility. 
The natural history of axSpA is c haracterized by a variable dis ease course. Over time, patients 
may develop structural damage or radiographic abnormalities invo lving their SI joints, and they 
may fulfill the mNY classification criteria for AS. However, th e rate of development of structural 
damage varies among patients (Rudwaleit and Sieper, 2012). Some  patients develop only 
unilateral sacroiliitis, and others may never develop definitiv e sacroiliitis on x-ray despite 
significant disease burden and other signs and symptoms of the disease, such as spinal lesions, 
uveitis, enthesitis, and peripheral arthritis. Approximately 10 % of patients with nr-axSpA (25% 
if CRP levels are elevated) deve lop definitive evidence of sacr oiliitis on x-ray within 2 years 
(Sieper and van der Heijde, 2013a). REDACTEDat 
ReveiReve
have ihave 
resseresseCOPY pactpac
exact exact 
of Rof R
This documendamaama
unilunicannotra
evelopvelop
y fulfifulfi
magagbel hisl hisusedmatmat
bony bonyto al, al, 
tortorsupportigg
ic featfea
atory patory 
, 20020anyult oult
ns ofns ofmarketinges to tes to 
erosis, arosis,
ding toing to
ofofauthorizationp
RA in RA in
ille et lle et 
nflamflamapplicationural ral
s et al, et al,
a substsubs
prevalrevalandposiposi
al chlc hany joint joint
tiextensionsmedmed
ch as h as 
with mwith m
(nr(nr-oin tin 
didivariations 010; 10; 
thththereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 20 of 2552.2 Burden of disease in axSpA 
Axial SpA typically presents in patients <45 years of age, and t hese relatively young and 
otherwise healthy patients face a significant disease burden re gardless of whether or not they 
have definitive evidence of sac roiliitis on x-ray. These patien ts experience substantial pain, 
prolonged, severe stiffness of joints, substantial sleep distur bances, reduced mobility and overall 
function, reduced quality of life (QoL), loss of productivity, and other disease-related symptoms 
(Huscher et al, 2006; Kobelt et al, 2006; Kobelt et al, 2004; B oonen et al, 2003; Boonen et al, 
2002; Ward, 2002). Moreover, studies  have shown that the econom ic impact of the disease on 
society or patients can be substantial and that the costs are m ainly driven by the cost associated 
with loss of work capacity (van der Heijde et al, 2013; Kobelt et al, 2006; Kobelt et al, 2004; 
Boonen et al, 2003; Ward, 2002). 
Several large observational a nd noninterventional cohort studie s (Cuirea et al, 2013; Sieper and 
van der Heijde, 2013a) re ported a similar burden of disease at study baseline across AS studies 
(captured through BASFI and BASDAI) in nonradiographic as well as radiographic axSpA 
(captured through BASDAI). A literature review of studies in bo th populations (Callhoff et al, 
2015) and a recent study with CZP (RAPID-AxSpA) (Landewe et al, 2014) confirmed this 
finding in the clinical study setting.
2.3 Diagnosing axSpA in clinical practice 
The diagnosis of AS and/or axSpA should be based on clinical as sessments considering typical 
signs and symptoms, but also excluding other diseases that may have similar presentations. The 
mNY classification criteria, of ten used to support the diagnosi s of AS, excludes patients who do 
not show definitive evidence of sacroiliitis on x-ray (Rostom e t al, 2010). For a definitive 
classification of AS, the mNY c lassification criteria require r adiographic evidence of sacroiliitis 
grade ≥2 bilaterally or sacroiliitis grade 3 to 4 unilaterally PLUS at least 1 of the following 
clinical criteria: low back pain and stiffness for ≥3 months, l imitation of lumbar spine motion, or 
limitation of chest expansion. These criteria were designed for  classification of patients in 
clinical trials rather than for  diagnostic purposes. However, t hey have historically been used for 
clinical diagnosis. The requiremen t for limitations in spinal mo tion and/or chest expansion has 
led to diagnoses being delayed until irreversible structural da mage is documented on SI joint 
x-rays. Several publications have documented that time from sym ptom onset until the diagnosis 
of AS ranges from 5 years to 10 years (van der Linden et al, 19 84b; Feldtkeller et al, 2003; 
Feldtkeller et al, 2000), thus demonstrating that x-ray changes  lag far behind other signs and 
symptoms. 
Due to the problem of delayed disease recognition, ASAS develop ed new classification criteria 
for axSpA that do not require the  presence of definitive sacroi liitis on x-ray, thus identifying a 
nonradiographic subpopulation (nr-axSpA) allowing for classific ation of all axSpA patients 
(Rudwaleit et al, 2009b; Rudwaleit et al, 2009c). These criteri a establish standards that apply to 
patients with or without radiographi c sacroiliitis enabling the  conduct of clinical trials in patients 
with both nr- axSpA and AS. In patients with a history of chronic back pain f or ≥3 months and 
age of onset <45 years, classifi cation of axSpA can be made base d on either evidence of 
sacroiliitis on radiographs or MRI plus ≥1 typical SpA feature or the presence of HLA -B27 plus 
≥2 typical SpA features ( Figure 2 ‒1). In these criteria, sacroiliitis is defined as MRI evidence o f 
SI joint inflammation or radiogra phic evidence of sacroiliitis meeting mNY criteria (Rostom et 
al, 2010).REDACTEDdisedise
upportupport
tis on is on
ficationcatio
ade ade COPYprapr
sed oned on
easea
This document(RudRud
patipatcannote e
SpA thpA th
nradiogradio
dwdbe probprobused200200to5 ye5 y
0000supportirere
layed ayed
ations htions
yeaearsanygnogno
emenmenmarketingn 
3 to 43 to 4
tiffnessffnes
ese critese cri
ostiostauthorizationn clinclin
ses thes th
rt the dthe d
xx--rayray
critecritapplicationt al, al,
ticeice
nicnicandopulaopula
2020any e e 
diogrdiog
tiextensionsal, 20l, 20
, 20132013
acracroociaoci
0000variations e on on 
atetthereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 21 of 255Figure 2 ‒1: ASAS Classification Criteria for axSpA 
ASAS=Assessment of SpondyloArthritis International Society; axS pA=axial spondyloarthritis; CRP=C-reactive 
protein; HLA-B27=human leukocyte antigen B27; mNY=modified New York; MRI=magnetic resonance imaging; 
NSAID=nonsteroidal anti-inflammatory drug; SpA=spondyloarthriti s. Adapted from Rudwaleit M, et al. Ann 
Rheum Dis. 2009; 68(6):777-783 (Rudwaleit et al, 2009c). 
2.4 Current management of axial spondyloarthritis 
There is increasing recognition of axSpA as an important clinic al entity, as evidenced by the 
efforts of the American Coll ege of Rheumatology (ACR) in cooper ation with the Spondylitis 
Association of America (SAA) and the  Spondyloarthritis Research  and Treatment Network 
(SPARTAN) to develop new treatmen t recommendations for axSpA in cluding AS (see 
Appendix 18.1 for classification criteria for a xSpA). To help Investigators a nd at the same time 
reduce the introduction of bias in the study resulting from cha nges in background medications, 
UCB is recommending allowed changes in background therapy. Thes e allowed changes were
prepared by expert rheumatologist s from North America and Europ e and have also been aligned 
with the draft ACR/SAA/SPARTAN R ecommendations for the Manageme nt of Axial 
Spondyloarthritis, including Ankylosing Spondylitis, and Childr en with the Enthesitis-Related 
Arthritis Form of Juvenile Idiopathic Arthritis presented at th e recent ACR Nov 2014 meeting in 
Boston. Furthermore, the update  of the 2006 ASAS recommendation s for the use of anti-tumor 
necrosis factor (TNFs) for AS extended the recommendations to p atients fulfilling the ASAS 
criteria, including patients wit h nr-axSpA (van der Heijde et a l, 2011). 
Nonsteroidal anti-inflammatory drugs are often rapidly effectiv e for the symptoms (pain and 
stiffness) of axSpA (Poddubnyy, 2013; Poddubnyy et al, 2012), b ut many patients lose 
symptomatic response and structural damage often progresses des pite their use. Conventional 
disease-modifying antirheumatic drugs (DMARDs; eg, methotrexate  [MTX] and sulfasalazine 
[SSZ]) have limited efficacy in axial disease, but may benefit patients with peripheral joint 
disease (Haibel et al, 2007; Braun et al, 2006; Haibel et al, 2 005). Therefore, DMARDs are 
recommended only in patients with predominantly peripheral mani festations (Braun and van den 
Berg, 2011).
Patients who are intolerant  of or have inadequately responded t o NSAIDs, or those in whom 
NSAIDs are contraindicated, have limited treatment options. Tum or necrosis factor-alpha 
inhibitors (TNFi) (CZP, adalimu mab [ADA] etanercept [ETN] infli ximab [IFX]), golimumab 
OR
SpA features
•Inflammatory back pain
•Arthritis
•Enthesitis (heel)
•Uveitis
•Dactylitis
•Psoriasis• Crohn’s /colitis
•Good response to NSAIDs
•Family history for SpA
•HLA-B27
•Elevated CRP*Sacroiliitis on imaging N = 649 patients with back pain
Overall
Sensitivity: 82.9%; Specificity: 84.4%
Imaging arm alone
Sensitivity: 66.2%; Specificity: 97.3%
HLA-B27 PLUS
≥2 Other SpA featuresSacroiliitis on imaging*
PLUS ≥ 1 SpA featurePatients with back pain ≥ 3 months & age of onset < 45 years
•Active (acute) inflammation on 
MRI highly suggestive of 
sacroiliitis associated with SpA
OR
•Definitive radiographic sacro iliitis
according to mNY criteria
REDACTEDologyology
pondylondyl
recomrecom
eria foeria fo
stsCOPYsposp
mpormpor
This documente
[SSZ[SSZ
didicannot) of of
tomatomat
easeasebeal anl a
fa xfausedng pang pa
antanttoNFs) Fs)supportg AnAn
ile Idiole Idi
the upthe up
fofanyRTARTA
AnkyAnkmarketingfor ar a
tudy reudy re
nges innges i
ts fromts fro
Nauthorizationrtant crtant c
(ACR(ACR
loarthoarth
mmenmmen
axSaxSapplication MR
ed fromed from
ondylondy
landdyloaryloar
RI=mRI=any hextensions 97.3%.3%
xtensionxtensionor variations thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 22 of 255[GOL]) are the only effective and approved treatment options as  of Dec 2014; IFX and GOL are 
indicated for active AS only, while CZP, ADA, and ETN are indic ated for axSpA without 
radiographic evidence of AS (nr-axS pA) as an addition to the AS  indication in several regions.   
At the 2014 Annual Meeting of the A CR/SPARTAN group a draft tre atment guideline was 
presented for the subject suffer ing from both AS and nr-axSpA. These guidelines recommend the 
use of a TNFi after NSAID treatment. 
With the advent of the ASAS cla ssification criteria for axSpA, several registration studies have 
been conducted in patients wit h nr-axSpA (Dougados et al, 2014) , or axSpA (Landewe et al, 
2014; Sieper et al, 2013b; Sieper et al, 2013c). These studies have shown that anti-TNFs are 
effective in nr-axSpA patients, particularly in patients with o bjective signs of inflammation as 
defined by MRI positivity or elevated CRP. The RAPID-axSpA stud y, the first axSpA study to 
enroll both AS and nr-axSpA patients in the same study, showed that baseline disease activity 
and treatment effect were simil ar between nr-axSpA and AS subje cts (Landewe et al, 2014). In 
this study, it was shown that CZP rapidly reduced the signs and  symptoms of axSpA disease over 
24 weeks of Double-Blind treatment in the broad axSpA populatio n, including the AS and the 
nr-axSpA subpopulations, and that the responses to the treatmen t were similar in both 
subpopulations (Landewe et al, 2014; Sieper and van der Heijde,  2013c) and maintained up to 
Week 96 (Mease et al, 2014; Sieper et al, 2014).
Based on the results of the RAPID-axSpA study, CZP received app roval for the treatment of 
adult patients with severe active axSpA (comprising AS and nr-a xSpA) in the European Union 
(EU) and several other countries, e g, Turkey, Argentina, Russia , Chile, Switzerland, Hong Kong, 
Dominican Republic, Ecuador, and P eru, and it was approved for the treatment of adults with 
active AS in the USA, Canada, Australia, and also Malaysia.
In accordance with the ASAS classi fication criteria a subject c an either be classified as having 
axSpA based on imaging evidence or on clinical assessment. Rece nt publications showed that 
sacroiliitis on imaging via MRI is highly specific for the diag nosis of axSpA and is commonly 
used in many regions to diagnose axSpA in daily clinical practic e (Rudwaleit et al, 2009a; 
Rudwaleit et al, 2009b; Rudwaleit et al, 2009c).
Because of the therapeutic response in early disease, the ASAS consensus recommendation on 
the use of TNFi in AS, updated in 2010, was extended to include  the full spectrum of axSpA 
(van der Heijde et al, 2011).
2.5 Rationale  
The RAPID-axSpA study enrolled subjects with objective signs of  inflammation, and the results 
indicated that baseline disease  burden was similar between the AS and nr-axSpA subpopulations 
(Landewe et al, 2014; Sieper et al, 2013b). In the RAPID-AxSpA study it was shown that CZP 
rapidly reduced the signs and symptoms of axSpA over 24 weeks of  double-blind treatment in 
the broad axSpA population, including in the AS and the nr-axSp A subpopulations, and that the 
responses to the treatment were similar in both subpopulations (Landewe et al, 2014; Sieper et al, 
2013b) and maintained up to Week 96 (Mease et al, 2014; Sieper et al, 2014).
To address the unmet need for tre atment options for nr-axSpA, A S0006 will be conducted 
focusing on subjects who do not meet the mNY classification cri teria for AS 
(see Appendix 18.2). Data suggest that patients with objective signs of inflammat ion and high REDACTED, Arg, Arg
and it and it 
ia, andia, and
ficatificatCOPY CZP reCZP re
sing Aing A
This documentapidpid
the bthe b
rcannoted thd th
ndewedewe
dlydlybeDD--axaxused RatiRatitoal, 2al, 2support tic respic res
S, upda, upda
2010anye ae a
aleit aleit marketingtion crion c
r on clinon cl
highly highl
axSpaxSauthorizationec
AS anAS an
entinaentina
t was at was a
nd alsod alsoapplicationwerwer
e, 2013e, 201
ceivedeive
dandinclunclu
ere sre sany dewdew
ms of ams of 
udextensionsF
mmatimati
axSpAxSpA
e diseadisea
we weors arearvariations ave ve 
al, al, thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 23 of 255disease activity are likely to run a chronic disease course and  unlikely to be well-managed on 
conventional therapy (Rudwaleit ACR, 2013). Furthermore, studie s where anti-TNFs have been 
withdrawn in nr-axSpA patients show that patients flare quickly  and hence the disease is unlikely 
to go into spontaneous remission. However, there are no long-te rm prospective studies to assess 
how patients meeting the ASAS c lassification criteria respond t o conventional therapies. With 
the conduct of the 52-week blinded study period comparing CZP t o placebo in combination with 
standard of care, a better unde rstanding should be gained of ho w a long-term anti-TNF therapy 
compares to standard of care in patients meeting the ASAS crite ria with objective signs of 
inflammation. Moreover, patients whose disease cannot be manage d under the blinded study 
treatment conditions will be able to discontinue the double-bli nd study treatment and transition 
to either open-label CZP or other therapies.
The addition of the SFE Period w ill allow collection of long-te rm safety data from eligible 
subjects on open-label CZP for up to 2 years. In addition, MRI assessment of SI joint structural 
damage and laboratory assessment for CRP will be performed, and  data from selected efficacy 
variables will be collected at the end of the SFE Period. During  the SFE Period, CZP will be 
provided by the Sponsor. The treat ing Investigator is requested  to apply routine, standard of care 
according to local standard medical practice and Investigator c linical judgment. 
Subjects enrolled into this st udy must have sacroiliitis on MRI  as set forth by the 
ASAS/OMERACT definition; or meet the requirements for the clini cal arm of the ASAS 
classification criteria for axSpA  (MRI-negative nr-axSpA) and h ave elevated CRP levels, as 
there is good evidence to suggest that CRP is a predictor of re sponse to anti-TNF therapy in 
axSpA. 
3 STUDY OBJECTIVES 
3.1 Primary objective 
The primary objective of the study is to demonstrate the effica cy of CZP 200mg Q2W on the 
signs and symptoms of subjects with active axSpA without x-ray evidence of AS.
3.2 Secondary objectives 
The secondary objectives of the study are to assess efficacy, s afety, and tolerability and to 
demonstrate the effect of CZP on: 
x Health outcomes
x Disease activity
x SI joint inflammation through MRI
x Changes in concomitant and background medications
3.3 Other objectives 
The other objectives of the study are to assess the effect of C ZP on the following: 
x Spinal mobility
x Total spinal pain (NRS)
x Spinal inflammation REDACTEDa prea pr
VESVES
eeCOPYents fents 
nrr-axSaxS
redred
This document 3.33.3
TTcannotoint int 
ChangChanbe ac
ininused mesme
ctivittivito esssupport y oy 
es of ths of t
t of CZof Cany objeobjemarketing is to des to d
with acith aauthorizationSpA)pA)
dictor ctor applicationp
nical jnical 
RI as sRI as 
for the or the
)a n)a nandFE PE P
pply rply ranyrom som 
PeriPerextensions tran
rom elom el
f SI joSI jornsitnsivariations y
dy dy thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 24 of 255x SI joint structural changes
x Treatment response over time 
x Additional signs and symptoms of the disease
 Morning stiffness 
 Fatigue 
 Extra-articular manifestations of axSpA 
 Sleep
 Physical function
x Subject’s health status
x Acute phase reactant (CRP)
x HRQoL
x Work and household productivity
x PK and immunogenicity
x Gene and protein expression and to e xplore the relationship bet ween genomic biomarkers 
and disease biology, drug treat ment and inflammatory and immune  responses (for those 
subjects who consent to the genomics substudy).
4 STUDY VARIABLES 
4.1 Efficacy variables 
4.1.1 Primary efficacy variable 
x ASDAS-MI at Week 52
The primary efficacy variable for Canada (and any other country  where applicable or where 
requested by Regulatory Authorities) is the ASAS40 response at Week 12.
4.1.2 Secondary efficacy variables 
The secondary efficacy variables are as follows:
x ASAS40 response at Weeks 12 and 52
x Change from Baseline in BASFI at Weeks 12 and 52
x Change from Baseline in BASDAI at Weeks 12 and 52
x Change from Baseline in SI joint SPARCC score at Week 12
x Number of subjects without relevant changes to background medic ation
x Change from Baseline in ASQoL at Week 52
x Change from Baseline in ASQoL at timepoints other than Week 52
x Change from Baseline in nocturnal spinal pain (NRS) at Week 52REDACTEDbstudybstud
SS
essCOPY  relatirelat
mmamma
This documentCC
xxcannot nge ge
Changhang
ChChbe e froe froused ficfic
responespoocacycacysupportAuthoutho
ndary daryany for Cfor Cmarketing ariableariablauthorizationatory atory 
y).y).application onshipnshiand any extensions or variations thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 25 of 255x Number of subjects with AU or new AU flares through Week 52 
For Canada (and any other country where applicable or where req uested by Regulatory 
Authorities), the secondary efficacy variables are:
x ASAS40 response at Week 52
x ASDAS-MI at Week 52 
x Change from Baseline in BASFI at Weeks 12 and 52
x Change from Baseline in BASDAI at Weeks 12 and 52
x Change from Baseline in SI joint SPARCC score at Week 12
x Number of subjects without relevant changes to background medic ation
x Change from Baseline in ASQoL at Week 52
x Change from Baseline in ASQoL at timepoints other than Week 52
x Change from Baseline in nocturnal spinal pain (NRS) at Week 52
x Number of subjects with AU or new AU flares through Week 52 
4.1.3 Other efficacy variables 
The following variables will be a nalyzed at scheduled time poin ts through Week 52 and at Week 
156 for selected variables:
x ASAS 20% response criteria (ASAS20), ASAS40, ASAS 20% improveme nt in 5 of 6 
domains (ASAS5/6), and ASAS partial remission response 
x Change from Baseline in individual ASAS components: 
 Patient’s Global Assessment of  Disease Activity (PGADA)
 Total spinal pain (NRS) 
 BASFI
 Average of Questions 5 and 6 of the BASDAI concerning morning s tiffness
 Change from Baseline in Bath Ankylosing Spondylitis Metrology I ndex (BASMI) lateral 
spine flexion
 CRP
x Change from Baseline in BASDAI and individual Questions 1, 2, 3 , and 4
x Change from Baseline in Ankylosing Spondylitis Disease Activity  Score (ASDAS)
x Change from Baseline in BASMI linear
x ASDAS disease activity (Ankylosing Spondylitis Disease Activity  Score inactive disease 
[ASDAS-ID], Ankylosing Spondylitis Disease Activity Score low d isease [ASDAS-LD; 
Machado et al, 2018], Ankylosing Spondylitis Disease Activity S core high disease activity 
[ASDAS-HD], Ankylosing Spondylitis Disease Activity Score very h igh disease activity REDACTED 20), A20), A
artial rartial r
dualdualCOPY duledduled
This document xxcannot hange ange 
ChaChabe PPusedomom
lexionexiontom Bm Bsupport uestionestionany marketing l ASASASA
nt of Dof Dauthorizationd timed tim
ASAS4SAS4
remisemisapplication k5 252
eek 52eek 52
epand 22any extensions or variations thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 26 of 255[ASDAS-vHD]) and clinical improvement (Ankylosing Spondylitis D isease Activity Score 
clinically important improvement [ASDAS-CII], ASDAS-MI)
x BASDAI 50 response
x Change from Baseline in Fatigue (NRS) (from BASDAI)
x Change from Baseline in sacroiliitis grading to Week 52 for str uctural damage
x Change from Baseline in SI joi nt SPARCC score at Week 52 and We ek 156 and ankylosing 
spine MRI acuity (ASspiMRI-a) in the Berlin modification at Wee k 12 and Week 52
x Proportion of subjects with SI joint SPARCC score <2 at Week 12,  Week 52, and Week 156
x Change from Baseline in ASAS-NSAID score
x Number of AU flares 
x Number of inflammatory bowel disease (IBD) exacerbations
x Number of psoriasis exacerbations 
x Work Productivity Survey (WPS) 
x Change from Baseline in the Sleep Problems Index II domains of the Medical Outcomes 
Study (MOS) Sleep scale
x Change from Baseline in enthesitis (Maastricht Ankylosis Spondy litis Enthesitis Score 
[MASES])
x Change from Baseline in swollen and tender joint counts (44 joi nt count)
x Change from Baseline in Phys ician’s Global Assessment of Diseas e Activity (PhGADA)
x Change from Baseline in the Short-Form 36-Item Health Survey (S F-36), Physical 
Component Summary (PCS), and Mental Component Summary (MCS)
x Change from Baseline in the SF-36 domains:
 Role Physical
 Bodily Pain
 General Health
 Vitality
 Social Functioning
 Role Emotional
 Mental Health
x Health status as assessed by the EuroQoL Health Status Question naire (5 dimensions) 
(EQ-5D) domains, visual analog s cale (VAS) actual score and cha nge from Baseline in VAS 
score
x Resources utilization: concomi tant medical procedures, health c are provider consultations not 
foreseen by the protocol, hospitalizations/emergency room visit sREDACTEDrichrich
nd tennd ten
ian’sian’sCOPY x Ix 
ht Aht
This document cannotSociSoci
RRbealityityusedHealHea
yyto ltlsupport any he SFhe SFmarketings Globs Glo
ortrt--ForFo
and Mand Mauthorization AnkylAnkyl
nder joder jo
bapplication omainomainand any extensionsd WeWor eeeevariations sing ng thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 27 of 2554.2 Pharmacokinetic, exploratory biomarker, and 
pharmacogenomic variables 
4.2.1 Primary pharmacokinetic variables 
Certolizumab pegol plasma concentrations will be measured at Ba seline and Weeks 1, 2, 4, 12,
24, 36, 52, and at the FU visit (8 weeks after the Week 52/WD v isit). 
These plasma samples may be used additionally for analyses of C ZP and its constituent moieties 
using alternative methods.
4.2.2 Other biomarker variables 
Selected samples collected for measurement of CZP plasma concen tration may be used 
additionally for analyses of candi date exploratory biomarkers a nd cytokines, where appropriate. 
The biomarkers to be analyzed may include, but will not be limi ted to the following:
Matrix metalloproteinase-3 (MMP -3), bone morphogenetic protein (BMP)-2,-4 and -7,
wingless-related mouse mammary tumor virus integration site pro tein (WNT1), WNT1-inducible
signaling pathway proteins (WISP), gremlin, dickkopf-related pr otein 1 (DKK1), sclerostin, 
hedgehog proteins (Sonic hedgehog [Shh], Indian hedgehog [Ihh],  Dessert hedgehog [Dhh]), 
collagen turnover/cleavage products, collagen type X, vascular endothelial growth factor 
(VEGF), citrullinated vimentin fragments, cytokines: interleuki n 13 (IL13), interleukin 17A and
F (IL17 A and IL17 F), interleukin 23 (IL23), interleukin 34 (I L34), transforming growth factor 
(TGF) β, macrophage colony -stimulating factors (M-CSF), granulocyte macrophage 
colony-stimulating factor (GM-CSF), colony-stimulating factor-1  (CSF-1), and soluble CSF-1
receptor (sCSF1r) levels.
4.2.3 Other pharmacogenomic variables 
For individuals consenting to the genomics substudy, blood samp les will be drawn for possible 
genetic/epigenetic, genomic , proteomic, and metabolomics analys is at Baseline and Week 12.
Additional samples will be coll ected for genomics, proteomics, and metabolomics analysis only, 
at Weeks 4 and 52/WD. 
Collection of the samples will e nable the exploratory evaluatio n of biomarkers relative to disease 
activity, drug treatment, and inflammatory and immune response processes. The nature and 
format of these tentative analyses will be determined when the results of the main study are made 
available. The samples will be s tored at -80°C at the central b iorepository for up to 20 years.
4.3 Other immunological variables 
Anti-CZP antibody/anti-drug antibody (anti-CZP Ab/ADAb) concent rations will be assessed at 
Baseline and Weeks 1, 2, 4, 12, 24, 36, 52/WD, and the FU visit  (8 weeks after the Week 52/WD 
visit). In addition, the anti-CZP Ab concentrations will be ass essed in subjects who withdraw 
from study drug and transition to open-label CZP. 
Determination of ADAb will be done using a validated screening,  confirmation and titration 
ADAb bridging assay, with potenti al further characterization by  a neutralizing antibody assay. 
The immunogenicity data will be processed according to dedicate d Bioanalytical Analysis plans.ors (rs 
nyy--stimstim
enomenomCOPY: inte: int
erleukerleuk
(M(M
This document isitsit
fromfrom
DcannotZP anP an
eline aine a
t). In). Inbe ttusedamplmp
OtOttotativativ
lelsupport s will ewill 
nt, and t, and
ve aveany ctectmarketing mic ic
omics somics
omic, amic, 
ted foed fauthorizationkin 3n 3
-CSFCSF
mulatimulati
c vavaapplication tein
h], Deh], De
lar endar end
rleukinleuki
34 (34andn (WN(W
in 1 n 1 any P)P)--2,2,--4
WNTNextensions used used 
here aere a
llowinowinor variations ties ties thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 28 of 2554.4 Safety variables 
4.4.1 Secondary safety variables 
Assessment time points for safety variables are specified in Table 5 ‒1and Table 5 ‒6. The 
secondary safety variables are as follows:
x Incidence of treatment-emergent adverse events (TEAEs)
x Incidence of serious adverse events (SAEs)
x Adverse events leading to withdrawal from investigational medic inal product (IMP)
4.4.2 Other safety variables 
Other safety variables are assessed as specified in Table 5 ‒1and Table 5 ‒6,and are as follows:
x Change from Baseline in vital signs (blood pressure, temperatur e, and pulse rate)
x Change from Baseline in clinical laboratory values (hematology,  biochemistry, and 
urinalysis)
Physical examination findings considered clinically significant  changes since the physical 
examination completed at the Screening Visit will be recorded a s AEs.
5 STUDY DESIGN 
5.1 Study description 
Study AS0006 is a 52-week, multicenter, randomized, double-blin d, parallel-group, 
placebo-controlled clinical study to evaluate the efficacy and safety of CZP in adult subjects with
active axSpA without x-ray evidence of AS and with objective si gns of inflammation (sacroiliitis 
on MRI and/or elevated CRP) and who have had an inadequate respo nse to, have a 
contraindication to, or are intolerant to NSAIDs. At the comple tion of the Week 52 visit 
assessments, eligible subjects may receive open-label CZP treat ment for an additional 2 years in 
an open-label, SFE Period.
5.1.1 Study periods 
The study includes 3 periods. An injection schedule is provided in Section 7.2.2 .
Period 1 (Screening Period): 1 day to 6 weeks before Baseline: 
Prior to any study activities, subjects will be asked to read a nd sign the Informed Consent form 
for the conduct of the study. A separate informed consent form will also be obtained from 
subjects consenting to the use of their blood samples in a subs tudy for possible 
genetic/epigenetic, genomic, proteomic, and metabolite analysis .
Laboratory data (hematology, urine, and biochemistry tests) wil l be obtained, and treatment of 
latent tuberculosis (LTB) will be  initiated when necessary. Subj ects must undergo a TB test and 
complete a TB questionnaire. The BASDAI, BASMI, and spinal mobi lity assessments will be 
performed. Concomitant medications permitted during the study s hould remain stable for at least 
4 weeks prior to Baseline at Week 0.
Sacroiliac-joint x-ray (not ol der than 12 months before Baselin e and verified by central reading 
during the Screening Period) must prove that the subject belong s to the mNY-negative axSpA REDACTED andomandom
luate tluate t
e of Ae of A
whowhoCOPY 
This documentLaboabo
latelatecanno concon
tic/epiic/epi
oraorbeductduct
nsensused ng
tudy audy a
tottog Peg Psupportriodsods
periodseriodany smarketing AS aS a
have hhave 
to NSAo N
y receiy receauthorization mizedmized
the efhe ef
andandapplicationchangechang
ed as Aed as Aand ococany chemhemextensions are aare a
lse rse ror variations thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 29 of 255subpopulation, ie, does not have sacr oiliitis grade ≥2 bilaterally or grade 3 to 4 unilaterally. 
Potentially eligible axSpA subjects without suitable SI-joint x -ray must undergo the x-ray with 
central reading within the Scree ning Period. Sacroiliac-joint x -rays (read centrally) will allow 
discrimination of subjects with AS and without definitive evide nce for sacroiliitis on x-ray 
(mNY negative-axSpA). Subjects with AS (mNY-positive) must be e xcluded from further 
participation in this study.
Confirmed mNY-negative axSpA subjects must undergo an MRI later during the Screening 
Period for central reading with results from the central readin g available by no later than at the 
Baseline visit. 
Additionally, the subjects must get a further measurement of CR P 3 to 5 days before Baseline 
(Week 0).  
Period 2 (Double-Blind Period): Week 0 to Week 52, placebo-controlled. 
Eligible subjects will be allocated to the following double-bli nd study treatments in a 1:1 ratio:
x CZP administered at the dose of 400mg at Weeks 0, 2, and 4 follo wed by 200mg Q2W 
(starting at Week 6 up to and including Week 50)
x Placebo
At on-site visit days (at Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 2 4, 28, 32, 36, 40, 44, 48, and 50), the 
double-blind study treatments will  be administered sc at the st udy site. At the Week 0, 2, 4, 6, 
and 8 visits, the administration must be done by dedicated, unbl inded, and adequately trained site 
personnel. At the Week 10 and 12 visits, the subject will recei ve training on self-injection and 
the study treatment will be self-administered under the supervi sion of the unblinded study 
personnel. At Weeks 16, 20, 24, 28, 32, 36, 40, 44, 48, and 50,  the study treatment administration 
should preferably be done by the unblinded study personnel, or alternatively by self-injection of 
the subject under the supervision of the unblinded study personn el. The double-blind study 
treatment will be self-injected at home at Weeks 14, 18, 22, 26 , 30, 34, 38, 42, and 46. 
Concomitant medications permitted during the study should remai n stable for at least 4 weeks 
prior to the Weeks 12, 24, and 52/WD assessments.
Alternative schedules 
Subjects who discontinue the double-blind study treatment and e nter open-label treatment with 
CZP will be assessed 2 and 4 weeks after open-label CZP treatme nt has been initiated and every 
12 weeks thereafter. Alternatively, subjects who discontinue th e double-blind study treatment 
and receive other treatment (including biologics) will be asses sed every 12 weeks after initiation 
of the other treatment. The alte rnative schedules for open-labe l CZP and other treatment can be 
found in Table 5 ‒2and Table 5 ‒3, respectively. In either alternative schedule, assessments 
should be conducted until as close as possible to Week 52 (with in ±4 weeks), where Week 52 is 
relative to the original randomization at Week 0. Subjects will  then be invited to the Week 52
assessment visit.
Period 3 (Follow-Up Period):
All subjects not participating in the SFE Period after Week 52,  including those withdrawn from 
the study prematurely, will have a  FU visit 8 weeks after the Wee k 52/WD visit.
Safety Follow-Up Extension (SFE) Period: Week 52 to Week 156, open-label.REDACTEDby dby d
he subhe sub
tered tered 
32, 3632, 36
blinblinCOPY16, 2016, 2
ed sc ed sc
d
This document houou
relatrelat
aacannotother ther 
d in d in TT
uld uldbee othe oth
ttusedessedssed
eafteeaftetontinntin
ddsupport and nd 
nuenuanymitteditte
d 52/52marketing 6, 4, 4
nded stded s
the unbhe u
home aome 
dddauthorizationat that th
edicatedicate
bject wect w
underunder
40, 40,application 0, 24, 2, 24,
eand lowedowedanyatmenatmeextensionse Bas Basor variations t the the thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 30 of 255At the completion of the Week 52 visit assessments, subjects on  double-blind study treatment 
may receive open-label CZP treatment for an additional 2 years.  Subjects who withdrew from 
double-blind study treatment and transitioned to open-label CZP  treatment are also eligible to 
participate in the SFE Period a fter completing the Week 52 visi t assessments. Subjects on 
alternative treatments are not eligible to participate in the S FE Period. 
Eligible subjects are allowed to roll-over to the SFE-Period up  to 3 months after completion of 
the Week 52 assessments.
In order to maintain the blind for subjects completing double-b lind treatment, their study 
treatment will be administered sc at the study site by unblinde d, dedicated study personnel on 
Weeks 52, 54, and 56. Subjects who withdrew from double-blind s tudy treatment and 
transitioned to open-label CZP treatment do not need to visit t he site at Week 54 and Week 56, 
and should continue their open-lab el CZP treatment regimen.
For the remainder of the SFE Per iod, CZP can be administered at  the site by dedicated study 
personnel, or by self-injection of the subject under the superv ision of the dedicated study 
personnel, or subjects may self-admi nister their study treatmen t Q2W at home. 
Starting at Week 64, all subjects are to visit the site approxim ately every 12 weeks (±2 weeks) 
for assessments. 
The last dosing visit will be at Week 154. The final study asse ssments are performed at 
Week 156/SFE-WD.
5.1.2 Study duration per subject 
For each subject, the first 3 periods of the study will last a maximum of 66 weeks, as follows:
x Up to 6 weeks in the Screening Period
x 52 weeks in the Double-Blind Period
x A FU visit 8 weeks after the Week 52/WD visit (for subjects not  participating in the SFE 
Period).
For subjects participating in the SFE Period, the study will ex tend up to a maximum of 
104 additional weeks.
The estimated recruitment period is up to 15 months. The first subject first visit is planned in 
Quarter 3 of 2015. The end of the stu dy will be defined as the date of the last subject’s last visit, 
defined as the FU visit 8 weeks after the Week 52/WD visit for subjects not participating in the 
SFE Period, or the last visit of the SFE Period  
5.1.3 Planned number of subjects and site(s) 
Approximately 1200 subjects are expected to enter the Screening  Period in order to have 
300 subjects randomized into the  Double-Blind Period. The end of  the study will be defined as 
the date of last subject last FU visit. It is planned to enroll  the subjects at approximately 
120 sites.
5.1.4 Anticipated regions and countries 
The study will be conducted in North America, Australia, Europe , Asia, and other regions as 
appropriate.REDACTED ectect
he studhe stu
PeriodPeriodCOPY l studyl stud
This documentApprppr
300300
thcannot odod
proxroxbe e
d, or d, orused015. T15. T
FU FUtouitmuitmsupportg in thein th
menany marketing d
riodriod
Week Weekauthorization y
dy wiy wiapplication elylyeveev
y assesasseand he e 
W at hW at hanyby by dd
dedidedextensions nn
nd d 
and Wand W
dedornel oel variations thereof. 
UCB 17 December 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 31 of 2555.2 Schedule of study assessments 
The Schedule of assessments is shown in Table 5 ‒1for subjects who complete 52 weeks of 
treatment on either CZP 200mg Q2W or placebo.
In order to optimize the treatment the Investigator may adjust the background medication in 
accordance with the specifications described in Table 7 ‒1.
At any time during the study course, but preferably not before Week 12, the Investigator may 
discontinue the double-blind study  treatment and start open-lab el treatment with either CZP 
(which will be provided free of ch arge by UCB) or an alternativ e drug (eg, other treatment 
[including biologics]). Table 5 ‒2shows the schedule of assessm ents for subjects receiving 
open-label treatment with CZP and Table 5 ‒3shows the schedule of assessments for subjects 
receiving an alternative treatment (not CZP).
Table 5 ‒6shows the schedule of assessments for subjects participating in  the SFE Period.
COPY 
This document cannot be used to support any marketing authorization application and any he eextensionseivinivin
for subor su
e SFSFor nt nt 
ngngvariations P thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 32 of 255Table  5‒1: Schedule of study assessments – Screening through Week 52 and FU  
Visit # Scr Scr 
day -5
to -31/
B
L23456789
H1
01
1
H1
21
3
H1
415
H1
617
H1
81
9
H2
02
1
H2
223
H2
42
5
H26 2
728
Week
Protocol 
Activity-6 weeks 
to -1 day 0 1 2 4 6 8 1
0
 1
2 1
4 
/
H 1
6 1
8 
/
H 2
0 2
2 
/
H 2
4 26 
/H 2
8 30 
/H 3
2 3
4 
/
H 3
6 3
8 
/
H 4
0 42 
/
H 4
4 4
6 
/
H 48 5
0 52
/
W
DF
U
b 
Inclusion/ 
Exclusion 
criteria  X X X 
Informed 
consentaX 
Demographic 
data X 
Medical history 
and procedure history (incl. 
axSpA history)X 
Vital signscX X  X X X X X X  X  X  X  X X X X X X X X X 
Hematology/ 
urine/ 
biochemistrydX Xe X X X X X X Xe X 
HBsAg/ 
antibodies to 
hepatitis C/HIV/ 
HLA -B27/
CKD -EPI Xf 
CRP Xg X X X X X X X X X X X X X X X X 
Pregnancy 
testinghX X            X X 
PEiX X  X X X X X   X   X X X 
Extra -articular 
assessmentsX  X X   X   X X X REDACTED E
AC
TED
XXEEEDRER
COPY 
YYYYCO
PYCCCCThis 
document 
nt cannot XXnnnonnonn
be bebebebebe
used Xdedddus
dto XXoo support sport
any yan
marketing Xngtinnnm
rke
n
authorization 
iniiioaut
ori
atiaaa
application 
iiionpli
atiplplplp
and an
any HHayaaanya
extensions22io
s 
6633
88ioioioete
io
or 232
HHo
variations 
on
33vavaava
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 33 of 255Table  5‒1: Schedule of study assessments – Screening through Week 52 and FU  
Visit # Scr Scr 
day -5
to -31/
B
L23456789
H1
01
1
H1
21
3
H1
415
H1
617
H1
81
9
H2
02
1
H2
223
H2
42
5
H26 2
728
Week
Protocol 
Activity-6 weeks 
to -1 day 0 1 2 4 6 8 1
0
 1
2 1
4 
/
H 1
6 1
8 
/
H 2
0 2
2 
/
H 2
4 26 
/H 2
8 30 
/H 3
2 3
4 
/
H 3
6 3
8 
/
H 4
0 42 
/
H 4
4 4
6 
/
H 48 5
0 52
/
W
DF
U
b 
Chest x -rayjX X 
TB testkX X 
TB 
questionnaire  X X X X X X 
Sacroiliac joint 
x-raylX X 
MRImX X X 
BASMI & spinal 
mobilitynX X XX X X X X X X X X X X X X X 
BASDAI X X XX X X X X X X X X X X X X X 
BASFI X XX X X X X X X X X X X X X X 
SF-36 X X X X X X X 
ASQoL X XX X X X X X X 
MOS Sleep 
ScaleX X X X X X 
EQ-5D X X X X X X X 
MASES X XX X X X X X X X X X 
Total and 
nocturnal spinal 
painX XX X X X X X X X X X X X X X 
Swollen and 
tender joint 
countsX X X X X X REDACTED 
EDEEDEDAC
TED
XXDAAARE
ARERERER
COPY 
YCO
PYCCOCOCOThis 
document 
tcannot XXtcnn
be bebbbb
used 
dXXdddus
dto XXo tsupport 
ortpooosposssus
any XXnXnnnyan
marketing 
gXXnngngke
ngkkekem
rke
XXmmmam
authorization 
nonnnati
n
XX
zaaut
oriutututaut
application 
onpli
atiplipliplipli
and nnnndan
any HHayaaanya
extensions22io
s 
6633
88ioioioete
io
or 232
HHo
variations 
on
33vavaava
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 34 of 255Table  5‒1: Schedule of study assessments – Screening through Week 52 and FU  
Visit # Scr Scr 
day -5
to -31/
B
L23456789
H1
01
1
H1
21
3
H1
415
H1
617
H1
81
9
H2
02
1
H2
223
H2
42
5
H26 2
728
Week
Protocol 
Activity-6 weeks 
to -1 day 0 1 2 4 6 8 1
0
 1
2 1
4 
/
H 1
6 1
8 
/
H 2
0 2
2 
/
H 2
4 26 
/H 2
8 30 
/H 3
2 3
4 
/
H 3
6 3
8 
/
H 4
0 42 
/
H 4
4 4
6 
/
H 48 5
0 52
/
W
DF
U
b 
PhGADA X XX X X X X X X X X X X X X X 
PGADA X XX X X X X X X X X X X X X X 
Productivity X X X X X X X 
Resources 
utilizationoX X X X X X X 
CZP plasma 
concentration/ 
anti-CZP Abs / 
BiomarkerX XX X X X X X X 
Genetics/epigene
ticsX X 
Gene expression 
and proteomicsX X  X X 
Prior and 
Concomitant 
medicationX X XX X X X X X X X X X X X X X X X X X X X X X X X X X X 
AEs X XX X X X X X X X X X X X X X X X X X X X X X X X X X X 
IXRSpX X  X X X X X X X X X X X X X X X X X X 
Study drug 
administration 
scqX X X X X X X X X X X X X X X X X X X X X X X X X X 
Subject training 
on self -injectionrX X 
Abs=antibodies; AE=adverse event ; Apo=Apolipoprotein; AsQoL=Ank ylosing Spondylitis Quality of Life; BASDAI=Bath Ankylosing Spo ndylitis Disease 
Activity Index; BASFI=Bath Ankylosing Spondylitis Functional In dex; axSpA=axial spondyloarthritis; BASMI=Bath Ankylosing Spond ylitis Metrology Index; REDACTED 
AC
TEDACACACRE
ACR
COPY XPYOPPPCO
PThis 
document =BathBath
cannot nn rse evese eve
th Ath
nnnnn
be ebebebebe
used Xus
dto X
XXtoo support 
ort XXXXortortortportsupXXuppppsp
any XXan
marketing 
nginngngm
rke
ng
XXXXmmmam
authorization XXtori
ati
ntuthtthaut
application 
onaticaaapli
aap
and XXnXXnnndan
any HHayaaanya
extensions22io
s 
6633
88ioioioete
io
or 232
HHo
variations 
on
33vavaava
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 35 of 255Table  5‒1: Schedule of study assessments – Screening through Week 52 and FU  
Visit # Scr Scr 
day -5
to -31/
B
L23456789
H1
01
1
H1
21
3
H1
415
H1
617
H1
81
9
H2
02
1
H2
223
H2
42
5
H26 2
728
Week
Protocol 
Activity-6 weeks 
to -1 day 0 1 2 4 6 8 1
0
 1
2 1
4 
/
H 1
6 1
8 
/
H 2
0 2
2 
/
H 2
4 26 
/H 2
8 30 
/H 3
2 3
4 
/
H 3
6 3
8 
/
H 4
0 42 
/
H 4
4 4
6 
/
H 48 5
0 52
/
W
DF
U
b 
BL=Baseline; CKD-EPI=Chronic Kidney Epidemiology Collaboration;  CRP=C-reactive protein; CZP=certolizumab pegol; EQ ̻5D=EuroQoL Health Status 
Questionnaire (5 dimensions); FU=Follow-Up; H=home; HbA1c=glycated hemoglobin; H BsAg=He patitis B surface antigen; HIV=human immunodeficiency 
virus; HLA -B27=Human Leukocyte Antigen-B27; IGRA=Interferon-Gamma Release  Assay; IXRS=Interactive Response System; MASES=Maastricht 
Ankylosis Spondylitis Enthesitis Score; MOS=Medical Outcomes St udy; MR I=magnetic resonance imaging; PE=physical exam; PhGADA=Physicia n’s Global 
Assessment of Disease Activity; PGADA=Patient’s Global Assessme nt of Disease Activity; sc=subcutaneously; Scr=Screening; SF ̻36=Short̻Form 36̻item 
Health Survey; SFE=safety Follow -up Extension; SI=sacroiliac; TB =tuberculosis; WD=Withdrawal 
Note: All weeks are ±3 day s compared to Baseline. 
Note: At the completion of the Week 52 Visit, subjects may rece ive open -label CZP treatment for an additional 2 years in the SFE Perio d
aInformed consent: Prior to any study activities, subjects will be asked to read and sign the informed consent form for the con duct of the study. A separate 
informed consent form will also be obtained from subjects conse nting to the use of their blood samples in a s ubstudy for possible genetic/epigenetic, genomic, 
proteomic, and metabolite analysis.
bFU: 8 weeks after Week 52/WD visit for subjects not participati ng in the SFE Period. 
cPulse rate, systolic and diastol ic blood pressures, temperature , and respiration rate are to be measured at Screening and Baseline, thereafter p ulse rate, systolic 
and diastolic blood pressures, tem perature are to be measured a t all on- site visits. If a subject exper iences an AE, respiration rate w ill be measured in addition.
dSubjects will be encouraged to be in fasting condition at Basel ine and at Week 52/WD or at the time the subject shifts to alter native treatment, for Apo A1, 
ApoB, and lipoprotein(a) assessments.
eHbA1c will be measured at Baseline and Week 52/WD. 
fTesting to rule out HBsAg, antibodies to hepatitis C, and HIV w ill be performed. In addition, testing for HLA- B27 and abnormalities for estimated glomerular 
filtration rate as measured by CKD-EPI are to be performed.
gOne retest of CRP is mandatory dur ing the Screening Period with in 3 to 5 days before the Baselin e visit in order to meet the i nclusion criteria.
hPregnancy testing must be carried out for women of childbearing  potential: A serum test will be performed at the Screening vis it and FU, and urine testing 
(dipstick) at Baseline and Week 52/WD.
iIncludes evaluation of signs and s ymptoms of active TB and risk  factors for exposure to TB. Weig ht is to be measured at Screen ing, Week 24, and at 
completion at Week 52/WD. Height will be measured at the Baseli ne visit only.
jA chest x-ray must be done at Screening unless a chest x-ray (o r computed tomography of the chest) has been done within 3 mont hs prior to the Screening 
visit. The chest x-ray will be repeated at Week 52/WD visit only  if the TB test was confirmed positive or any further evidence is suggestive of potential TB 
infection (eg, exposure).
kTB test: IGRA test (QuantiFERON test [or Elispot test when the QuantiFERON indicated is not available]). The TB test will be r epeated at Week 52 (or at 
WD visit if medically indicated) for subjects with previously ne gative TB test result. Subjects who tested positive for TB shou ld be encou raged to complete a 
FU visit (8 weeks after the Week 52/WD visit for subjects not pa rticipating in the SFE Period) and follow-up information of sus pected and confirmed TB cases REDACTEDad andad an
 the us the us
in the in the
nd respnd resp
allal
COPYD=WD=W
CZP trZP tr
dThis 
documenter ther the
cannot FEROERO
dicateicate
W
beeni
ated aated 
used ms os o
will be mll be m
ing ung u
to of aof a
support formeorm
ing Perng Pe
en of chn of ch
any d HIV wHIV 
medd
marketing piratioirati
onon--sitesite
e and atand 
authorizationreatmeeatme
sign thsign th
se of the of th
SFE PSFE P
ioi
application =Interanter
ce image ima
=subcu=subcu
thdrawahdraw
andrtolizoliz
tis B sis B s
rac
any HHay
izumzumaaany
extensions22io
s 
6633
88ioioioete
io
or 232
HHo
variations 
on
33vavaava
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 36 of 255Table  5‒1: Schedule of study assessments – Screening through Week 52 and FU  
Visit # Scr Scr 
day -5
to -31/
B
L23456789
H1
01
1
H1
21
3
H1
415
H1
617
H1
81
9
H2
02
1
H2
223
H2
42
5
H26 2
728
Week
Protocol 
Activity-6 weeks 
to -1 day 0 1 2 4 6 8 1
0
 1
2 1
4 
/
H 1
6 1
8 
/
H 2
0 2
2 
/
H 2
4 26 
/H 2
8 30 
/H 3
2 3
4 
/
H 3
6 3
8 
/
H 4
0 42 
/
H 4
4 4
6 
/
H 48 5
0 52
/
W
DF
U
b 
should be provided to UCB at leas t after 3, 9, and 12 months of the start date of anti-TB treatment.
lSacroiliac joint x-rays will be performed at Screening and Week  52/WD for all subjects. An SI joint x-ray will be performed ≤12 months prior to the Baseline 
visit.
mMagnetic resonance imaging of the spine and SI joints to be per formed at Screening and at the  Week 12 and at the Week 52/WD v isits if MRI was performed 
more than 12 weeks prior to WD visit.
nOcciput to wall distance; chest expansion; and BASMI, which inc ludes modified Schober test, late ral spinal flexion, cervical r otation, tragus to wall distance, 
and maximal intermalleolar distance.
oResource utilization includes: concomitant medical procedures, health care provider consultations  not foreseen by the protocol , hospitalizations/emergency 
room visits.
pContact IXRS to register the vis it and obtain next kit number, where applicable.
qAt on-site visit days (Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 24,  28, 32, 36, 40, 44, 48, and 50), the double-blind study treatm ents will be administered sc at the 
study site. At the Week 0, 2, 4, 6, and 8 visits, the administr ation must be done by dedicated, unblinded, and adequately tra ined site personnel. At the Week 10
and 12 visits, the subject will receive training on self-inject ion and the study treatment will be self- administered under the supervision of the unblinded study 
personnel. At Weeks 16, 20, 24, 28, 32, 36, 40, 44, 48, and 50,  the study treatment adminis tration should preferably be done by the unblinded study person nel, 
or alternatively by self-injection of the subject under the sup ervision of the unblinded study personnel. The double-blind stu dy treatment will be self- injected at 
home at Weeks 14, 18, 22, 26, 30, 34, 38, 42, and 46. From Week  52 onwards, after completion of  all onsite assessments and pro cedures, the subject may
receive open-label CZP at the discretion of the Investigator.
rAll subjects will receive training for self-injection at the st udy site on Weeks 10 and 12. Durin g the training at the Weeks 1 0 and 12 visits, the double- blind 
study treatment will be self-adm inistered under the supervision  of the unblinded study personnel.REDACTED licableicable
, 40, 4, 40, 4
ust be ust be 
nd the nd the 
he she s
COPYhobehob
vider cvider This 
document 
cannot 
be 
used 
to support upervperv
anystudstudy y
rvisiovis
marketing studtud
tudy treudy tre
ion of ton of 
Week 52 eek 52
authorizationconsuconsu
4, 48, 4, 48, 
done bdone b
dy tdy
application Week 12eek 12
test, lateest, la
t
and ray ray wiwi
any HHayaaany
extensions22io
s 
6633
88ioioioete
io
or 232
HHo
variations 
on
33vavaava
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 37 of 255Table  5‒2: Schedule of alternative study assessment with CZP - after subject discontinuation of the 
double-blind study treatment 
Visit # 1
wdt2
wdt3
wdt4
wdt5
wdt
Week
Protocol 
Activity0 2 4 6H 8H 10H 12 14H 16H 18H 20H 22H 24 and 
Q12W 
 52/WD
aFUa
Vital signsb X X X X X
Continue W24 assessments every 1 2 weeks until as close as possi ble to W52/WD of the 
original visit schedule. Subject will then be invited to the final assessment visit at 
W52/WDgX X
Hematology/ 
urine/biochemis
try Xc,dX X XdX
CRP X X X X X
Pregnancy 
testingeX X X
PEfX X X X X X
Extra -articular 
assessmentsX X X
TB testhX
TB 
questionnaireX X X X
BASMI & 
Spinal mobilityiX X X X X
BASDAI X X X X X
BASFI  X X X X X
SF-36 X X X X
AsQoL X X X X
MOS Sleep 
ScaleX X X X
EQ-5D X X X X
MASES X X X XREDACTED 
DCCCCTACED
COPY 
PYCOThis 
document 
ntcannot 
otananananan
be be
used 
dus
toto tosupport 
tporpppps
any a
marketing 
g
XX
tinmXmmmm
authorization 
atioriorioriorioria
application 
oncapppppap
and nd
any nyanynynyny
extensions 
sio22H22H
ssss
or 55or
variations 
onn of tn of t
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 38 of 255Table  5‒2: Schedule of alternative study assessment with CZP - after subject discontinuation of the 
double-blind study treatment 
Visit # 1
wdt2
wdt3
wdt4
wdt5
wdt
Week
Protocol 
Activity0 2 4 6H 8H 10H 12 14H 16H 18H 20H 22H 24 and 
Q12W 
 52/WD
aFUa
Total and 
nocturnal spinal 
painX X X X X
Swollen and 
tender joint 
countsX X X X X
Patient’s Global 
assessmentX X X X X
Investigator’s 
AS assessmentX X X X X
CZP plasma 
concentration/ 
anti-CZP Abs/ 
Biomarker  X X X X X X
Gene expression 
and proteomicsjX
Telephone 
contactkX X X
Prior and 
Concomitant 
medicationX X X X X X X
AEs X X X X X X X
IXRS X X X X X X X
CZP 
administration 
sc XlXlXlX X X X X X X X X XmREDACTED 
EDACAACACACA
COPY 
PYCOThis 
document 
eeeen
cannot X
XXllotan
be bebebebebe
used se
to tosupport 
tporup
any a
marketing m
gmmmam
authorization 
atorith
application 
ononononap
onapapapap
and 
any nyanynynyny
extensions 
sio22H22H
ssss
or 55or
variations 
onn of tn of t
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 39 of 255Table  5‒2: Schedule of alternative study assessment with CZP - after subject discontinuation of the 
double-blind study treatment 
Visit # 1
wdt2
wdt3
wdt4
wdt5
wdt
Week
Protocol 
Activity0 2 4 6H 8H 10H 12 14H 16H 18H 20H 22H 24 and 
Q12W 
 52/WD
aFUa
Abs=antibodies; AE=adverse event; AS=ankylosing spondylitis; As QoL=Ankylosing Spondylitis Quality of Life; BASDAI=Bath Ankylos ing Spondylitis 
Disease Activity Index; BASFI=Bath Ankylosing Spondylitis Functional Index; BASMI=Bath Ankylosing Spondylitis Metrology Index; CRP=C ̻reactive 
protein; CZP=certolizumab pegol; EQ -5D=EuroQoL Health Status Ques tionnaire (5 dimensions); FU= Fol low-Up; H=home, no site visit; HbA1c=glycated 
hemog lobin; IGRA=Interferon-Gamma Re lease Assay; IXRS=Interactive Re sponse System; MASES=Maastricht Ankylosis Spondylitis Enthesiti s Score; 
MOS=Medical Outcomes Study; PE=physical exam; Q2W=every 2 weeks ; Q12W=every 12 weeks; sc=subcutaneously; SF ̻36=Short ̻Form 36̻item Health 
Survey; SFE=Safety Follow -up Extension; W=Week; WD=Withdrawal; wdt=withdrawal treatment
Note: If a subject switches from open -label CZP to other treatment (including biologics), the subjec t must follow the assessment schedule ( Table 5 ‒3)for other 
treatment (including biologics)
Note: All weeks are ±3 days comp ared to Baseline. Week 0 of the  alternative schedule starts 2 weeks after the la st dose of the double-blind study treatment.
Note: At the completion of the Week 52 visit, subjects who tran sitioned to open -label CZP treatment after withdrawal from the Double- Blind Period are eligible 
to participate in the SFE Period.
aFU: 8 weeks after Week 52/WD visit for subjects not participati ng in the SFE Period.
bPulse rate, systolic and diastol ic blood pressures, temperature , and respiration rate are to be measured at wdt Week 0 therea fter pulse rate, sys tolic and diastolic 
blood pressures, temperature are  to be measured at all on-site visits. If a subject experience s an AE, respiration rate will b e measured in addition. 
cSubjects will be encouraged to be in fasting condition at the t ime the subject shifts to alternative treatment, for Apo A1, ApoB, and lipoprotein(a) assessments.
dHbA1c will be measured at wdt Week 0 and Week 52/WD.
ePregnancy testing must be carried out for women of childbearing  potential and will be a serum tes t at the FU visit and a urine  test (dipstick) at wdt Week 0 
(prior to initiation of open-label CZP) and Week 52/WD visit.
fIncludes evaluation of signs and s ymptoms of active TB and risk  factors for exposure to TB. Weight is to be measured at wdt We ek 0, Week 24, and at 
completion at Week 52/WD. 
gIf the last Q12W assessment for a subject who discontinues study treatment is ≤4  weeks before the final assessme nts visit at Week 52/WD, the a ssessment 
should be cancelled and the subject should instead be invited t o undergo the final assessments visit at Week 52 (the Week 52/WD  visit is to be scheduled 
52 weeks [±3 days] after Baseline).
hTB test: IGRA test (QuantiFERON test [or Elispot test when the QuantiFERON test is indicated but not available]). The TB test will be repeated at Week 52 
(or at WD visit if medically indicated) for subjects with previ ously negative TB test result.
iOcciput to wall distance; chest expansion; and BASMI, which inc ludes modified Schober test, lateral spinal flexion, cervical rotation, tragus to wall distance, 
and maximal intermalleolar distance.
jA separate informed consent will be obtained prior to gene expr ession and proteomic assessments, if applicable.
kA telephone contact will be made with the subject every 4 weeks  after the on-site visit (ie, at Weeks 8H, 16H, 22H, and every 4 weeks after Week 24 until 
Week 52/WD visit).
REDACTEDschedsche
openopen
in the in the
nd respnd resp
itsits
COPYwal twal 
ogics), gics
dThis 
document 
cannotsttancanc
nt will t will 
be mabe m
beed
pansipans
used t [or E[or E
d) for ) for
to nste
support TB aB a
discontiiscont
tead bead
any ariar
visit.visit.
andan
marketing piratirati
. If a subIf a su
e the subthe s
ring ping
authorization th
ule stale sta
label Cbel C
SFE PSFE P
ionio
application U= Fo= Fo
SES=MaES=M
eeks; sceeks; s
eatmentatmen
he subje sub
and of Lf L
ng Spong Spo
olloll
any nyLife; Lifeanynyny
extensions 
sio22H22H
ssss
or 55or
variations 
onn of tn of t
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 40 of 255Table  5‒2: Schedule of alternative study assessment with CZP - after subject discontinuation of the 
double-blind study treatment 
Visit # 1
wdt2
wdt3
wdt4
wdt5
wdt
Week
Protocol 
Activity0 2 4 6H 8H 10H 12 14H 16H 18H 20H 22H 24 and 
Q12W 
 52/WD
aFUa
lLoading dose of CZP 400mg at Weeks 0, 2, and 4 must be administ ered by dedicated site staff.
mCZP administration will be continued Q2W.  
REDACTED 
COPY This 
document 
cannot 
be 
used 
to support 
any 
marketing 
authorization 
application 
and 
any nyanynyny
extensions 
sio22H22H
ssss
or 55or
variations 
onn of tn of t
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 41 of 255Table  5‒3: Schedule of alternative study assessment with other treatment (including biologics) - after 
subject discontinuation of the double-blind study treatment 
Visit # 1  
wdt 2
wdt3
wdt
Week
Protocol Activity0 12 24 and Q12W  
Continue W24 assessments every 1 2 weeks until as close as possi ble to W52/WD of the 
original visit schedule. Subject will then be invited to the fi nal assessment visit at 
W52/WD ±4 weeks.d 52/WD FUa 
Hematology/urine/biochemistry Xb,c    
CRP X X X X 
Pregnancy testinggX X X
PE X  X 
BASDAI X X  X 
BASFI  X X  X 
Total and nocturnal spinal pain X X  X 
Swollen and tender joint counts X 
Patient’s Global assessment X X  X 
Investigator’s AS assessment X X  X 
CZP plasma concentration/anti-CZP Abs/ 
BiomarkerX X  X 
Prior and Concomitant medication X X X X X
AEs X X X X X 
IXRSeX X X X X 
Other treatment administration Xf Follow the regimen of the particular 
alternative treatment. Telephone contact 
to be performed on the discretion of the 
Investigator    REDACTED XXTEDACEDEDEDEDED
COPY 
PYPYPYPYPYCThis 
document 
cannot 
be euseused se
to support XX
Xorup
any an
marketing 
tinkem
authorization 
oioioiontioiza
XXthoa
application 
tiolicap
and ddndan
anyW52/W52/W
nt vistv i sextensions sit asit
sxte
or or
variations 
oncs) cs) -
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 42 of 255Table  5‒3: Schedule of alternative study assessment with other treatment (including biologics) - after 
subject discontinuation of the double-blind study treatment 
Visit # 1  
wdt 2
wdt3
wdt
Week
Protocol Activity0 12 24 and Q12W  
Contin
ue W24 
assess52/WD FUa 
Abs=antibodies; AE=adverse event ; Abs=antibodies; AE=adverse ev ent; BASDAI=Bath Ankylosing Spondylitis Disease Activity Index;  BASFI=Bath 
Ankylosing Spondylitis Functional Index; CRP=C ̻reactive protein; CZP=certolizum ab pegol; eCRF= electronic case report form; FU= Follow- Up; H=home, no 
site visit; IXRS=Interactive Response System; PE=physical exam;  Q12W=every 12 weeks; W=Week; WD=Withdrawal, wdt=withdrawal tr eatment
Note: All weeks are ±3  days compared to Baseline. Week 0 of the alternative schedule starts 2 weeks aft er the last dose of the double-blind study treatment.
Note: Local guidelines on initiation and monitoring of the part icular treatment should be followed.
aFU: 8 weeks after Week 52/WD visit.
bSubjects will be encouraged to be in fasting condition at the t ime the subject shifts to alternative treatment, for Apo A1, A poB, and lipoprotein(a) assessments.
cHbA1c will be measured at wdt Week 0.
dIf the last Q12W assessment for a subject who dis continues study treatment is ≤4 weeks before the final assessme nts visit at Week 52/WD, the assessment 
should be cancelled and the subject should instead be invited t o undergo the final assessments visit at Week 52/WD (the Week 5 2/WD visit is to be schedul ed 
52 weeks [±3 days] after Baseline).
eFor registration of visit only. Interactive Response System won 't assign any open treatment medication.
fFollow the regimen of the particu lar alternative treatment. Arr ange for additional site visits for administration and record t he treatment in the Concomitant 
Medication eCRF as appropriate.
gPregnancy testing must be carried out for women of childbearing  potential and will be a serum t est at the FU visit and a urin e test (dipstick) at wdt Week 0 and 
Week 52/WD visit.
REDACTEDe finae fina
gn any n any 
for adfor ad
pop
COPYo alteo alt
≤4 we≤4 we
lThis 
document 
cannot 
be 
used 
to support 
any 
marketing otential aential 
authorizationeks beeks be
assessmssessm
open tropen t
ditionaditiona
application afterfte
native trative 
f
andtronion
WD=WD=W
rtt
anytis Ditis D
nic cic
yyextensions ue Wue
assesasse
sxtee
or or
variations 
oncs) cs) -
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 43 of 255At any time during the study course, but preferably not before Week 12, the Investigator may 
discontinue the double-blind study  treatment and start open-labe l treatment with either CZP 
(which will be provided free of ch arge by UCB) or an alternativ e drug (eg, other treatment 
[including biologics]).
The determination by the Investigator to switch a subject from double-blind study treatment to 
either open-label CZP or other tre atment will generally be done  after the subject has completed 
the assessments at a given scheduled study visit. That study vi sit then becomes the withdrawal 
treatment (wdt) Week 0 visit of the  given alternative schedule of assessments. Since many of the 
assessments required at the wdt Week 0 visit may have already b een completed as part of the 
originally scheduled study visit, only those not already done a t that visit should be completed. 
Table 5 ‒4outlines which additional study assessments would be required a t wdt Week 0 for 
subjects switching to the open-label CZP alternative schedule, and Table 5 ‒5shows this 
information for subjects switching to the other treatment alter native schedule.
It may be possible that an Investigator determines that a subje ct should switch to the alternative 
schedule with either open-label C ZP or another treatment withou t initiating the alternative 
treatment at the study visit wh en this determination is made. I n this case, the subject will come 
back another day shortly thereaf ter to initiate the treatment a nd to complete all assessments 
outlined on the relevant alternati ve schedule of assessments (s ee Table 5 ‒4orTable 5 ‒5) for the 
wdt Week 0 visit. It is important then to schedule the wdt Week  0 and the subsequent on-site 
visits accordingly in order to end up at Week 52 with the same visit date as originally planned for 
the regular double-blind study course.
REDACTED COPY mem
he wdhe wd
with with
This document cannot be used to support any marketing authorizationdt
h the sthe sapplicationhis cahis ca
d to cod to co
s (see (seeT
t WeeWeeand sws
itiatintiatinany le.le
witchwitextensionst o
complompl
WeekWeek
showhow
eory
of thf thvariations wal al 
of thof ththereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 44 of 255Table  5‒4: Schedule of study assessments – additional assessments for wdt 0 visit required for subjects 
transitioning to open-label CZP  
Visit #a1/
BL 234567 8 9
H10 11
H12 13
H14 15
H16 17
H18 19
H20 21
H22 23
H24 25
H26 27
Week
Protocol Activity0 1 2 4 6 8 10 12 14 
/H 16 18 
/H 20 22 
/H 24 26 
/H 28 30 
/H 32 34 
/H 36 38 
/H 40 42 
/H 44 46 
/H 48 50 
Vital signs X X X X X X X X X
Hematology/urine/ 
biochemistry X X X X X X X X X X X X X X X X X X X
CRP  X X X X X X X X X X X X
Pregnancy testing   XXX X X X X X X X X X X X X X X X X X X X X
PE X X X X X X X X X X X X X X X X X X
TB questionnaire    XXX X X X X X X X X X X X X X X X X X
BASMI & spinal 
mobilityX X X X X X X X X X X X
BASDAI X X X X X X X X X X X X
BASFI X X X X X X X X X X X X
SF-36   XXX X X X X X X X X X X X X X X X X
ASQoL XXX X X X X X X X X X X X X X X X X
MOS Sleep Scale   XXX X X X X X X X X X X X X X X X X
EQ-5D   XXX X X X X X X X X X X X X X X X X
MASES X X X X X X X X X X X X X X X X
Total and nocturnal 
spinal painX X X X X X X X X X X X
Swollen and tender joint 
counts  XXX X X X X X X X X X X X X X X X X X
PhGADA X X X X X X X X X X X X
PGADA X X X X X X X X X X X XREDACTED 
DACTEDCTED
DDDAC
DEEXXACACACACE
ACREREEEEDRE
COPYOPY PYYOPXX
OOPOPOPOThis 
document 
ccanca
nonnot otnotannnnnonnonocaann
bbe ebbbbbbb
useded eduXXedededued
toXXtottosupport 
tportport
trt
X
uppoppopoup
XX
usuuuu
any XX
yy
Xa
marketingXX
gg g
XXtinrke
XXarrm
rm
thorization 
nnationation
na
nthXX
zatiatiaaatith
zaauthautthththththaa
application 
atioatiXXnio
XXatpliXX
plplplpla
andXXnd
anyanyanXXnyannn
extensions 2121
HHio
/HH3636sioiooxte
ioe
or orororor
variations 
ond for sfor s
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 45 of 255Table  5‒4: Schedule of study assessments – additional assessments for wdt 0 visit required for subjects 
transitioning to open-label CZP  
Visit #a1/
BL 234567 8 9
H10 11
H12 13
H14 15
H16 17
H18 19
H20 21
H22 23
H24 25
H26 27
Week
Protocol Activity0 1 2 4 6 8 10 12 14 
/H 16 18 
/H 20 22 
/H 24 26 
/H 28 30 
/H 32 34 
/H 36 38 
/H 40 42 
/H 44 46 
/H 48 50 
CZP plasma 
concentration/anti -CZP 
Abs/BiomarkerXXX X X X X X X X X X X X X X X X X X
IXRS  X X X X X X X X X
Study drug 
administration sc 
Abs=antibodies; ASQoL= Ankylosing Spondylitis Quality of Life ;BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; BASF I=Bath Ankylosing 
Spondylitis Functional Index; BASMI=Bath Ankylosing Spondylitis  Metrology Index; BL=Baseline; CRP=C reactive protein; CZP=certolizumab pegol; 
EQ̻5D=EuroQoL Health Status Questionnaire (5 dimensions); H=home; I XRS=Interactive Response System; MASES=Maastricht Ankylosis Spo ndylitis 
Enthesitis Score; MOS=Medical Outcomes Study; PE=physical exam;  PhGADA=Physician’s Global Assessment of Disease Activity; PGAD A=Patient’s Global 
Assessment of Disease Activity; sc=subcutaneously; SF ̻36=Short̻Form 36̻item Health Survey; TB=tuberculosis; wdt=withdrawal treatment  
aAdditional assessments to be perf ormed correspond to the assess ments to be performed at wdt Week 0. REDACTEDRS=InRS=I
GADAGADA
m 36m 36̻
smentssment
COPYnkylosnkylos
Index; ndex;
ntt
YPY This 
document 
cannot 
be 
used 
to support 
any 
marketing 
authorizationBL=BBL=
eractivractiv
=PhysPhys
item Htem H
to be to be 
application 
tiotiXXioppliplicatioicati
ootioioopli
io
ng Spong Spo
Bapppp
and ndann
anyXXny
extensions 2121
HHio
/HH3636sioiooxte
ioe
or orororor
variations 
ond for sfor s
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 46 of 255Table  5‒5: Schedule of study assessments – additional assessments for wdt 0 visit required for subjects 
transitioning to alternative treatment  
Visit #a1/
BL 23456 7 8 9
H10 11
H12 13
H14 15
H16 17
H18 19
H20 21
H22 23
H24 25
H26 27
Week
Protocol Activity0 1 2 4 6 8 10 12 14 
/H 16 18 
/H 20 22 
/H 24 26 
/H 28 30 
/H 32 34 
/H 36 38 
/H 40 42 
/H 44 46 
/H 48 50 
Hematology/urine/ 
biochemistry X X X X X X X X X X X X X X X X X X X 
CRP  X X X X X X X X X X X X 
PE  X X X X X X  X X X X X  X X X X X X X 
BASDAI X X X X X X X X X X X X 
BASFI X X X X X X X X X X X X 
Total and nocturnal 
spinal painX X X X X X X X X X X X 
PhGADA X X X X X X X X X X X X 
PGADA X X X X X X X X X X X X 
IXRS X X X X X X X X X 
BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; BASF I=Bath Ankylosing Spondylitis Functional Index; BL=Baseline; CR P=C reactive protein; 
H=home; IXRS=Interactive Response System; MOS=Medical Outcomes Study; PE=ph ysical exam; PhGADA=Physician’s Global Assessment of Disease 
Activity; PGADA=Patient’s Global Assessment of Disease Activity ; sc=subcutaneously; wdt=withdrawal treatment  
aAdditional assessments to be perf ormed correspond to the assess ments to be performed at wdt Week 0.REDACTED 
TETEDACTEACTE
TETEEA
TE
XXDACACAAACDA
XXEDRR
COPY 
YYOPYOPY
YO
Y
XXCOOOOOPCOThis 
document 
cannot 
be 
used 
to support 
anythe asthe a
marketing
ingng tinASFI=BASFI=
Outcomeutcom
tivity;ivity
tintinin
autauthXXthorization 
nnizationatioXXnnniz
on
XX
rizzizizizat
rizttthautaaa
application XXnatiplicatplicat
atatatp
at
XXpplplppplppa
and X
andndnnndan
any XXan
extensions 211
HHsio
H3636
sisiosioext
sioe
or oooro
variations 
ond for sfor s
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 47 of 255Table  5‒6: Schedule of study assessments - Safety Follow-Up Extension Period  
Visit # 29 30 31 32 33 34 35 36 37 38 39 40
Overall Study Week/SFE Week
Protocol Activity52/0a54/2 56/4 64/12 76/24 88/36 100/48 112/60 124/72 136/84 148/96 156/104/SFE-
WD 
Informed consentbX   
CRP   X
BASDAI   X
BASFI   X
ASQoL   X
Total and nocturnal spinal pain   X
PGADA   X
MRI SI joints   X
AEs X X X X X X X X X X X 
IXRScX X X X X X XX  XX  XX
Study drug loading dose 
administration scd XX X         
Study drug dispensationeXX X X X X X X X
AEs=adverse events; ASQoL=Ankylosing Spondylitis Quality of Lif e; BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; B ASFI= Bath 
Ankylosing Spondylitis Functional Index; CRP=C -reactive protein; CZP=certolizum ab pegol; FU=Follow-Up; IXRS=I nteractive Response System; 
MRI=magnetic resonance imaging; PGADA=Patient’s Global Assessme nt of Disease Activity; sc=subcutaneously; SFE=Safety Follow -Up Extension; 
SI=sacroiliac; WD=Withdrawal 
aAssessments performed at the Week 52 Visit for subjects who com pleted the previous Double-Blind Period are in Table 5 ‒1; Assessments performed at the 
Week 52 Visit for subjects who tr ansitioned to open-label CZP t reatment after withdrawal from the Double-Blind Period are in Table 5 ‒2.
bA separate informed consent form will be obtained from subjects  consenting to particip ate in the SFE Period.
cContact IXRS to register the visit an d obtain next kit number, where applicable, or to indicate that  the subject has completed the SFE Period or withdrawn from 
the study.
dAt Weeks 52, 54, and 56, study t reatment administration should be performed at the site by unbli nded study personnel in order to keep the blind (see 
Section 7.2.1).
eStarting at Week 52 for subjects completing open- label CZP treatment and the Week  52 Visit, dispense the assigne d study medication to the subject for use at 
home, as appropriate.
REDACTED 
DXX
DDDD
XXCTDADDADAD
COPY 
YCOCThis 
document 
cannot tretr
ubjectsbjects
be eatmeatm
usede obtob
obtainobtain
to to oto o
btaibtai
support GlobGlo
or subjer subje
openop
any y oy 
e protee prot
obalba
maof Liof Lmarketing 
etiXX
ketetetema
authorization 
nnnnn
XXatoooorhoau
application 
nioatpp
and nd
any nynynynyny
extensions 11onsex
or 3838o
variations 
onva
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 48 of 2555.3 Schematic diagram 
Figure 5 ‒1: Schematic diagram for subjects completing the double-blind study treatment 
ASDAS-MI=Ankylosing Spondylitis Disease Activity Score major im provement; axSpA=axial spondyloarthritis; BL=Baseline; CRP=C-re active protein; 
CZP=certolizumab pegol; FU=Follow-Up; mNY=modified New York cri teria; MRI= magnetic resonance imaging; N=number of subjects; P I=Principal 
Investigator; Q2W=every 2 weeks (every other week); SCR=Screenin g; TNFi=tumor necrosis factor-alpha inhibitor; WD=withdrawal
N=150
N=150
CZP 200mg Q2W
Placebo
Double Blind
::HHN%/)
SCR
axSpA Subjects 
mNY-negative
MRI+ / CRP+MRI+ / CRP-
MRI -/ CRP+
ASDAS-MI 
Week 52/WD 
FU
Week 12
xCZP administered at the dose of 400mg at Weeks 0, 2, and 4 foll owed by 200mg Q2W (starting 
at Week 6 up to and including Week 50).
xAdjust background medication at any time upon discretion of the  PI, but preferably not before 
Week 12 and within 4 weeks prior to Weeks 24 and 52. 
xAt the discretion of the Investigator or the subject, the subje ct may be withdrawn from the 
study treatment at any time. In any case, the Investigator shou ld encourage the subject to 
perform the remaining study visits according to the appropriate  alternative Schedule of Study 
Assessments and the scheduled visit window. 
xAt the discretion of the Investigator, the subject may be treate d further with CZP or other TNFi 
after the study medication was discontinued.
Week 24
 Week 6
CZP 400mg
DACTED 
D
ACTEDDACAC
REDA
e dose
e dose
d
COPOPYOP
PY 
CCThis 
document ; F;
ery 2ry 2
cannot ondyliondyli
FU=FFU=F
tot
tb
be
a
used 
e
At th
At th
af
f
to
ssme
ssm
support 
ion o
on o
tment 
ment 
 a
m the re
the r
any
n 4 
n 4
of t
of
marketing 
e of 4
of 4
ding W
ing W
medicati
edicat
4w e
4w
tion thorizatio
tio
thorizat
P
Puthth
aut
40
40
application applicatioapplicatio
applicat
ZP 200
P 200
anandan
nd 
y
any 
extensions eex
e
or 
variations 
on
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 49 of 255Figure 5 ‒2: Schematic diagram for subjects discontinued from the double-blind study treatment 
Scenario A: The subject initiates treatment with CZP for treatme nt to be supplied to discontinued subjects
W0/BL W52/WD
randomized treatment (CZP or PBO) Open -label treatment with CZP
SCRLoading 
dose200 mg Q2W (open) FU
 
At the discretion of the PI the double-blind study treatment is  
discontinued and treatment with CZP is initiated. The new treat ment 
shall continue through to Week 52 of the regular visit schedule .
Scenario B: The subject initiate s treatment with other treatmen ts (including biologics)
W0/BL W52/WD
randomized treatment (CZP or PBO) open other treatment  
SCR other treatments (including biologics) (open) FU
 
At the discretion of the PI the double-blind study treatment is  
discontinued and treatment with other treatments (including bio logics) 
is initiated. The new treatment shall continue through to Week 52 of the 
regular visit schedule.
BL=Baseline; CZP=certolizumab pe gol; FU=Follow-Up; PBO=placebo;  PI=Principal Investigator; Q2W=every 2 weeks (every other week ); SCR=Screening; 
W=week; WD=withdrawal
REDACTEDar visiar vis
ments (ments 
COPY atmentatment
new new This 
document walal
cannot zumabumab
l
bed. Thd. Th
usedetiontion
and tand t
to n
support
rt portporrtpo
anyany ot
marketing other trother mma
authorizationtreatmreatm
t schedt sched
(inclu(inclu
applicatio
tion tio
is s 
and and
any aa
extensions De
or 
variations 
onentent
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 50 of 255Figure 5 ‒3: Schematic diagram for subjects completing the double-blind study treatment and rolling over to the 
SFE Period  
             
  W0/BL    W52/SFE-W0    W156/SFE-
W104/SFE -WD  
  randomized treatment (CZP or PBO)        
 SCR Double-Blind Period   Open-Label SFE Period     
             
             
             
BL=Baseline; CZP=certolizumab pego l; FU=Follow-Up; SFE=Safety E xtension; PBO=placebo; SCR=Screening; SFE=safety Follow-Up Exte nsion; W=week; 
WD=withdrawal
Note: Subjects who complete either double-blind treatment or op en-label CZP-treatment and all assessments at Week 52 are eligib le to roll-over to the SFE 
Period. Subjects who complete alternative treatment must finish  the study at Week 52 and be sch eduled for the final FU visit ( 8 weeks after the Week 52 Visit).REDACTED ExtensExten
COPY This 
document 
cannot 
be 
used 
to support 
any 
marketing n--label label
h the stuthe st
authorization sion; Pon; P
application 
atatat
and d
any annn
extensions 
or 
variations 
onrollinrollin
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 51 of 2555.4 Rationale for study design and selection of dose 
The current study will evaluate  nr-axSpA subjects receiving eit her CZP or placebo in 
combination with standard of care for a duration of 52 weeks. Th is is a unique study design to 
achieve an understanding of the natural history of nr-axSpA and  to support the assumption that 
treatment with a TNFi is necessary in this group of subjects. T he lack of a mandatory escape arm 
for placebo subjects is balanced by the ability of the Investiga tors to modify background 
medications (NSAIDs, corticoster oids, analgesics, and SAARDs) d uring the course of the study. 
If the Investigator determines th at a subject should be treated  with other medicines (including 
biologics), the study medication will be discontinued and subje cts will be asked to continue to 
come to the office for study visits to track their response to other treatments. If the Investigator 
choses to withdraw subjects on the other therapy, the local gui delines on initiation and 
monitoring of the particular t reatment should be followed.
In accordance with prescribing information for CZP, 3 loading do ses of 400mg Q2W should be 
administered upon initiation of t herapy. Thus all subjects who withdraw from double-blind 
treatment prior to Week 52 and transition to open-label CZP wit hin the AS0006 study will 
receive this loading dose prior to the maintenance dose of 200m g Q2W. It is recognized that 
some subjects would have been on active CZP prior to transition  to open-label CZP. However, 
this dosing approach is justified in all transitioning subjects  as there will be no change in benefit-
risk due to administration of loading dose and the blinding wil l be maintained in the study, 
preserving the data integrity.
The enrollment criteria will  result in the following subgroups based on MRI and CRP:
x MRI+/CRP+
x MRI+/CRP-
x MRI-/CRP+
This 3-level MRI/CRP classifi cation variable will be used as a stratification factor in the 
randomization to ensure balance across these subgroups. Taken t ogether, these 3 subgroups 
encompass the nr-axSpA subject population that would benefit mo st from anti-TNF therapy and 
who have the most limited treatment options.  
6 SELECTION AND WITHDRAWAL OF SUBJECTS 
6.1 Inclusion criteria 
To be eligible to participate in this study, all of the followi ng criteria must be met:
1. An Institutional Review Board  (IRB)/Independent Ethics Committe e (IEC) approved written 
Informed Consent form is signed and dated by the subject or leg al representative. The 
2. Subject/legal representative is considered reliable and capable  of adhering to the protocol 
(eg, able to understand and compl ete questionnaires), visit sch edule, or medication intake 
according to the judgment of the Investigator.
3. Subject is at least 18 years old at the Screening visit.REDACTED followfollowCOPYo t
subjesubje
e bline blin
This documentII
2.2cannotligibgib
An InAn In
nfbe llusedSELEL
InInto LELEsupport alanclanc
A subjeA sub
mited mitedanycatiocatio
cecemarketing authorizationndingnding
wing suwing suapplication hin thn th
mg Q2mg Q
sition tition 
cts as tts as
wandf 4f4
raw faw f
heheany 400m400mextensionsontinontin
he Invee Inve
ation aion aorudinudivariations m 
studystudythereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 52 of 2554. Female subjects must be either postmenopausal for at least 1 ye ar, surgically incapable of 
childbearing, or effectively practicing an acceptable method of  contraception (either 
oral/parenteral/implantable horm onal contraceptives, intrauteri ne device, or barrier and 
spermicide). Abstinence only is not an acceptable method. Subje cts must agree to use 
adequate contraception during t he study and for at least 10 wee ks (or [for participating 
countries of the EU –5 months in accordance with the S ummary of Product Characteristi cs, 
SPC] longer if required by local regulations) after the last do se of study treatment. Male 
subjects must agree to ensure they or their female partner(s) u se adequate contraception 
during the study and for at least 10 weeks (or [for participatin g countries of the 
EU - 5 months in accordance with the SPC] longer if required by l ocal regulations) after their 
last dose of study treatment.
5. Subjects must have a documented diagnosis of adult-onset axSpA and meet the ASAS 
criteria for axSpA (not including family history and good respo nse to NSAIDs; see 
Appendix 18.1).
6. Subjects must have had back pai n for at least 12 months before Screening.
7. Subjects must NOT have sacroiliiti s defined by mNY criteria (see  Appendix 18.2) (bilateral 
≥Grade 2; unilateral ≥Grade 3) on SI joint x -rays (based on central reading of x-rays, within 
the last 12 months from Baseline).
8. Subjects must have active disease as defined by each of the fol lowing at Screening and 
Baseline:
 BASDAI score ≥4
 Spinal pain ≥4 on a 0 to 10 NRS (from BASDAI item 2)
9. Subjects must have a combina tion of current evidence of sacroil iitis on the screening MRI as 
defined by ASAS/OMERACT scoring confirmed via central reading (M RI+) and CRP either 
>upper limit of normal (ULN) or ≤ULN (for CRP the ULN is define d as the ULN indicative 
for inflammatory disease) at Baseline (CRP+  or CRP-), or no evi dence of sacroiliitis on the 
screening MRI (MRI-) and CRP >ULN (CRP+) as follows:
 MRI+/CRP+
 MRI+/CRP-
 MRI-/CRP+
10. Subjects must have had an inade quate response to, have a contra indication to, or have been 
intolerant to at least 2 NSAIDs.  Inadequate response to an NSAI D is defined as lack of 
response to at least 14 days of continuous NSAID therapy at the highest tolerated dose of the 
administered NSAID.
6.2 Exclusion criteria 
Subjects are not permitted to enroll in the study if any of the  following criteria is met:
1. Subject has previously participated in this study or subject has  previously been assigned to 
treatment in a study of the medication under investigation in t his study.REDACTED d b
NRS (NRS (COPY bab
by eby e
This documentaa
66cannotectsects
ntoleraolera
resprespbe /
smsmused RPP--
CRPCRPto supporte) )
) and ) andanyN) oN) 
at Baat Bamarketing (fromfrom
n of cun of c
scorinscori
or ≤orauthorization each oach o
mmapplication e S
ria (seeia (se
d on cenon ceand ScreecreeanyNSANSAextensionsns) afns) a
eet theet the
AIAIor variations ,
n thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 53 of 2552. Subject has participated in another study of an investigational  medicinal product (IMP) (or a 
medical device) within the previ ous 3 months (or 5 half-lives, whichever is greater) or is 
currently participating in another study of an IMP (or a medica l device). 
3. Subject has history of chronic alcohol abuse or drug abuse with in the last year.
4. Subject has any medical or psychiatric condition that, in the o pinion of the Investigator, 
could jeopardize or would compromise the subject’s ability to p articipate in this study.
5. Subject has a known hypersensitivity to any components of the I MP or comparative drugs as 
stated in this protocol.
Axial SpA-disease-related exclusions
6. Subjects must not have AS or any other inflammatory arthritis ( eg, RA, systemic lupus 
erythematosus, or sarcoidosis).
7. Subject must not have fibromyalgia.
8. Subjects must not have a secondary, noninflammatory condition ( eg, osteoarthritis) that in 
the Investigator’s opinion is symptomatic enough to interfere w ith evaluation of the effect of 
study drug on the subject’s primary diagnosis of axSpA.
Prior medications exclusions
9. Subjects must not have used the following medications in the ma nner as detailed by the 
exclusion criteria in the following table (see Table 7 ‒1).
Previous clinical studies and previous biological therapy exclus ions
10. Subjects must not have received any nonbiological therapy for a xSpA not listed in Table 7 ‒1
within or outside a clinical st udy in the 3 months or within 5 half-lives prior to the Baseline 
visit (whichever is longer).
11. Subjects must not have received any experimental biological age nts (defined as those agents 
unlicensed for use in axSpA in Europe or the USA).
12. Subjects must not have received previous treatment with a PEGyl ated compound that 
resulted in a severe hypersensitivity reaction or an anaphylact ic reaction.
13. Subjects may not have been exposed to more than 1 TNFi prior to  the Baseline visit and may 
not be a primary failure to any TNFi therapy (defined as no res ponse within the first 
12 weeks of treatment with the TNFi).
Medical History Exclusions
14. Female subjects who are breastfeeding, pregnant or plan to beco me pregnant during the study 
or within 3 months following the final dose of the investigatio nal product.
15. Subjects with a history of chroni c or recurrent infections (mor e than 3 episodes requiring 
antibiotics or antivirals during the preceding year), recent se rious or life –threatening 
infection within the 6 months prior to the Baseline visit (incl uding hospitalization for any 
infection in the last 6 months or a ny current sign or symptom t hat may indicate an infection).REDACTED ing meng me
ble (sele (se
revioureviouCOPY axSpaxS
This document14.14.FFcannotweekweek
MediMedbea pria pri
kkused evev
may nmay novereveresupport recec
axSpAaxSp
havehave
hany ceiveceivmarketingus bs b
any nonany no
dy in thy in tauthorization edicatdicat
ee e TabTab
biobioapplicationtion (eion (
fere witere w
A.and any extensions ystemystemor uvariations ugs ugs thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 54 of 25516. Subjects with a history of herpe s zoster infection within 6 mon ths prior to the Baseline visit.
17. Subjects with known TB infection, at high risk of acquiring TB infection, or LTB infection 
are excluded.  
a. Known TB infection whether present or past is defined as:
i) Active TB infection or clinical signs and symptoms suspicious  for TB (pulmonary or 
extra-pulmonary)
ii) History of active TB infection involving any organ system or  findings in other organ 
systems consistent with TB infection
iii) Any evidence by radiography or other imaging modalities con sistent with previously 
active TB infection that is not reported in the subjec t’s medical history.
b. High risk of acquiring TB infection is defined as:
i) Known exposure to another person with active TB infection wit hin the 3 months prior 
to Screening
ii) Time spent in a healthcare delivery setting or institution w here individuals infected 
with TB are housed and where th e risk of transmission of infect ion is high.
c. Latent TB infection (unless appropriate prophylaxis is initiate d prior to study treatment and 
continued to completion of prophylaxis). Please refer to Sectio n 12.6.3 for further details and 
instructions.
18. Subjects with concurrent acute or chronic viral hepatitis B or C or with human 
immunodeficiency virus (HIV) infection.
19. Subjects with history of or curren t active infection with Histo plasma, Coccidiodes, 
Paracoccidioides, Pneumocystis, nontuberculous mycobacteria  (NTMB), Blastomyces, or 
Aspergillus.
20. Subjects must not have a history of an infected joint prosthesi s at any time.
21. Subjects receiving any live (inc ludes attenuated) vaccination w ithin the 8 weeks prior to 
Baseline (eg, inactivated influenza and pneumococcal vaccines a re allowed but nasal 
influenza vaccination is not permitted).
22. Subjects who in the Investigator’s opi nion have a high risk of infection (eg, subjects with leg 
ulcers, indwelling urinary catheter, persistent or recurrent ch est infections, and subjects who 
are permanently bedridden or wheelchair bound).
23. Subjects with a history of a lymphoproliferative disorder inclu ding lymphoma or current 
signs and symptoms suggestive of lymphoproliferative disease.
24. Concurrent malignancy or a history of malignancy (subjects with  less than 3 excised basal 
cell carcinomas or with cervical ca rcinoma in situ successfully  surgically treated more than 
5 years prior to Screening may be included).
25. Subjects with Class III or IV congestive heart failure as per t he New York Heart Association 
(NYHA) 1964 criteria.REDACTED lealea
hronic hronic
nfectionfectio
ttCOPY ranra
ylaxisylaxi
ase rase r
This documents
2424cannotpermerm
Subjeubje
sigsigbeindwindw
mamaused who inho in
wewetonatinatisupport a h
ny liveny liv
tivatedivated
onany historhistormarketing on
active active 
s, nontu nonauthorization s isis
refer tefer t
viral viral 
napplication ution wtion 
missionission
s initiniandon wn wany withitextensions with pwith p
story.tory.orer oer ovariations or r 
orgorgthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 55 of 25526. Subjects with a history of, or suspected, demyelinating disease  of the central nervous system 
(eg, multiple sclerosis or optic neuritis).
27. Subjects having had major surgery (including joint surgery) wit hin 8 weeks prior to 
Screening, or having planned surgery within 6 months after ente ring the study.
28. Subjects with a current or recent history, as determined by the  Investigator, of severe, 
progressive, and/or uncontrolled re nal, hepatic, hematological,  endocrine, pulmonary, 
cardiac, or neurological disease. 
29. Subjects with significant laboratory abnormalities, including b ut not limited to: 
 liver function tests >2.0xULN
 estimated Glomerular Filtration Rate as measured by Chronic Kid ney Disease 
Epidemiology Collaboration (CKD-EPI; Levey et al, 2009) <60mL/m in/1.73m2
 white blood cell ([WBC] <3.0x109/L).
30. Subjects with any other conditi on which, in the Investigator’s judgment, would make the 
subject unsuitable for inclusion in the study.
6.3 Withdrawal criteria  
Subjects are free to withdraw from the study at any time, witho ut prejudice to their continued 
care.
Subjects should be withdrawn from the study if any of the follo wing events occur:
1. Subject develops an illness that would interfere with his/her c ontinued participation.
2. Subject is noncompliant with the study procedures or medication s in the opinion of the 
Investigator.
3. Subject withdraws his/her consent.
4. There is confirmation of a pregnancy during the study, as evide nced by a positive pregnancy 
test (see Section 12.1.6 for more information regarding pregnancies).
5. The Sponsor or a regulatory agency requests withdrawal of the s ubject.
6. Subject’s subsequent TB test was confirmed positive or any furt her evidence is suggestive of 
potential TB infection (eg, exposure). Refer to Section 12.6.3 for further details and 
instructions.
Subjects should be withdrawn from the study-treatment if,
7. The Investigator decides to ini tiate an alternative treatment  due to an unsatisfactory response 
to the study treatment, or
8. Subjects take any of the prohibited medications in Table 7 ‒1and Section 7.8.2
If a subject is withdrawn from the double-blind study treatment , the Investigator should 
encourage the subject to continue  participation in the study in accordance with the appropriate 
alternative schedule of study assessments ( Table 5 ‒2orTable 5 ‒3). The treatment that the 
subject receives following withdrawal of study medication is at  the discretion of the Investigator, REDACTED udy if udy if 
ould inould 
es t ues t uCOPY ny timny tim
This documenttot
88cannotcts shos sho
The The betionsonusedbseqseq
TB infTB in
sto quequesupport f a a
66for for
regularegulany nn
pregpremarketing udy prudy pr
nsent.sentauthorizationme, we, w
f any oany o
nterfeterfeapplicationjudgud
withwithand dgmdgmany/mi/mextensions DiseaDisea
min/in/or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 56 of 255with open-label CZP available as a treatment option according t o the local requirement mandated 
in the region. UCB will provide this medication free of charge.  Alternatively, the Investigator 
may treat the subject with other treatments (including biologic s) as deemed appropriate by local 
regulations. If the Investigator chooses to withdraw subjects on  the other therapy, the local 
guidelines on initiation and monitoring of the particular treat ment should be followed.
Investigators should contact the Medical Monitor, whenever poss ible, to discuss the withdrawal 
of a subject from the double-blind study treatment in advance. The reason for discontinuation of 
the double-blind study treatment must be recorded in the case r eport form (CRF) as appropriate.
Although the subject may be withdrawn from the double-blind stu dy treatment at any time, every 
effort should be made to retain the subject in the study and en courage compliance of the subject 
with the scheduled study visits. For subjects who fail to retur n to study visit(s) or are considered 
lost to follow up, the Investigator should specifically communi cate (at least 1 phone call and 
1 written message to the subject ), and document his/her effort ( date and summary of the phone 
call and copy of the written message in the source documents). In case the attempts to direct 
contact the subject fail, the Investigator is encouraged to gain  information about the wellbeing of 
the subject at the end of the regular visit schedule (Week 52/W D) from other sources in 
compliance with local regulations. All results of observations and communication with the 
subject, including and not limited to the relevant information on his/her wellbeing, must be 
recorded in the source documents.  
If a subject is withdrawn from the study, the narrative descrip tion of the reason(s) for removing 
the subject must be recorded in the source documents. The CRF m ust document the primary 
reason for withdrawal.
Subjects withdrawn from the study will not be replaced.  
6.4 Eligibility for the SFE Period 
To be eligible to participate in the SFE Period, subjects on do uble-blind study treatment and 
subjects who withdrew from double-blind study treatment and tra nsitioned to open-label CZP 
treatment must complete all of the Week 52 visit assessments. S ubjects on alternative treatments 
are not eligible to participate in the SFE Period. 
Eligible subjects are allowed to roll-over to the SFE-Period up  to 3 months after completion of 
the Week 52 assessments.
Prior to initiating the SFE asse ssments, all subjects will be a sked to read and sign a separate 
informed consent form.
Questions concerning the eligibi lity of a subject to continue p articipation in the study should be 
made in consultation with the Medical Monitor.
7 STUDY TREATMENTS 
7.1 Description of investigational medicinal product(s) 
The IMP (double-blind study treatment: CZP or placebo), will be  supplied under the 
responsibility of the UCB Clinical Supply Unit. The frequency a t which IMP will be supplied to 
each individual center will be ada pted to the recruitment capac ity of that center and to the expiry 
date of the IMP and will be manag ed by the interactive response  system (IXRS).REDACTEDnarranarra
documdocum
will nwill nCOPYormaorma
atii
This document a
77cannot c
tions cons 
de ine inbeat
onseonseused essmssm
ting ting to e ale al
memesupport ll of l of
cipate ipate 
allowllowanydoubledoubl
ft hftmarketing not beot b
SFE SFE
 SFESFEauthorization ive deve de
mentsments
beapplicationrm
D) fromD) fro
s and cs and 
ion on on onande thethe
matioatioanyummumm
ea teaextensionsy timtim
e of thof th
or areor ar
1 phophoor opropvariations al l 
on of n of 
priatpriatthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 57 of 255Drug supplies will consist of the following:
Certolizumab pegol is supplied as a sterile, clear, colorless t o slightly yellow liquid solution with 
a pH of approximately 4.7 in 1mL single use glass prefilled syr inge (PFS) with a 25G ½ inch 
thin wall needle for sc inject ion. Each syringe contains an ext ractable volume of 1mL at a 
concentration of 200mg/mL of CZP in 10mM sodium acetate buffer and 125mM sodium 
chloride as a tonicity agent.
Placebo is supplied in a PFS with a 25G ½ inch thin wall needle , containing an injectable volume 
of 1mL 0.9% saline for single use.
Due to the difference in presentation and viscosity between CZP  and placebo, special precautions 
will be taken in order to ensure maintained blinding of the stu dy (unblinded/blinded site 
personnel and monitors).
7.2 Treatment(s) to be administered 
Treatments to be adm inistered are as de scribed in Section 5.1.
7.2.1 Treatment administration 
A pharmacy manual will be provided to each site containing inst ructions regarding drug 
preparation and dosing. The injec tion schedule through Week 52 is presented in Figure 7 ‒1. The 
injection schedule for the SFE Period is presented in Figure 7 ‒2.
At on-site visit days (at Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 2 4, 28, 32, 36, 40, 44, 48, and 50), the 
double-blind study treatments will  be administered sc at the st udy site. At the Week 0, 2, 4, 6, 
and 8 visits, the administration must be done by dedicated, unb linded, and adequately trained site 
personnel. At the Week 10 and 12 visits, the subject will recei ve training on self-injection and 
the study treatment will be self-administered under the supervi sion of the unblinded study 
personnel. At Weeks 16, 20, 24, 28, 32, 36, 40, 44, 48, and 50,  the study treatment administration 
should preferably be done by the unblinded study personnel, or alternatively by self-injection of 
the subject under the supervision of the unblinded study person nel. The double-blind study 
treatment will be self-injected at home at Weeks 14, 18, 22, 26 , 30, 34, 38, 42, and 46.
Injections should be administered with a minimum of 10 days bet ween the CZP 200mg Q2W 
injections.
During the SFE Period, CZP will be administered sc by dedicated  unblinded study personnel at 
the study site on Weeks 52, 54, and 56 for subjects completing double-blind treatment in order to 
maintain the blind. Subjects who complete the Week 52 Visit on p lacebo treatment will receive 
loading doses of CZP 400mg at these visits. Subjects who comple te the Week 52 Visit on CZP 
treatment will receive 1 injection of CZP 200mg and 1 injection of placebo at these visits to 
continue their previous CZP treatment regimen.
Subjects who withdrew from double-blind study treatment and tra nsitioned to open-label CZP 
treatment do not need to visit the site at Week 54 and Week 56,  and should continue their 
open-label CZP treatment regimen.
For the remainder of the SFE Per iod, CZP can be administered at  the site by dedicated study 
personnel, or by self-injection of the subject under the supervi sion of the dedicated study 
personnel, or subjects may self-admi nister their study treatmen t Q2W at home. REDACTED0, 120, 12
ministeiniste
 done done 
isits, tisits, t
nisniCOPYugh Wugh W
d in d in FiF
This documentontionti
SuSucannotg dosedose
tment ment
tinuinubehe blhe blusedPeriPeri
on Won Wto supportted aed 
dministminianyon ofon o
at hatmarketingthe she 
stered stered 
, 32, 3632, 3
unblinunbli
ftauthorizationigurgur
, 16, 2, 16, 2
ered scred sc
e by deby d
susuapplication instruinstru
Week 52eek 5
rere77and any extensions ial preial pre
nded sided sor variations volumvolumthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 58 of 2557.2.2 Study AS0006 injection schedule 
Figure 7 ‒1: Injection schedule through Week 52 
CZP=Certolizumab pegol; H=home
REDA
DA
CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCTEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
COPY This all
document 
cannot 
be 
used 
to support 
any 
marketing 
auth
uthori
zzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaation 
appl
iiiiicccccaaaaaaaattttiiiiooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooonnnnnnnnnnnnnnnnnnn 
aaannnddd 
aaannnnnnnnnnnnnnnnnnyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyy 
eeexxxxxtteeeennnnssssiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooonnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnns or 
orvariations 
on
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 59 of 255Figure 7 ‒2: Injection schedule for the SFE Period   
CZP=Certolizumab pegol; FU=follo w-up; H=home; SFE=Safety Follow -Up Extension; W=week
* Subjects who complete either double-blind treatment or open-l abel CZP-treatment and all asse ssments at Week 52 are eligible t o roll-over to the SFE Period. 
Subjects who complete alternative treatment must finish the stu dy at Week 52 and be scheduled f or the final FU visit (8 weeks a fter the Week 52 Visit).
** Subjects rolling over from open-label CZP-treatment to the SF E Period can self-administer their study medication at home fro m Weeks 2 to 10.
*** Subjects will complete the study assessments at Week 52 acc ording to the protocol and be invited for the final FU visit 8 weeks after Week 52.W 5 0  HHHHHHHHH
week and before SFE-W 0 2 4 6 - 10 12 14-22 24 26-34 36 38-46 48 50-58 60 62-70 72 74-82 84 86-94 96 98-102 104
● ● ●●●●●●●●●●●●●●●●●●
○○
○ ● ●●●●●●●●●●●●●●●●●●
●●
● ●●●●●●●●●●●●●●●●
according to the 
assigned treatment regimenCZP        
200 mg
Placebo●
○Safety Follow-up Extension Double-blinded
●
●W52*
open other 
treatment***● open CZP 
200 mg● **
REDFolloFollo
ED
ACCCCCCCCCCCCCTTTTTTTTTTTTTEEEEEEEEEEEEDDDDDDDDDDDDD 
PY Y
CCCCCCCCOPPPYYYThis all
document 
cannot 
be 
used 
to support 
any2 acc2 ac
marketingww-Up Up
CZPCZP-t
dy at Wdy at W
SFE PeSFE P
corc
au
aut
hhhhhhhhhhhhhooooooooooooorrrrrrrrrrrrriiiiiiiiiiiiizzzzzzzzzzzzzaaaaaaaaaaaaatttttttttttttiiiiiiiiiiiiiooooooooooooon application 
licatioliclic
tiotioontiolicpp
aaappp
andandddddda
any yyayyyyananaa
xtensions 
ssion
nsexte●
●
ss
nsnsnsnssenenxtexte
oror -8-8rroo
variations 
on
8282
arararivava
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 60 of 2557.3 Packaging 
Certolizumab pegol and placebo are packaged and labeled accordi ng to Good Manufacturing 
Practice (GMP) guidelines and applicable laws or regulations. T hey are suitably packaged in 
such a way as to protect the IMP from deterioration during tran sport and storage.
7.4 Labeling 
Clinical drug supplies will be labeled in accordance with the c urrent International Council for 
Harmonisation (ICH) guidelines  on Good Clinical Practice (GCP) and GMP and will include any 
locally required statements. If necessary, labels will be trans lated into the local language. Details 
on Labeling will be provided in the Pharmacy manual.
7.5 Handling and storage requirements 
The Investigator (or designee) is responsible for the safe and proper storage of IMP at the site. 
The IMP stored by the Investigat or is to be kept in a secured a rea with limited access. The IMP 
containers should be stored at  2 to 8°C and protected from ligh t. Additional information 
regarding the receipt of the drug and return handling will be s pecified in the Pharmacy Manual.
Appropriate storage conditions m ust be ensured by a controlled temperature and by completing a 
temperature log in accordance with local requirements but at le ast once per working day with 
minimum and maximum temperatures  reached over the time interval .
In case an out of range temperature is noted, it must be immedi ately communicated to the 
Sponsor’ designee in accordance with the Pharmacy Manual.
The Investigator (or designee) will instruct the subject to sto re the IMP following the instructions 
on the label.
Detailed information on handling and storage of IMP will be giv en in the Pharmacy Manual.
7.6 Drug accountability 
A drug accountability form will  be used to record IMP dispensin g and return information during 
the course of the study. Details of any drug lost (due to break age or wastage), not used, disposed 
of at the study site, or returned must also be recorded on the appropriate forms. All supplies and 
pharmacy documentation must be made available throughout the st udy for UCB (or designee) to 
review.
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers) and unused IMP containers must be reconciled and re turned to UCB (or designee), 
preferably in their original packaging. Instructions on how to use and store the IMP will be 
provided. Investigational medicin al product intended for the st udy cannot be used for any other 
purpose than that described in this protocol. 
The Investigator (or designee) is responsible for retaining all  used, unused, and partially used 
containers of IMP until returned or destroyed.
The Investigator may assign some of the Investigator’ s duties for drug accountabilit y at the study 
site to an appropriate pharmacist/designee.
The Investigator must ensure that the IMP is used only in accor dance with the protocol.REDACTEDarmaarma
uct thect the
ds tdsCOPYthe tthe 
must bust b
This document The The 
cococannot ly iy i
ded. Ined. I
pose pose be andand
in thin thused nd/or d/or 
nd undu nto support ailsail
turned urned
tion muion manyl be l be
s of somarketing storageorage
bilitybility
usauthorizationbe immbe im
cy Macy Ma
e subjesubjapplication d tempetemp
t least oleast
me intme inandtionon
d in td in tanymited ited
nal inalextensions of IMf IMo. D. Dvariations ude ande an
DetDetthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 61 of 255All study drug documentation (eg, shipping receipts, drug accou ntability logs, IXRS 
randomization materials) must be maintained and accessed by unb linded, trained site personnel 
only. Designated, unblinded site personnel must be appropriatel y trained and licensed (per 
country guidelines) to administer injections. Each site will be required to have a written blinding 
plan in place signed by the Principal Investigator, which will detail the site’s steps for ensuring 
that the double-blind nature of the study is maintained from Wee k 0 to Week 52/WD.  
7.7 Procedures for monitoring subject compliance 
Drug accountability must be re corded on the drug accountability  form. 
If a subject is found to be persistently noncompliant (missing 3 or more doses over any period of 
52 weeks), the subject will be w ithdrawn from the study. A subje ct will be withdrawn from the 
study if 3 consecutive doses we re missed prior to the primary e ndpoint assessment. No missing 
doses are allowed in the first 12 weeks of the study. Doses of IMP that were missed due to a 
reasonable interfering AE that does not allow administration of an anti-TNF due to safety 
reasons will not be considered for the evaluation of subject co mpliance. Evaluation of the 
reasonability of the AE must be di scussed immediately with the Medical Monitor.
7.8 Concomitant medication(s)/treatment(s) 
For any subject taking any medication, including over the count er products, nutraceuticals, or 
herbal medications at Screening or at any time during the cours e of the study, an accurate record 
must be kept in the clinic chart (source documentation) and the  CRF. This record should in clude
the name of the drug, the dose, the date(s) of administration, and the indication for use.
Changes in the concomitant medication to treat the burden of th e predominantly existing disease 
of the nr-axSpA symptoms is allowed during the Placebo-Controll ed Period of the study under 
the conditions listed below. A change in the first 12 weeks of the study should be avoided.  
Table  7‒1: Concomitant Medications (prior to Baseline and Study Visits) 
Drug class Dose  Exclusion criteria Study Visits
Analgesics 
(including, but not 
limited to 
acetaminophen, 
paracetamol, opiates, 
or combinations 
thereof)Up to 
maximum 
approved dose  Any change in stable dose regimen is 
excluded in the 14 days prior to the 
Baseline visit.  Any ad hoc (prn) use of 
analgesics is not 
permitted within 
24 hours prior to any 
post-Screening visit.  
An increase or addition 
in opiates or a 
combination with 
opiat es is not 
recommended between 
Week 0 and Week 12 or 
within 4 weeks prior to 
the Week 24 or 
Week 52 visits.  REDACTEDf admifa d m
to treao trea
d durindurin
ge in ge in COPY r thr t
ing thing th
tationtation
This document umcannot be used ates, tes, 
s s to tosupport o 
aximumximu
approapproany amarketingn the fi the f
dicatidicat
mmmmauthorizationhe
n) ann) an
inistranistra
at the t the 
g theg theapplication t(s)(s)
counterounte
 courcour
dande. E. E
dical ical anyNF duNF d
EvalEvaextensionsny py p
awn frwn fr
ment. Nment. N
missemissor pervariations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 62 of 255Table  7‒1: Concomitant Medications (prior to Baseline and Study Visits) 
Drug class Dose  Exclusion criteria Study Visits
NSAIDs (including 
COX -2 inhibitors)Up to 
maximum 
approved dose 
regimen  Any change in stable dose regimen is 
excluded in the 14 days prior to the 
Baseline visit.  Any ad hoc (prn) use of 
NSAIDs is not 
permitted within 
24 hours prior to any 
post-Screening visit.  
Changes in NSAID 
doses should be avoided 
between Week 0 and 
Week 12 or within 
4 weeks prior to the 
Week 24 or Week 52
visits.  
Oral corticosteroids Maximum 
allowed 
≤10mg daily 
total 
prednisone 
equivalenta Any change in stable dose used for 
axSpA in the 28 days prior to the 
Baseline visit.  
If a taper of oral corticosteroids is 
planned this should be completed 
14days prior to Baseline visit.  Maximum allowed 
≤10mg daily total 
prednisone equivalenta 
Changes in dose or 
initiation of 
corticosteroids 
(including tapers) should be avoided 
between Week 0 and 
Week 12 or within 
4 weeks prior to the 
Week 24 or Week 52visits.  
Corticosteroids (im) Any dose  Use in the 28 days prior to the 
Baseline visit.  Corticosteroids (im) 
must not be used during 
the study.  
Corticosteroids (ia) Up to 
maximum approved dose  Use in the 28 days prior to the 
Baseline visit.  SIJ corticosteroid (ia) 
injections are not allowed during the 
study.
 
Peripheral joint 
injections are permitted.REDACTED RCOPYould bould 
r to Bar to B
This document cannot otbe used toaatotosuppoUp to p to 
maximmaxiort orany marketing aUaaarmaauthorizationaseliseliapplication the he 
steroidsteroid
e compe com
lineineand or danyvisivisaaaaaextensions d bb
Week Week
12 or 2 or 
weeks peeks 
Week eek or AIDAI
be aveavariations sit.t.
ID IDonthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 63 of 255Table  7‒1: Concomitant Medications (prior to Baseline and Study Visits) 
Drug class Dose  Exclusion criteria Study Visits
Corticosteroids (iv) Up to 
maximum 
approved dose  Use in the 28 days prior to the 
Baseline visit.  Doses of corticosteroids 
(iv) may be used during 
the study for acute 
illnesses as long as the 
dose is not given within 1 week prior to 
Week
12, Week 24, or 
Week 52 and the 
underlying disease does 
not present a 
contraindication to the 
subject remaining in the 
study. Indications might 
include dermatitis, 
gastroenteritis, asthma exacerbation, and 
pneumonia.  
Hyaluronic acid (ia) Any dose  Use in the 28 days prior to the 
Baseline visit.  Used in knee as needed 
after Week 12 visit.  
SAARDsb:
SSZ and/or HCQ 
and/or MTX and/or 
LFN and/or AZAMaximum 
allowed:  
SSZ ≤3g daily  
HCQ ≤400mg 
daily  
MTX ≤25mg 
weekly 
AZA 
≤150mg/day  
LFN 
≤20mg/day  SAARD initiated and or any change 
in the dose regimen in the 28 days prior to the Baseline visit.
 
 Changes in SAARD 
doses should not be made between Week 0
and Week 12 or within 
4
weeks prior to 
Week 24 or Week 52
visit.  
SAARD dose reduction 
to manage intolerance 
or safety issues is 
allowed at any time 
during the study at the Investigator’s 
discretion.  
SAARDs:
cyclosporine, 
cyclophosphamide, 
mycophenolic acid, 
apremilastUp to 
maximum 
approved dose  Use within 28 days prior to the 
Baseline visit  Changes in SAARD 
doses or initiation of a 
new SAARD should be 
avoided between 
Week 0 and Week 12 or 
within 4 weeks prior to 
Week 24 or Week 52visit REDACTED D initiD initi
he doshe dos
prior toprior toD
RCOPY days pdays p
it. it.Y
C
This document ycoyc
apremaprem
umcannotorineorine
ophospphosp
cophophbe used usto ≤
tosupport0mg/dmg/d
LFN FN 
≤20m≤20any marketing maauthorization pr
iated aated a
e regime regi
o the Bthe Btioapplication ior to or topand anysubjsub
stusaextensionsee
and thnd th
ying ding d
presenpresen
ontraintrai
jorekk242variations e e 
within withinonthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 64 of 255Table  7‒1: Concomitant Medications (prior to Baseline and Study Visits) 
Drug class Dose  Exclusion criteria Study Visits
Anti-TNF therapies
IFX
ADA
ETN
GOLCZPAny dose  Only 1 previous biologic is allowed.
For IFX, ADA, and GOL, any use 
within the 3 months prior to the 
Baseline visit.  
For ETN, use within the 28 days 
prior to the Baseline visit.  
For CZP any exposure history.  If biologic therapy is 
required the subject 
must be discontinued 
from study medication 
and should conduct the remaining visits 
according to 
Figure 5‒2. 
Other rheumatologic 
therapies:
ABA
rituximab
anti-IL17 
tocilizumab
ustekinumab
tofacitinib
biosimilars to any 
approved biologicAny dose  Any exposure history.  If other rheumatologic 
therapies are required 
the subject should be 
discontinued from study 
medication and should conduct the remaining 
visits according to 
Figure
5‒2. 
Osteoporosis 
medications:
eg,
risedronatealendronate 
ibandronate
denosumab
cathepsin K inhibitor
cinacalcetcalcitoninUp to 
maximum 
approved dose  All stable osteoporosis medications 
are permitted except for 
bisphosphonates (iv).  If the treatment is 
initiated during the 
study, the subject should 
be discontinued from 
study medication and 
should conduct the 
remaining visits 
according to Figure 5‒2. 
Osteoporosis 
medications with the 
exception of 
bisphosphonates (iv) are 
allowed without 
restriction.  
Bisphosphonates (iv) 
are not permitted any 
time within the study.   REDACTED able osble os
permipermi
bisphobisphoD
RCOPY 
This document cannot anbe used to tosupport any marketing maauthorization steopoeopo
itted extted e
sphonphonatiapplication and anye
discdis
maextensions F
er rheur rheu
rapiesapies
e sube subonoriguriguvariations n n 
t the the onthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 65 of 255Table  7‒1: Concomitant Medications (prior to Baseline and Study Visits) 
Drug class Dose  Exclusion criteria Study Visits
Intravenous 
bisphophonates:
zoledronic acid
ibandronate
pamidronateAny dose  Zoledronic acid: any use within the 
3years prior to randomization  
Ibandronate or pamidronate: any use 
within the past 2 years.  If iv bisphosphonate 
treatment is initiated 
during the study, the 
subject should be 
discontinued from study medication and should 
conduct the remaining 
visits according to 
Figure
5‒2. 
ABA=abatacept; ADA=adalimumab; axS pA=axial spondyloarthritis; A ZA=azathioprine; COX-2=cyclooxygenase 
2; CZP=certolizumab pegol; DMARD=disease -modifying antirheumatic drug; ETN=etanercept; GOL=golimumab; 
HCQ=hydroxychloroquine; IFX=infliximab; ia=intra -articular; IL=interleukin; im=intramuscular; iv=intravenous; 
LFN=leflunomide; MTX=methotrexate; NSAID=nonsteroidal anti -inflammatory drug; RA=rheumatoid arthritis; 
SAARD=slow -acting antirheumatic drug; SIJ=sacroiliac joint injection; SSZ= sulfasalazine; TNF=tum or necrosis 
factor
aA table of corticosteroid equivalent doses can be found in Appe ndix 18.3.
bThroughout the text, we refer to  compounds such as SSZ and MTX as SAARDs. These medications are also 
commonly referred to as DMARDs, but since there is no evidence that they are in fact disease- modifying in axSpA 
(unlike in RA), we have opted for the more appropriate SAARD te rminology.
7.8.1 Permitted concomitant treatments for axSpA (medications and 
therapies) 
The Investigator must make decisions regarding changes in backg round medications based upon 
the subject’s response to previous therapy, medical history and  the physician’s judgment as to 
how to manage the axSpA disease symptoms. If possible, the foll owing treatment 
recommendations for modifying background medications should be considered: 
x NSAIDs including cyclooxygenase-2 (COX-2) inhibitors: ad hoc as  needed (prn) should not 
be used 24 hours of any post-Screening study visit. As subjects  should be on stable dose of 
background medication at study entry, a change in the first 12 weeks of the study should be 
avoided. Changes in dose and type of NSAID should not be made w ithin 4 weeks prior to 
Week 24 and 52 visits.
x Modify the SAARD if needed to treat peripheral symptoms. 
x Specific SAARDs only (SSZ and/or hydroxychloroquine [HCQ] and/o r MTX): maximum 
SSZ ≤3g daily; HCQ ≤400mg daily; MTX ≤25mg weekly allowed. As s ubjects should be on 
stable dose of background medication at study entry, a change i n the first 12 weeks of the 
study should be avoided. Changes in SAARDs doses should not be made within 4 weeks 
before Week 24 or Week 52 visit.
x Stable doses of analgesics (including, but not limited to aceta minophen, paracetamol, 
NSAIDs, opiates, or combinations  thereof) will be permitted exc ept that ad hoc prn usage is 
prohibited within 14 days of Baseline and no ad hoc use prior t o any post-Screening visit. As 
subjects should be on stable dose of background medication at s tudy entry, a change in the 
first 12 weeks of the study should be avoided. An initiation of  a new chronic opiate or a REDACTED atmatm
egardiegard
erapy, erapy,
ympympCOPY enceenc
ARD tARD t
menme
This documentbb
xxcannot ≤3g≤3
ble dble d
studystudy
bbbe  SASA
3g d3g dusedSAAAA
AAAAto v
ARARsupportn at sn at s
n dose dose
visits.isits.any gege
ostost--ScS
stutmarketing , m
ptoms.ptoms
kgrounkgrou
enaseenasauthorization nts fonts fo
ing chng ch
medimediapplication AARDAARD
at they at they
rminolminoand ug; Rg; 
fasalazsalazanymuscumusc
RA=RAextensionsrem
ordingrding
5‒‒22
XX--2=c2=c
cept; ept; enormainmaivariations studystudy
houlhoulonthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 66 of 255combination with opiates is not recommended between Week 0 and Week 12 or within 
weeks 4 of the Week 24 or Week 52 visits. 
x Add or modify the corticosteroids (see Section 7.8.2 for prohibited corticosteroids):
 Oral (maximum allowed daily tota l prednisone equivalent dose o f ≤10mg). Oral 
corticosteroid tapers of 14 days prior to Baseline are allowed as long as the maximum 
daily dose is ≤10mg. Changes in dose or initiation of corticost eroids (including tapers) 
should be avoided between Week 0 and Week 12 or within 4 weeks prior to Week 24 or 
Week 52 visits.
 Corticosteroids administered intravenously (iv) will be permitt ed for the purposes of 
stress dosing for a surgical procedure under general or spinal anesthesia. Further they 
may be used during the study for acute illnesses as long as the  dose is not given within a 
week of an assessment (Week 12, 24 or 52) and the underlying dis ease does not present a 
contraindication to the subject  remaining in the trial. Indicat ions might include dermatitis, 
gastroenteritis, asthma exacerbation, and pneumonia.
x Other treatments (including biologics): If the subject requires  the start of other treatments 
(including biologics) at the discretion of the Investigator, th e subject must be withdrawn from 
the blinded study medication. Every effort should be made to re tain the subject in the study 
and encourage attendance at future study visits.
x The Investigator should refrain from making major changes in ba ckground medication 
between Week 0 and Week 12, as muc h as possible. Major changes in background
medications within 4 weeks of Week 24 or Week 52 should be avoi ded.
Depending on the subject’s response to previous therapy, the In vestigator may also reduce the 
assigned background medication. This change should not be made between Week 0 and 
Week 12. Major changes in background medications should be avoid ed within 4 weeks prior to 
Week 24 or Week 52. 
If the Investigator discontinues the double-blind study treatme nt and initiates therapy with CZP, 
UCB will supply the subject with the CZP. If the decision is mad e to start a different treatment 
(including biologics), UCB will not be supplying the medication . 
7.8.2 Prohibited concomitant and rescue treatments (medications and 
therapies) 
Prior medication exclusions and washout periods are listed in Section 6.2 . In addition, use of the 
following concomitant medications is prohibited during the stud y, except where indicated:
x Corticosteroids (administered iv/ intra-articular [ia]) are perm itted only as described in 
Section 7.8.1 . Intramuscular and sacroliliac joint injection (SIJ) ia cortic osteroids are not 
permitted. 
x Hyaluronic acid is permitted for  the use in the knee after Week 12.
x Biologicals (TNFi: IFX, ADA, E TN, GOL, abatacept (ABA), commerc ially available CZP), 
anti-CD20, tocilizumab, ustekimumab, also any other biological response modifiers are 
excluded.
x All iv bisphosphonates are excluded.g g
as posas po
24 or 4 or 
to preto pre
his chis cCOPY majomajo
This documentpp
xcannot orticoortico
SectSectbeconcconcusedheraera
ion eon eto hib
raprapsupportct wit w
CB wiCB w
bitedbitedanys the s the
withwithmarketingev
changehang
und mend m
dauthorizationor chaor cha
ssiblessible
WeekWeek
viousiousapplicationthe she 
he subje sub
ade to rde to and stastanymightmighextensionsposesoses
Furtherurthe
not givot giv
se doe door sovariations 4 or or thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 67 of 255If the subject requires any of the medications specified in thi s section, the subject must be 
discontinued from the study treatment prior to the initiation o f these medications. Before starting 
these therapies the Investigator should contact the Study Physi cian.
If the subject is discontinued fr om study treatment in order to  initiate other treatments (including 
biologics), the subject will be encouraged to return to the sit e for future study visits to continue 
to collect data important for study integrity.
If the subject initiates therapy with CZP, UCB will supply the subject with CZP. If the decision 
is made to start a different therapy, UCB will not supply such medication.
Subjects must not participate in any other clinical study for a ny indication or receive any 
unauthorized medication during the study period.
The administration of live vaccines is not recommended for subj ects treated with TNFi. Live 
vaccines should not be administered 8 weeks prior to Baseline. If immunization with a live 
organism based vaccine is considered during the study, the clin ician is urged to carefully weigh 
the risks versus benefits of immunization. If the subject is go ing to proceed with live organism 
based immunization, the subject must be withdrawn from the stud y prior to administration of the 
vaccine. Such vaccines must be recorded in the respective secti on of concomitant module of the 
CRF.
7.8.3 Concomitant medication(s)/treatments during the SFE Period 
At the completion of the Week 52 visit assessments, subjects on double-blind study treatment 
may receive open-label CZP treatment for an additional 2 years during the SFE Period. During 
this time, CZP will be provided by the Sponsor. Concomitant med ication usage during the SFE 
Period is at the discretion of the Investigator.
7.9 Blinding 
Due to differences in presentation and viscosity between CZP an d placebo, special precautions 
will be taken in order to ensure blinding during the Double-Bli nd Period of the study. The 
subject will receive the IMP throughout the study duration for each single administration in a 
sealed box with PFS containing either CZP 200mg or placebo. Pac kaging and labeling will be 
done in a way to ensure that the provided box including the PFS  will not provide any information 
about the assigned treatment  (CZP 200mg or placebo). Administra tion of the IMP will be done 
according to the schedule of study assessments ( Table 5 ‒1) either on-site by appropriately 
trained unblinded study personnel or at home by the subject him /herself. Pharmacokinetic and 
antibody data will be provided only after the study is unblinde d.
7.9.1 Maintenance of study treatment blind 
All subject treatment details will be allocated and maintained by the IXRS.
The study will be double-blind and placebo-controlled for 52 wee ks. No study team member 
involved in the clinical conduct will have access to the random ization schedule until after 
database lock and unblinding. 
If the Investigator decides to discontinue the double-blind stu dy treatment and initiate open-label 
treatment with CZP or other treatment (including biologics), ef forts will be made to ensure that 
the blinding of the previously assigned double-blind study trea tment will be maintained. 
Therefore, if the open-label treatment with CZP is chosen by the  Investigator, the 3 loading doses REDACTED menmen
n addin add
ponsorponso
tigatortigatorCOPY eatmeatme
nts, nts
This document The The 
inincannot subjesubjebeata wa wused schch
ded stued stu
wilwiltore
heduhedsupportainingning
e that ththat 
atmenatmeany blili
hroughroug
gemarketing and visnd vi
indinndiauthorization , subjesubje
ditionationa
r. Conr. Con
r.application y py p
on of cn of
nts dnts dandroceeocee
priorioany tit
rged toged t
eddextensions any any
with TNth TN
ion won wor variations iononthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 68 of 255of CZP 400mg Q2W will be administe red by dedicated study person nel without disclosing to the 
subject the use of the PFS. After the last loading dose, the su bject can self-administer CZP until 
Week 52/WD of the regular visit schedule. 
For the SFE Period, in order to maintain the blind for subjects  completing the Double-Blind 
Period, study treatment will be administered sc by unblinded st udy staff at the study site on 
Weeks 52, 54, and 56. Subjects who completed the Week 52 Visit o n placebo treatment will 
receive loading doses of CZP 400mg at these visits. Subjects wh o completed the Week 52 Visit 
on CZP treatment will receive 1 injection of CZP 200mg and 1 inj ection of placebo at these 
visits to continue their previ ous CZP treatment regimen. 
7.9.2 Breaking the treatment blind in an emergency situation 
All Sponsor, Investigator site , and Contract Research Organizat ion (CRO) staff involved with the 
study will be blinded to the tre atment code until the database lock ie, after completion of the 
Double-Blind Period with the following exceptions:
x Sponsor clinical study supplies coordinator, packager, and qual ified person
x Pharmacy monitors that monitor unblinded pharmacy documentation
x Sponsor pharmacovigilance staff reporting SAEs to regulatory au thorities
x Laboratory staff analyzing blood samples for CZP plasma concent rations and anti-CZP 
antibodies
x Site study drug administrator
The appropriate persons (Investigators, Single Safety Case Mana gement [SSCM] - Safety 
Officer, Medical Monitor) will be provided with an individual p assword to access the IXRS 
menu that will enable them to unblind a subject’s double -blind treatment allocation. This 
password must be kept confidential and not shared with any othe r persons. The IXRS will be 
able to identify the individual who has unblinded a subject’s t reatment allocation. The IXRS will 
be accessible at all times. I f possible, Investigators are advi sed to contact the company or its 
representatives prior to unblinding the treatment allocation of  subjects. 
Under normal circumstances, the bl inded treatment must not be r evealed. In the case of a 
medical emergency, UCB or its representatives preferably should  be contacted prior to any 
unblinding. The blind should be broken only if doing so will ch ange the decision making as to 
the subject’s treatment or clinical intervention. Any unblindin g performed by the Investigator of 
the IMP must be documented and explained by the Investigator. I f the blind is broken, the date, 
the reason for the breaking the blind, and person doing so must  be recorded. UCB or its 
representatives must be notified immediately if the blind is br oken.
In the event of an emergency, it will be possible to determine which treatment arm and dose the
subject had been allocated to by calling the IXRS. All sites wi ll be provided with details of how 
to contact the system for code bre aking at the start of the stu dy. The Medical Monitor (or 
equivalent) should be consulted prior to unblinding, whenever p ossible.
For the product and study informa tion and emergency unblinding purposes, the Sponsor will 
provide each Investigator with a n appropriate quantity of clini cal study subject cards. Each 
subject will be instructed to keep the card with him/her at all times. These subject cards will be REDACTED SinglSingl
ovideovide
nd and aCOPY CZP plCZP p
This document n thth
subjsubj
totcannoton fon f
sentatientat
he ehe ebeust bst b
forforused blinlin
reatmeeatme
bebetoU
nd sndsupportlindind
ances, ances
UCB UCB anyssiblssib
ndingdinmarketing ed wd w
a subjesubje
and nond n
o has uo has 
lelauthorization le Safee Safe
withwithapplicationentatientat
latory latory
asma csma anded peed p
iiany erextensions f involf invo
omplempleor variations sit sit 
e thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 69 of 255written in the language of the subject. The Investigator will f ill in each card with the details of 
his/her contact information (eg, Investigator stamp) and subjec t identifier. The card will be 
distributed to the subject at t he time of informed consent.
The Clinical Project Manager (CPM) will be informed immediately  via the IXRS when a code is 
broken, but will remain blinded to specific treatment informati on. Any unblinding of the IMP 
performed by the Investigator must be recorded in the source doc uments and on the Study 
Termination CRF page.
7.10 Randomization and numbering of subjects 
7.10.1 Interactive Response System 
An IXRS is used for subject registration as well as randomizati on and treatment administration. 
To enroll a subject, the Investigator must contact the IXRS and  provide brief details of the 
subject to be enrolled. Each subject will be assigned a unique subject number. Enrolled subjects 
who withdraw from the study prior to randomization will retain their subject number without 
receiving a randomization number  (ie, subject numbers will not be reassigned).
The IXRS will allocate kits of s tudy medication at Weeks 0, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 
40, 44, 48, and 50.
7.10.2 Randomization 
Randomization will be stratified on:
x Region
x MRI/CRP classification
Subjects will be classified as MRI+/- depending on whether or no t they have evidence of 
sacroiliitis on MRI at Screenin g based on the ASAS/OMERACT defi nition. Subjects will be 
classified as CRP+/- based on the  CRP value obtained at the seco nd Screening visit scheduled to 
occur 3 to 5 days prior to Baseline. Subjects will be categoriz ed as CRP+ if their CRP value is 
above the level indicative of inf lammatory disease at this visi t. Otherwise, they will be 
considered CRP-. Based on these de finitions, the stratification for MRI/CRP classification will 
have the following 3 levels:
x MRI+/CRP+
x MRI+/CRP-
x MRI-/CRP+
The IXRS will be designed to ens ure that at least 20% of the ra ndomized subjects belong to each 
of the 3 clinical subgroups above.
To randomize a subject, the Investigator must contact the IXRS and provide brief details of the 
subject that is to be randomized. The IXRS will automatically i nform the Investigator of the 
subject’s randomization number. Each subject will be assign ed a unique randomization number. 
This randomization number will be r equired in all communication s between the Investigator (or 
his/her designee) and the IXRS regarding a particular subject. The IXRS will allocate kit 
numbers to the subjects based on the randomization list over th e course of the study. REDACTED dedeCOPY 
This document ft ht
To rTo cannot /C/C
IXRS XRS 
he 3 he 3be CRPCRPused PP--to support f ini
on theon the
evels:vels:anyine. ine
nflamnflammarketingependipendi
ed on thd on t
CRP vCRP 
SuSauthorization application 4, 6, 84, 6, 8and ubjbj
eassigassiganyber. ber
ject necextensions admindmin
fd e t a idetai
EEor variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 70 of 255Randomization numbers and kit numbers will be tracked via the I XRS and also will be required 
to be entered into the CRF. 
Randomization schedules will be  generated prior to start of the  study. Subjects will be allocated 
to treatment in a 1:1 ratio (CZP 200mg: placebo). 
8 STUDY PROCEDURES BY VISIT  
Section 5.2(Schedule of study assessments) provides a general overview of study assessments. 
A detailed listing of procedures to be undertaken at each visit  is described below. 
During the first 3 periods of the study the Investigator will a ssess the subjects over the entire 
study period of approximately 66 weeks including a FU Period of 8 weeks after the 
Week 52/WD visit. Visit windows of ±3 days on either side of the  scheduled visit are permitted; 
however, the Investigator should try to keep the subjects on th e original dosing schedule. The 
window of ±3 days is relative to Baseline and is applicable for all subsequent visits. Changes to 
the dosing schedule outside of the 3-day window must be discuss ed with the Medical Monitor 
and may result in subject withdrawal. 
8.1 Screening visit (Week -6 to Day -1) 
Prior to any study activities, subjects will be asked to read a nd sign an informed consent form 
that has been approved by an IEC/IRB and the Sponsor and which complies with regulatory 
requirements. Subjects will be given adequate time to consider any information concerning the 
study given to them by the Investigator or designee. As part of  the informed consent process, 
subjects will be given the opportunity to ask the Investigator any questions regarding potential 
risks and benefits of participation in the study.  
Assessments at the Screening visit include:
x Confirm inclusion/exclusion criteria (to be performed within We eks -6 and Day -1 and 
confirmed between Days - 5 and -3 before Baseline)
x Confirm informed consent
x Demographic data (includes date of  birth, gender, race/ethnicit y)
x Significant past medical and procedure history and concomitant disease (includes allergy and 
any current symptoms) including axSpA history
x Vital signs (pulse rate, systolic and diastolic blood pressure,  temperature, and respiratory 
rate)
x Hematology, biochemistry, and urine for clinical laboratory val ues (includes a serum 
pregnancy test for women of childbearing potential; testing to rule out hepatitis B surface 
antigen, antibodies to hepatiti s C, and HIV; testing of CRP, HL A-B27, and abnormalities for 
estimated Glomerular Filtration Rate as measured by CKD-EPI wil l be performed) 
x Physical examination (including weight) 
x Chest x-ray to be done at Screening (unless a chest x-ray or co mputed tomography of the 
chest has been done within 3 months prior to the Screening visi t)REDACTEDgnegne
k the Ik the I
study.tudy.
ncludencludeCOPYsor asor 
me to cme to 
ee.ee
This document acannotmatolmato
pregnaregna
antantbe used  (puls(pulstomptomptosupportcludelude
medical edical
omomany smarketing e:
ria (to ria (to
d --3 be3 bauthorizationconsons
 As paAs pa
Investnvestapplication nd signnd sig
nd whid wh
nsidesidand any nt nt
the Mthe Mextensions en
it are pt are p
g scheg sch
t visviorntirntirvariations ts. s. thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 71 of 255x TB test: Interferon-Gamma Release Assay (IGRA) test (QuantiFERON  test [or Elispot test 
when the QuantiFERON test is indicated but not available])
x TB evaluation questionnaire 
x SI joint x-ray (centrally read). An SI joint x-ray perform ed ≤12 months prior to the Baseline 
visit maybe used as the Baseli ne assessment provided that the f ilm can be submitted and 
meets the requirements for central reading.
x MRI (spine and SI joints, centrally read)
x BASMI and spinal mobility assessments
x BASDAI
x Prior and concomitant medication
x Contact the IXRS to indicate the subject has been screened
The period between the Screening and Baseline visits should not  exceed 6 weeks. The Screening 
chest x-ray should be read by a radiologist /pulmonologist and must exclude evidence of TB. The 
qualifying CRP levels from the Screening visit will be used for  the inclusion criteria review at 
Baseline. 
One retest of CRP is mandatory during the Screening Period with in 3 to 5 days before the 
Baseline visit in order to meet the inclusion criteria. 
One rescreen is permitted for subjects with LTB. In this event,  all Screening assessments must be 
repeated. Subjects are allowed t o start the IMP after at least 4 weeks of prophylactic TB 
treatment (if compliant with t he local regulations on initiatio n of biologic therapy in subjects 
with LTB) within the Screening Period. The subject is required to complete the full prophylactic 
treatment.
8.2 Baseline visit (Week 0) 
Subjects agreeing to participate in the study, after giving sign ed informed consent, will have the 
following procedures performed/recorded prior to study drug adm inistration:
x Review of inclusion/exclusion cr iteria. Note: The qualifying CRP  levels from the Screening 
Period 3 to 5 days before Baseline  will be used for the inclusi on criteria review and for 
randomization stratification. The result of the centrally read MRI and X-ray must be 
available for the inclusion criteria review.
x Vital signs (pulse rate, systolic and diastolic blood pressure,  temperature, and respiration 
rate)
x Blood samples (subjects should be e ncouraged to be under fastin g conditions, the same 
condition [fasting or not fastin g] should be applied at Week 52 ) will be collected for 
hematology and biochemistry analyses (biochemistry assessment w ill include the 
measurement of apolipoprotein (Apo) A1, ApoB, lipoprotein(a), a nd glycated hemoglobin 
[HbA1c])
x Urine will be collected for urinalysis and for a urine pregnanc y test for women of 
childbearing potentialLTB. LTB. 
e IMPe IMP
regularegul
iod. Tiod. COPY ng Peng Pe
ria. ria. 
This documentBcannotl sigsig
ate)e)
BloBlobe gnsgnusedon stn st
for thfor thtoays bays supportformerme
on/excn/exc
befbany te in te in 
dmarketingThe sThe s
WeeWeeauthorization In thiIn thi
P afterafter
ationstionsapplicationst ext ex
the incthe in
riod wod wandeed 6ed 6
exclxclany extensions or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 72 of 255x Physical examination (including height and extra-articular asse ssments)
x TB questionnaire 
x BASMI and spinal mobility 
x BASDAI 
x BASFI 
x SF-36
x ASQoL 
x MOS Sleep Scale 
x EQ-5D
x MASES
x Total spinal pain NRS and nocturnal spinal pain NRS 
x Swollen and tender joint counts
x PGADA
x PhGADA
x Productivity measures (WPS)
x Resources utilization 
x Plasma for CZP concentration, anti-CZP antibodies, and biomarke rs 
x Genetics/epigenetics, if applicable
x Gene expression and proteomics, if applicable
x Concomitant medication
x AEs
x Contact IXRS to randomize subject and to obtain kit number 
x Study drug administration (after all other visit assessments ar e completed and laboratory 
samples are drawn)
8.3 Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 
36, 38, 40, 42, 44, 46, 48, and 50 (all visits ±3 days relative to 
Baseline) 
Assessments at these visits include:
x Vital signs; pulse rate, systolic and diastolic blood pressures  and temperature (respiration rate 
will be assessed in addition if the subject experiences an AE) (at all on-site visits except 
Week 1)
x Blood samples will be collected for hematology, biochemistry, a nd CRP (Weeks 2, 4, 8, 12, 
24, and 36 only)REDACTED titi--CZPCZ
leleCOPY 
This documentAsseAsse
xcannot be used dmim
re drawe draw
Wtominisminisupport randomandomany marketing cs, if aps, if aauthorization P antiantiapplication and any extensions or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 73 of 255x CRP for the calculation of ASDAS (Weeks 16, 20, 28, 32, 40, 44,  and 48)
x Urine will be collected for urinalysis (Weeks 2, 4, 8, 12, 24, and 36 only) 
x Physical examination (Weeks 2, 4, 8, 12, 16, 24, and 36), inclu ding weight at Week 24
x Extra-articular assessments (Weeks 4, 12, 24, 36, and 48 only) 
x TB questionnaire (Weeks 12, 24, and 36 only)
x MRI (spine and SI joints; Week 12 only)
x BASMI and spinal mobility (at all on-site visits except Weeks 6 , 10, and 50)
x BASDAI (Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, a nd 48 only)
x BASFI (Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, an d 48 only)
x SF-36 (Weeks 4, 12, 24, 36, and 48 only)
x ASQoL (Weeks 1, 2, 4, 12, 24, 36, and 48 only)
x MOS Sleep Scale (Weeks 4, 12, 24, 36, and 48 only)
x EQ-5D (Weeks 4, 12, 24, 36, and 48 only)
x MASES (Weeks 1, 2, 4, 8, 12, 16, 24, 32, 40, and 48 only)
x Total spinal pain NRS and nocturnal spinal pain NRS (Weeks 1, 2,  4, 8, 12, 16, 20, 24, 28, 
32, 36, 40, 44, and 48 only)
x Swollen and tender joint counts (Weeks 4, 12, 24, and 36 only)
x PhGADA (Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, a nd 48 only) 
x PGADA (Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, an d 48 only)
x Productivity measures (WPS) (Weeks 4, 12, 24, 36, and 48 only)
x Resource utilization (Weeks 4, 12, 24, 36, and 48 only)
x Plasma for CZP concentration, anti-CZP antibodies, and biomarke rs (Weeks 1, 2, 4, 12, 24, 
and 36 only)
x Genetics and epigenetics (Week 12 only), if applicable
x Gene expression and proteomics  (Weeks 4 and 12), if applicable
x Concomitant medication
x AEs
x Contact IXRS to register the visit and obtain next kit number, where applicable (Weeks 2, 4, 
6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 50)
x Study drug administration (after all other visit assessments ar e completed and laboratory 
samples are drawn) (all visits except Week 1)
x Subject training on self-injection (Weeks 10 and 12)REDACTEDl pal pa
Weeks 4eeks 4
16, 216, 2COPY and 48nd 48
ainain
This document xxCcannotncomom
AEsAEsbexprepre
iiusedd epepii
essessto supportWeekeek
ncentracentrany S) (S) 
ksks4marketing20, 2420, 2
16, 20, 6, 20
(We(Wauthorization n NRSNRS
4, 12, , 12,
4application only)only)and any extensions or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 74 of 2558.4 Every 4 weeks (± 3 days) during home injection period from 
Week 14 to Week 46 (Weeks 14, 18, 22, 26, 30, 34, 38, 42, and 46) 
The following assessments are to be performed by telephone:
x Concomitant medication 
x AEs 
8.5 Week 52/WD (±3 days) 
A subject is regarded to have completed the Double-Blind Period of the study if s/he completes 
the Week 52 assessments. Assessments at this visit include:
x Vital signs; pulse rate, systolic and diastolic blood pressure,  and temperature (respiration rate 
will be assessed in addition if the subject experiences an AE) 
x Blood samples (subjects should be e ncouraged to be under fastin g conditions, the same 
condition [fasting or not fastin g] should be applied at Week 52 ) will be collected for 
hematology, biochemistry, and CRP (biochemistry assessment will  include the measurement
of Apo A1, ApoB, lipoprotein(a), and HbA1c)
x Urine will be collected for urinalysis and for a urine pregnanc y test for women of 
childbearing potential
x Physical examination (including weight)
x Extra-articular assessments
x Chest x-ray only if the TB test was confirmed positive or any fur ther evidence is suggestive 
of potential TB infection
x TB test: IGRA test (QuantiFERON test [or Elispot test when Quan tiFERON test is indicated 
but not available]) only for subjects who have not had a previo usly positive TB test result
x TB Questionnaire 
x SI joint x-ray
x MRI for spine and SI joints (at Week 52/WD visit if previous MR I was performed more than 
12 weeks prior to Week 52/WD visit)
x BASMI and spinal mobility
x BASDAI
x BASFI
x SF-36
x ASQoL
x EQ-5D
x MASES
x Total spinal pain NRS and nocturnal spinal pain NRSREDACTED confirconfiCOPY 
This document SS
xxcannot ASFIASFI
SFSFbe AIAIused nd spid spitoto Wto Wsupport d SI joSI jo
WeWany marketing ON test N tes
bjects wjects authorization irmed rmed application gnancynancandill bl b
will inill inanynditioditi
be cbe cextensions e (resp(respomplmplvariations letltthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 75 of 255x Swollen and tender joint counts
x PhGADA
x PGADA
x Productivity measures (WPS)
x Resources utilization
x Plasma for CZP concentration, anti-CZP antibodies, and biomarke rs 
x Gene expression and proteomics, if applicable
x Concomitant medication
x AEs
x Contact IXRS to indicate that s ubject has rolled over to the SF E Period or withdrawn from 
the study
8.6 SFE Period (Week 52 to Week 156)  
All eligible subjects must complete the Week 52 visit assessmen ts.
Eligible subjects are allowed to roll-over to the SFE-Period up  to 3 months after completion of 
the Week 52 assessments.
Prior to rolling over to the SFE Period, subjects will be asked  to read and sign a separate 
informed consent form.
Telephone contacts are upon the discretion of the Investigator.  Starting at Week 56, and at the 
discretion of the Investigator, i t is recommended to contact th e subject by phone at least once in 
between the on-site visits.
Starting at Week 64, all subjects  are to visit the site approxim ately every 12 weeks (±2 weeks) 
for assessments performed according to local standard medical pr actice, as needed, including:
x Document AEs (Note: any [possible] drug-related AE must be foll owed-up, at least by 
phone.) 
x Contact IXRS 
 to register the visit and obtain next kit number at Weeks 54 an d 56 for subjects receiving 
loading doses of study drug administration at the study site 
 to register the visit and obtain next kit number for subjects r eceiving study drug 
administration at the study site approximately Q12W during the remainder of the study
 to indicate that the subject has withdrawn from the study, if a pplicable
At Week 156/SFE-WD (±1 week), all subjects are to visit the sit e for the following assessments:
x Blood sample for CRP
x BASDAI
x BASFIREDACTEDcts wcts w
etion oetion o
commcomCOPYPeriPer
il
This document 
AAcannotto reo re
admadbe dingngused ster ther th
gd ogd oto supportany any anyordinordi
[p[marketingmmendmend
are to vre to 
ngauthorization ill be al be 
of thef the
ddapplication ments.ents.
od up tod up tand anyd or d orextensions or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 76 of 255x ASQoL
x Total and nocturnal spinal pain
x PGADA
x MRI SI joints
x AEs
x Contact IXRS to indicate that the  subject has completed the SFE  Period (Week 156/SFE-
WD)
8.7 FU visit (8 weeks after the Week 52/WD visit [±3 days])  
Subjects not participating in the SFE Period will attend a FU v isit 8 weeks after the 
Week 52/WD visit (±3 days). 
Assessments at this visit include:
x Vital signs; pulse rate, systolic and diastolic blood pressure,  and temperature (respiration rate 
will be assessed in addition if the subject experiences an AE)
x Blood samples will be collected for hematology, biochemistry, C RP, and serum pregnancy 
test for women of childbearing potential
x Urine will be collected for urinalysis 
x Physical examination 
x Plasma for CZP concentration, anti CZP antibodies, and biomarke rs 
x Concomitant medication
x AEs
x Contact IXRS to indicate that subject has completed FU
8.8 Unscheduled visits 
It is at the Investigator’s di scretion to initiate an Unschedul ed Visit, if deemed necessary by the 
Investigator for the subject’s safety and well -being. At this visit, any of the following or other 
assessments at the Investigator ’s discretion may be performed d epending on the reason for the 
visit:
x Vital signs 
x Blood samples for hematology, biochemistry, other testing such as for TB or CRP 
x Urine for urinalysis and/or preg nancy testing (for women of chil dbearing potential)
x Physical examination 
x Concomitant medication
x AEsanti Canti CCOPY y, biocy, bio
This document xxcannot ital sigtal si
BloBlobe usedthe she s
t the t the toatorator
susupport te the th
eduleedul
r’s dr’sany that hatmarketingCZP aCZP aauthorization application  and teand t
AE)AE)
hemishemiand any aftfextensions ays]) ays])
fter tteror variations FE--thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 77 of 255x TB questionnaire 
x Contact IXRS to indicate that subject attended an unscheduled v isit
8.9 Alternative visit schedules after subject discontinuation of the 
double-blind study treatment 
Subjects who discontinue the double-blind study treatment and e nter open-label treatment with 
CZP will be assessed 2 and 4 weeks after open-label CZP treatme nt has been initiated and every 
12 weeks thereafter. Alternatively, subjects who discontinue the  double-blind study treatment 
and receive other treatment (including biologics) will be asses sed every 12 weeks after initiation 
of the other treatment. The alte rnative schedules for open-labe l CZP and other treatment can be 
found in Table 5 ‒2and Table 5 ‒3, respectively. In either alternative schedule, assessments 
should be conducted until as close as possible to Week 52 (withi n ±4 weeks), where Week 52 is 
relative to the original randomization at Week 0. Subjects will  then be invited to the final 
assessment visit at Week 52.
The following assessments will be performed for subjects who ar e treated with open-label CZP 
after discontinuation of the doubl e-blind study treatment:
x Vital signs; pulse rate, systolic and diastolic blood pressure,  and temperature (respiration rate 
will be assessed in addition if the subject experiences an AE) at wdt Weeks 0, 2, 4, 12, 24 
(and every 12 weeks [Q12W]), 52, and F U (8 weeks after Week 52 V isit)
x Blood samples will be collected for hematology, biochemistry, a nd CRP analyses, and urine 
will be collected for urinalys is at wdt Weeks 0, 12, 24 (and Q1 2W), 52 and FU (8 weeks 
after Week 52 Visit)
Note: Fasting blood samples will be collected for hematology, b iochemistry, and CRP 
analyses at wdt Week 0 (biochemistry assessment will include th e measurement of Apo A1, 
ApoB, lipoprotein(a), and HbA1c). At Week 52, the biochemistry assessment will include the 
measurement of HbA1c.
x Pregnancy test for women of childbearing potential at wdt Weeks  0, 52 (urine testing), and 
FU (serum testing)
x Physical examination at wdt Weeks 0, 4, 12, 24 (and Q12W), 52, and FU
x Extra-articular assessments at wdt Weeks 12, 24 (and Q12W), and  52
x TB test at wdt Week 52 only
x TB questionnaire at wdt Weeks 0, 12, 24 (and Q12W), and 52
x SF-36, AsQoL, MOS Sleep Scale, EQ-5D, and MASES at wdt Weeks 0, 12, 24 (and Q12W), 
and 52
x BASMI & spinal mobility, BASFI, total and nocturnal spinal pain , swollen and tender joint 
counts, BASDI, Patient’s Global assessment, and Investigator’s AS assessment at wdt 
Weeks 0, 4, 12, 24 (and Q12W), and 52
x Plasma for CZP concentration, anti-CZP antibodies, and for biom arkers at wdt Weeks 0, 4, 
12, 24 (and Q12W), 52, and FUREDACTEDtologtolog
Weeks Weeks 
l be cl be c
misiCOPYncesnce
weeksweek
gy
This documentaa
xxcannoquesues
SFF--3636
andanbe at w
stistisedar asr a
wdtwdtto assasssupport enn
tion ation aany of chof chmarketingcollecolle
stry astry as
1c). Atc). Aauthorization s a
y, bioc, bioc
s 0, 120, 12
ectectapplication re, andre, an
an AE)n AE
after fter andeatedeatedany extensionsment ent 
sessmessm
wherewhere
d to td to tonitinitivariations ery ery 
ment nt 
iattthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 78 of 255x Gene expression and proteomics at wdt Week 52 only
x Concomitant medication at wdt Weeks 0, 2, 4, 12, 24 (and Q12W),  52, and FU
x AEs at wdt Weeks 0, 2, 4, 12, 24 (and Q12W), 52, and FU
x IXRS (for treatment assignment) at wdt Weeks 0, 2, 4, 12, 24 (a nd Q12W), 52, and FU
x CZP administration at wdt Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and every 
2 weeks thereafter, until Week 52. Loading dose of CZP 400mg at W eeks 0, 2, and 4 must be 
administered by dedicated site-staff 
x Telephone contact will occur every 4 weeks after the on-site vi sit at the discretion of the 
investigator
The following assessments will be applied for subjects who rece ive an alternative study 
assessment with other treatment (including biologics) after dis continuation of the double-blind 
study treatment:
x Blood samples will be collected for hematology and biochemistry  analyses, and urine will be 
collected for urinalysis at wdt Week 0. C-reactive protein anal yses will be performed at wdt 
Weeks 0, 12, 52, and FU 
Note: Biochemistry assessment will include the measurement of H bA1c at wdt Week 0 
x Physical examination at wdt Week 0 and FU.
x BASDAI, BASFI, to tal and nocturnal spinal pain, Patient’s Global assessment, and  
Investigator’s AS assessment at wdt Weeks 0, 12, and 52
x Swollen and tender joint counts at wdt Week 52 only
x Plasma for CZP concentration, anti-CZP antibodies, and for biom arkers at wdt Weeks 0, 12, 
and FU
x Concomitant medication at wdt Weeks 0, 12, 24 (and Q12W), 52, a nd FU
x AEs and IXRS (for the registration of visits) at wdt Week 0, 12 , 24 (and Q12W), 52, and FU
x Other treatment administration at wdt Week 0. For Week 12 and 2 4 (and Q12W) the regimen 
of the particular medicine should be followed. If the Investigat or choses to withdraw the 
subject, the local guidelines on initiation and monitoring of t he particular treatment should be 
followed.
x Telephone contact will occur every 4 weeks after the on-site vi sit at the discretion of the 
Investigator
9 ASSESSMENT OF EFFICACY 
Most of these tools have been use d in AS studies but early data  support their use in axSpA as 
well (Barkham et al, 2009; Haibel et al, 2008).pinal ppinal p
WeekWeek
at wdtat wdtCOPYmeasmea
This document 9
MMcannotphopho
nvestigvestigbe oneonusedlocalocaltor mer msupporte regireg
dminisdminis
edidanywdtwdmarketingt WW
ntiti--CZPCZ
Wauthorization pain, Pain, 
ks 0, 1s 0, 1
WeeWeeapplicationalysesalyse
uremenuremeand y anay anaany of ofextensionsn of of 
ative stive s
f theft hor ththvariations ust be st be thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 79 of 2559.1 Assessment of efficacy variables 
9.1.1 ASDAS 
The ASDAS is comprised of a number of assessments which are sco red by the subject and 
physician and multiplied by a proven formula (van der Heijde et  al, 2009) as listed:
0.121 x Back pain (BASDAI Q2 result, see Section 9.1.5 )
0.058 x Duration of morning stiffness (BASDAI Q6 result)
0.110 x PGADA (see Section 9.1.13 )
0.073 x Peripheral pain/swelling (BASDAI Q3 result)
0.579 x (natural logarithm of the (CRP [mg/L] + 1)) 
Back pain, PGADA, duration of morni ng stiffness, peripheral pai n/swelling and fatigue are all
assessed on a numerical scale ( 0 to 10 units) (Lukas et al, 2009 ).
The variables related to ASDAS disease activity are defined as follows:
x ASDAS-Inactive Disease (ASDAS-ID): ASDAS <1.3
x ASDAS-Low Disease (ASDAS- LD): ASDAS ≥1.3, <2.1
x ASDAS-High Disease Activity (ASDAS- HD): ASDAS ≥2.1, ≤3.5
x ASDAS-very High Disease Activity (ASDAS-vHD): ASDAS >3.5
The variables related to ASDAS im provement are defined as follo ws:
x ASDAS-Clinically Important Improvement (ASDAS-CII): ASDAS reduc tion (improvement) 
of ≥1.1 relative to Baseline
x ASDAS-Major Improvement (ASDAS- MI): ASDAS reduction (improvement) of ≥2.0 
relative to Baseline
The ASDAS will be calculated at Screening, Baseline, Weeks 2, 4 , 8, 12, 16, 20, 24, 28, 32 36, 
40, 44, 48, 52/WD, and Week 156/SFE-WD.
9.1.2 ASAS20, 40, ASAS 5/6 response, and ASAS partial remission 
The ASAS20 is defined as an im provement of at least 20% and abs olute improvement of at least 
1 unit on a 0 to 10 NRS in at least 3 of the 4 following domain s:
x PGADA (see Section 9.1.13 )
x Pain assessment (the total spinal pain NRS score)
x Function (represented by BASFI, Section 9.1.6 )
x Inflammation (the mean of the  BASDAI questions 5 and 6, [see Se ction 9.1.5 ] concerning 
morning stiffness intensity and duration) 
and absence of deterioration in the potential remaining domain [deterioration i s defined as a 
relative worsening of at least 20% and an absolute worsening of  at least 1 unit].REDACTED DASDAS
ment ament a
provemrovemCOPY ,
 ASDASD
SS-vv
This document xxcannot ain assin as
FunFunbeA (sA (sused defief
o 10 N10 NtofinefinesupportWeek 1eek 
20, 400, 4
dany d at Sd at S
15marketing ASDASSDAauthorization DA
vHD):HD):
are deare de
ment (ent (application AS ≥2AS ≥2and ws:ws:any extensions and fnd for variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 80 of 255The ASAS criteria for 40% improvement are defined as relative i mprovements of at least 40%, 
and absolute improvement of at least 2 units on a 0 to 10 NRS i n at least 3 of the 4 domains and 
no worsening at all in the remaining domain.
The ASAS 5/6 response is defined as at least 20% improvement in  5 of 6 domains, including 
spinal mobility (lateral spinal flexion) and CRP as more object ive measures (Brandt et al, 2004).
The ASAS partial remission respons e is defined as a score of ≤2 units on a 0 to 10 unit scale in 
all 4 domains listed above for ASAS20.
The ASAS variables will be calculated at Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 
52/WD, and Week 156/SFE-WD.
9.1.3 ASAS-NSAID score 
The ASAS-NSAID score is a tool that has been developed to measu re the magnitude of NSAID 
intake during clinical studies  (Dougados et al, 2011). In order  to calculate the ASAS-NSAID 
score, the following information will be collected:
x Has there been NSAID intake since last visit?
x NSAID name
x Average daily intake (mg)
x Days with intake
 <1 day/week
 1 to 3 days/week
 3 to 5 days/week
 ≥5 days/week
 Every day
x Starting date
x End date (or ongoing)
The general formula for  calculation is as follows:
x (equivalent NSAID score) × (days of intake during period of int erest) × (days per 
week)/(period of interest in days)
Each of the components of the above  calculation is described bel ow:
x Equivalent NSAID score: This is reported in terms of NSAID equi valent dose in mg/day on a 
0 to 100 scale where the diclofenac 150mg equivalent is set to 100. An NSAID equivalence 
table was developed based on a survey of ASAS members. The tabl e including the consensus 
equivalence score for various  NSAIDs can be found in the Statis tical Analysis Plan (SAP).
x Days of intake during period of interest: Equivalent to the tot al number of days covered 
during the period that is being measured.REDACTED COPY 
This document00cannotthe he 
EquivEquiv
0t0tbe per
cocosedNSANSA
riodriodtoa foa fosupport g)g)
for cor cany marketing authorization application and anythe Atheextensions agnitugnitu
AAor4444variations 4444thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 81 of 255x Days per week: Proportion of days per week when the NSAID is ta ken. This is collected in 
the categories described in the days with intake category liste d above. Each category 
corresponds to a score as follows (score in parentheses):
 Every day (7/7)
 ≥5 days/week (6/7)
 3 to 5 days/week (4/7)
 1 to 3 days/week (2/7)
 <1 day/week (0.5/7)
 No NSAID intake (0)
x Period of interest in days: Refers to the number of days covere d for a given NSAID. If only 
1 NSAID was taken during the period of interest, this will be th e same as days of intake 
during period of interest.
Dougados et al 2011 provided the following example. If during a  period of interest (between 
2 visits) of 6 months, the subject has taken piroxicam 20mg duri ng 4 months and if during this 
4 month-period he has taken pirox icam 3 to 5 days per week the c alculation is as follows:
x 100 (20mg piroxicam score) × 120 (4 months) × 4/7 (3 to 5 days/ week)/180 
(6 months) = 38.1
If the subject has used 10mg piroxicam during the remaining 2 m onths on 2 days a week, the 
NSAID score for this period is:
x 50 (10mg piroxicam score) ×60 (2 months) × 2/7 (1 to 3 days/wee k)/180 (6 months) = 4.8
In this example the total score for the 6-month period is 42.9 (38.1 plus 4.8).
9.1.4 ASQoL 
The ASQoL, a validated disease-sp ecific 18-item questionnaire, has been developed specifically 
for measuring HRQoL in subjects with AS (Doward et al, 2003). T he ASQoL has been used and 
has shown to be responsive in axSpA (Barkham et al, 2009; Haibe l et al, 2008). The ASQoL 
score ranges from 0 to 18 with higher score indicating worse HR QoL. A change of 1.8 points, 
which represents 10% of the possible score range, has been used  as the minimal clinically 
important difference (MCID) criteria to guide the interpretatio n of ASQoL score changes in 
previous trials with a TNFi (van der Heijde et al, 2009; Davis et al, 2007). A change in ASQoL 
score of 2 points (ie, 10% of the t otal score range) will be us ed as the MCID to guide the 
interpretation of ASQoL score changes (see Appendix 18.4).
The ASQoL assessments per visit are described in Table 5 ‒1, Table 5 ‒2, and Table 5 ‒6.
9.1.5 BASDAI 
The most common instrument use d to measure the disease activity  of AS from the subject’s 
perspective is the BASDAI (Garrett et al, 1994). The BASDAI is a validated self-reported 
instrument which consists of six 10-unit horizontal NRSs to meas ure severity of fatigue, spinal 
and peripheral joint pain and swelling, enthesitis, and morning  stiffness (both severity and 
duration, respectively) over the las t week (van Tubergen et al,  2015). The final BASDAI scoreing thing th
(2 mo(2 moCOPY × 4/7 × 4/7 
This document he he
9.19.1cannot 2 p2 p
retatioretati
e ASASbe als ls 
poinpoinused 1010
erencerence
sw iwitoto
0% 0% supportsubjeubje
sive insive in
o 18 w 18 wany sese--spsp
ectmarketingonthnth
66--monmoauthorization  (
he reme rem
hs)hs)applicationperieri
ring 4 ming 4
k the cathe c
(3 to 53 to and riodiodanye as das extensions en Nen N
dor variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 82 of 255ranges from 0 to 10, with lower scores indicating lower disease  activity. The MCID used to 
interpret scores is 10mm on a VAS or 22.5% of the Baseline score  (Pavy et al, 2005). An MCID 
of 1 unit will be selected for the NRS version (see Appendix 18.5).
The BASDAI 50 is defined as an improvement of at least 50% in t he BASDAI response.
The BASDAI is calculated as follows: 
Fatigue item of the BASDAI
Fatigue as a major symptom of AS can effectively be measured wi th single-item questions such 
as the BASDAI item (van Tubergen et al, 2002b). This item has s hown moderate to good 
reliability and responsiveness (van Tubergen et al, 2002b). The  same MCID will be used for the 
fatigue item of the BASDAI as for the total BASDAI score, ie, a  change of 1 unit on the NRS.
The BASDAI assessments per visit are described in the schedule of study assessments Table 5 ‒
1, Table 5 ‒2,Table 5 ‒3, and Table 5 ‒6.
9.1.6 BASFI 
The BASFI is a validated disease-specific instrument for assess ing physical function (van der 
Heijde et al, 2005; Calin et al, 1994). The BASFI comprises 10 items relating to the past week. 
The NRS version will be used for the answering options of each item on a scale of 0 (“Easy”) to 
10(“Impossible”) (van Tubergen e t al, 2015 and van Tubergen et al , 2002a). The BASFI is the 
mean of the 10 scores such that the total score ranges from 0 to  10, with lower scores indicating 
better physical function. The MCID  used to interpret scores is 7mm on a 0 to 100mm VAS or 
17.5% of the Baseline score (Pavy et al, 2005); an MCID of 1 unit  will be used for the NRS 
version (see Appendix 18.6).
The BASFI assessments per visit are described in Table 5 ‒1, Table 5 ‒2,Table 5 ‒3, and Table 5 ‒
6.
9.1.7 BASMI 
The BASMI characterizes the spinal mobility of subjects with AS . The BASMI is a 
disease-specific measure consisting of 5 clinical measures to r eflect subject axial status: cervical 
rotation; tragus to wall distan ce; lateral spinal flexion; modi fied Schober test;  intermalleolar 
distance. Each of the 5 movements is scored according to the li near BASMI definition. The mean 
of the 5 scores provides the BASMI score. The higher the BASMI score the more severe the 
subject’s limitation of movement due to their axSpA.
The BASMI assessments per visit are described in Table 5 ‒1and Table 5 ‒2.
9.1.8 Enthesitis (MASES) 
The MASES is an index that measures the severity (ie, intensity  and extent) of enthesitis through 
the assessment of 13 entheses (bilateral costochondral 1, costo chondral 7, anterior superior iliac 
spine, posterior iliac spine, iliac crest and proximal insertio n of the Achilles tendon sites, and the 
REDACTEDASFI ASFI
weringwering
2015 2015 
total sctotal s
useusCOPY ment ment
This document The The
9cannot EaEa
5 sco5 sco
ject’sect’sbe agusgus
achachused actac
ic mea mea
us tost oocteritersupport Iany isit arisit amarketingscoreor
ed to ined to i
et al, 20t al, 2authorizationfor afor a
comprcompr
g optiooptio
and vand v
re rre rapplicatione of stof standnge onge oany derde
CID wCID w
fextensions em qum qu
eraterator variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 83 of 255fifth lumbar vertebral body spinous process) (Heuft-Dorenbosch et al, 2003) each scored as 0 or 
1 and then summed for a possible score of 0 to 13.
Enthesitis assessments per  visit are described in Table 5 ‒1andTable 5 ‒2.
9.1.9 Extra-articular assessments 
The evolution of associated nonmuscu loskeletal features includi ng IBD, psoriasis and uveitis 
(including their severity) and flare rate will be assessed as d escribed Table 5 ‒1andTable 5 ‒2.
9.1.10 Health status (EQ-5D) 
The EQ-5D is comprised of a 5-item health status measures and a  VAS. Each of the 5 health 
states is divided into 3 levels: no problem, some or moderate p roblems and extreme problems 
and is scored as 1, 2, and 3, respectively. The EQ- 5D VAS records the respondent’s self -rated 
health status on a vertical  20 cm scale, 0 to 100 graduated (0= worst imaginable health status, 
100=best imaginable health status) (see Appendix 18.7).
This instrument is to be completed by the subject as described in Table 5 ‒1andTable 5 ‒2.
9.1.11 MOS Sleep Scale 
The MOS Sleep Scale is a validated g eneric self-administered sc ale measuring specific aspects 
of sleep. The frequency with which each problem has been experi enced during the previous 
4 weeks is rated on a 5- point scale ranging from “none of the time” to “all of the time ,” except 
sleep quantity, which is report ed in hours. All scores are tran sformed linearly to range from 0 to 
100, again with the exception of the sleep quantity subscale, w hich is scored in hours. Higher 
scores indicate more of the attribut e implied by the scale name  (eg, more sleep disturbance, more 
adequate sleep, and greater sleep quantity). The psychometric p roperties of the MOS Sleep Scale 
have been found to be satisfactory by Hayes and colleagues (Hay s et al, 2005). The domains of 
interest for this study are the Sleep Disturbance and the Sleep  Problems Index II domains. The 
MCID for the Sleep Problems Index II is 6 points on a 0 to 100 scale (Wells et al, 2007) (see 
Appendix 18.8).
Subjects will be asked to complete the MOS Sleep Scale as descr ibed in Table 5 ‒1and
Table 5 ‒2.
9.1.12 MRI assessments 
Magnetic Resonance Imaging according to the ASAS/OMERACT defini tion is the presence of 
bone marrow oedema (BMO) or osteitis highly suggestive of SpA t hat is located in the typical 
anatomical areas (subchondral or periarticular bone marrow). Th ere must be either more than 
1 BMO lesion on 1 slice or a lesion that is present on at least 2 consecutive slices (Rudwaleit et 
al, 2009d). In practice this is very similar to the SI joint S PARCC score ≥2 definition of MRI 
that requires at least 2 BMO lesi ons to be present. A recent pa per showed that the sensitivity and 
specificity of the ASAS/OMERACT and SI joint SPARCC score ≥2 de finitions of MRI positive 
were identical (sensitivity 0.80, specificity 0.76) (Weber et a l, 2014). The Berlin modification of 
the ASspiMRI-a is a scoring system with a concentration on shor t-tau-inversion recovery (STIR) 
sequences without other fat saturation techniques (Braun and Ba raliakos, 2011; Lukas et al, 
2007; Braun and van der Heijde , 2002; Braun et al, 2003). This scoring method quantifies 
changes in 23 vertebral units  (VU) of the spine (from C2 to S1) . A VU is defined as the region 
between 2 virtual lines through the middle of each vertebra. Ac tive inflammation is scored by REDACTEDco
uantityuantity
ied ed byby
tity). Ttity). 
y Hayy Hay
iiCOPYs beebe
none onone o
ores ores 
This documentat
specispeci
wwcannotlesioesi
009d).09d).
t requrequbeareaare
ionionusedancence
oedemedem
asasto ce Imce Isupport mpm
ssessssessany pletepletemarketing yes ayes a
sturbanturba
x II is II isauthorization of 
are trare tr
y subsy subs
y the sy the s
The pThe p
ananapplication d scale d scale
n experexpe
f the tthe tand e55‒any 11extensions hehe
e probe prob
ent’s snt’s s
ble heale heor ealtealtvariations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 84of 255grading the degree of BMO from 0 to 3 in 1 dimension on 1 or mo re consecutive slices that 
represent the highest level of inflammation in a particular VU.  Total spine ASspiMRI -a score in 
the Berlin modificatio n can range from 0 to 69. In addition to the method mentioned above, 
MRIs may be evaluated using other reading criteria.
Magnetic resonance imaging of the  spine and SI joints will be p erformed at Screening and at the 
Week 12 and at the Week 52/WD visits if MRI was performed more than 12 weeks prior to 
Week 52/WD. A further MRI of the SI joints w ill be performed at Week 156/SF E-WD. 
Magnetic resonance images will be  assessed centrally and scorin g will be done by 2 independent 
readers, who are blinded to both the order of the scans and to the treatment group, using a 
previously reported scoring system.
9.1.13  PGADA (NRS)  
Subjects will score their global assessment of their disease ac tivity in response to the question 
“How active was your spondylitis on average during the last week?” using a NRS where 0 is 
“not active” and 10 is “very active” (van Tubergen et al, 2015) (see Appendix 18.9).
The PGADA assessments per visit are described in Table 5‒1,Table 5‒2,Table 5‒3, and 
Table 5‒6.
9.1.14  PhGADA  
The Investigator will assess the overall status of the subject with respect to the axSpA signs and 
symptoms and the functional capacity of the subject using a VAS  where 0 is “ve ry good, 
asymptomatic and no limitation of normal activities” and 100 is  “very poor, very severe 
symptoms which are intolerable and inability to carry out all n ormal activities.”
This assessment by the Investigator should be blinded.
The PhGADA will be com pleted as described in Table 5‒1,Table 5‒2, and Table 5‒3.
9.1.15  Productivity measures (Work Productivity Survey)  
The WPS is an instrument used to assess productivity at work an d within the home. The WPS 
has been found to be valid, reliab le, and responsive to clinica l change s in RA, PsA, and axSpA 
subjects (Osterhaus and Purcaru, 2014). 
Site personnel should obtain information from the subject in or der to complete this survey. The 
WPS is a 9 -question instrument used to assess
 One of the WPS questions concerns the 
.  will be asked questions about the 
;
,  on 
a 0 to 10 scale (0=no interference; 10=complet e interference). In addition, all subjects regardless 
of their employment status  will be asked questions 
;
 on a 0 to 10 scale (0=no interference; 10=complete int erference).
The WPS assessments per visit are described in Table 5‒1.REDACTED ubjeubj
ctivitictiviti
bility toility t
shouldshould
ddCOPY he subhe su
ect ect
This documenta 0 toa 0 to
ofoftannoannocaot bebe busedtionon
useduto ld o
ni nni nsupport relireli
PurcarPurca
obtaobtanyd to ad to 
iabiabmarketing d bb
escribescrib
asureasureauthorization bjecjec
usingusing
ies” anes” a
to carro car
be be bapplication lee
ect wct wand ppepe
55‒‒anyg a Ng a N
endixendextensions se to te to t
NRNRor a a variations endenndenthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 85 of 2559.1.16 Resources utilization 
Study-specific questionnaires (s tandard CRF modules) will be use d to capture data regarding 
resources utilization during the study, ie:
x Concomitant medical procedures
x Health care provider consultations not foreseen by the protocol
x Hospitalizations/emergency room visit
Site personnel should obtain information from the subject and al so corroborate data with known 
AEs and SAEs in order to comple te this survey as described in Table 5 ‒1. The recall period for 
the questionnaire will be the previous 4 weeks.
9.1.17 SF-36 
The SF-36 (version 2, standard recall) is a 36-item generic HRQ oL instrument that uses a recall 
period of 4 weeks. Items are grouped into 8 domains as follows:  Physical Functioning (10 items), 
Role Physical (4 items), Bodily Pain (2 items), General Health ( 5 items),Vitality (4 items), Social 
Functioning (2 items), Role Emotional (3 items), Mental Health (5 items), and 1 item for 
perceived stability or change in health (Health Transition) dur ing the last year. The concepts 
represented by these domains contribute to physical, mental, an d social aspects of HRQoL.
In addition to domain scores, the PCS and MCS scores are calcul ated from the 8 domains 
(excluding the Health Transition item). Component scores apprec iate the impact of each domain 
on physical and mental health status (Ware et al, 1994). Each o f the 8 domain scores and the 
component summary scores range from 0 to 100, with a higher sco re indicating a better health 
status. The 2 component summary s cores are standardized with a mean of 50 and a standard 
deviation (SD) of 10 in the general USA population. The MCIDs f or SF-36 domains and 
component summaries are 5 and 2.5 points, respectively (Strand et al, 2005) (see 
Appendix 18.10 ).
The SF-36 has been used and has shown to be responsive in axSpA  (Haibel et al, 2008) and is 
also validated (van Tubergen et al, 2015). The SF-36 will be ad ministered per visit as described 
inTable 5 ‒1and Table 5 ‒2.
9.1.18 Spinal mobility 
In addition to the assessments performed for the BASMI, additio nal spinal mobility assessments 
include:
x Occiput to wall distance
x Chest expansion
Spinal mobility will be a ssessed as described in Table 5 ‒1andTable 5 ‒2.
9.1.19 Swollen and tender joint counts (44 joints evaluation) 
The following 44 joints are to be examined for swelling and ten derness by the Principal 
Investigator, another delegated physician, or an appropriately qualified medical professional 
(based on local requirements) who has had documented training o n how to perform these 
assessments correctly. Preferably the same assessor should eval uate the subject at each arthritis 
assessment. REDACTED oneone
et al, 1et al, 
0 to 100 to 10
ores aores a r
USA USA COPY meme
cores ores
ent sent
This documenSpinpin
9.9.cannot putu
Chest ehest e
nalnalbe ut to ut to usede assassto sesesupport en en e
‒22..
al mol moanyas shas s
et alet amarketingpopupopu
points, points
hohauthorization areare
scorescore
1994)994)
00, wi00, w
e stane stanapplication(5 ite5 ite
ing theng th
l, and s, and 
re calec aand calal
ms),Vms),V
emanymentmen
l FunFunextensionsperiper
nt tnt torknkn
riodiovariations knownowthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 86 of 255Upper body (4) –bilateral sternoclavicular, a nd acromioclavicular joints
Upper extremity (26) –bilateral shoulders, elbows, wrist s (includes radiocarpal, carp al and 
carpometacarpal bones considered as a single unit), metacarpoph alangeals (MCPs) I, II, III, IV, 
and V, and thumb interphalangeals (IPs), and proximal IPs (PIPs ) II, III, IV, and V
Lower extremity (14) –bilateral knees, ankles, and metatarsophalangeals (I, II, III, IV, and V)
The assessment for swelling and tenderness is made on 44 joints from the above list. Artificial 
and ankylosed joints are excluded from swelling and tenderness assessments.
The assessments per visit are described in Table 5 ‒1andTable 5 ‒2.
Table  9‒1: Swelling and tenderness grading 
Grade Swelling response (44) Tenderness response (44)
0 None None
1 Swelling present Tenderness present
9.1.20 Total and nocturnal spinal pain NRS 
The pain experienced by AS sub jects is adequately measured by 2  separate questions: 1) total 
pain in the spine due to AS (ie, “ How much pain of your spine d ue to spondylitis do you have?”); 
and 2) pain in the spine at night due to AS (ie, “How mu ch pain of your spine due to spondylitis 
do you have at night?”) (Sieper et al, 2009; van der Heijde et al, 2005; CPMP/EWP/556/9 5). 
Usually, a 10% difference (ie , a 1 point difference on a NRS ra nging from 0 to 10) is considered 
the MCID used to interpret scores (Dworkin et al, 2008). Pain e xperienced by axSpA subjects 
has also been measured with this assessment (Haibel et al, 2008 ) and is validated (van Tubergen 
et al, 2015) (see Appendix 18.11 ).
The pain NRS assessments per  visit are described in Table 5 ‒1, Table 5 ‒2,Table 5 ‒3, and 
Table 5 ‒6.
10 ASSESSMENT OF PHARMACOKINETICS, EXPLORATORY 
BIOMARKERS, AND PHARMACOGENOMICS VARIABLES 
Plasma samples for the measuremen t of CZP concentrations will b e taken at Baseline and 
Weeks 1, 2, 4, 12, 24, 36, 52/WD, and at the FU visit (8 weeks a fter the Week 52/WD visit). 
These plasma samples may be used additionally for analyses of C ZP and its constituent moieties 
using alternative methods and the results of those analyses may  be reported separately.
These plasma samples may be used for possible analyses of explo ratory biomarkers which might 
include, but are not limited to:  MMP-3, BMP-2, -4 and -7, WNT1, W ISP, Gremlin, DKK1, 
Sclerostin, Hedgehog proteins (Shh, Ihh, Dhh), Collagen turnove r/cleavage products, collagen 
type X, VEGF, citrullinated vimentin fragments, cytokines: IL13 , IL17 A and F, IL23, IL34, 
(TGF- β, M -CSF, GM-CSF, CSF-1, sCSF1r levels. The results of the analyses  of CZP and its 
constituent moieties from alte rnative methods may be reported s eparately.
For subjects participating in the optional substudy, blood samp les will be drawn for possible 
genetics/epigenetics, genomic, proteomics and metabolomic analy sis at Baseline and Week 12, ain oin 
ie, “Hie, “H
09; van9; van
nt diffnt dif
DworDworCOPY NRNR
ly mealy me
of yof
This documenthe
inclunclu
ScScannotasmsm
alternltern
ese pse pbe 4,,
ma sma sseds for tfor 
, 12,12toOMOMsupport SSMSSM
MARMARanyvisitvismarketingrkin erkin 
essmenssmen
taauthorizationasursur
your syour 
How mow m
an der n der 
erencrencapplicationTenTe
attiott
ured redand nee
anany nyextensions s respresenor variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 87 of 255and for genomic, proteomics, and metabolomic analysis only, at Week 4 and Week 52/WD to 
enable exploratory evaluation of  biomarkers relative to drug tr eatment, disease biology and 
inflammatory and immune response processes. 
Samples will be moved from the Ce ntral Laboratory (ACM) at the end of the study to a 
long-term storage facility - BioStorage Technologies, GmbH - and will be stored at -80°C at a 
central biorepository for up to 20 years.
11 ASSESSMENT OF IMMUNOGENICITY VARIABLES 
Plasma samples for the measurement of anti-CZP antibodies and p otentially neutralizing 
antibodies will be taken at Baseline and Weeks 1, 2, 4, 12, 24, 36, 52/WD, and the FU visit 
(8 weeks after the Week 52/WD visit). 
The sampling, handling, and shipment of samples will be perform ed as detailed in the Laboratory 
Manual.
12 ASSESSMENT OF SAFETY 
Safety variables to be assessed are physical examinations, AEs,  vital signs, and measurements of 
laboratory parameters. 
Adverse events will be solicite d at every visit, and recorded a nd coded according to the latest 
version of the Medical Dictionary for Regulatory Activities (Me dDRA®) criteria.
Physical examination findings will be recorded in the CRF only at Screening. Clinically 
important abnormal changes in subsequent physical examinations will be recorded as AEs at all 
visits from Baseline to the FU visit.
Clinical laboratory values (hematology, biochemistry, urinalysi s) will be collected and assessed 
at Screening, Baseline, Weeks 2, 4, 8, 12, 24, 36, at the end of  study completion at Week 52/WD 
visit and at the FU visit (8 weeks after the Week 52/WD visit).  In addition, clinical laboratory 
values will be collected and a ssessed at study visits during th e administration of open-label CZP 
in subjects who withdraw from the double-blind study treatment.
Furthermore, CRP will be coll ected and assessed either in a bli nded or open manner at 
Screening, 3 to 5 days before Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 
at the end of study completion a t Week 52/WD visit and at the F U visit (8 weeks after the 
Week 52/WD visit).
At Screening, all subjects will have an  IGRA test (QuantiFERON®TB test or Elispot®test, when 
the QuantiFERON test indicated i s not available), and a chest x -ray reading (or, if done, 
computed tomography of the chest) which must be reported consis tent with standard clinical 
reporting practice by an experi enced qualified TB specialist, r adiologist, or a pulmonologist, who 
is specifically required to look for signs of active TB or sign s of past/inactive TB infection. A 
chest x-ray will not be done at Screening if a chest x-ray (or computed tomography of the chest) 
was done within 3 months prior to the Screening visit. The offic ial report of the imaging must
specifically indicate the absence of findings suggestive of cur rent active TB or prior inactive TB. 
In addition to a physical examination done intermittently throu ghout the study, subjects will be 
evaluated at Screening, Baseli ne, and every 12 weeks thereafter  up to Week 36 and including the 
Week 52/WD visit, for signs and symptoms of LTB or active TB in fection and risk factors for 
exposure to TB using the TB questionnaire.REDACTEDd in d in
physicphysic
ogy, biogy, bi
818COPY cordcor
ActivitActivi
nt hnt h
This documents spsp
chesches
wcannotted toed to
orting ting 
pecpecbeg,
FERFERused sit).t)
all sall sto com
)support collecolle
before efore
mplempleanym the m themarketingiochoch
12, 24,2, 24,
ter the er the
sed at sed a
dauthorization iti
he CRe CR
cal exal ex
chemheapplicationital sal 
d and cand 
ies (Mes (Mand sigsigany extensionsU viU vi
ed in td in tor g
siivariations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 88 of 25512.1 Adverse events 
12.1.1 Definition of adverse event 
An AE is any untoward medical occurrence in a subject or clinic al investigation subject 
administered a pharmaceutical  product which does not necessaril y have a causal relationship 
with this treatment. An AE can therefore be any unfavorable and  unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally as sociated with the use of an IMP, 
whether or not related to the IMP. 
If a surgical procedure is performed during the study participa tion, the underlying condition 
should be re ported as the AE (eg, “appendicitis” is the AE resulting in app endectomy).
The following laboratory values and physical findings are also to be considered AEs:
x Laboratory value(s) that are out of reference range AND of clin ical relevance, excluding 
Screening values
x Laboratory value(s) that change from a subject’s Baseline AND a re of clinical relevance
x Pre-existing physical findings (including vital sign measuremen ts) that worsen compared 
with Baseline AND that are “clinically important”
In order to ensure complete safe ty data collection, all AEs occ urring during the study (ie, after 
signing the informed consent form), including any Screening and  FU Periods required by the 
protocol, must be reported in the  CRF even if no IMP was admini stered but specific study
procedures were conducted. This includes all AEs not present pr ior to the Screening visit and all 
AEs which recurred or worsened a fter the Screening visit. 
Signs or symptoms of the condition/disease for which the IMP is  being studied should be 
recorded as AEs only if their na ture changes considerably or th eir frequency or intensity 
increases in a clinically significant manner as compared to the  clinical profile known to the 
Investigator from the subject’s history or the Baseline Period.
12.1.2 Procedures for reporting and recording adverse events 
The subject will be given the opportunity to report AEs spontan eously. A general prompt will 
also be given at each study visit to detect AEs. For example:
“Did you notice anything unusual about your health (since your last visit)?”
In addition, the Investigator shoul d review any self assessment  procedures (eg, questionnaires) 
employed in the study.
12.1.3 Description of adverse events 
When recording an AE, the Investigator should use the overall d iagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The CRF and 
source documents should be consisten t. Any discrepancies betwee n the subject’s own words on 
his/her own records (eg, diary card) and the corresponding medic al terminology should be 
clarified in the source documentation.
Details for completion of the Adverse Event CRF (including judg ment of relationship to study 
drug) are described in the CRF Completion Guidelines.REDACTED no Ino 
ll AEsll AE
e Scree Scre
diseasdiseas
chachaCOPYl AEl AE
y Screy Scr
IMIM
This documentstantandd
sosocannot en reen rebein thin thused ouou
he Inve Inv
hehtou nou nosupport n the opthe o
study vudy v
tiany for reor rmarketing se fe f
anges cnges 
manneranne
story otory authorizationeenieni
MP wasP wa
s not p not p
eeningeening
for forapplicationments)ments
s occuroccu
ning ingandare ofre of
))any fcfextensions y).)
AEs:AEs:
ance, ance, orionionvariations MP, P, 
nnthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 89 of 25512.1.4 Follow up of adverse events 
An AE should be followed until it has resolved, has a stable se quelae, the Investigator 
determines that it is no longer clinically significant, or the subject is lost to follow up. 
If an AE is still ongoing at the end of the study for a subject , follow up should be provided until 
resolution/stable level of sequelae is achieved, or until the I nvestigator no longer deems that it is 
clinically significant, or until the subject is lost to follow up. If no follow up is provided, the 
Investigator must provide a justification. The follow up will u sually be continued for 70 days 
after the subject has discontinued his/her IMP.
12.1.5 Rule for repetition of an adverse event 
An increase in the intensity of an AE should lead to the repeti tion of the AE being reported with:
x The outcome date of the first AE that is not related to the natu ral course of the disease being 
the same as the start date of t he repeated AE, and the outcome of “worsening”
x The AE verbatim term being the same for the first AE and AE ver batim term repeated 
including worsening, so that the r epeated AE can be easily ident ified as the worsening of the 
first one
12.1.6 Pregnancy 
If an Investigator is notified that a subject has become pregna nt after the first intake of any IMP, 
the Investigator must immediately notify UCB’s Drug Safety (DS)  department by providing the 
completed Pregnancy Report and Outcome form (for contact detail s see Serious Adverse Event 
reporting information at the beginning of this protocol). The s ubject should be withdrawn from 
the study as soon as the pregnancy is known (by positive pregna ncy test), and the following 
should be completed:
x The subject should return for an Early Withdrawal Visit.
x The subject should immediately stop the intake of the IMP. 
x A FU visit should be scheduled 8 weeks after the Week 52/WD vis it.
The Investigator must inform the subject of information current ly known about potential risks 
and about available treatment alternatives.
The pregnancy will be documented on the Pregnancy Report and Ou tcome form provided to the 
Investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
followed up using the Pregnancy Report and Outcome form upon wh ich the Investigator has to 
report the health of the mother and of the child. Every reasona ble attempt should be made to 
follow the health of the child for 30 days after birth for any s ignificant medical issues. In certain 
circumstances, UCB may request  that follow up is continued for a period longer than 30 days. If 
the subject is lost to follow up and/or refuses to give informa tion, written documentation of 
attempts to contact the subject needs to be provided by the Inv estigator and filed at the site. 
UCB’s DS department is the prim ary contact for any questions re lated to the data collection for 
the pregnancy, eventual birth, and follow up.
In cases where the partner of a male subject enrolled in a clin ical study becomes pregnant, the 
Investigator or designee is asked to contact the subject to req uest consent of the partner via the 
Partner Pregnancy Consent form th at has been approved by the re sponsible IRB/IEC and should REDACTED s Ds 
form (form (
f this pthis p
knowknow nCOPY ome pome 
DruDru
This document rcuc
the sthe s
atatannothe hee he
wwthe the 
umsumsbep usp us
eaeausedwill bill 
The prThe p
inito bebesupport hee
nform form
eatmeeatmany ele
duleddulemarketing Early WEarly 
ly stoly stauthorization pre
ug Safg Saf
(for cofor co
protocprotoc
n (by p(by papplication ntif
egnangnaandrbatimbati
ifiedfiedanysenisen
mextensions g repog repo
of the f the 
ninior variations s thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 90 of 255be available in the Investigator s ite file. In case of question s about the consent process, the 
Investigator may contact the UCB/CRO contract monitor for the s tudy. The Investigator will 
complete the Pregnancy Repo rt and Outcome form and send it to UCB’s DS department (for 
contact details see Serious A dverse Event reporting information  at the beginning of this protocol) 
only after the partner has agreed that additional information c an be captured and has provided the
signed Partner Pregnancy Consent  form. UCB’s DS department is a lso the primary contact for 
any questions related to the data  collection for the partner pr egnancy, eventual birth, and follow 
up.
A pregnancy becomes an SAE in t he following circumstances: misc arriage, therapeutic abortion, 
and unintended pregnancy after hormonal contraceptive failure ( if the hormonal contraceptive 
was correctly used), ectopic pregnancy, fetal demise, or any co ngenital anomaly/birth defect of 
the baby. Those SAEs must be additionally reported using the In vestigator SAE report form.
Should a subject become pregnant while participating in the stu dy, the subject may be offered the 
option to enroll in a separate observational pregnancy follow-u p study sponsored by UCB and 
conducted independently from study AS0006. If the study is avai lable locally, the AS0006 
Principal Investigator will be provided with the locally approv ed information about the 
observational pregnancy follow-up study to inform the subject a t the time the pregnancy is
reported. Participation in this separate study will be voluntar y and will not impact therapeutic 
management of the subject nor interfere with termination and fo llow-up procedures as described 
in study protocol AS0006.
12.1.7 Overdose of investigational medicinal product 
Excessive dosing (beyond that pr escribed in the protocol and in cluding overdose) should be 
recorded in the appropriate CRF module and drug accountability forms. Any SAE or nonserious 
AE associated with excessive dosin g must be followed as any oth er serious or nonserious AE. 
These events may be symptomatic, in that the excessive dosing r esults in clinical signs and 
symptoms, or the excessive int ake may itself be a symptom.
12.1.8 Safety signal detection 
Selected data from this study will be reviewed periodically to detect as early as possible any 
safety concern(s) related to the  IMP so that investigators, cli nical study subjects, regulatory 
authorities, and IRBs/IECs will be informed appropriately and a s early as possible.
The Study Physician or medical ly qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE  reconciliations in collaboratio n with the DS representative.
As appropriate for the stage of development and accumulated exp erience with the IMP, 
medically qualified personnel at UCB may identify additional sa fety measures (eg, AEs, vital 
signs, laboratory or ECG results) for which data will be period ically reviewed during the course 
of the study.
12.2 Serious adverse events 
12.2.1 Definition of serious adverse event 
Once it is determined that a subject experienced an AE, the ser iousness of the AE must be 
determined. An SAE must meet 1 or more of the following criteri a:
x DeathREDACTEDnal mnal m
d in thd in th
ule anule an
g mug muCOPYnationation
This documentof thof th
11cannot opripr
cally qally q
ns, labs, labbe p
riateriateusediciancian
perfoperfoto s/I
nosupportudy wdy w
ed to thd to th
/IECsIECsanydetedet
wilmarketingust be ust be
n that ththat 
may itmay 
ecauthorization medicmedic
he proe pro
d drudruapplicationinfornfo
at the tat the
ry and y and
and foand fandpp
le locloc
ormormany ectec
onsoronso
lextensionstracerace
birth drth d
E repoE repo
ct mtmoaboabo
epvariations w w 
ortortthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 91 of 255x Life-threatening
Life-threatening does not include a reaction that might have ca used death had it occurred in a 
more severe form.
x Significant or persistent disability/incapacity
x Congenital anomaly/birth defect (including that occurring in a fetus)
x An important medical event that, based upon appropriate medical  judgment, may jeopardize 
the patient or subject and may require medical or surgical inte rvention to prevent one of the 
other outcomes listed in the definition of serious.Examples of important medical events may include allergic bronc hospasm requiring 
intensive treatment in an emergency room or at home, blood dyscr asias that do not result in 
inpatient hospitalization, infections that require treatment wi th parenteral antibiotics or the 
development of drug dependency or drug abuse.
Confirmed active TB is an SAE and must be captured on an SAE re port form and provided to 
the Sponsor in accordance with SAE reporting requirements. As w ith all SAEs, periodic 
follow-up reports should be compl eted as per protocol requireme nts until such time as the TB 
infection resolves.
x Initial inpatient hospitalization or prolongation of hospitaliz ation
A subject admitted to a hospi tal, even if he/she is released on  the same day, meets the criteria 
for the initial inpatient hospitalization. An emergency room vi sit that results in admission to 
the hospital would also qualify for the initial inpatient hospi talization criteria. However, 
emergency room visits that do not  result in admission to the ho spital would not qualify for 
this criteria and, instead, s hould be evaluated for 1 of the ot her criteria in the definition of 
serious (eg, life-threatening adve rse experience, important medi cal event).
Hospitalizations for reasons not associated with the occurrence  of an AE (eg, preplanned 
surgery or elective surgery for a pre-existing condition that h as not worsened or manifested 
in an unusual or uncharacteristic manner) do not qualify for re porting. For example, if a 
subject has a condition recorded on his/her medical history and  later has a preplanned surgery 
for this condition, it is not appropriate to record the surgery  or hospitalization as an SAE, 
since there is no AE upon which to assess the serious criteria.  Please note that, if the 
pre-existing condition has worsened or manifested in an unusual  or uncharacteristic manner, 
this would then qualify as an AE and, if necessary, the serious ness of the event would need to 
be determined.
Hospitalization for diagnostic or therapeutic procedures in the  absence of any associated AE 
will not be considered as an SAE , except when otherwise require d by regulatory authorities. 
If a hospitalization is planned pri or to the subject receiving the first dose of IMP (at Week 0),
it will not be classified as either an AE or SAE. This also app lies to a scheduled elective 
surgery where no AE is present. A noncomplicated, preplanned el ective surgery will not be 
considered an AE or SAE even if it involves hospitalization. Ho wever, if a hospitalization is 
unplanned or is a result of an AE, this will be considered to b e an SAE.REDACTEDe/shee/sh
An emAn em
he initie ini
t resulresu
be ebe eCOPY n of hoof ho
he ihe i
This documentIIcannot ee
Hospitaospita
will will be uld
rminrminsedg condcond
d thethetoo AEo Asupportracteacte
ion recon rec
it is nit is 
Eanyfor afor 
eriserimarketinglt 
evaluaevalua
rse expse ex
ot assot asauthorization osp
is reles rele
mergenmergen
tial inpal in
in ain aapplicationAs ws w
uiremenreme
spitalipitaliandE reporepo
witwiany textensions uiring uiring 
do noto not
antibiantibior variations dize ize 
of thef thethereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 92 of 25512.2.2 Procedures for reporting serious adverse events 
If an SAE is reported, UCB m ust be informed within 24 hours of r eceipt of this information by 
the site (see contact information for SAE reporting listed in t he Serious Adverse Event Reporting 
section at the front of the protocol). The Investigator must fo rward to UCB (or its representative) 
a duly completed “Investigator SAE Report Form for Development Drug” (SAE report form) 
provided by UCB, even if the data are incomplete, or if it is o bvious that more data will be 
needed in order to draw any concl usions. Information recorded o n this form will be entered into 
the global safety database.
An Investigator SAE report form w ill be provided to the Investi gator. The Investigator SAE 
Report form must be completed in English. 
It is important for the Investigator, when completing the SAE r eport form, to include the 
assessment as to a causal relationship between the SAE and the IMP administration. This insight 
from the Investigator is very important for UCB to consider in assessing the safety of the IMP 
and in determining whether the SAE  requires reporting to the re gulatory authorities in an 
expedited manner.
Additional information (eg, autopsy or laboratory reports) recei ved by the Investigator must be 
provided within 24 hours. All documents in the local language m ust be accompanied by a 
translation in English, or the relevant information included in  the same document must be 
summarized in the Investigator SAE report form.
The Investigator is specifically requested to collect and repor t to UCB (or its representative) any 
SAEs (even if the Investigator is certain that they are in no w ay associated with the IMP), up to 
30 days from the end of the study for each subject (which is us ually the FU visit), and to also 
inform participating subjects of the need to inform the Investi gator of any SAE within this 
period. Serious AEs that the Investigator thinks may be associa ted with the IMP must be reported 
to UCB regardless of the time between the event and the end of the study.
Upon receipt of the SAE report f orm, UCB will perform an assess ment of expectedness of the 
reported SAE. The assessment of t he expectedness of the SAE is based on the current version of 
the CZP Investigator Brochure (IB).
12.2.3 Follow up of serious adverse events 
An SAE should be followed until it has resolved, has a stable s equelae, the Investigator 
determines that it is no longer clinically significant, or the subject is lost to follow up. 
Information on SAEs obtained after clinical database lock will be captured through the DS 
database without limitation of time.
12.3 Adverse events of interest 
An AE of interest is any AE wh ich is listed in the European Ris k Management Plan, or meets 
another commitment requiring nonstandard expedited reporting, e ven if the AE does not fulfill 
the expedited reporting criteria  of “serious,” “unexpected,” an d “associated with the use of the 
drug.” Adverse events of interest include: 
x Serious infections includi ng opportunistic infections
x Malignancies including lymphomaREDACTEDcolleccollec
hat theat the
ach suach su
need toneed t
gatogatoCOPYcludeclud
This document An AAn A
anancannote witwi
33ben onn on
ththused e fe 
t it is it is 
SStofollfollsupportchure hure
w up ow up oany forfo
t of tht of t
(marketingto ino in
or thinor thin
een theen th
orm, Urm,authorization t and rt and 
ey are y are 
ubject bject
infonfoapplication ved byved b
ge musge mu
d in thd in thand ry ay aanyhe sahe s
authautextensions r S
ncludeclude
stratiotratio
fforSAEAEvariations to o thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 93 of 255x Congestive heart failure
x Demyelinating-like disorders
x Aplastic anemia, pancytopenia , thrombocytopenia, neutropenia, a nd leucopenia
x Serious bleeding events
x Lupus and lupus-like illness
x Serious skin reactions (eg., Stevens Johnson Syndrome, toxic ep idermal necrosis, and 
erythema multiforme)
Note : Potential Hy’s Law, defined as ≥3xULN ALT or AST with co existing ≥2xULN total 
bilirubin in the absence of ≥2xULN ALP, with no alternative exp lanation for the biochemical 
abnormality, must ALWAYS be reported to UCB as an AE of interes t (ie, without waiting for 
any additional etiologic investigations to have been concluded) . Follow-up information should 
then be reported if an alternati ve etiology is identified durin g investigation and monitoring of the 
subject.
12.4 Immediate reporting of adverse events 
The following AEs must be reported immediately:
x SAE: AE that the Investigator classifies as serious by the abov e definitions regardless of 
causality
x Suspected transmission of an infect ious agent via a medicinal p roduct
x AE of interest (see Section 12.3)
12.5 Laboratory measurements 
Hematology, biochemistry, urinalysis, and CRP samples will be t aken at Screening, Baseline, 
Weeks 2, 4, 8, 12, 24, 36, 52/WD, and at the FU visit (8 weeks after the Week 52/WD visit). 
Testing to rule out hepatitis B, hepatitis C, and HIV will be p erformed at Screening as well as the 
HLA-B27 antigen determination. S ubjects will be encouraged to b e in fasting condition at 
Baseline and at Week 52/WD or at the time the subject shifts to  alternative treatment, for 
Apo A1, ApoB, and lipoprotein(a) assessments.
The urinalysis will be performe d with a dipstick, and in case o f a positive outcome, on a clean 
catch urine sample sent to the central laboratory for analysis.  
The central laboratory will analyze and assess blood and urine samples for the following (except 
where indicated):
Table  12‒1: Laboratory measurements up to Week 52 (including the FU visit 
(8 weeks after the Week 52/WD visit) 
Hematology Serum biochemistry Urinalysis Others
Red blood cells Sodium pH
Hemoglobin Potassium Protein Hepatitis B surface 
antigenREDACTED agentagent
suresureCOPY ous byous by
This document TaTa
mmmmcannotindicndic
ableblebel labl labused ill bl b
mple smple sto be pbesupportnatioatio
2/WD o/WD
ipopropoproanyhepahep
ion. onmarketingemeneme
is, ands, an
, and aand
tauthorization y 
t via avia aapplication the athe aand any infin
on andn anextensionsLN toLN to
e biochbioch
thout whout 
nforforor variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 94 of 255Table  12‒1: Laboratory measurements up to Week 52 (including the FU visit 
(8 weeks after the Week 52/WD visit) 
Hematology Serum biochemistry Urinalysis Others
Hematocrit Chloride Glucose Antibodies to 
hepatitis C
Platelets Bicarbonate Blood Antibodies to HIV
White blood cells Total calcium Esterase HLA-B27
Neutrophils Inorganic phosphorus
Lymphocytes CRP
Monocytes Creatine phosphokinasea
Eosinophils Glucose Microscopy (WBC, 
RBC, casts, crystals, 
bacteria) (Microscopy 
will be performed only when there are 
abnormalities on 
dipstick)
Basophils Creatinine Urine-sample to be 
collected for 
central -laboratory 
analysis only when 
there are abnormalities 
on dipstick
Uric acid
Urea
Total protein
Albumin
Alkaline phosphatase
Aspartate 
aminotransferase 
Alanine aminotransferase 
Bilirubin
Total cholesterol
HDLbDEDCOPYhen then 
abnoabno
didC
This document nt
mcannot otbe used usto tosupport reaea
ToToppsuany dd
amarketing maauthorization rmam
ipstickpstick
UriUriat
hoapplication stals, tals
croscoprosco
rformedforme
here arere ar
malitialitiand , dany yaaaaaextensions ns
teneor variations on
Vtio
vthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 95 of 255Table  12‒1: Laboratory measurements up to Week 52 (including the FU visit 
(8 weeks after the Week 52/WD visit) 
Hematology Serum biochemistry Urinalysis Others
LDLb
HbA1cc
Apo A1
ApoB
Lipoprotein(a) 
Apo=Apolipoprotein; CRP=C-reactiv e protein; FU=Follow-Up; HbA1c =glycated hemoglobin; HDL=high density 
lipoprotein; HIV=human immunodeficiency virus; HLA -B27=human leukocyte antigen B27; LDL= low- density 
lipoprotein; RBC=red blood cells ; WBC=white blood cells; ULN=up per limit of normal  
aCreatine phosphokinase subtypes (CK-MM; CK-MB, and CK-BB) are r equired if the creatine phosphokinase 
measurement is >2 ULN.
bHDL and LDL are to be measured every 6 months and at the time t he subject shifts to open-label CZP.
cHbA1c is to be measure at Baseline and Week 52/WD or at the tim e the subject shifts to open-label CZP.
For subjects participating in the SFE Period after Week 52, it is recommended that laboratory 
assessments be performed at the lo cal laboratory at the discret ion of the Investigator according to 
local standard medical practice to evaluate potential AEs. At W eek 156/SFE-WD, a blood 
sample will be taken for CRP mea surement and analyzed at the ce ntral laboratory.
12.6 Other safety measurements 
12.6.1 Pregnancy testing 
Pregnancy testing must be carried out for women of childbearing  potential and will consist of 
serum testing at Screening and FU and urine testing (dipstick) at Baseline, at wdt Week 0 of the 
alternative study assessment (for s ubjects administering either  open-label CZP or alternative 
treatment), and at Week 52/WD. 
For subjects participating in the SFE Period after Week 52, it is recommended that pregnancy 
testing be performed according to local standard medical practi ce.
12.6.2 Physical assessments 
Physical examination will be perform ed at Screening, Baseline, Weeks 2, 4, 8, 12, 16, 24, 36, 
52/WD, and at the FU visit (8 weeks after the Week 52/WD visit fo r subjects not participating in 
the SFE Period). It is recomme nded that physical examinations b e performed according to local 
standard medical practice for subjects participating in the SFE  Period after Week 52,
Physical examination findings will be recorded in the CRF only at Screening. Clinically 
important abnormal changes in subsequent physical examinations will be recorded as AEs. 
Physical examinations must be  documented in source documentatio n.
The following body systems will be examined:
x General AppearanceREDACTEDory ary 
potentpotent
ent anent an
asureasureCOPY he te 
WeekWee
at tat
This documentstandtand
PhPcannot exex
D, andD, and
SFE PSFE 
ddbe xamxamused medmed
PhyPhytoat
ed acdasupportnt (ft (f
52/WD2/W
ting iing ianyFU FU
for sformarketingemem
out foout f
anauthorizationk 5252
the dihe di
tial Aal A
nd anad ana
menmenapplicationred ied 
subject subject
 the the subsu
2, it2i tand tigege
fn o r m anorma
if tif tanyogloboglob
en B2en Byextensions s
ns
eor variations onononon
vathereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 96 of 255x Ear, nose and throat
x Eyes
x Hair and skin
x Respiratory
x Cardiovascular
x Gastrointestinal
x Musculoskeletal
x Hepatic
x Neurological (including limb reflexes)
x Mental Status
In addition, the TB signs and sym ptoms will be assessed at Scre ening, Baseline, Weeks 2, 4, 8, 
12, 16, 24, 36, completion at Week 52/WD visit and FU (8 weeks a fter the Week 52/WD visit for 
subjects not participating in the SFE Period).
Weight is to be measured at Screening, Week 24, and at completi on at Week 52/WD. Height will 
be measured at the Baseline visit only.
12.6.3 Assessment and management of TB and TB risk factors 
As TNFi are known to be associated with significant risk of rea ctivation of LTB, appropriate 
rigorous precautions are being taken within the protocol to add ress this (see Section 6.2
[Exclusion Criterion 16] and Section 6.3[Withdrawal Criterion 6]).
Signs and Symptoms
The Investigator should consider all potential sites of infecti on when assessing for TB during the 
subject’s history and the physical examination, and other evalu ations. Sites commonly infected 
by TB include: the lungs, larynx, lymph glands, pleura, gastroi ntestinal system, genito-urinary 
tract (including renal), bones and joints, meninges, peritoneum , pericardium, and skin. This is 
not an exhaustive list and unusual presentations and areas of i nvolvement should always be 
considered. 
Common symptoms that the subject may present with include cough , blood in sputum, night 
sweats, lymphadenitis, joint pain /swelling, spinal deformity, h eadache/confusion, abdominal 
pain mimicking IBD, frequent or pa inful urination, scrotal mass  in men and pelvic inflammatory 
disease in women as well as other symptoms, or nonspecific symp toms. This is not an exhaustive 
list and unusual presentations should always be considered.
The subject may present an absence of signs, symptoms (ie, evid ence of organ-specific 
involvement), or physical findings suggestive of TB infection w ith a positive IGRA test (or 
2 indeterminate IGRA test results) and a chest x-ray (or other i maging) without evidence of TB 
infection. If the result of the IGRA test is indeterminate, the  particular IGRA test previously 
performed may be repeated once;  if positive or indeterminate on  retest, the subject may not be 
randomized to study medication without further evaluation, trea tment, and discussion with Study 
Physician, if LTB infection is identified. (If active TB is iden tified, subject must undergo REDACTED menmen
signifisignifi
thin ththin th
6.36.3[W[COPY at a
nt ont
This documentThe The 
inincannot micic
e in we in w
and uand ube phap
ckingckinusedptoms toms
hadeadeto support ryny
ones annes a
and unnd unanyal exal e
nx, lnx, lmarketing WiW
all potell po
exaexauthorization of TBof TB
ficant rcant r
he he propro
Withdithdapplication afteaft
mpletiompletandg, Ba, Ba
fter terany seextensions or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 97 of 255appropriate study-specified withdrawal procedures.) The retest must be done during the 
protocol-defined Screening window.
Note: If available, respiratory or other specimens must also be  smear and culture negative for TB 
(CDC diagnosis of LTB infection [http://www.cdc.gov/TB/topic/te sting/default.htm]).
Test Conversion
Tuberculosis test conversion is  defined as a positive result (I GRA) for the current test but 
previous test results were negati ve (IGRA). All subjects with T B test conversion must 
immediately stop study drug administration. In case of a TB tes t conversion, the subject must be 
considered as having either a suspected new LTB or an active TB  infection and be promptly 
referred to an appropriate spec ialist (ie, pulmonologist, infec tious disease specialist) must be 
consulted for further evaluation. If test conversion indicates LTB infection, active TB, or 
nonmycobacterial TB infection then per UCB TB working instructi ons, TB test conversion 
(confirmed) should be classified as due to LTB infection, active  TB infection, or NTMB 
infection. Additional assessments (eg, blood tests or IGRA test , chest x-rays or other imaging) 
should be performed as medically indicated.
Latent TB
In case the evaluation by the appropriate specialist indicates a new LTB infection, a prophylactic 
TB treatment (as described in Section 6.2, Exclusion Criterion 16) should be initiated and study 
medication can be continued no soone r than 4 weeks after start of prophylactic TB treatment, if it 
is deemed likely that prophylactic TB treatment is continued to  completion by the Investigator.
If prophylaxis is not initiated, the subject must to be withdra wn. 
Every action should be discussed in advance with the Medical Mo nitor. Latent TB must be 
reported as an SAE.
Active TB/NTMB
Subjects who develop active TB or NTMB infection during the stu dy (conversion demonstrated 
by IGRA) must be immediately discontinued from study medication , and a withdrawal visit must 
be scheduled as soon as possib le, but not later than the next r egular visit. The subject should be 
encouraged to keep the FU visit (8 weeks after the Week 52/WD v isit for subjects not 
participating in the SFE Peri od). The TB must be  documented as an SAE. Treatment for TB 
should be started based on local guidelines.
Note that subjects with histor y of or active NTMB infection are  excluded from the study 
regardless of prior or current therapy.
Confirmed active TB is an SAE and an adverse event of special i nterest (AESI) and must be 
captured on an SAE report form  and provided to the Sponsor in a ccordance with SAE reporting 
requirements. As with all SAEs, periodic follow-up reports shou ld be completed as per protocol 
requirement until such time as the TB infection resolves. 
Subjects who prematurely discontinue treatment for LTB, or, in the opinion of the Investigator or 
Sponsor, are noncompliant with anti-TB therapy must discontinue  further use of study 
medication and be immediately wit hdrawn. Once withdrawn from st udy treatment, subjects not
participating in the SFE Per iod should return for the Week 52/WD  visit, complete all 
Week 52/WD assessments, and complete a FU visit (8 weeks after t he Week 52/WD visit).REDACTEDent isent is
t must must
advanadvanCOPY dicic
on Crion Cri
eeks aeeks 
This documentaptpt
requirequi
rerecannot s os 
firmedrmed
turedurebe bjej
of pof pusedd basba
ectsectstoSFESF
asesesupport tele
possiblossib
e FU vFU 
FE PEPanyB or B or
lly diy dimarketing nce ce
rNrNauthorizationafter after 
continconti
t to to bebe
e wiwiapplication s a newa ne
terion erion
tand x--raraanyion, ion,
ays aysextensionsompomp
st) mut) mu
ve TBve TB
est coest coormumu
ptlptlvariations ustustthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 98of 25512.6.3.1  Tuberculosis assessments  
During conduct of the study the TB assessment by IGRA will be p erformed at Screening and 
should be repeated at Week 52/WD for all subjects not participating in the SFE Period. It is 
recommended that TB testing be perfor med according to local standard medical practice during 
the SFE Period. 
The test results will be reported as positive, negative, or ind eterminate and mu st be reviewed by 
an experienced TB specialist, radiologist, or a pulmonologist. If the assessment by I GRA is 
positive or indeterminate on retest  for subjects who were previ ously negative at Screening and 
not treated for LTB, the subject may not continue study treatme nt without further evaluation by a 
TB specialist, prophylactic TB treatment, and discussion with the Medical Monitor, if LTB 
infection is identified. If active TB is identified, subject mu st undergo appropriate study 
specified withdrawal procedures. The retest must be done during  the protocol -defined Screening 
window.
12.6.3.2  Chest x -ray 
A plain postero anterior chest x -ray must be done at Screening unless a chest x -ray (or a 
computed tomography of the chest) has been done within 3 months  prior to the Screening visit. 
The chest x -ray must be clear of signs of TB infection (previous or current ) before firs t study 
drug administration. For subjects not participating in the SFE Period the chest x -ray will be 
repeated at Week 52/WD visit (if chest x -ray was performed more than 12 weeks prior to 
Week 52/WD visit), only if the TB test was confirmed positive or an y further evidence is 
suggestive of potential TB infe ction (eg, exposure). It is reco mmended that the chest x -ray be 
repeated for subjects participating in the SFE Period, if the T B test was confirmed positive or 
any further evidence is suggestive of poten tial TB infection (eg, exposure). Radiographic 
findings suggestive of inactive TB or active TB may include but  are not limited to: apical 
fibrosis, pleural thickening, pulmonary nodules, fibrotic scars , calcified granulomas, upper lobe 
infiltrates, cavitat ions and pleural effusions, calcified lung nodules, calcified h ilar lymph nodes, 
and pericardial calcification.
The chest x -ray (or, if done, the computed tomography of the chest) must be  negative for TB 
infection as determined by a qualified radiologist and/ or pulmonary physician. Any new 
clinically significant findings post -Baseline during physical exam or on chest x -ray must be 
documented in the source doc uments and CRF as an AE.
12.6.3.3  QuantiFERON or Elispot testing  
At Screening all subjects will have an IGR A test (QuantiFERON tube test or Elispot, if 
QuantiFERON test indicated is not available). The TB test will be repeated at completion at 
Week 52/WD for subjects not participating in the SFE Period. It  is recommended that TB testing 
be performed according t o local standard medical practice during the SFE Period. Result s of the 
tests will be reported as posi tive, negative, or indeterminate.
12.6.3.4  Tuberculosis questionnaire  
The questionnaire ” should be used as a 
source document. The questionnaire will  be completed at Screening, Baseline, and every 
12weeks thereafter including and up to Week 36 and including Week  52/WD visit. REDACTEDnfirnfi
posureposure
SFE PSFE P
potenpoten t
r actr actCOPYn the n the
 perfoperf
irmrm
This document e pee pe
teststestscannotFEROERO
ek 52/Wk 52/W
perferfbeng ang a
OOused QuaQua
ltosoursousupport, theth
by a quby a q
findinginding
rceany he cohe cmarketingtive Ttive T
ry nodury nod
effusioffusiauthorizationormrm
med poed po
re). It i). It i
PeriodPeriod
ial TBal TBapplication ess 
nths prths p
ous or ous o
SFE PeFE P
med medand s a ca cany extensionsua
, if LTif LT
te stude stud
defindefinorationtiovariations y y
and and thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 99of 255The questionnaire will assist wi th the identification of subjec ts who may require therapy fo r TB. 
A subject who answers “Yes” to the question “  
 at Screening 
is excluded. A “Yes” response to any of the other questions wit hin the questionnaire at Screening 
should trigger further careful assessment to determine if subje ct has LTB or active TB (see 
Exclusion Criterion 16, Section 6.2). A “Yes” response to any of the questions during the study 
should trigger further assessmen ts to determine if the subject has either LTB or active TB 
infection (see Appendix 18.12 ).
Subjects with a LTB infection mus t receive prophylactic therapy  prior to continuing study drug 
(if allowed by prophylactic therapy specific protocol).
Subjects with active TB infection must be withdrawn fro m the study and will have further 
assessments.
12.6.3.5  Tuberculosis management  
For inclusion in the study, see Section 6.2(Exclusion Criterion 16).
It is t he Sponsor’s requirement that all subjects who are on LTB treat ment at Baseline must 
comply with the full therapy course (see Section 6.2, Exclusion Criterion 16). 
LTB infection and active TB identified during study
During the study, subjects who develop evidence of LTB infectio n or active TB must 
immediately stop further administration of study medication and  will be referred to an 
appropriate TB specialist (pulmonol ogist or infectious disease specialist) for further evaluation. 
Evidence of LTB infection is defined as subject’s IGRA test con verts to positive or 
indeterminate (and confirmed i ndeterminate on repeat), or the s ubject’s questionnaire or history 
and physical indicates that TB infection or exposure may have occurred. Evidence of active TB 
includes, in addition to the aforementioned tests, signs and sy mptoms of organ involvement. In 
either situation, the subject should be carefully assessed by a  TB specialist for active TB. 
Subjects diagnosed with active TB or LTB infection should receive appropriate TB or 
prophylaxis therapy. 
If a TB specialist excludes an active TB infection the subject can proceed with the study drug no 
earlier than 4 weeks after the s tart of an appropriate prophyla ctic therapy. 
Any presum ptive diagnosis or diagnosis of a TB infection is a reportable event. Confirmed active 
TB must be reported as an SAE; confirmed LTB as AESI (please se e Sections 12.2 and 12.3).
The Investigator is to complete and submit the TB follow up for m provided.
The subject should be transferred to the care of his/her physic ian and managed according to the 
best available standard of care . Subjects identified as having converted to active TB during the 
study must be withdrawn and sch eduled to return for the Week 52 /WD visit as soon as possible 
but no later than the next schedu led study visit and complete a ll Week 52/WD visit assessments. 
The subject should be encouraged to complete a FU visit (8 week s after the Week 52/WD visit).
If infection with NTMB is identifie d during the study, the same procedure as for active TB 
acquired during the study must be followed.REDACTEDudy mudy m
or infeor infe
s subjes subje
rminatrminat
tiontionCOPY udyudy
PYe of LTof LT
m
This documentstudyudy
butbutcannotubject bject 
t availavai
ybeigatoigatousede diae dia
eporteporteto agagsupport des an es an
after thfter tanyTB TBmarketing ate e 
n or exor ex
ntionedioned
d be cabe c
orauthorizationLTB iLTB i
medicatedicat
ectiousctiou
ect’s Ict’s I
 on on applicationtreatmreat
n CriteCrit
infand many extensions ve furve furody ddy dvariations drudrthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 100 of 255Subjects with LTB infection mus t not undergo IGRA testing. The IGRA test should be used for 
any protocol mandated monitoring.
Follow-up information of suspected and confirmed TB cases shoul d be provided to UCB at least 
after 3, 9, and 12 months of the start  date of anti-TB treatmen t, including hematological and 
biochemical safety parameters, x-ray evolution data, and TB dia gnostic procedures used to 
follow up and confirm recovery of TB.
12.6.4 Vital signs 
Subjects should be sitting for 5 minutes prior and during the co llection of blood pressure, pulse 
rate, and respiration rate measurements. 
Vital signs, including temperature will be measured at all on-s ite visits including the FU visit 
(8 weeks after the Week 52/WD visit) with the exception of the W eek 1 visit (respiration rate 
will be measured at Screening and Baseline only unless the subj ect has an AE). It is 
recommended that vital signs be measured according to local sta ndard medical practice during 
the SFE Period. 
13 STUDY MANAGEMENT AND ADMINISTRATION 
13.1 Adherence to protocol 
The Investigator should not deviate from the protocol. However,  the Investigator should take any 
measure necessary in deviation from or not defined by the proto col in order to protect clinical 
study subjects from any immediate hazard to their health and sa fety. In this case, this action 
should be taken immediately, without prior notification of the regulatory authority, IRB/IEC, or 
sponsor.
After implementation of such measure, the Investigator must noti fy the CPM of the Sponsor 
within 24 hours and follow any local regulatory requirements.
13.2 Monitoring 
UCB (or designee) will monitor the study to meet the Sponsor’s monitoring Standard Operating 
Procedures (SOPs), ICH-GCP guideline, and applicable regulatory  requirements, and to ensure 
that study initiation, conduct, and closure are adequate. Monit oring of the study may be 
delegated by UCB to a CRO or a contract monitor.
The Investigator and his/her staff are expected to cooperate wi th UCB (or designee) and to be 
available during the monitoring  visits to answer questions suff iciently and to provide any 
missing information. The Investigator(s)/institution(s) will pe rmit direct access to source 
data/documents for study-related monitoring, audits, IRB/IEC re view, and regulatory 
inspection(s).
The Investigator will allow UCB (or designee) to periodically r eview all CRFs and 
corresponding source documents (eg, hospital and laboratory reco rds for each study participant). 
Monitoring visits will provide UCB (or designee) with the oppor tunity to evaluate the progress 
of the study, verify the accuracy and completeness of CRFs, ens ure that all protocol 
requirements, applicable authorities’ regulations, and Investig ator’s obligations are being 
fulfilled, and resolve any inconsistencies in the study records .REDACTEDtheirtheir
or notir noti
ure, thure, thCOPY col. Hcol. H
ned byed b
This documentThe The 
corcorcannot cumume
ectionction
Ibeformformusedr andand
ng thng thto o a
dhdhsupportGCP gCP 
nduct, nduct
a CRa CRany or theor th
gmarketingthe Inhe In
regulatregulaauthorizationy the y the
healthhealth
ificatificatiapplication STRST
owevewevand RRany AE
edicaledicaextensions the FUthe F
(respirespir
E). IE). Ior, pu, pvariations pulspulsthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 101 of 25513.2.1 Definition of source data  
All source documents must be accurate, clear, unambiguous, perm anent, and capable of being 
audited. They should be made usin g some permanent form of recor ding (ink, typing, printing, 
optical disc). They should not be obscured by correction fluid or have temporary attachments 
(such as removable self-stick notes). Photocopies/printouts of electronic CRFs (eCRFs) are not 
considered acceptable source documents. Source documents are ori ginal records in which raw 
data are first recorded. These m ay include hospital/clinic/gene ral practitioner records, charts, 
diaries, x-rays, laboratory results, printouts, pharmacy record s, care records, ECG or other 
printouts, completed scales , or QoL questionnaires, for example . Source documents should be 
kept in a secure, limited access area.
The following data will be recorded directly in the electronic patient reported outcome (ePRO) 
Tablet on site and will not appea r in a source document as defi ned above:
x Patient Reported Outcome questi onnaires: SF-36, EQ-5D-3L, PGADA , BASDAI, BASFI, 
ASQoL, MOS Sleep Scale, Total and Nocturnal Spinal Pain Questio nnaire
Source documents that are comput er generated and stored electro nically must be printed for 
review by the monitor (eg, ECG r eports). Once printed, these co pies should be signed and dated 
by the Investigator and become a permanent part of the subject’ s source documents. The 
Investigator will authorize the monitor to compare the content of the printout and the data stored 
in the computer to ensure  all data are consistent.
Electronic data records such as MR I records must be saved and s tored as instructed by UCB (or 
designee).
13.2.2 Source data verification 
Source data verification ensures accuracy and credibility of th e data obtained. During monitoring 
visits, reported data are reviewe d with regard to being accurat e, complete, and verifiable from 
source documents (eg, subject file s, recordings from automated i nstruments, ECG tracings, x-ray 
films, laboratory notes). All data reported on the CRF should b e supported by source documents, 
unless otherwise specified in Section 13.2.1 .
13.3 Data handling 
13.3.1 Case report completion 
This study will be using remote  data capture (RDC); the Investi gator is responsible for prompt 
reporting of accurate, complete, and legible data in the eCRF a nd in all required reports.
Serious adverse event reporting will be done using the SAE form  (see Section 12.2) while also 
entering the event in the appropri ate eCRF section. The safety d atabase and the clinical database 
will be reconciled during the s tudy and discrepancies will be c orrected as needed.
The Investigator should maintain a list of personnel authorized  to enter data into the eCRF. 
Access to the RDC will be given a fter training has been receive d. A training certificate will be 
provided and filed. 
Detailed instructions on the use of the RDC will be provided in  the eCRF Completion 
Guidelines.REDACTEDmust must
ationation
uracuracCOPYhe cohe co
b
This document ill ll
TheThe
Acannotadvadv
ring thng th
l be be be fa cac
ererusedl be usbe us
ccurccurtose re rsupport n Sn S
andliandl
repreanyta reta re
SectiSecmarketing cy andcy and
th regah reg
es, recos, rec
epoauthorization be savbe savapplication nicaica
opies spies 
ect’s soect’s s
ntent ontent and ionon
allyallyanyA, BAA, B
nnairnnaextensions tcomecome
AAoruld uldvariations db edbthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 102 of 255Corrections made after the Investigator’s review and approval ( by means of a 
password/electronic signature) wil l be re-approved by the Inves tigator. Any change or correction 
to the eCRF after saving must b e accompanied by a reason for th e change.
13.4 Electronic reporting outcome 
Compared to the paper patient que stionnaires, the new electroni c options have several 
advantages combining handheld devices in conjunction with onlin e technologies in order to send 
subject self assessments directly to a central server. The coll ected data could then be reviewed in 
real time for monitoring of subject symptoms and compliance. Th e ePRO possibilities will be 
used in this study.
This study will use an electronic Site Tablet having a large sc reen and intuitive fingertip data 
entry to ensure all questionnaire data are captured appropriate ly, completely and on time. Only 
subjects’ data will be collected with the tablets; the data of both the physicians (joint counts and 
PhGADA) and WPS will be entere d directly in the eCRF or collect ed on worksheets.
Access to the system by site personnel will be given after trai ning has been received. A training 
certificate will be provided and filed. The Investigator should  maintain a list of personnel 
authorized to enter data into the electronic ePRO device.
13.5 Database entry and reconciliation 
Case Report forms/external electronic data will be entered/load ed into a validated electronic 
database using a clinical data monitoring system (CDMS). Comput erized data cleaning checks 
will be used in addition to manua l review to check for discrepa ncies and to ensure consistency of 
the data. Case Report form data are entered into the clinical d atabase by site personnel. 
An electronic audit trail system will be maintained within the C DMS to track all data changes in 
the database once the data have been saved initially into the s ystem or electronically loaded. 
Regular backups of the elect ronic data will be performed.
The subject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
Log.
The Investigator will keep a list containing all subjects enrol led into the study. This list remains 
with the Investigator and is us ed for unambiguous identificatio n of each subject. The list contains 
the subject identification number, full name, date informed con sent signed, date of screening, 
and the hospital number or National Health Security number, if applicable.
The subject’s consent and enrollmen t in the study must be recor ded in the subject’s me dical 
record. These data should identify the study and document the d ates of the subject’s 
participation.
13.6 Termination of the study 
UCB reserves the right to temporarily suspend or prematurely di scontinue this study either at a 
single site, multiple sites, or at all sites at any time for re asons including, but not limited to, 
safety or ethical issues, inaccura te or incomplete data recordi ng, noncompliance, or 
unsatisfactory enrollment with respect to quality or quantity.
If the study is prematurely terminated or suspended, UCB (or it s representative) will inform the 
Investigators/institutions and the regulatory authority(ies) of  the terminatio n or suspension and REDACTEDem (m (
o checo chec
red inted int
bebemama
ns ans aCOPY tiotio
e entee ente
(CD(C
This document 3.63.
UCUCcannot Thehe
ipatiopatio
66be s cs c
ese dese dusednumnum
concontocatiocati
bbsupport ep a lisp a li
and is und is 
ononany ollmollmarketingaintint
aved inved in
ata wilta wi
lmenmeauthorizationereded
DMS)DMS)
ck for k for 
to theo the
ntaintainapplication ntaintai
d/lod/loands beebee
ain ainanyworkwork
nextensions ngertipgertip
d on td on t
ns (jons (jo
kor variations nd nd 
ed in d in 
l be be thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 103 of 255the reason(s) for the termination or suspension, in accordance with applicable regulatory 
requirement(s). The IRB/IEC also should be informed and provide d with reason(s) for the 
termination or suspension by the Sponsor or by the Investigator /institution, as specified by the 
applicable regulatory requirement(s). In addition, arrangements  will be made for the return of all 
unused study drug and other mater ial in accordance with UCB pro cedures for the study.
Upon completion of the study, the monitor will conduct the foll owing activities in conjunction 
with the Investiga tor, as appropriate:
x Return of all study data to t he Sponsor or its representative
x Data clarification and/or resolution
x Accountability, reconciliation, and arrangements for used and u nused study drugs
x Review of site study records for completeness
x Discussion/reminder on archiving responsibilities
Further details will be given i n the monitoring guidelines.
13.7 Archiving and data retention 
The Investigator will maintain ade quate records for the study, including CRFs, medical records, 
laboratory results, Informed Consent documents, drug dispensing  and disposition records, safety 
reports, information regarding participants who discontinued, a nd other pertinent data.
All essential documents are to be retained by the Investigator until at least 2 years after the last 
approval of a marketing applicat ion in an ICH region and until t here are no pending or 
contemplated marketing applications in an ICH region, or at lea st 2 years have elapsed since the 
formal discontinuation of clinical development of the investiga tional product. These documents 
should be retained for a longer period, however, if required by  the applicable regulatory 
requirement(s) or by an agreement with UCB (CPMP/ICH/135/95, 20 02 [Section 4.9.5]). The 
Investigator will contact UCB for authorization prior to the de struction of any study records or in 
the event of accidental loss or destruction of any study record s. The Investigator will also notify 
UCB should he/she relocate or move  the study-related files to a  location other than that specified 
in the Sponsor’s study master file.
13.8 Audit and inspection 
The Investigator will permit study-related audits mandated by U CB, after reasonable notice, and 
inspections by domestic or foreign regulatory authorities.
The main purposes of an audit or inspection are to confirm that  the rights and well-being of the 
subjects enrolled have been protected, that enrolled subjects ( ie, signing consent and undergoing 
study procedures) are appropriate for the study, and that all d ata relevant for the evaluation of the 
IMP have been processed and reporte d in compliance with the pla nned arrangements, the 
protocol, investigational site , and IRB/IEC SOPs, ICH GCP, and applicable regulatory 
requirements.
The Investigator will provide direct access to all study docume nts, source records, and source 
data. If an inspection by a regulatory authority is announced, the Investigator will immediately 
inform UCB (or designee).REDACTED y the Iy the 
n ICH ICH
in an Iin an 
eveloeveloCOPY he se 
rug dirug d
discondisco
This document tudyudy
IMPIMP
ppcannotain puin pu
ects encts e
dy pypbeby by used or wilor wil
yd odotodit dit supportate or e or
mastermaste
anaany or aor 
destrdestrmarketingopmenpmen
d, howe, how
with Uwith 
authautauthorizationntinuntinu
Investnves
regioregio
CH rCH rapplication dy, incly, in
spensipensand any extensions drugsrugsor variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 104 of 25513.9 Good Clinical Practice 
Noncompliance with the protocol, ICH-GCP, or local regulatory r equirements by the 
Investigator, institution, institution staff, or designees of t he Sponsor will lead to prompt action 
by UCB to secure compliance. C ontinued noncompliance may result  in the termination of the 
site’s involvement in the study.
14 STATISTICS 
A description of statistical m ethods follows and will be descri bed in more detail in the SAP.
14.1 Definition of analysis sets 
The Enrolled Set (ES) will consist of all subjects who have giv en informed consent. 
The Randomized Set (RS) will consist of all subjects randomized  into the study. 
The Safety Set (SS) will cons ist of all subjects who have recei ved at least 1 dose of study 
medication. 
The Full Analysis Set (FAS) wil l consist of all subjects in the  RS who have received at least 
1 dose of study medication. 
The Per Protocol Set (PPS) will consist of subjects in the FAS without any important protocol 
deviations that may influence th e validity of the primary effic acy data. The PPS may also require 
that a defined period of exposure to study medication be comple ted. Important protocol 
deviations will be predefine d and evaluated prior to study unbl inding/database lock. 
The SFE Safety Set (SFE-SS) will be defined as all subjects who  continued into the SFE Period 
and who received at least 1 dose of CZP in the SFE Period.
The SFE Full Analysis Set (SFE-FAS) will be defined as all subj ects in the FAS who continued 
into the SFE Period and who received at least 1 dose of CZP in the SFE Period.
14.2 General statistical considerations 
All efficacy analyses will be pe rformed using the FAS. The PPS will be used for a sensitivity 
analysis on the primary endpoint only. Analyses of efficacy vari ables in the SFE Period will be 
performed on the SFE-FAS.
The statistical analysis of the  primary efficacy variable and s elected secondary efficacy variables 
will account for multiplicity by us ing a fixed sequence testing  procedure. The predefined order 
of hypothesis testing, each at a 2-sided 0.05 significance leve l for the comparison between 
CZP 200mg Q2W and placebo, will be p erformed in the sequence sho wn below. After the first 
test, each subsequent test is performed only if the previous te st is significant in favor of CZP at 
the 2-sided 0.05 level. Note that the first test relates to the  primary efficacy variable while the 
others provide the sequence testing for selected secondary effi cacy variables.
1. ASDAS-MI response at Week 52 
2. ASAS40 response at Week 12 
3. Change from Baseline in BASDAI at Week 12
4. Change from Baseline in BASFI at Week 12 REDACTEDprior trior 
fined afined 
ZP in tZP in
AS) wAS)COPY theh
imary imary
ation ation
This documentotherother
11cannot mgm
ach suach su
22--sidsidbe is t
g Qg Qusedalyly
or mulr mul
testtesttoysis ysissupport e pp
endpoinndpoi
FAS.FASany tt
perfoerfmarketing will bewill b
d at led at l
ical icaauthorizationy
be cobe c
o studo stud
as all as all 
the SFhe SFapplication whowh
AS witAS w
efficaefficaand ho hohany1 do1 doextensions nt. t. 
dy. y. or variations P..thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 105 of 2555. ASAS40 response at Week 52
6. Change from Baseline in BASDAI at Week 52
7. Change from Baseline in BASFI at Week 52
8. Change from Baseline in SI joint SPARCC score at Week 12
9. Change from Baseline in ASQoL at Week 52
10. Change from Baseline in nocturnal spinal pain (NRS) at Week 52
11. Number of subjects with AU or new AU flares through Week 52
Hierarchical testing of efficacy  variables for Canada (and any o ther country where applicable or 
where requested by Regulatory Authorities):  
1. ASAS40 response at Week 12 
2. ASDAS-MI response at Week 52  
3. Change from Baseline in BASDAI at Week 12
4. Change from Baseline in BASFI at Week 12 
5. ASAS40 response at Week 52
6. Change from Baseline in BASDAI at Week 52
7. Change from Baseline in BASFI at Week 52
8. Change from Baseline in SI joint SPARCC score at Week 12
9. Change from Baseline in ASQoL at Week 52
10. Change from Baseline in nocturnal spinal pain (NRS) at Week 52
11. Number of subjects with AU or new AU flares through Week 52
Variables evaluated over time will be summarized using imputed and observed case values. 
Further details on data summari zation will be provided in the S AP.
14.3 Planned efficacy analyses 
The primary efficacy variable measurement for this study is bas ed on ASDAS-MI response at 
Week 52. The associated primary  outcome of the study will be de fined as a composite endpoint 
that is achieved if a subject fulfills the following 2 componen ts:
1. Remain in the study and on the double-blind study treatment thr ough 52 weeks
2. Achieve an ASDAS-MI response at 52 weeks
For simplicity, this primary efficacy variable will be referred  to as ASDAS-MI response at 
Week 52. However, the composite de finition as described above wi ll apply when this endpoint is 
analyzed. The primary analysis for this endpoint will be based on logistic regression. The odds 
ratio of the ASDAS-MI responder ra tes at Week 52 will be estima ted and tested between 
treatment groups using a logist ic regression model with factors  of treatment group, region, and 
MRI/CRP classification (MRI+/CRP+; MRI+/CRP-; MRI-/CRP+). If th e logistic regression REDACTEDek 52ek 5
Week 5Week 5
SPARSPAR
aaCOPY 22
This document2.AA
FoFcannotchiehie
RemaiRemai
AAbeThe ahe 
eveeveused ffficacyicacyfff
assasstonnennsupporttime wme 
summaumm
ededanyU orU omarketing RC
at Weekt Week
urnal sprnal authorization 5252
CC sCC sapplication and any extensions here apere apteor variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 106 of 255model is unable to converge, then the MRI/CRP classification va riable may be dropped from the 
model to facilitate convergence. The study design is likely to result in some sites with a small 
number of enrolled subjects. The use of region as a stratificat ion variable and as a factor in the 
model is intended to combine study centers in similar geographi c regions. The geographic
regions to be used will be define d in the IXRS and in the SAP. Given the composite endpoint 
definition described above, the re will be no missing data for t he primary endpoint, as subjects 
that discontinue the double-blind study treatment prior to Week  52 or who do not have an 
ASDAS-MI status at Week 52 are considered nonresponders to the d ouble-blind study treatment.
As described in Section 6.3, subjects who discontinue the double-blind study treatment wil l not 
necessarily be withdrawn from the study. In an attempt to minim ize missing data, efforts will be 
made to continue to collect safety and efficacy data on these s ubjects through study completion.
Sensitivity analyses will be performed to evaluate the impact o f missing data on the analysis of 
the primary efficacy variable (see Section 14.8).
For Canada (and any other country where applicable or where req uested by Regulatory 
Authorities), the primary efficacy variable measurement is the ASAS40 response at Week 12.
Analysis of the ASAS40 response at Week 12 will be performed as  described above for 
ASDAS-MI response at Week 52. Simil ar to the ASADAS-MI efficacy  endpoint, the ASAS40 
will be treated as a composite endpoint when it is analyzed. Sp ecifically, subjects will need 
to: 1) achieve the relevant response (ASAS40); and 2) remain in t he study and on their 
randomized double-blind study treatment through Week 12.
Subgroup analyses by age, gender, race, symptom duration, smoki ng history, HLA-B27 
genotype, anti-CZP Ab (ADAb) status, region, prior anti-TNF exp osure, Baseline SPARCC 
score ≥5, and MRI /CRP classification (MRI+/CRP+; MR I+/CRP-; MRI-/CRP+) will be 
performed for the primary efficacy variable. Subgroup analyses will be summarized using 
descriptive statistics only.
14.4 Secondary efficacy analyses 
The changes from Baseline in BASDAI and BASFI at Week 12 and We ek 52, change from 
Baseline in ASQoL at Week 52, and change from Baseline in noctu rnal spinal pain at Week 52
are specified as secondary efficacy variables. As these are con tinuous variables, missing data 
must be handled using a different approach from what is specifi ed for the primary efficacy 
endpoint (a responder variable). In the current study, Investig ators will be given discretion to 
discontinue the double-blind study treatment for subjects not r esponding in order to provide them 
with alternative therapy to t reat the condition. Therefore, in many cases, missing efficacy data 
due to the double-blind study tre atment discontinuation should be dependent on the observed 
efficacy scores, but independent of unobserved data. This would  be consistent with a missing at 
random (MAR) assumption. However, the possibility of discontinu ation due to tolerability or 
other unobserved data cannot be completely discounted. Therefor e, a missing not at random 
mechanism will be used for the a nalysis of continuous secondary  efficacy variables.
A reference-based multiple imputation (MI) procedure will be us ed for this analysis, which will 
impute missing data as well as data at the time points followin g the discontinuation of the 
double-blind study treatment for both the CZP and placebo group s. This procedure will use an 
imputation model developed based on available data from the pla cebo group, thereby assuming a 
placebo trajectory for missing data following study treatment d iscontinuation for subjects in both REDACTEDmptommptom
gion, gion, 
(MRI+(MRI+
variabvariabCOPYyy
2) re2) re
h Weeh Wee
This documenotherther
mecmecannotcy scoy sco
dom (om (
rurubetiv
doubdoubseddoubdoub
ve thve thtoder vder supportek 52k 52
ry effiry eff
g a difg a dif
vaanyBASBAS
52, a2marketingble. Sle. S
cacy acacy
Dauthorizationek 12k 1
duratdurat
prior prior 
+/CRP+/CRP
SuSuapplicationas des d
efficaceffica
SpecifSpeci
main inmain i
22andS40 re40 re
descdescany by Reby Rextensionsforts orts
dy comy com
n the n the owillwill
wvariations ment.ment.
lnlnthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 107 of 255treatment groups (Mallinckrodt , 2013). The estimand being evalu ated in this case is the 
difference in the outcome of improvement in all randomized subj ects at the planned endpoint, 
attributable to the initially randomized medication. This is an  effectiveness estimand of the de 
facto hypothesis which has been referred to as “estimand 6” (Ma llinckrodt, 2012).
Additionally, change from Baselin e in SI joint SPARCC score at Week 12 is a continuous 
secondary efficacy variable. The  same MI procedure specified as  the main analysis approach for 
BASDAI and BASFI will be used to account for missing SPARCC dat a. However, it should be 
noted that, unlike BASDAI and BASFI, SPARCC score will not be m easured at any time points 
between Baseline and Week 12, meaning that those are the only 2  time points that can be 
considered in the evaluation of S PARCC score at Week 12. Compar isons between treatment 
groups will be made using an ana lysis of covariance (ANCOVA) mo del on the imputed data set. 
The model will include Baseline score, treatment group, region,  and MRI/CRP classification. 
The ASAS40 response at Week 12 and Week 52 are responder second ary efficacy endpoints. 
(For Canada and any other country where applicable or where req uested by Regulatory 
Authorities, the ASAS40 response at Week 12 is the primary effic acy variable; the ASAS40 
response at Week 52 and the ASDAS-MI response at Week 52 are se condary efficacy variables). 
As a responder variable, ASAS40 will be analyzed using logistic  regression based on a model 
similar to the one described for the primary analysis. 
The number of subjects with new  onset post-Baseline AU or new A U flares through Week 52 is 
a categorical secondary efficacy endpoint for all regions. Subj ects with a new event at one or 
more visits post-Baseline will be classified as having had a fl are, subjects without new events at 
all visits post-Baseline will be  classified as not having had a  flare. As a dichotomous outcome 
variable, treatment groups will be compared for differences usi ng logistic regression based on a 
model similar to the one descri bed for the primary analysis.
The comparison of CZP 200mg Q2W to placebo as described above f or the ASAS40 response, 
BASDAI, and BASFI at Week 12 and Week 52, for SI joint SPARCC s core at Week 12, for 
ASQoL at Week 52, nocturnal pain score at Week 52, and number o f subjects with AU or new 
AU flares through Week 52 will be pa rt of the fixed sequence te sting procedure outlined in 
Section 14.2.
Additionally, sensitivity ana lyses will be conducted on these s econdary efficacy endpoints. In 
particular, the assumptions related to missing data will be inv estigated further. These analyses 
are described in Section 14.8.
An additional secondary efficacy variable is the number of subj ects with relevant changes to 
background medication. This variable will be based on whether o r not subjects take certain 
pre-specified background medications during the course of the s tudy and will be defined in the 
SAP. The analysis for this variable will use the same logistic regression model described for the 
primary variable. 
14.5 Other efficacy analyses 
Double-Blind Period treatment group comparisons for CZP 200mg Q 2W versus placebo will be 
performed based on the change from Baseline in other selected e fficacy variables. These 
analyses will be performed using an ANCOVA model including Base line score, treatment group, 
region, and MRI/CRP classification. T he treatment differences a nd corresponding 95% REDACTEDs havs hav
as not s not 
pared pared 
or theor theCOPY ine AUine A
regioregio
This documentprimprim
11cannotundund
pecifieecifi
P. ThP. Thbenal sal s
dmdmusedSectSec
secsectomptmpt
isupport w
ity anaty ana
ionianypainai
will beill bemarketinge primpri
W to plaW to pl
and Wand W
n scnsauthorizationAU
ons. Sons. S
ing haing ha
havinhavin
for difor di
imimapplicatione secse
tic regrc reg
U or nor nandy varivar
ecoecoany ffiff
by Reby Rextensionseatmatm
mputedputed
 classclass
ficacicaor e e 
mevariations be be 
pointsointsthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 108 of 255confidence intervals (CIs) will  be calculated based on the adju sted means. Missing values or 
values observed after discontinuing the double-blind study treat ment will be imputed using last 
observation carried forward (LOCF ). The following variables wil l be analyzed in this manner:
x PGADA
x Morning stiffness (average of BASDAI questions 5 and 6)
x BASMI
x Total spinal pain
x SF-36, PCS, MCS, and individual domains
x Fatigue NRS
x Sleep Problems Index II domains of the MOS Sleep scale
Statistical analyses will also be done for BASDAI, BASFI, and S I joint SPARCC score for time 
points not specified in the secondary efficacy analyses, using the same analysis methods 
described in Section 14.4. Additionally, ASDAS and ASAS response variables will be analyze d 
using a logistic regression mod el similar to the one specified for the primary analysis at time 
points not covered in the primary  and secondary efficacy analys es.
These comparisons are not part of the multiplicity-controlled t esting procedure described in 
Section 14.2. The p-values reported for these  analyses will not be adjusted  for multiplicity and 
will be considered nominal. Exploratory statistical comparisons  for CZP 200mg Q2W versus 
placebo will also be performed for WPS scores using the nonpara metric bootstrap-t method. This 
will be explained in greater detail in the SAP. 
Summary statistics will be provide d for other variables. Summar y statistics will consist of 
frequency tables and percentages for categorical variables. Con tinuous variables will be 
summarized by visit (where applicable) with descriptive statisti cs (number of available 
observations [n], mean, median, SD, minimum and maximum). Detai ls on the analysis of the 
other endpoints will be provided in the SAP.
14.6 Planned safety and other analyses 
The Safety Set (SS) will be used for analysis of safety data fr om the Double-Blind Period as well 
as the combined Double-Blind and S FE Period (as applicable), an d the SFE-SS will be used for 
analysis of safety data from the SFE Period.
14.6.1 Safety analyses 
The frequency of all AEs during the study period will be presen ted for each treatment group 
separately by system organ class, high level term, and preferre d term. The data will be displayed 
as number of subjects experiencing the AEs, percentage of subje cts, and number of AEs. Data 
will also be corrected for ex posure and reported by 100 patient -years. 
Since subjects will be permitted to change background medicatio ns and because they may also 
discontinue the double-blind study treatment and initiate a new  treatment (including biologics) 
during the course of the study, special consideration will be g iven to how AEs are attributed to 
the double-blind study treatment. This, along with other specia lized AE summaries, will be 
described in greater detail in the SAP.REDACTEDisticalstica
cores cores 
e SAPe SAP
for ofor oCOPY controcontr
alyseslyse
This documentas nuas nu
wilwicannot requenequen
aratelaratelbe used DoDo
fety daety da
Stow
oubloubsupport d safed saf
will beill beany SDS
ded ined inmarketingother other
categocatego
able) wable)
SD, mD,authorizations wills will
 comp comp
usingusing
P. application nsense
or the pr the 
alyses.alyses
lled teled tandme anae an
ev aev aany SPARPAR
alylextensions or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 109 of 255Laboratory evaluations and vital signs will be analyzed over ti me in the SS for observed cases 
and at the end of treatment.
14.6.2 Pharmacokinetic and immunogenicity variable analysis 
Certolizumab pegol plasma concentrations will be tabulated and summarized by treatment group 
for each visit at which samples were taken using the geometric mean, geometric coefficient of 
variation, 95% CIs, arithmetic mea n, arithmetic SD, minimum and  maximum. Individual plasma 
concentrations for CZP and anti-CZP levels versus time will be produced on the same graph.
Immunogenicity will be assessed through listing of individual r esults by subject and summary 
table. Immunogenicity data will be correlated with PK and effic acy readout. In addition, 
immunogenicity will be correlated with possible safety findings.
14.7 Handling of protocol deviations 
Important protocol deviations are deviations from the protocol which could potentially have a 
meaningful impact on study conduct or on the primary efficacy o utcome for an individual 
subject. The criteria for identifying important protocol deviat ions will be defined within the 
appropriate protocol-specific  document. Important protocol devi ations will be reviewed as part 
of the ongoing data cleaning process and all important deviatio ns will be identified and 
documented prior to unblinding to confirm exclusion from analys is sets.
14.8 Handling of dropouts or missing data 
For analysis purposes, the primary efficacy variable is defined  as a composite endpoint in which 
it is necessary to achieve ASDAS-MI at Week 52 and to remain on  randomized double-blind 
study treatment through Week 52 in order to be considered a res ponder (see Section 14.3).
Because this composite endpoint definition does not allow for a  missing response status, no 
formal method for handling missing data is needed in the primar y efficacy analysis. However, in 
order to assess the impact of various missing data assumptions on the analysis, additional 
sensitivity analyses of the primary efficacy variable will be p erformed as follows:
x Including observed data at Week 52: The observed data at Week 5 2 will be used and 
analyzed according to randomize d treatment, regardless of wheth er or not the subject is still 
on his/her randomized double-blind study treatment at that time.  Despite efforts to continue 
to collect data on all subjects (even if they discontinue the d ouble-blind study treatment), 
there may still be subjects w ith missing data at Week 52. Such subjects will be considered as 
non-responders in accordance with the composite endpoint defini tion outlined above. The 
same logistic regression model sp ecified for the primary analys is will be used.
x MI: The Markov Chain Monte Carlo (MCMC) method will be used to i mpute intermittent 
missing data. The resulting multiply imputed data sets will be monotone missing and will be 
imputed using monotone regression (assuming a MAR pattern). Not e that the MI procedure 
will be done on the continuous ASDAS variable, which will be dic hotomized for the logistic 
regression analysis. Ankylosing Spondylitis Disease Activity Sc ore data collected following 
the discontinuation of double-blind study treatment will be tre ated as missing in the original 
data set for this sensitivity analysis.
x Tipping point analysis: In this analysis, various assumptions w ill be made about average 
outcomes among the subsets of subjects who prematurely disconti nued double-blind study REDACTEDariabariab
Week 5Week 5
der to der to 
finitionfinitio
dadaCOPY frofr
issinissin
l
This documentimcannotTheThe
missinmissi
impimpbeogististused ll beb
nders ders 
ticticto n a
be sbe ssupportrandoand
zed doed do
all suall suany t WeeWeemarketingon dn d
ata is neta is n
s missimiss
y efficeffiauthorizationng dg d
le is dle is d
52 and2 and
be cobe co
doedoeapplicationationsation
ons wions w
analysanaly
datdaand me e 
ll be l be anyd pod po
for aforextensions on, on, 
ottormamvariations ma ma 
maryarythereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 110 of 255treatment. Various “delta adju stments” will be made to the assu med responses a mong 
missing data in each treatment arm with varying degrees of plau sibility (O’Kelly, 2014). The 
goal of the tipping point analysis is to identify assumptions a bout the missing data under 
which the conclusions change, ie, under which there is no longe r evidence of a treatment 
effect. Then, the plausibility of such assumptions would be dis cussed. Further details of this 
procedure will be described in the SAP.
x Observed case analysis: This analysis will only include the obs erved data for subjects still on 
the original double-blind study treatment. Data collected after the discontinuation of 
double-blind study treatment a nd all other missing data will be  excluded from the analysis. 
The same logistic regression model specified for the primary ef ficacy analysis will be 
performed.
Sensitivity analyses of the primary efficacy variable for Canad a (and any other country where 
applicable or where requested by Regulatory Authorities), ASAS4 0 response at Week 12, will 
mirror the approach describe d above for ASDAS-MI at Week 52. 
The sensitivity analyses of the secondary binary efficacy varia bles (ASAS40 at Week 52) will be 
as follows:
x Including observed data at Week 52: As described for the primar y efficacy variable.
x MI: As described for the primary efficacy variable. Note that a s ASAS40 is a composite of 
4 different variables, the MI procedure will be performed on eac h of these components, and 
the ASAS40 response will be derived based on the multiply imput ed datasets.
x Reference-based MI: This procedure will impute missing data as w ell as data at the time 
points following the discontinuation of the double-blind study treatment for both the CZP 
and placebo groups. This procedure will use an imputation model  developed based on data 
from the placebo group (Mallinckrodt, 2013). The estimand being evaluated in this case is 
the difference in the outcome of improvement in all randomized subjects at the planned 
endpoint, attributable to the initially randomized medication, which has been referred to as 
“estimand 6” (Mallinckrodt, 20 12).
x Observed case analysis: As described for the primary efficacy v ariable.
For the secondary efficacy variable “number of subjects with AU  or new AU flares through 
Week 52,” missing values should only occur in the unlikely case  that a subject does not h ave any 
post-Baseline AU assessments performed. Therefore, sensitivity analyses for this variable will 
focus on analyses adjusting for exposure time at risk such as e vent rate, incidence rate, and 
confidence interval.
The sensitivity analyses of secondary continuous efficacy varia bles (the change from Baseline in 
BASDAI and BASFI at Weeks 12 and 52, a nd the change from Baseli ne in the SI joint SPARCC 
score at Week 12, change from Baseline in ASQoL at Week 52, and  change from Baseline in 
nocturnal spine pain at W eek 52) will be as follows:
x Including observed data at Week 52: As described for the primar y efficacy variable.
x MI: As described for the primary efficacy variable.
x Observed case analysis: As described for the primary efficacy v ariable.REDACTEDsed onsed o
 will iwill
on of on of
dure wdure COPY able. Nable. N
e pere per
This documentBASAS
scorsco
ncannot nce ice i
sensisensi
SDSDbenalysnaly
intinusedng vg v
AU aAU a
seseto ffic
valvalsupport od
ysis: Assis: A
icacycacanyinitini
dt, 20dt, 20marketingt
will uwill u
krodt, 2rodt, 
of imprf imp
itialitiaauthorizationN
rformrform
n the mn the m
imputmpu
he dohe dapplication (
e prime prim
otote the thand ASAASAany se se extensionsll bel be
er cour cou
ea tatoalysalyvariations l on l on 
ysiithereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 111 of 255x LOCF
Missing data for the other efficacy variables described in Sect ion 14.5 will be handled as 
follows:
x With imputation: Non-responder imputation for binary variables and LOCF for continuous 
variables (as described in Section 14.5)
x Observed case analysis: As described for the primary efficacy v ariable.
Additionally, algorithms for imputing missing or partial dates for safety evaluations will be 
detailed in the SAP.
14.9 Planned interim analysis and data monitoring 
An interim analysis is planne d after the completion of the Doub le-Blind Period of the last subject 
at Week 52. At this time, the database from the Double-Blind Pe riod will be locked, the 
treatment codes will be made available to relevant UCB personne l, and an interim study report 
will be written. The Investigat ors and subjects will remain bli nd to the assigned CZP dose 
regimen of the Double-Blind Peri od. After the completion of the  SFE Period of the last subject, 
the database will be locked, and a final study report will be w ritten. From the Week 52 Visit 
onward, subjects will be treated with open-label CZP until the last dosing visit of the study 
(SFE Week 104).
Regular monitoring of safety data collected during clinical stu dies will be performed as 
described in the Safety Signal D etection in the Ongoing Clinica l Trials Charter for CZP.
A specific data monitoring, steering, or evaluation committee i s not planned for this study.
14.10 Determination of sample size 
Subjects will be randomized in a 1:1 ratio to the CZP 200mg Q2W  and placebo treatment 
groups. The expected responder rates for ASDAS-MI at Week 52 ar e 40% and 20% for CZP and 
placebo, respectively. A to tal sample size of 300 (150 subjects  per treatment group) provides 
95% power to detect a statistical ly significant difference in t he ASDAS-MI responder rate at 
Week 52 between CZP and placebo, using a 2-sided significance le vel of 0.05.
With Protocol Amendment 4, ASAS40 response at Week 12 was eleva ted to be the primary 
efficacy variable for Canada (and any other country where appli cable or where requested by 
Regulatory Authorities); however, the study was fully enrolled at the time of this amendment. 
The expected responder rates f or ASAS40 response at Week 12 are also 40% for CZP and 20% 
for placebo, which are identical to the assumed response rates cited for ASDAS-MI at Week 52. 
Therefore, the planned total sample size of 300 would provide 9 5% power for this variable, as 
well.
15 ETHICS AND REGULATORY REQUIREMENTS 
15.1 Informed consent 
Subject’s informed consent must be obtained and documented in a ccordance with local 
regulations, ICH-GCP requirements, and the ethical principles t hat have their origin in the 
principles of the Declaration of Helsinki.REDACTEDhe Onhe On
evaluavalua
f samf samCOPY ng cling cli
This document 1515
11cannotore, tre, tbeo, who, wh
hhusedhoritorit
resporespotoor Cr C
iisupportnd plad pla
dment 4ment 
CanaCanany mpmp
cally scally marketingmplpl
ratio toratio t
tes for es for
ple spleauthorizationinicalinical
goinggoing
ation ction c
ple sle sapplication SFEFE
tten. Frten. F
he last e lastandhe asse ass
EPEPany e l
n inten int
igiextensions d of thd of t
lockocor variations e e thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 112 of 255Prior to obtaining informed consent, information should be give n in a language and at a level of 
complexity understandable to the subject in both oral and writt en form by the Investigator (or 
designee). Each subject will have the opportunity to discuss th e study and its alternatives with 
the Investigator.
Prior to participation in the study, the written Informed Conse nt form should be signed and 
personally dated by the subject, or his/her legal representativ e, and by the person who conducted 
the informed consent discussi on (Investigator or designee). The  subject or his/her legal 
representative must receive a copy of the signed and dated Info rmed Consent form. As part of 
the consent process, each subject must consent to direct access  to his/her medical records for 
study-related monitoring, auditing, IRB/IEC review, and regulat ory inspection. An additional 
Informed Consent form for participation in the substudy should be completed.
If the Informed Consent form is amended during the study, the I nvestigator (or the Sponsor, if 
applicable) must follow all applicable regulatory requirements pertaining to the approval of the 
amended Informed Consent form by the IRB/IEC and use of the ame nded form.
All studies conducted at centers in the USA must include the us e of a Health Insurance 
Portability and Accountability Act Authorization form.
The subject may withdraw his/he r consent to participate in the study at any time. A subject is 
considered as enrolled in the study when he/she has signed the Informed Consent form. A CRF 
must not be started, nor may any stu dy specific procedure be pe rformed for a given subject, 
without having obtained his/her w ritten consent to participate in the study.
15.2 Subject identification cards 
Upon signing the Informed Consent and Assent form (as applicabl e), the subject or legal 
representative will be provided with a subject identification c ard in the language of the subject. 
The Investigator will fill in the subject identifying informati on and medical emergency contact 
information. The Investigator will  instruct the subject to keep  the card with them at all times.
15.3 Institutional Review Boards and Independent Ethics 
Committees 
The study will be conducted under the auspices of an IRB/IEC, a s defined in local regulations, 
ICH-GCP, and in accordance with the ethical principles that hav e their origin in the Declaration 
of Helsinki.
The Investigator/UCB will ensure that an appropriately constitu ted IRB/IEC that complies with 
the requirements of the current ICH-GCP version or applicable c ountry-specific regulations will 
be responsible for the initial and continuing review and approv al of the clinical study. Prior to 
initiation of the study, the Investigator/UCB will forward copi es of the protocol, Informed 
Consent form, Investigator’s Brochure, Investigator’s curriculu m vita e (if applicable), 
advertisement (if applicable) , and all other subject-related do cuments to be used for the study to 
the IRB/IEC for its review and approval.
Before initiating a study, the I nvestigator will have written a nd dated full approval from the 
responsible IRB/IEC for the protocol.REDACTEDnt tont to
n cardcard
nd Asnd A
a sua suCOPYsignesign
roceduroced
opop
This documentConsons
advadv
thcannotponsibonsib
ation tion
nsensenbemenmenused tor/Uor/Uto ccosupport eses
ducted uucted
ordanordananyRevRemarketingubjectubject
ct identct iden
instrucnstru
viauthorizationure re 
particiartici
dsds
sent fent fapplication he studhe stu
d the Id the 
eb ebeand a Heaa Heaany o tho t
d formd formextensionsdditidditi
or the r the 
the aheos fos fo
ioivariations t of of 
ororthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 113 of 255The Investigator will also promptly report to the IRB/IEC all c hanges in the study, all 
unanticipated problems involving risks to human subjects or oth ers, and any protocol deviations, 
to eliminate immediate hazards to subjects.
The Investigator will not make an y changes in the study or stud y conduct without IRB/IEC 
approval, except where necessary  to eliminate apparent immediat e hazards to the subjects. For 
minor changes to a previously approved protocol during the peri od covered by the original 
approval, it may be possible f or the Investigator to obtain an expedited review by the IRB/IEC as 
allowed.
As part of the IRB/IEC require ments for continuing review of ap proved studies, the Investigator 
will be responsible for submitting periodic progress reports to  the IRB/IEC (based on IRB/IEC 
requirements), at intervals approp riate to the degree of subjec t risk involved, but no less than 
once per year. The Investiga tor should provide a final report t o the IRB/IEC following study
completion.
UCB (or its representative) will communicate safety information  to the appropriate regulatory 
authorities and all active Investigators in accordance with app licable regulatory requirements. 
The appropriate IRB/IEC will also be informed by the Investigat or or the Sponsor, as specified 
by the applicable regulatory requirements in each concerned cou ntry. Where applicable, 
Investigators are to provide the Sponsor (or its representative ) with evidence of such IRB/IEC 
notification.
15.4 Subject privacy 
UCB staff (or designee) will affirm and uphold the subject’s conf identiality. Throughout this 
study, all data forwarded to UCB (or designee) will be identifi ed only by the subject number 
assigned at Screening.
The Investigator agrees that representatives of UCB, its design ee, representatives of the relevant 
IRB/IEC, or representatives of regulatory authorities will be a llowed to review that portion of the 
subject’s primary medical records t hat directly concerns this s tudy (including, but not limited to, 
laboratory test result reports, E CG reports, admission/discharg e summaries for hospital 
admissions occurring during a subject’s study participation, an d autopsy reports for deaths 
occurring during the study).
15.5 Protocol amendments 
Protocol changes may affect t he legal and ethical status of the  study and may also affect the 
statistical evaluations of sample size and the likelihood of th e study fulfilling its primary 
objective.
Significant changes to the protocol will only be made as an ame ndment to the protocol and must 
be approved by UCB, the IRB/IEC, and the regulatory authorities  (if required), prior to being 
implemented.
16 FINANCE, INSURANCE, AND PUBLICATION 
Insurance coverage will be hand led according to local requireme nts.
Finance, insurance, and publication rights are addressed in the  Investigator and/or CRO 
agreements, as applicable.REDACTED phold hold 
esigneesigneCOPY entaen
This documente ape ap
impimpcannot e.
nificanfican
apprpprbevalualuused ges mes m
uatuatootoctocsupporting a sng a 
udy).dy).
cocoanyds tds 
ECG ECG marketing tatives atives
ulatoryulator
thatthaauthorization the suthe su
ee) wie) wiapplicationor or or or
countryountr
ve) witve) wand e apap
 regureguany ppropprextensionsnve
on IRBon IRB
no leno le
followolloworestigestivariations C as C as thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 114 of 25517 REFERENCES 
Barkham N, Keen HI, Coates LC, O'Connor P, Hensor E, Fraser AD,  et al. Clinical and imaging 
efficacy of infliximab in HLA –B27–Positive patients with magnetic resonance imaging –
determined early sacroiliitis. A rthritis Rheum. 2009;60:946-54.
Boonen A, van der Heijde D, Landewé R, Guillemin F, Rutten-van Mölken M, Dougados M, et 
al. Work status and productivity costs due to ankylosing spondy litis: comparison of three 
European countries. Ann Rheum Dis. 2002;61:429-37.
Boonen A, van der Heijde D, Landewé R, Guillemin F, Rutten-van Mölken M, Dougados M, et 
al. Direct costs of ankylosing spondylitis and its determinants : an analysis among three European 
countries. Ann Rheum Dis. 2003;62:732-40.
Braun J. Axial spondyloarthritis: thoughts about nomenclature a nd treatment targets. Clin Exp 
Rheumatol. 2012;30:S132-5.
Braun J, Baraliakos X. Imaging of axial spondyloarthritis inclu ding ankylosing spondylitis. Ann
Rheum Dis. 2011;70(Suppl 1):i97-103.
Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing  J, et al. Magnetic resonance 
imaging examinations of the spine in patients with ankylosing s pondylitis, before and after 
successful therapy with infliximab: evaluation of a new scoring  system. Arthritis Rheum. 
2003;48:1126-36.
Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, B raun J. Development and 
preselection of criteria for shor t term improvement after anti- TNFα treatment in ankylosing 
spondylitis. Ann Rheum Dis. 2004;63:1438-44.
Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:137 9-90.
Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R , Collantes-Estevez E, et al. 
2010 update of the ASAS/EULAR recomm endations for the managemen t of ankylosing 
spondylitis. Ann Rheum Dis. 2011;70:896-904.
Braun J, van der Heijde D. Imaging and scoring in ankylosing sp ondylitis. Best Pract Res Clin 
Rheumatol. 2002;16:573-604.
Braun J, Zochling J, Baraliakos  X, Alten R, Burmester G, Grased yck K, et al. Efficacy of 
sulfasalazine in patients with inflammatory back pain due to un differentiated spondyloarthritis 
and early ankylosing spondylitis: a multicentre randomised cont rolled trial. Ann Rheum Dis. 
2006;65:1147-53.
Calin A, Garrett S, Whitelock H, K ennedy LG, O'Hea J, Mallorie P, et al. A new approach to 
defining functional ability in ankylosing spondylitis: the deve lopment of the Bath Ankylosing 
Spondylitis Functional Index. J Rheumatol. 1994;2:2281-5.
Callhoff J, Sieper J, Weiß A, Zink A, Listing J. Efficacy of TN Fα blockers in patients with 
ankylosing spondylitis and non-radiographic axial spondyloarthr itis: a meta-analysis. Ann 
Rheum Dis. 2015;74:1241-8.
CPMP/EWP/556/95. Points to consid er on the clinical investigatio n of medicinal products other 
than NSAIDS for the treatment of RA. June 2004.REDACTEDan dean de
rovemovem
14381438 44
dylitisdylitisCOPYnew snew 
This documentSponpon
CCcannot A, GaA, Ga
ining ning 
nddbe 147147--usedpatiepatie
ylosinylosin
55toJ, BaJ, B
enensupport. ImaIma
3--604604
BaraBarany011;011
agimarketings. Lans. La
s X, BoX, B
R recomR reco
;707authorization r Heijdr Heij
ment afnt af
44.4.application ng J, etg J, 
ng spong spo
coring oringand kylkylany losinlosextensionsree Eee E
targetargetoos Mos M
EuEvariations MMthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 115 of 255Cuirea A, Scherer A, Exer P, Bernhard J, Dudler J, Beyeler B, e t al. Tumor necrosis factor α 
inhibition in radiographic and nonradiographic axial spondyloar thritis: results from a large 
observational cohort. Arthritis Rheum. 2013;65:3096-106.
Davis JC Jr, Revicki D, van der Heijde DM, Rentz AM, Wong RL, K upper H, et al. 
Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with 
adalimumab: results from a ra ndomized controlled study. Arthrit is Rheum. 2007;57:1050-7.
Dougados M, Braun J, Burgos-Vargos R, Maksymowych W, Sieper J, van der Heijde D. ASAS 
recommendations for collecting, analysing and reporting NSAID i ntake in clinical 
trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis. 2011;70:249-251.
Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych W,  Citera G, et al. Efficacy of 
etanercept in nonradiographic axial spondyloarthritis. The sympt omatic efficacy and effect on 
objective signs of inflammation of etanercept in early nonradio graphic axial spondyloarthritis. 
Ann Rhuem. 2014;66:2091-102.
Dougados M, van der Linden S, Juhlin R, Huitfeld B, Amor B, Cal in A, et al. The European 
Spondylarthropathy Study Group preliminary criteria for the cla ssification of 
spondylarthropathy. Arthritis Rheum. 1991;34:1218-27.
Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay  LJ, et al. Development of 
the ASQL: a quality of life instrument specific to ankylosing s pondylitis. Ann Rheum Dis. 
2003;62:20-6.
Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the 
clinical importance of treatment outcomes in chronic pain clini cal trials: IMMPACT 
recommendations. J Pain. 2008;9:105-21.
Feldtkeller E, Bruckel J, Khan MA. Scientific contributions of ankylosing spondylitis patient 
advocacy groups. Curr Opin Rheumatol. 2000;12:239-47.
Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Bra un J. Age at disease onset and 
diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. 
Rheumatol Int. 2003;23:61-6.
Garrett S, Jenkinson T, Kennedy L G, Whitelock H, Gaisford P, Ca lin A. A new approach to 
defining disease status in ankylosing spondylitis: the Bath Ank ylosing Spondylitis Disease 
Activity Index. J Rheumatol. 1994;21:2286-91.
Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M,  et al. No efficacy of 
subcutaneous methotrexate in active ankylosing spondylitis: a 1 6-week open-label trial. Ann 
Rheum Dis. 2007;66:419-21.
Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label  trial of leflunomide in active 
ankylosing spondylitis. Ann Rheum Dis. 2005;64:124-6.
Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H , et al. Efficacy of 
adalimumab in the treatment of axial spondylarthritis without r adiographically defined 
sacroiliitis: results of a twelv e-week randomized, double-blind , placebo-controlled trial by an 
open-label extension up to week fifty-two. Arthritis Rheum. 200 8;58:1981-91.REDACTED ton D,ton D
es in chs in c
21.21.
SciSciCOPY Hellel
nkylonkylo
This documentaibai
ankyanky
Hcannot eoeo
m Dis.Dis.
bel Hbel Hbe ran
ous mous musedRhRh
ndt ndt toatus us
heuheusupport -6.6.
T, KennKen
s in si nany rH
negatinegatmarketing ientificentific
atol. 20tol. 2
HeijdHeijauthorization , CleeClee
chronihroniapplication ificfic
ell PS,ll PS
sing sping sandA, eA, e
caticatiany ttextensions 2
al. Efal. Ef
y and y and
spondspondor251.51variations SAS AS thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 116 of 255Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric propert ies of the Medical Outcomes 
study sleep measure. Sleep Med. 2005;6:41-4.
Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh K C, et al. Estimates of the 
prevalence of arthritis and other rheumatic conditions in the U nited States. Part I. Arthritis 
Rheum. 2008;58:15-25.
Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewé R, v an der Tempel H, Mielants 
H, et al. Assessment of enthesitis in ankylosing spondylitis. A nn Rheum Dis. 2003;62:127-32.
Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. Cost of illness in 
rheumatoid arthritis, ankylosing spondylitis, psoriatic arthrit is and systemic lupus erythematosus 
in Germany. Ann Rheum Dis. 2006;65:1175-83.
Kobelt G, Andlin-Sobocki P, Brophy S, Jönsson L, Calin A, Braun  J. The burden of ankylosing 
spondylitis and the cost-effectiveness of treatment with inflix imab (Remicade). Rheumatology 
(Oxford). 2004;43:1158-66.
Kobelt G, Andlin-Sobocki P, Maksymowych WP. Costs and quality o f life of patients with 
ankylosing spondylitis in Canada. J Rheumatol. 2006;33:289-95.
Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Meas e PJ, et al. Efficacy of 
certolizumab pegol on signs and symptoms of axial spondyloarthr itis including ankylosing 
spondylitis: 24-week results of a double-blind randomised place bo-controlled Phase 3 study. Ann 
Rheum Dis. 2014;73:39-47.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new 
equation to estimate glomerular filtration rate. Ann Intern Med . 2009;150:604-12.
Lukas C, Braun J, van der Heijde D, Hermann KG, Rudwaleit M, Os tergaard M, et al. Scoring 
inflammatory activity of the spine by magnetic resonance imagin g in ankylosing spondylitis: a 
multireader experiment. J Rheumatol. 2007;34:862-70.
Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an 
ASAS-endorsed disease activity score (ASDAS) in patients with a nkylosing spondylitis. Ann 
Rheum Dis. 2009;68:18-24.
Machado PM, Landewé R, van der Heijde D, Assessment of Spondylo Arthritis international 
Society (ASAS). Letter. Ankylosing Spondylitis Disease Activity  Score (ASDAS): 2018 update 
of the nomenclature for disease activity states. Ann Rheum Dis.  2018;77:1539-40.
Mallinckrodt CH. Preventing and T reating Missing Data in Longit udinal Clinical Trials: A 
Practical Guide. New York, NY: Cambridge University Press; 2013 .
Mallinckrodt CH, Lin Q, Lipkovich I, Molenberghs G. A structure d approach to choosing 
estimands and estimators in longitudinal clinical trials. Pharm aceutical Statistics. 
2012;11:456-61.
Mease PJ, Fleischmann R, Wollenhaupt J, Deodhar A, Gladman D, H oepken B, et al. Long-term 
safety and efficacy of certolizumab pegol in patients with psor iatic arthritis with and without 
prior anti-tumor necrosis factor exposure: 96-week outcomes fro m the RAPID-PsA trial. 
Presented at the European League Against Rheumatism (EULAR) 201 4 Congress. Abstract 
#OP0077.REDACTED g YL,g YL,
on raten rate
 Herm HermCOPYsponspon
domisdom
This documentestimstim
201201cannoal GuGu
llinckrlinck
mamabeodt Codt C
uiduidusedLe
ature ature 
CHCHtoetterettesupport iviv
24.4.
wé R, wé RanyDouDo
ity scty scmarketing mannman
magnemagne
tol. 200ol. 20
ugaugauthorization seded
, CastrCast
e. Ann. Ann
nnapplication ych WPych W
dyloarthyloart
d pladp land of lifof lifany dedeextensionsythemthem
den ofen of
e). Re). Ror mamvariations nts ts 
2..thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 117 of 255Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of 
rheumatoid arthritis rising?: results from Olmsted County, Minn esota, 1955-2007. Arthritis 
Rheum. 2010;62:1576-82.
O’Kelly M, Ratitch B. Clinical Tri als with Missing Data: A Guid e for Practitioners. John Wiley
& Sons; 2014.
Osterhaus JT, Purcaru O. Discriminant validity, responsiveness and reliability of the 
arthritis-specific Work Productivity Survey assessing workplace  and household productivity 
within and outside the home in patients with axial spondyloarth ritis, including non-radiographic 
axial spondyloarthritis and ankylosing spondylitis; Arthritis R es Ther. 2014;16:R164.
Pavy S, Brophy S, Calin A. Establis hment of the minimum clinica lly important difference for the 
bath ankylosing spondylitis indices: a prospective study. J Rhe umatol. 2005;32:80-5.
Poddubnyy D. Axial spondyloarthritis: is there a treatment of c hoice? Ther Adv Musculoskelet 
Dis. 2013;5:45-54.
Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E , Zeidler H, et al. Effect of 
non-steroidal anti-inflammatory drugs on radiographic spinal pr ogression in patients with axial 
spondyloarthritis: results from the German Spondyloarthritis In ception Cohort. Ann Rheum Dis. 
2012;71:1616-22.
Reveille JD, Witter JP, Weisma n MH. Prevalence of axial spondyl arthritis in the United States: 
estimates from a cross-sectional survey. Arthritis Care Res (Ho boken). 2012;64:905-10.
Rostom S, Dougados M, Gossec L. New tools for diagnosing spondy loarthropathy. Joint Bone 
Spine. 2010;77:108-14.
Rudwaleit M. American College of Rheumatology 77thannual meeting, association of 
rheumatology health professionals. October 25th-30th2013. San Diego, CA. 
Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral 
spondyloarthritis. Curr Opin Rheumatol. 2010;22:375-80.
Rudwaleit M, Haibel H, Baraliakos X, Listing J, Mäarker-Hermann  E, Zeidler H, et al. The early 
disease stage in axial spondylarthritis: results from the Germa n Spondyloarthritis Inception 
Cohort. Arthritis Rheum. 2009a;60:717-27.
Rudwaleit M, Jurik A-G, Hermann K-GA, Landewe´ R, van der Heijd e D, Baraliakos X, et al. 
Defining active sacroiliitis on m agnetic resonance imaging (MRI ) for classification of axial 
spondyloarthritis –a consensual approach by the ASAS/ OMERACT MRI Group. Ann Rheum 
Dis. 2009d; 68:1520-7.
Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early 
ankylosing spondylitis: do we need new criteria? Arthritis Rheu m. 2005;52:1000-8.
Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Ch ou CT, et al. The 
Assessment of SpondyloArthritis International Society classific ation criteria for peripheral 
spondyloarthritis and for spondyloarthritis in general. Ann Rhe um Dis. 2011;70:25-31.
Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, B randt J, et al. The 
development of Assessment of SpondyloArthritis international So ciety classification criteria for REDACTED tis tis 
ools foools fo
RheuRheuCOPY  of axof a
s CaCa
This documentankynky
RuRucannot09d; 9d; 
dwaleiwalei
yloyloberthritrthri
66usedrik Ak 
ve sace sac
tististo AAsupporaraliarali
ondylaondy
um. 20um. 2any heuheum
iakiakmarketing umatomat
ctober tober
diagnodiagn
mamauthorization xialial
are Rere Re
or diagr dia
tolapplicationgressgres
nceptioncepti
allspospand E, ZeiE, Zei
iiany AAextensions fferenferen
:80:80--55
Adv Mdv or variations y
raphiaphithereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 118 of 255axial spondyloarthritis (part II): validation and final selecti on. Ann Rheum Dis. 
2009c;68:777-83.
Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development 
of Assessment of SpondyloArthritis  international Society classi fication criteria for axial 
spondyloarthritis (part I): classification of paper patients by  expert opinion including uncertainty 
appraisal. Ann Rheum Dis. 2009b;68:770-6.
Rudwaleit M, Sieper J. Referral strategies for early diagnosis of axial spondyloarthritis. Nat Rev 
Rheumatol. 2012;8:262-8.
Sieper J, Kivitz A, van Tubergen A, Deodhar A, Coteur G, Wolteri ng F, et al. Rapid 
improvements in patient-reported outcomes with certolizumab peg ol in patients with axial 
spondyloarthritis, including ankylosing spondylitis: 24-Week re sults of RAPID-axSpA trial. 
European League Against Rheumatism (EULAR) 2013b, Congress 2013 ; Abstract # THU0360.
Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos- Vargas R, et al. The Assessment 
of SpondyloArthritis International Society (ASAS) handbook: a g uide to assess 
spondyloarthritis. Ann Rheum Dis. 2009;68(Supple 2):ii1-ii44.
Sieper J, van der Heijde D. Review: Nonradiographic axial spond yloarthritis: new definition of 
an old disease? Arthritis Rheum. 2013a;65:543-51.
Sieper J, van der Heijde D, Dougados M, et al. Efficacy and saf ety of adalimumab in patients 
with non-radiographic axial spondyloarthritis: results of a ran domised placebo-controlled trial 
(ABILITY-1). Ann Rheum Dis. 2013c;72:815-22.
Sieper J, Rudwaleit M, van der Heijde D. Long-term safety and e fficacy of certolizumab pegol in
patients with axial spondyloarthritis, including ankylosing spo ndylitis and non-radiographic axial 
spondyloarthritis: 96-week outcomes of the RAPID-axSpA trial. P resented at the European 
League Against Rheumatism (E ULAR) 2014 Congress. Abstract #SAT0 351.
Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, e t al. Physical function and 
health related quality of life: analysis of 2-year data from ra ndomized, controlled studies of 
leflunomide, sulfasalazine, or methotrexate in patients with ac tive rheumatoid arthritis. 
J Rheumatol. 2005;32:590-601.
van der Heijde D, Dougados M, Davis J, Weisman MH, Maksymowych W, Braun J, et al. 
Assessment in Ankylosing Spondylitis International Working Grou p/Spondylitis Association of 
America recommendations for conduc ting clinical trials in ankyl osing spondylitis. Arthritis 
Rheum. 2005;52:386-94.
van der Heijde D, Purcaru O, Kav anaugh A. Economic burden of ax ial spondyloarthritis related 
to paid work and household productivity  at baseline in the RAPI D-axSpA Study: differences and 
similarities between ankylosing spondylitis and non-radiographi c axial spondyloarthritis. Value 
in Health. 2013;16:A323-A636.
van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupp er H, et al. Adalimumab 
effectiveness for the treatment of ankylosing spondylitis is ma intained for up to 2 years: 
long-term results from the ATLAS trial. Ann Rheum Dis. 2009;68: 922-9.REDACTED resres
1515--2222
D. LonD. Lon
includinclu
so fso fCOPY fficacyfficac
sultssul
This documentsimilmil
in Hin Hcannot er Heijr Heij
paid waid w
lalbe05;505;5usedAnkynky
mmenmmen
5252toDouDou
yloylosupport, or mor m
59090--6060
ugadugaany ala
analysnaly
memarketing udindin
f the Rthe R
AR) 20R) 20
lden Jdenauthorization y anan
ts of a s of a
.
ngng--terter
ng ang aapplication ondyloondyl
and sndande to ato aany R, et aR, et 
assextensions ith axth ax
axSpaxSp
bstracstracor variations Rev Rev thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 119 of 255van der Heijde D, Sieper J, Maksymowych W, Dougados M, Burgos-V argas R, Landewé R, et 
al. 2010 Update of the internati onal ASAS recommendations for t he use of anti-TNF agents in 
patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70:9 05-8.
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnost ic criteria for ankylosing 
spondylitis. A proposal for modification of the New York criter ia. Arthritis Rheum. 
1984a;27:361-68.
van der Linden S, Valkenburg HA, de  Jongh BM, Cats A. The risk of developing ankylosing 
spondylitis in HLA-B27 positive individuals. A comparison of re latives of spondylitis patients 
with the general population. Arthritis Rheum. 1984b;27:241-9.
van Tubergen A, Black PM, Coteur G. Are patient-reported outcom e instruments for ankylosing 
spondylitis fit-for-purpose for the axial spondyloarthritis pat ient? A Qualitative and 
Psychometric Analysis. Rheum. 2015;54:1842-51.
van Tubergen A, Coenen J, Landewé R, Spoorenberg A, Chorus A, B oonen A, et al. Assessment 
of fatigue in patients with ankylosing spondylitis: a psychomet ric analysis. Arthritis Rheum. 
2002b;47:8-16.
van Tubergen A, Debats I, Ryser L, Londoño J, Burgos-Vargas R, Cardiel MH, et al. Use of a 
numerical rating scale as an answer modality in ankylosing spon dylitis-specific questionnaires. 
Arthritis Rheum. 2002a;47:242-8.
Ward MM. Functional disability predicts total costs in patients  with ankylosing spondylitis. 
Arthritis Rheum. 2002;46:223-31.
Ware JE, Kosinski M, Keller SD. SF- 36 Physical and Mental Health Summary scales: a user’s 
manual; 1994.
Weber U, Ostergaard M, Lambert RG, Pedersen SJ, Chan SM, Zubler  V, et al. Candidate 
lesion-based criteria for defini ng a positive sacroiliac joint MRI in two cohorts of patients with 
axial spondyloarthritis. Ann Rheum Dis. 2015;74:1976-82.
Wells G, Li T, Maxwell L, MacLean R, Tugwell P. Determining the  minimal clinically 
important differences in activity, fatigue, and sleep quality in  patients with rheumatoid arthritis. J 
Rheumatol. 2007;34:280-9.REDACTED cosco
6 Phys6 Phys
GGCOPY osios
osts sts
This document cannot be used to support MaM
activityctivit
8080--9.9.any umu
acLeacLemarketing , PederPede
positivositi
m Dim Dauthorization in patn pa
sical aical aapplication as R, Cs R, C
spondsponandalysislysisany nen Anen A
sAextensions for anor an
 and and or variations g 
ents ents thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 120 of 25518 APPENDICES  
18.1 ASAS classification criteria for axial SpA 
ASAS classification criteria for axial SpA  
(for subjects with chronic b ack pain ≥3 months and age at onset <45 years)
Imaging criteria ASAS clinical criteria for axial SpA
Sacroiliitis (MRI or radiographs*) plus ≥1 SpA 
featureHLA- B27 plus ≥2 other SpA features
SpA features**
Inflammatory back pain*** Psoriasis
Arthritis Crohn’s disease/ulcerative colitis
Enthesitis (heel) HLA-B27
Uveitis Elevated CRP
Dactylitis
CRP=C-reactive protein; MRI=magnetic resonance imaging; HLA-B27 =human leukocyte antigen B27; 
NSAID=nonsteroidal anti-inflammatory drug; SpA=spondyloarthriti s
*Active inflammatory lesions of sacroiliac joints with  definite bone marrow oedema/o steitis suggestive of 
sacroiliitis associated with spondy loarthritis in MRI or radiog raphic sacroiliitis grade 2 to4 bilaterally or 
grade 3 to 4 unilaterally according to modified NY criteria.
** Family history for SpA and Good response to NSAIDs are exclu ded as SpA feature criteria.
***Inflammatory back pain according to ASAS criteria for Axial SpA defined as the presence of 4 out of 5 
of the following parameters:
1) age at onset <45 years
2) insidious onset
3) improvement with exercise
4) no improvement with rest
5) pain at night (with improvement upon getting up)REDACTED =spsp
with dewith d
MRI oMRI o
ied NYed NY
ponse tponse t
ASACOPging; Hging; H
pondponPY OPY
This document cannot be used to support exex
nt with t with
t (with (withany xercisxercmarketingto NS N
SAS criAS criauthorization HLALA
dyloartyloart
efinite finite
or radior radio
Y critercriter
NSANSAapAB2B2application apand ve e ccany colicoextensions ns
exor orvariations ariariariarthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 121 of 25518.2 Modified NY criteria for ankylosing spondylitis 
Subjects meeting the NY criteri a in the context of this protocol  are defined as subjects meeting 
the definite AS diagnosis according to the modified NY criteria  below. 
Modified NY criteria for ankylosing spondylitis  
Diagnosis
1) Clinical criteria
a) Low back pain and stiffness for more than 3 months which imp roves with exercise, but is not 
relieved by rest.
b) Limitation of motion of the lumbar spine in both the sagitta l and frontal planes.
c) Limitation of chest expansion relative to normal values corr ected for age and sex.
2) Radiologic criterion
Sacroiliitis grade ≥2 bilaterally or sacroiliitis grade 3 to 4 unilaterally.
Grading
1) Definite ankylosing spondylitis if the radiologic criterion is associated with at least 1 clinical 
criterion
Note: A second grading of “probably ankylosing spondylitis” is part of the modified NY criteria, but it is 
not applicable for this study. It is included here for complete ness. The grading will be probable ankylosing 
spondylitis if three clinical crit eria are present and the radi ologic criterion is present without any signs or 
symptoms satisfying the clinic al criteria (other causes of sacr oiliitis should be considered).
REDACTEDmpp
he radhe rad
auses oauses oCOPYlitis” islitis” 
pletenletePY PY
This document cannot be used to support any marketing authorizations parpa
ness. Tess. T
iologiciologic
of sacrofs a c r oapart ofrt oapplication associatssociatio
apand anany anextensions ns
ex.x.ns
exor ot ot variations aaavathereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 122 of 25518.3 Table of corticosteroid equivalent doses  
Table of corticosteroid equivalent doses  
Prednisone (reference) 10mg  
Cortisone 50mg  
Hydrocortisone  40mg  
Prednisolone  10mg  
Triamcinolone  8mg 
Methylprednisolone  8mg 
Betamethasone  1.5mg  
Dexamethasone  1.5mg  
Corticosteroid equivalent doses (with reference to prednisone 1 0mg dose) (Meikle and Tyler, 1977)
REDACTED COPY 
This document cannot be used to support any marketing authorization application and(MeikMeikdaany aextensions on
en
eor orvariations riaarrrthereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 134 of 25518.9 PGADA (NRS) 
NRS patient global disease activity 
How active was your spondyloarthritis on average during the las t week?  
Please tick the box that represents your answer ( i.e.     10          ) 
Not active very active0 1 2 3 4 5 6 7 8 9 10
REDACTED COPY 
This document cannot be used to support any marketing authorization application and ndany extensions ensensionsonsioor variations othereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 141 of 25518.11 Total spinal pain NRS and nocturnal spinal pain NRS 
NRS pain
 n
p
Please tick the box that represents your answer ( i.e. 
 )
1
.
Total Spine
 e
Pain
n
 p
How much pain of your spine due to spondyloarthritis do you hav e?
 o
no pain
 n
 most severe pain
 n
2
.
Nocturnal Spine
 e
ePain
n
 p
How much pain of your spine due to spondyloarthritis do you hav e at night?
no pain
 n
 most severe pain
 n
10
0
1
 2
 3
 4
 6
 7
 8
 9
 10
0
 5
 0
1
 2
 3
 4
 6
 7
 8
 9
t
10
e
0
 5
n
n
0
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any
y
m
m
any
y
yext
extensions extenexten
te
1
1xor 
or
o
orvariations nn
n
n
n
nvvthereof. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 143 of 25518.13 Protocol Amendment 1 
Rationale for the amendment
The substantial amendment include s several changes to clarify a nd/or add supporting 
information regarding the procedures and assessments, and to re move inconsistencies and errors: 
a range of sensitivity analyses, previously discussed with the regulatory authorities, to evaluate 
the impact of missing data on the analysis of the primary effic acy variable. 
Other changes included the following: the exclusion criterion r egarding the upper limit of normal 
of the liver function tests for subjects who are not treated wi th methotrexate, the requirement for 
plasma samples to be analyzed to confirm the washout of specifi c prohibited medications was 
removed, and the reporting-needs of particular physician-comple ted assessments in the eCRFs 
were clarified. Two tables were included to assist the Investig ators in identifying the assessments 
to be performed when subjects sw itch to alternative treatments.  Inconsistencies in the laboratory 
assessments performed, the defi nition of study treatment, and t he use of Week 52 and 
Week 52/Withdrawal (WD) visit we re corrected, study personal inf ormation was updated, and 
minor editorial changes were made.
Modifications and changes
Global changes
The following changes were made throughout the protocol:
x The study contact information is updated
x Week 52 and Week 52/Early Withdrawal visits are updated to Week  52/WD visit throughout 
the protocol, as defined in the  Schedule of Assessments.
x Double-blind study treatment ad ministration during the Double-B lind Period has been 
defined consistently throughout the protocol.
x The laboratory assessments to be  performed throughout the study  are updated so that they are 
described consistently throughout the protocol.
x Magnetic resonance imaging (MRI) for the spine is to be perform ed at Week 12, along with 
the already planned sacroiliac (SI) MRI.
x “Are Patient -Reported Outcome Instruments for Ankylosing Spondylitis Fit-Fo r-Purpose for 
the Axial Spondyloarthritis Patient? A Qualitative and Psychome tric Analysis” by van 
Tubergen et al has been published and the protocol is updated t o reflect the publication
x The protocol is updated to reflec t that the recording of the Ph ysician’s Global Assessment of 
Disease Activity (PhGADA), joint count, and Work Productivity S urvey (WPS) will be on 
the electronic Case Report form (eCRF) only.
x For subjects who discontinue the study treatment during Study P eriod 2, the assessments 
completed at the scheduled vi sit do not need to be repeated at the withdrawal treatment (wdt) 
Week 0 visit of the alternative s chedule. Therefore, 2 addition al tables are added to facilitate 
the Investigators understanding of which remaining assessments are required to be 
performed, when the subject enterseither the open-label certoli zumab pegol (CZP) or the 
alternative treatment schedule.REDACTED awal vawal v
edule edule
minminCOPY e protoe prot
This document th
xxcannote protprot
DiseasDiseas
thethebeen en eused RepRe
Spondpond
et aet atoeporeposupport imaginmagi
ed sacrd sacrany o o 
oughooughomarketing nistratinistrat
the prohe pr
be pbe authorizationocolco
visits avisits 
of Asof Asapplication ol:l:andmatiatianyWeekWeek
tion ionextensionstionsons
n the n the 
ng the ng the
ies ines in
kkormenmen
swvariations normaorma
entntthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 144of 255x The use of the I nteractive response system (IXRS) is updated to clarify that it  will be used to 
register subjects attending Visit 1 without issuing any kit num ber.
x The current study does not analyze the samples collected data f or methotrexate (MTX), 
sulfasalazine (SSZ), hydroxychloroquine (HCQ), nonsteroidal anti -inflammatory drug 
(NSAID), corticosteroids, and the washout of any prohibited med ications; the text that 
describes this is deleted.
x The Safety Set (SS) definition is updated.
x Following discussion with the regulat ory authorities, a range of different sensitivity analyses 
have been included to investiga te the missing data assumption.
x The use of graphs for individual  plasma concentrations for CZP and anti -CZP levels versus 
time analysis is included.
x Other changes mad e in this amendment are to provide clarification or are adminis trative in 
nature, including minor editorial changes to abbreviations.
Specific changes
This section displays the modifications in this amendment compa red with the Final Protocol 
dated 01 Jun 2015. The changes are displaye d in the order of appearance.
Change #1
Study Contact Information  
Sponsor Study Physician  
Name: , MD
Address: 208 Bath Road
Slough 
Berkshire
UK
SL1 3WE  
Phone:
Fax:REDACTED RCOPYdmendme
the orthe o
This document cannot be beused seto tosupportBerkerk
UKUK
upany gh gh 
kshikshmarketing , MMing
h Roadh Roarkketiauthorizationrder derapplication t compcom
ro fro fand anyare aare extensions P leve leveoanaanavariations alylthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 145of 255Has been changed to:
Sponsor Study Physician  
Name: , MD
Address: Alfred-Nobel-Str 10
40789 MonheimGermany
 
Phone:  
Fax: 
Change #2
List of abbreviations
The following abbreviati ons have been added:
Apo apolipoprotein
HbA1c Hemoglobin A1c
MAR missing at random
MCMC Markov Chain Monte Carlo
MI multiple imputation
Change #3
List of abbreviations
The following abbreviati on has been deleted:
TNFα tumor necrosis factor alpha
Change #4
Section 1 Summary, paragraphs 3, 4, 6, 7, 12, 15, and 16
Additionally, subjects must have had an inadequate response to,  have a contraindication to, or 
have been intolerant to at least  2 NSAIDs. Inadequate response to a NSAID is defined as lack of 
response to at least 14 days of continuou s NSAID therapy at the highest tolerated dose of the 
administered NSAID. Eligible subjects will be allocated to the following study treatments in a 
1:1 ratio:
x CZP administered subcutaneously (sc) at the dose of CZP 400mg a t Weeks 0, 2, and 4 
followed by CZ P 200mg every 2 weeks (every other week; Q2W) sc (starting at W eek 6)
x PlaceboREDACTED onte Conte C
utationutationCOPY 
This documentav
resporespo
adadcannot 1 SS
tionalonal
e bee bebe SumSumused to supporton hn h
tumtuany hashasmarketing authorization arloarlo
napplication and any extensions ns
nsor rvariations vthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 146 of 255At on-site visit days (at Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 50), 
study treatments will be administered sc at the study site by d edicated, unblinded, and adequately 
trained site personnel. The study treatment will be self-inject ed at home at Weeks 14, 18, 22, 26, 
30, 34, 38, 42, and 46. All subjects will receive training for self-injection at the study site at 
Weeks 10 and 12. During the training at the Weeks 10 and 12 vis its, the study treatment will be 
self-administered under the  supervision of the dedicated unblin ded study personnel.
Subjects whose disease activity cannot be controlled by study m edication and changes in 
background therapy (including and not limited to analgesics, NS AIDs, and slow-acting 
antirheumatic drug [SAARDs]) will be permitted to withdraw from  the double-blind study drug. 
Subjects will either transition to open-label treatment offered  by UCB with the marketed product 
of CZP, after Week 52, ie, complet ion of all study assessments,  or at the discretion of the 
Investigator and in accordance with the local regulatory requir ements for a maximum duration of 
2 years or until marketing authorization is granted for CZP (if  applicable), whichever comes first, 
or subjects will transition to receive other treatment (includi ng biologics). These subjects will 
remain in the study until the assessment of the primary endpoin t at Week 52.
All subjects, including those withdrawn from study treatment, wi ll have a FU Visit 8 weeks after 
their final Week 52 visit.
The primary efficacy variable is Ankylosing Spondylitis Disease  Activity Score major 
improvement (ASDAS-MI) response at Week 52. The secondary effic acy variables are 
Assessment in Axial SpondyloArthr itis International Society 40%  (ASAS40) response at 
Weeks 12 and 52, change from Baseline in Bath Ankylosing Spondyl itis Functional Index 
(BASFI) at Weeks 12 and 52, change from Baseline in BASDAI at W eeks 12 and 52, change 
from Baseline in Sacroiliac-Spond yloarthritis Research Consorti um of Canada (SI-SPARCC) 
score at Week 12, and the number  of subjects without relevant c hanges to background 
medication.
Safety variables to be assessed are adverse events (AEs), vital  signs, physical examination, and 
measurements of laboratory parameters. In addition, subjects wi ll be evaluated at Screening, 
Baseline, and at every 12 weeks thereafter up to and including Week 36 for signs and symptoms 
of latent or active tuberculosis (TB) infection and risk factor s for exposure to TB using the TB 
questionnaire.
Approximately 900 subjects will be screened in order to have 30 0 subjects (150 subjects per 
treatment group) randomized into the study. Randomization will be stratified by presence of 
sacroiliitis on MRI and elevated CRP to ensure balanced treatmen t allocation across three 
subgroups: MRI+/CRP+; MRI+/CRP-; MRI-/CRP+. For each subject, t he study will last a 
maximum of 66 weeks and will consist of 3 periods: 
x Screening Period lasting up to 6 weeks
x Double-Blind, placebo-controlled Period for 52 weeks
x FU Period 8 weeks after the Week 52/Withdrawal (WD) visit.
Have been changed to:
Additionally, subjects must have had an inadequate response to,  have a contraindication to, or 
have been intolerant to at least  2 NSAIDs. Inadequate response to a NSAID is defined as lack of Bath ABath A
m Basm Bas
rthritirthriti
f subjf subjCOPY itis iti
The seThe se
onal onal 
This document xxcannotmum oum o
ScreScreben
 MR MRusedp) ranran
MRMRto0 subsu
dsupportee
ulosis losis 
bjebjanyameam
ks theks th
(Tmarketingjectsects
e adveradve
metemetauthorizationec
SocieSocie
AnkyloAnkylo
seline seline 
is Ress Res
swswapplicationl haha
isease sease
condacondaandeek ek 
aveaveanyTheThe
k5 2 .52extensionseted ted
n of thof th
ximumximum
hichehicheody ddy 
pvariations drdrthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 147 of 255response to at least 14 days of continuous NSAID therapy at the  highest tolerated dose of the 
administered NSAID. Eligible subjects will be allocated to the following double-blind study 
treatments in a 1:1 ratio:
x CZP administered subcutaneously (sc) at the dose of CZP 400mg a t Weeks 0, 2, and 4 
followed by CZP 200mg every 2 weeks (every other week; Q2W) sc (starting at Week 6)
x Placebo
At on-site visit days (at Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 50), the 
double-blind study treatments will  be administered sc at the st udy site by dedicated, unblinded, 
and adequately trained site personnel. The double-blind study t reatment will be self-injected at 
home at Weeks 14, 18, 22, 26, 30, 34, 38, 42, and 46. All subje cts will receive training for self 
injection at the study site at Weeks 10 and 12. During the trai ning at the Weeks 10 and 12 visits, 
the double-blind study treatment will be self administered unde r the supervision of the dedicated 
unblinded study personnel.
Subjects whose disease activity cannot be controlled by study m edication and changes in 
background therapy (including and not limited to analgesics, NS AIDs, and slow-acting 
antirheumatic drugs [SAARDs]) wil l be permitted to withdraw fro m the double-blind study drug. 
Subjects will either transition to open-label CZP treatment off ered by UCB or to other treatment 
(including biologics) at the discretion of the Investigator unt il the assessment of the primary 
endpoint at Week 52. At the comp letion of the Week 52 visit, an d in accordance with the local 
regulatory requirements, CZP will be provided for a maximum dur ation of 2 years or until 
marketing authorization is gran ted for CZP (if applicable), whi chever comes first.
All subjects, including those withdrawn from double-blind study  treatment, will have a FU 
visit 8 weeks after their final Week 52 visit.
The primary efficacy variable is Ankylosing Spondylitis Disease  Activity Score major 
improvement (ASDAS-MI) response at Week 52. The secondary effic acy variables are 
Assessment in Axial SpondyloArthritis International Society 40%  (ASAS40) response at 
Weeks 12 and 52, change from Baseline in Bath Ankylosing Spondyl itis Functional Index 
(BASFI) at Weeks 12 and 52, change from Baseline in BASDAI at W eeks 12 and 52, change 
from Baseline in SI-Spondyloarthritis Research Consortium of Ca nada (SPARCC) score at 
Week 12, and the number of subjects without relevant changes to background medication.
Safety variables to be assessed are adverse events (AEs), vital  signs, physical examination, and 
measurements of laboratory parameters. In addition, subjects wi ll be evaluated at Screening, 
Baseline, and at every 12 weeks thereafter up to and including Week 52/Withdrawal (WD) for 
signs and symptoms of latent or active tuberculosis (TB) infecti on and risk factors for exposure 
to TB using the TB questionnaire.
Approximately 900 subjects will be screened in order to have 30 0 subjects (150 subjects per 
treatment group) randomized into the study. Randomization will be stratified by presence of 
sacroiliitis on MRI and elevated CR P to ensure balanced treatme nt allocation across 
3 subgroups: MRI+/CRP+; MRI+/CRP- ; MRI-/CRP+. For each subject, the study will last a 
maximum of 66 weeks and will consist of 3 periods: 
x Screening Period lasting up to 6 weeksREDACTEDd ford fo
(if ap(if ap
n fromn from
52 vis52 visCOPYgator gator
Week 5Week 5
or ara
This documentApprAppr
tretrecannotndndsysy
TB usinB usibets
and aand auseds to bto b
s of lof lto umsupportd 52, c52, c
pondyloondy
mber mberanyArthArth
m Basm Ba
hmarketing it.t.
ylosingylosin
nse ase at Wt
thritihritauthorization52 vi2 vi
a maxmax
pplicabplicab
m doubm doubapplicationAIDsID
from tfrom 
ffered ffered
until thuntil t
visitisitandation tion
Ds, asaany anextensionsinjecnjec
ining fning 
s 10 an10 an
ion oon oorlindlind
ctetvariations 0), the0), the
dedethereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 148 of 255x Double-Blind, Placebo-Controlled Period for 52 weeks
x FU Period 8 weeks after the Week 52/Withdrawal (WD) visit.
Change #5
Section 2.2 Burden of disease in axSpA, paragraph 2
Several large observational a nd noninterventional cohort studie s (Cuirea et al, 2013; Sieper and 
van der Heijde, 2013a) re ported a similar burden of disease at study baseline across AS studies 
(captured through BASFI and BASDAI) in nonradiographic as well as radiographic axSpA 
(captured through BASDAI). A literature review of clinical stud ies in both populations (Callhoff 
et al, 2015) and (RAPID-AxSpA) (Landewe et al, 2014) confirmed this finding in the clinical 
study setting.
Has been changed to:
Several large observational a nd noninterventional cohort studie s (Cuirea et al, 2013; Sieper and 
van der Heijde, 2013a) re ported a similar burden of disease at study baseline across AS studies 
(captured through BASFI and BASDAI) in nonradiographic as well as radiographic axSpA 
(captured through BASDAI). A literature review of studies in bo th populations (Callhoff et al, 
2015) and a recent study with CZP (RAPID-AxSpA) (Landewe et al,  2014) confirmed this 
finding in the clinical study setting.
Change #6
Section 2.4 Current management of  axial spondyloarthritis, para graphs 3 and 4
Patients who are intolerant  of or have inadequately responded t o NSAIDs, or those in whom 
NSAIDs are contraindicated, have limited treatment options. Tum or necrosis factor alpha 
(TNFα) inhibitors (CZP, ada limumab [ADA] etanercept [ETN] infliximab [IFX]), golimumab 
[GOL]) are currently the only ef fective and approved treatment options as of Dec 2014; IFX and 
GOL are indicated for active AS only, while CZP, ADA, and ETN a re indicated for axSpA 
without radiographic evidence of AS (nr-axSpA) as an addition t o the AS indication in several 
regions.
At the 2014 Annual Meeting of the A CR/SPARTAN group a draft tre atment guideline was 
presented for the subject suffer ing from both AS and nr-axSpA. These guidelines recommend the 
use of a TNF inhibitor after NSAID treatment.
Have been changed to:
Patients who are intolerant  of or have inadequately responded t o NSAIDs, or those in whom 
NSAIDs are contraindicated, have limited treatment options. Tum or necrosis factor-alpha 
inhibitors (TNFi) (CZP, adalimu mab [ADA] etanercept [ETN] infli ximab [IFX]), golimumab 
[GOL]) are the only effective and approved treatment options as  of Dec 2014; IFX and GOL are 
indicated for active AS only, while CZP, ADA, and ETN are indic ated for axSpA without 
radiographic evidence of AS (nr-axS pA) as an addition to the AS  indication in several regions.   REDACTED of axof axCOPYudud
A) (LaA) (L
This documentPatieatie
NSANS
iicannot NN
e beenbeen
entenbe r t
NF inNF insednnual nual 
the sthe to supportly y
tive Aive A
evidencvidenanymummum
effeceffecmarketing xial spal s
e inadeinad
e limitelimit
mabmabauthorization spspapplication udy bdy b
s well awell
in bothin bot
ndewendewanduirea eirea e
babany extensionsaxSpxSp
tions (ions 
in thein thortudtu
pApAvariations r and and 
udiediethereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 149 of 255At the 2014 Annual Meeting of the A CR/SPARTAN group a draft tre atment guideline was 
presented for the subject suffer ing from both AS and nr-axSpA. These guidelines recommend the 
use of a TNFi after NSAID treatment.
Change #7
Section 2.5 Rationale, paragraph 2
To address the unmet need for tre atment options for nr-axSpA, A S0006 will be conducted 
focusing on subjects who do not meet the mNY classification cri teria for AS (see 
Appendix 18.2). Data suggest that patients with objective signs of inflammat ion and high disease 
activity are likely to run a chronic disease course and unlikel y to be well managed on 
conventional therapy (Rudwaleit ACR 2013). Furthermore, studies  where anti-TNFs have been 
withdrawn in nr axSpA patients show that patients flare quickly  and hence the disease is unlikely 
to go into spontaneous remission. However, there are no long-te rm prospective studies to assess 
how patients meeting the ASAS classification criteria respond t o conventional therapies. With 
the conduct of this 52-week study comparing CZP to placebo in c ombination with standard of 
care, a better understanding should be gained of how a long-ter m anti-TNF therapy compares to
standard of care in patients meeting the ASAS criteria with obj ective signs of inflammation. 
Moreover, patients whose diseas e cannot be managed under the bl inded study treatment 
conditions will be able to discont inue the study treatment and transition to either open-label CZP 
or other therapies.
Has been changed to:
To address the unmet need for tre atment options for nr-axSpA, A S0006 will be conducted 
focusing on subjects who do not meet the mNY classification cri teria for AS (see 
Appendix 18.2). Data suggest that patients with objective signs of inflammat ion and high disease 
activity are likely to run a chronic disease course and unlikel y to be well managed on 
conventional therapy (Rudwaleit ACR 2013). Furthermore, studies  where anti-TNFs have been 
withdrawn in nr-axSpA patients show that patients flare quickly  and hence the disease is unlikely 
to go into spontaneous remission. However, there are no long-te rm prospective studies to assess 
how patients meeting the ASAS c lassification criteria respond t o conventional therapies. With 
the conduct of this 52-week study comparing CZP to placebo in c ombination with standard of 
care, a better understanding should be gained of how a long-ter m anti-TNF therapy compares to 
standard of care in patients meeting the ASAS criteria with obj ective signs of inflammation. 
Moreover, patients whose diseas e cannot be managed under the bl inded study treatment 
conditions will be able to disc ontinue the double-blind study t reatment and transition to either 
open-label CZP or other therapies.
Change #8
Section 4.1.3 Other efficacy variables
The following bullet has been added :
x Change from Baseline in sacroiliitis grading to Week 52 for str uctural damageREDACTED ent optent opt
et theet theCOPYed uned un
eatmeeatm
This document ChChcannot ns ws 
label abel bepatiati
wilwiused dersers
re in pe in p
ieniento 2
stanstansupportmissioissio
he ASAe AS
--weeweeany t At A
nts shots shmarketinge mNe mN
tients wtients 
diseasediseas
ACRACRauthorizationent ant a
tions ions 
NYNYapplication ombm
m antim ant
objectivbject
der the er the
andandandventiventi
mbinbinany hh
ectiveectiv
ioniextensionsd highhigh
d on d on 
TNFTNF
he die dior variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 150 of 255Change #9
Section 4.2.3 Pharmacogenomic variables
For individuals consenting to the genomics substudy, blood sampl es will be drawn for possible 
genetic/epigenetic, genomic , proteomic, and metabolomics analys is at Baseline and Week 12. 
Additional samples will be coll ected for genomics, proteomics, and metabolomics analysis only, 
at Baseline, Weeks 4, 12, and 52. Col lection of the samples wil l enable the exploratory 
evaluation of biomarkers relative to disease activity, drug tre atment, and inflammatory and 
immune response processes. The  nature and format of these tenta tive analyses w ill be determined 
when the results of the main study are made available. The samp les will be stored at -80°C at the 
central biorepository for up to 20 years.
Has been changed to:
For individuals consenting to the genomics substudy, blood samp les will be drawn for possible 
genetic/epigenetic, genomic , proteomic, and metabolomics analys is at Baseline and Week 12. 
Additional samples will be coll ected for genomics, proteomics, and metabolomics analysis only, 
at Weeks 4 and Week 52/WD. Collection of the samples will enabl e the exploratory evaluation 
of biomarkers relative to disease activity, drug treatment, and  inflammatory and immune 
response processes. The nature a nd format of these tentative an alyses will be determined when 
the results of the main study are made available. The samples wi ll be stored at -80°C at the 
central biorepository for up to 20 years.
Change #10
Section 4.3 Immunological variables, paragraph 1
4.3 Immunological variable(s) 
Anti-CZP antibody (anti-CZP Ab) concentrations will be assessed  at Baseline and Weeks 1, 2, 4, 
12, 24, 36, 52, and the FU Visit (8 weeks after the Week 52/WD Visit). In addition, the anti CZP 
Ab concentrations will be assessed in subjects who withdraw fro m study drug and transition to 
open-label CZP. The number and perc ent of subjects with anti-CZP  Ab concentrations above 
2.4 units/mL will be reported as follows:
Has been changed to:
4.3 Immunological variables 
Anti-CZP antibody (anti-CZP Ab) concentrations will be assessed  at Baseline and Weeks 1, 2, 4, 
12, 24, 36, 52/WD, and the FU visit (8 weeks after the Week 52/ WD visit). In addition, the 
anti-CZP Ab concentrations will be assessed in subjects who wit hdraw from study drug and 
transition to open-label CZP. The number and percent of subject s with anti-CZP Ab 
concentrations above 2.4 units/mL will be reported as follows:REDACTED es, paes, pa
((COPYe same sam
This documentransans
conconcannot36, 536, 5
CZP CZP
sitisitbeantibantibused dd
munounoto to:to:support sses
mber anmber a
eportedporteany(8 w(8 
essedessedmarketing arara
s)s)
) concecon
wewauthorization agraagraapplication le te 
nflammflam
analysanaly
ples wples wandmetabetab
thetheany dd
aselinaselin
bolbextensions 0
drawdrawor°C °C variations rminrminthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 151 of 255Change #11
Section 4.4 Safety variables, paragraphs 4 through 6
Clinical laboratory values (hematology, biochemistry, urinalysi s) will be collected and assessed 
at Screening, Baseline, Weeks 2, 4, 8, 12, 24, 36, at the end o f study Completion at 
Week 52/Early Withdrawal Visit and at the FU Visit (8 weeks afte r the Week 52/WD Visit). In 
addition, clinical laboratory values will be collected and asse ssed at study visits during the 
administration of open-label CZP i n subjects who withdraw from t he study treatment.
Furthermore, CRP will be coll ected and assessed either in a bli nded or open manner at 
Screening, 3 to 5 days before Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 
at the end of study Completion a t Week 52/Early Withdrawal Visi t and at the FU Visit (8 weeks 
after the Week 52/WD Visit).
At Screening, all subjects will have an Interferon-Gamma Releas e Assay (IGRA) test 
(QuantiFERON®TB test or Elispot®test, when the QuantiFERON test indicated is not available), 
and a chest x-ray read (or, i f done, computed tomography of the  chest) which must be reported 
consistent with standard clinical reporting practice by an expe rienced qualified TB specialist, 
radiologist, or a pulmonologist, who is specifically required t o look for signs of active TB or 
signs of past/inactive TB infection. The official report of the  imaging must specifically indicate 
the absence of findings suggestive of current active TB or prio r inactive TB. In addition to a 
physical examination done intermittently throughout the study, subjects will be evaluated at 
Screening, Baseline, and every 12 weeks thereafter up to and in cluding Week 36, including the 
Completion/Early Withdrawal Visit, for signs and symptoms of la tent or active TB infection and 
risk factors for exposure to TB using the TB questionnaire
Have been changed to:
Clinical laboratory values (hematology, biochemistry, urinalysi s) will be collected and assessed 
at Screening, Baseline, Weeks 2, 4, 8, 12, 24, 36, at the end o f study completion at Week 52/WD 
Visit and at the FU Visit (8 weeks after the Week 52/WD Visit). In addition, clinical laboratory 
values will be collected and a ssessed at study visits during th e administration of open-label CZP 
in subjects who withdraw from the double-blind study treatment.
Furthermore, CRP will be coll ected and assessed either in a bli nded or open manner at 
Screening, 3 to 5 days before Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 
at the end of study completion at Week 52/WD visit and at the F U visit (8 weeks after the 
Week 52/WD visit).
At Screening, all subjects will have an Interferon-Gamma Releas e Assay (IGRA) test 
(QuantiFERON®TB test or Elispot®test, when the QuantiFERON test indicated is not available),
and a chest x-ray read (or, i f done, computed tomography of the  chest) which must be reported 
consistent with standard clinical reporting practice by an expe rienced qualified TB specialist, 
radiologist, or a pulmonologist, who is specifically required t o look for signs of active TB or 
signs of past/inactive TB infection. The official report of the  imaging must specifically indicate 
the absence of findings suggestive of current active TB or prio r inactive TB. In addition to a 
physical examination done intermittently throughout the study, subjects will be evaluated at 
Screening, Baseline, and every 12 weeks thereafter up to and in cluding the Week 52/WD visit, REDACTEDeafteafte
gns andns and
TB qTB qCOPYTB oTB o
hout thhout th
ter uer
This documentconscons
radradcannot ninnin
ntiFERtiFER
a chea ch
ibe ng, ng,usedudy cdy c
visitvisittoays ays supportfromfrom
ll be col be c
bebany ks ks
ssessessess
tmarketing gy, biocgy, bio
, 8, 128, 12
s afteaftauthorizationhe ste st
up to up to 
d symsym
questiouestioapplication ceded
look foook f
imaginimag
r prior prior
studtudandt) wh) wh
d qudq uany GRG
dicatedicat
hichiextensions44, 44, 4
Visit (Visit (
GRARAor 4848variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 152 of 255for signs and symptoms of latent tuberculosis (LTB) or active T B infection and risk factors for 
exposure to TB using the TB questionnaire.
Change #12
Section 5.1.1 Study periods
The study includes 3 periods. An injection schedule is provided  in Section 7.2.2 .
Period 1 (Screening Period): 1 to 6 weeks before Baseline: 
Prior to any study activities, subjects will be asked to read a nd sign the Informed Consent form 
for the conduct of the study. A separate informed consent form will also be obtained from 
subjects consenting to the use of their blood samples in a subs tudy for possible genetic, 
genomic/epigenetic, and proteomic analysis.
Laboratory data is to be obtained to verify the doses of MTX, S SZ, hydroxychloroquine (HCQ), 
NSAIDs, and corticosteroids, if us ed, are stable. Laboratory da ta will also be collected to ensure 
the washout of any medications not permitted for use during the  study has been performed, and 
to initiate latent TB treatment where necessary. Concomitant me dications permitted during the 
study should remain stable for at least 4 weeks prior to Baseli ne.
Sacroiliac-joint x-ray (not olde r than 12 months before Baselin e and verified by central reading 
during the Screening Period) must prove that the subject belong s to the mNY-negative axSpA 
subpopulation, ie, does not have sacroiliitis grade ≥2 bilatera lly or grade 3 to 4 unilaterally. 
Potentially eligible axSpA subjects without suitable SI-joint x -ray must undergo the x-ray with 
central reading within the Screening Period. SI-joint x-rays (r ead centrally) will allow 
discrimination of subjects with AS and without definitive evide nce for sacroiliitis on x-ray 
(mNY negative-axSpA). Subjects with AS (mNY-positive) must be e xcluded from further 
participation in this study.
Confirmed mNY-negative axSpA subjects must undergo an MRI later  during the Screening 
Period for central reading with results from the central readin g available by no later than at the 
Baseline visit. 
Additionally the subjects must get a further measurement of CRP  3 to 5 days before Baseline 
(Week 0).  
Period 2 (Double-Blind Period): Wee k 0 to Week 52, placebo controlled. 
Eligible subjects will be allocated to the following study trea tments in a 1:1 ratio:
x CZP administered at the dose of 400mg at Weeks 0, 2, and 4 foll owed by 200mg Q2W 
(starting at Week 6 up to and including Week 50)
x Placebo
At on-site visit days (at Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 50), 
study treatments will be administered sc at the study site by d edicated, unblinded and adequately 
trained site personnel. The study treatment will be self-inject ed at home at Weeks 14, 18, 22, 26, 
30, 34, 38, 42, and 46. All subjects will receive training for self-injection at the study site on 
Weeks 10 and 12. During the training on Weeks 10 and 12 visits,  the study treatment will be he 
grade grade
ut suitut suit
eriod. eriod.
and wand w
hhCOPY o B
efore Bfore
subjsubj
This document xxcannot u
ZP adZP ad
(star(starbebjecbjecused ubleble--Bto support ithth
ects mcts manypA spA 
h resuh resumarketing withouitho
h AS (mAS (
subsuauthorization Ba
bject bect b
≥2 bi≥2 bi
itable table 
SISI--jojo--
ouapplicationstudyudy
medicatedica
eline.line.
aselinaselinanddro
ll alsoalso
yhyhany oxychoxych
bextensionsnsennsen
ned froed fro
e genegeneor variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 153 of 255self-administered under the s upervision of the unblinded study p ersonnel. Concomitant 
medications permitted during the study should remain stable for  at least 4 weeks prior to the 
Week 12, 24, and 52 assessments.
Period 3 (Follow-Up Period):
All subjects, including those withdrawn from study treatment, w ill have a FU Visit 8 weeks after 
the Week 52/WD visit.
Alternative schedules  
Subjects who discontinue the study treatment and enter open-lab el treatment with CZP or other 
treatments (including biologics) will follow alternative schedu les of assessments. Assessments
are to be continued as at Week 12 every 12 weeks until as close  as possible to Week 52 (within 
±4 weeks of the originally planned Week 52 Visit) of the regula r visit schedule. Subjects will 
then be invited to the final assessment visit at Week 52.
Has been changed to:
The study includes 3 periods. An injection schedule is provided  in Section 7.2.2 .
Period 1 (Screening Period): 1 day to 6 weeks before Baseline: 
Prior to any study activities, subjects will be asked to read a nd sign the Informed Consent form 
for the conduct of the study. A separate informed consent form will also be obtained from 
subjects consenting to the use of their blood samples in a subs tudy for possible 
genetic/epigenetic, genomic, proteomic, and metabolite analysis .
Laboratory data (hematology, urine, and biochemistry tests) wil l be obtained, and treatment of 
LTB will be initiated when necessary. Subjects must undergo a T B test and complete a TB 
questionnaire. Bath Ankylosing Spondylitis Disease Activity Ind ex, BASMI, and spinal mobility 
assessments will be performed. Concomitant medications permitte d during the study should 
remain stable for at least 4 weeks prior to Baseline at Week 0.
Sacroiliac-joint x-ray (not ol der than 12 months before Baselin e and verified by central reading
during the Screening Period) must prove that the subject belong s to the mNY-negative axSpA 
subpopulation, ie, does not have sacroiliitis grade ≥2 bilatera lly or grade 3 to 4 unilaterally. 
Potentially eligible axSpA subjects without suitable SI-joint x -ray must undergo the x-ray with 
central reading within the Scree ning Period. Sacroiliac-joint x -rays (read centrally) will allow 
discrimination of subjects with AS and without definitive evide nce for sacroiliitis on x-ray 
(mNY negative-axSpA). Subjects w ith AS (mNY-positive) must be e xcluded from further 
participation in this study.
Confirmed mNY-negative axSpA subjects must undergo an MRI later  during the Screening 
Period for central reading with results from the central readin g available by no later than at the
Baseline visit. 
Additionally the subjects must get a further measurement of CRP  3 to 5 days before Baseline 
(Week 0).  
Period 2 (Double-Blind Period): Wee k 0 to Week 52, placebo controlled. 
Eligible subjects will be allocated to the following double-bli nd study treatments in a 1:1 ratio:mpp
metabmeta
d biochd bioc
y. Subjy. Subj
ndyndyCOPYo reare
consencons
ples ples 
This documenteriri
BaseBase
Acannot tioio
irmedrmed
iod fod fbe tiv
on inon inusedth
of subof sub
vee--axaxtohin thin suppord) md) m
not havnot ha
xSpA sSpA
thanyer thaer tha
musmumarketingje
ylitis Dlitis D
comitanomita
prior tpriorauthorization nt 
 in a sin a s
abolitebolite
hemishemis
ects mcts mapplication Se
e: 
and siand s
t formformnd ectioectioany extensionsssesssessm
eek 52ek 5
e. Sub. Suboror otr ovariations hthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 154 of 255x CZP administered at the dose of 400mg at Weeks 0, 2, and 4 foll owed by 200mg Q2W 
(starting at Week 6 up to and including Week 50)
x Placebo
At on-site visit days (at Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 50), the 
double-blind study treatments will  be administered sc at the st udy site by dedicated, unblinded 
and adequately trained site personnel. The double-blind study t reatment will be self-injected at 
home at Weeks 14, 18, 22, 26, 30, 34, 38, 42, and 46. All subjec ts will receive training for self-
injection at the study site on Weeks 10 and 12. During the trai ning on Weeks 10 and 12 visits, 
the double-blind study treatment will be self-administered unde r the supervision of the unblinded 
study personnel. Concomitant med ications permitted during the s tudy should remain stable for at 
least 4 weeks prior to the Weeks 12, 24, and 52/WD assessments.
Period 3 (Follow-Up Period):
All subjects, including those withdrawn from the double-blind s tudy treatment, will have a FU 
visit 8 weeks after the Week 52/WD visit.
Alternative schedules  
Subjects who discontinue the doubl e-blind study treatment and e nter open-label treatment with 
CZP will be assessed 2 and 4 weeks after open-label CZP treatme nt has been initiated and every 
12 weeks thereafter. Alternatively, subjects who discontinue th e double-blind study treatment 
and receive other treatment (including biologics) will be asses sed every 12 weeks after initiation 
of the other treatment. The alte rnative schedules for open-labe l CZP and other treatment can be 
found in Table 5‒2 and Table 5‒3 , respectively. In either alternative schedule, assessments 
should be conducted until as close as possible to Week 52 (with in ±4 weeks), where Week 52 is 
relative to the original randomization at Week 0. Subjects will  then be invited to the final 
assessment visit at Week 52.
Change #13
Section 5.1.2 Study duration, paragraph 2
The estimated recruitment period is up to 15 months. The first subject first visit is planned in 
Quarter 3 of 2015. A completed subj ect is one who completes the  Week 52 Visit. UCB will offer 
continuation of open-label treatm ent with the marketed product of CZP, after Week 52, ie, 
completion of all study assessments, on discretion of the Inves tigator and in accordance with the 
local regulatory requirements, for a maximum duration of 2 year s or until marketing 
authorization is granted for CZP (if applicable), whichever com es first.
Has been changed to:
The estimated recruitment period is up to 15 months. The first subject first visit is planned in 
Quarter 3 of 2015. A completed subj ect is one who completes the  Week 52/WD visit. Subjects 
will either transition to open-label  CZP treatment offered by U CB or to other treatment 
(including biologics) at the discretion of the Investigator unt il the assessment of the primary 
endpoint at Week 52/WD. At the completion of the Week 52/WD vis it, and in accordance with 
the local regulatory requirements, CZP will be provided for a m aximum duration of 2 years or 
until marketing authorization is granted for CZP (if applicable ), whichever comes first.REDACTED cs) wcs) 
dules fdules f
ctivelyctivel
possibpossi
n at Wn at WCOPYl CZP CZ
discondisco
wilwi
This document Hasas
TheThe
Qcannot ulaula
rizatioizatio
s bebebe of of 
atoratorused. A. A
f openopen
fa l l  alltoA cA csupport ration, ation
ment pment any marketingWeekWeekauthorizationntinutin
ll be al be a
for opor op
ly. In ey. In 
le to e to 
kapplication nd entend ent
treatmreatm
nue nueand any tmenttmenextensions e u
in stabn staborunblnbvariations elfelf--fff
sits, sits, thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 155 of 255Change #14
Section 5.2 Schedule of stu dy assessments, paragraph 3
At any time during the study course, but preferably not before Week 12, the Investigator may 
discontinue the study treatment and start open-label treatment with either CZP (which will be 
provided free of charge by UCB) or an alternative drug (eg, oth er treatment [including 
biologics]). Table 5‒2 shows the schedule of assessments for subjects receiving open-l abel 
treatment with CZP and Table 5‒3 shows the schedule of assessmen ts for subjects receiving an 
alternative treatment (not CZP).
Has been changed to:
At any time during the study course, but preferably not before Week 12, the Investigator may 
discontinue the double-blind study  treatment and start open-lab el treatment with either CZP 
(which will be provided free of ch arge by UCB) or an alternativ e drug (eg, other treatment 
[including biologics]). Table 5‒2 shows the schedule of assessm ents for subjects receiving 
open-label treatment with CZP and Table 5‒3 for subjects receiving an a lternative treatment (not 
CZP).
REDACTED COPY 
This document cannot be used to support any marketing authorization application andan altn alany otot
subjecsubje
tertextensions stigattigat
th eithh eith
ther her or variations an an thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 156 of 255Change #15
Section 5.2 Schedule of s tudy assessments, Table 5 –1
The following row has been added:
Table  5‒1: Schedule of study assessment - Stud y Periods 1 to 3 (S creening until FU)  
Visit # Scr Scr 
day -5
to -31/
B
L234 567 89
H1
01
1
H1
21
3
H1
415
H1
617
H1
81
9
H2
02
1
H2
223
H2
42
5
H26 2
728 29
Week
Protocol 
Activity-6 weeks 
to -1 day0 124 681
01
21
4
/
H1
61
8
/
H2
02
2
/
H2
426
/H2
830
/H3
23
4
/
H3
63
8
/
H4
042
/
H4
44
6
/
H48 5
052
/
W
DF
U
b
HBsAg/
antibodies to 
hepatitis 
C/HIV/HLA-B
27/CKD -EPIXf   
Change #16
Section 5.2 Schedule of s tudy assessments, Table 5 –1 (The row describing IXRS)
Table  5‒1: Schedule of study assessment - Stud y Periods 1 to 3 (S creening until FU)  
Visit # Scr Scr 
day -
5 to-
31/
B
L234 567 89
H1
01
1
H1
21
3
H1
415
H1
617
H1
81
9
H2
02
1
H2
223
H2
42
5
H26 2
728 29
Week
Protocol 
Activity-6 to 
-1 0 1 24 6 8 1
0
 1
2 1
4 
/
H 1
6 1
8 
/
H 2
0 2
2 
/
H 2
4 26 
/H 2
8 30 
/H 3
2 3
4 
/
H 3
6 3
8 
/
H 4
0 42 
/
H 4
4 4
6 
/
H 48 5
0 52
/
W
DF
U
b
IXRS X X XXX XXX X X X X X X X X X X X X X REDACTED 
ACCACACT
TED
COPY 
YCO
PYThis 
document 
cannot 
nnnnnocnn
be b
used 
d22dddus
dto o support 667tttsport
anyStuStuaaaa
marketing 1 (Th1 (T
authorization 
hoorioo
ati
napplication /H/Hliatiplipliplicpli
and0 33d an
any 99
HHayextensions 22xteteteete
or 
variations 
on
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 157 of 255Has been changed to:
Table  5‒1: Schedule of study assessment - Stud y Periods 1 to 3 (S creening until FU)  
Visit # Scr Scr 
day -5to -31/
BL234 567 89
H1
01
1H1
21
3H1
415
H1
617
H1
81
9H2
02
1H2
223
H2
42
5H26 2
728 29
Week
Protocol 
Activity-6 weeks 
to -1 day 0 1 24 6 8 1
0
 1
2 1
4 
/
H 1
6 1
8 
/
H 2
0 2
2 
/
H 2
4 26 
/H 2
8 30 
/H 3
2 3
4 
/
H 3
6 3
8 
/
H 4
0 42 
/
H 4
4 4
6 
/
H 48 5
0 52
/
W
DF
U
b
IXRS X X XX XXX X X X X X X X X X X X X X REDACTED 
COPY This 
document 
cannot 
be 
used 
to support 
any 
marketing 
authorization 
application 
titititio
and anaaaa
any44
//any ayextensions11
HH22
22ste
io
s 
33xteteeteete
or o
variations 
on
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 158 of 255Change #17
Section 5.1 Schedule of stud y assessments, Table 5-1: footnotes  d to o have been reordered 
and footnotes with changes are noted.
aInformed consent: Prior to any study activities, subjects will be asked to read and sign the 
informed consent form for the conduct of the study. A separate informed consent form will 
also be obtained from subjects consenting to the use of their b lood samples in a substudy for 
possible genetic, genomic/epigenetic, and proteomic analysis.
dTesting to rule out hepatitis B surface antigen and antibodies to hepatitis C and testing for 
HLA-B27 and abnormalities for est imated Glomerular Filtration R ate as measured by 
CKD-EPI are to be performed at Screening only.
fPregnancy testing must be carried out for women of childbearing  potential and will be serum 
testing at the Screening Visit and FU and urine testing (dipsti ck) at Baseline and 
Week 52/Withdrawal.
gIncludes evaluation of signs and symptoms of active TB and risk  factors for exposure to TB. 
Weight is to be measured at Screening, Week 24, and at Completi on at Week 52/Early 
Withdrawal. Height will be measured at the Baseline Visit only.
kMagnetic resonance imaging of t he spine and SI joints to be per formed at Screening, 
Weeks 12 (SI only), 52, or Early Withdrawal Visit if MRI was per formed more than 12 weeks 
prior to Early Withdrawal Visit.
nAt on-site visit days (Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 24,  28, 32, 36, 40, 44, 48, and 50), 
study treatments will be administered sc at the study site by de dicated, unblinded and 
adequately trained site personnel. The study treatment will be self-injected at home at 
Weeks 14, 18, 22, 26, 30, 34, 38, 42, and 46. From Week 52 onwar ds, after completion of all 
on site assessments and procedures, the subject may receive fur ther open-label treatment with 
CZP to be supplied to discontinued subjects or another biologic s at the discretion of the 
Investigator.
oAll subjects will receive trainin g for self-injection at the st udy site on Weeks 10 and 12. 
During the training at the Weeks 10 and 12 visits, the study tr eatment will be 
self-administered under the s upervision of the unblinded study personnel.
Have been changed to: 
aInformed consent: Prior to any study activities, subjects will be asked to read and sign the 
informed consent form for the conduct of the study. A separate informed consent form will 
also be obtained from subjects consenting to the use of their b lood samples in a substudy for 
possible genetic/epigenetic, genomic, proteomic, and metabolite  analysis.
dSubjects will be encouraged to b e in fasting condition at Basel ine and at Week 52/WD or at 
the time the subject shifts to alternative treatment, for Apo A 1, ApoB, and lipoprotein(a) 
assessments.
eHbA1c will be measured at Baseline and Week 52/WD. REDACTED 8, 10, 8, 10, 
d scd scatat
The sThe s
42,42,COPYointsoint
Visit ifVisit 
This documentdSuSucannot mede
o be obbe ob
possibossibbe co
d cod cousedngedged
onseonseto u
dtdsupporte traitrai
at the Wthe W
under nderany iniimarketing studtu
, and 4and 4
es, the s, the
nued sunued authorization f MM
12, 162, 16
t the sthe s
udy tdy tapplicationpletiopletio
only.only.
to be po be 
MRI MRIand factorfactorany ininextensions d by by 
and wnd w
ne ane aorg fog fovariations fororthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 159 of 255fTesting to rule out HBsAg, antibodies to hepatitis C, and HIV w ill be performed. In addition, 
testing for HLA-B27 and abnormalitie s for estimated glomerular filtration rate as measured by 
CKD-EPI are to be performed.
hPregnancy testing must be carried out for women of childbearing  potential: A serum test will 
be performed at the Screening vi sit and FU, and urine testing ( dipstick) at Baseline and 
Week 52/WD.
iIncludes evaluation of signs and symptoms of active TB and risk  factors for exposure to TB. 
Weight is to be measured at Screening, Week 24, and at completi on at Week 52/WD. Height 
will be measured at the Baseline visit only.
mMagnetic resonance imaging of t he spine and SI joints to be per formed at Screening and at the 
Week 12 and at the Week 52/WD visits if MRI was performed more th an 12 weeks prior to 
WD visit.
pContact IXRS to register the visit and obtain next kit number, where applicable.
qAt on-site visit days (Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 24,  28, 32, 36, 40, 44, 48, and 50), the 
double-blind study treatments will  be administered sc at the st udy site by dedicated, unblinded 
and adequately trained site personnel. The double-blind study t reatment will be self-injected at 
home at Weeks 14, 18, 22, 26, 30, 34, 38, 42, and 46. From Week  52 onwards, after 
completion of all onsite assessments and procedures, the subjec t may receive open-label CZP 
at the discretion of the Investigator. 
rAll subjects will receive trainin g for self-injection at the st udy site on Weeks 10 and 12. 
During the training at the Weeks 10 and 12 visits, the double-b lind study treatment will be 
self-administered under the s upervision of the unblinded study personnel.
REDACTED injectinject
nd 12 nd 12 
ision osion COPY 46.6
ures, tures, 
This document cannot be used to support any marketing authorization tion ation a
visitsvisits
of the f the applicationudy sudy 
dy tready tre
om Wem W
he subhe suand 2, 36,2, 36,
iiany pplicapplicextensions ening aning 
 weekweekor variations TB. B. 
Heigheighthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 160 of 255Change #18
Section 5.2 Schedule  of study assessments
The following row has been added:
Table 5‒2: Schedule of alternative study assessment with CZP - after subject discontinuation of study 
treatment 
Visit # wdt 2
wdt3
wdt5
wdt6
wdt
Week
Protocol 
Activity0 2 4 6H 8H 10 12 14 H 16H 18 H 20 H 22 H 24 and 
Q12W 
 52/
WD FUa
Telephone 
contactk   X    X  X   
   
Change #19
Section 5.2 Schedule  of study assessments
Table  5‒2: Schedule of alternative study as sessment with CZP - after subject discontinuation of study treatment 
Visit # 1
wdt2
wdt3
wdt5
wdt6
wdt
Week
Protocol 
Activity0 2 4 6 H 8 H 10 12 14 H 16H 18 H 20 H 22 H 24 and 
Q12W 
 52/WD FUa
Has been changed to:
Table  5‒2: Schedule of alternative study assessment with CZP - after subjec t discontinuation of the double- blind study 
treatment 
Visit # 1
wdt2
wdt3
wdt4
wdt5
wdtREDACTED 
COPY OPOPOPOPThis 
document wdween
cannot dtdt
noan
belterer
used rnarna
to support 11sppo
any y
100anyyyymarketing ment went w
55
wrk
authorization 
application 
caapli
andd an
any 
extensions ontinontinexexexex
or 
variations 
on
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 161 of 255Week
Protocol 
Activity0 2 4 6H 8H 10H 12 14H 16H 18H 20H 22H 24 and 
Q12W 
 52/WD FUa
Change #20
Section 5.2 Schedule of s tudy assessments, Table 5 –2
Table  5‒2: Schedule of alternative study as sessment with CZP - after subject discontinuation of study treatment 
Visit # 1
wdt2
wdt3
wdt5
wdt6
wdt
Week
Protocol Activity0 2 4 6 H 8 H 10 12 14 H 16H 18 H 20 H 22 H 24 and 
Q12W 
 52/WD FUa
CZP administration sc Xi Xi Xi X X X X X X X X X X 
Continue assessments as at W24 every 12 weeks 
until as close as possible to W52 of the original 
visit schedule. Subject will then be invited to the 
final assessment visit at W52X XREDACTED 
DAC
ED
COPY 16PY
XXCOThis 
document 
cannot 
be 
used usse
to support u
rtany a
marketinm
ing in
authorizatiuth
ation Xonati
application 
io
H 18 H18licp
anddiscoiscoa
any on
extensions 
or o
variations 
onionva
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 162 of 255Has been changed to: 
Table  5‒2: Schedule of alternative study assessment with CZP - after subjec t discontinuation of the double- blind study 
treatment 
Visit # 1
wdt2
wdt3
wdt4
wdt5
wdt
Week
Protocol Activity0 2 4 6H 8H 10H 12 14H 16H 18H 20H 22H 24 and 
Q12W52/WD FUa
CZP administration sc XlXlXlX X X X X X X X X Xm
Continue assessments as at W24 every 12 weeks 
until as close as possible to W52 of the original 
visit schedule. Subject will then be invited to 
the final assessment visit at W52  REDACTED
AC
ED ED
COPY 
PYThis 
document 
cannot 
be 
used 
to support 
any ymarketing mmmm
in
authorization th
atio
application pp
io
andX
ddd dany 2HHaa
extensions 55
ww
onte
HHex
ortheth
variations 
on
hehe
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 163 of 255Change #21
Section 5.2 Schedule of stud y assessments, Table 5‒2: footnotes  have been reordered and 
footnotes with changes are noted.
Note: All weeks are ±3 days compared to Baseline. Week 0 of the  alternative schedule starts 
2 weeks after the last dose  of the study treatment.
dIncludes evaluation of signs and symptoms of active TB and risk  factors for exposure to TB. 
Weight is to be measured at wdt Week 0, Week 24, and at complet ion at Week 52/Early 
Withdrawal Visit.
eIf the la st Q12W assessment for a subject who discontinues study treatme nt is ≤4 weeks 
before the final assessments visit at Week 52, the assessment s hould be cancelled and the 
subject should instead be invited to undergo the final assessme nts visit at Week 52 (the
Week 52 Visit is to be scheduled 52 weeks (±3 days) after Baseli ne).
Have been changed to:
Note: All weeks are ±3 days compared to Baseline. Week 0 of the  alternative schedule starts 
2 weeks after the last dose of t he double-blind study treatment.
cSubjects will be encouraged to be in fasting condition at the t ime the subject shifts to 
alternative treatment, for Apo A 1, ApoB, and lipoprotein(a) ass essments.
dHbA1c will be measured at wdt Week 0 and Week 52/WD.
fIncludes evaluation of signs and symptoms of active TB and risk  factors for exposure to TB. 
Weight is to be measured at wdt Week 0, Week 24, and at complet ion at Week 52/WD. 
gIf the last Q12W assessment for a subject who discontinues stud y treatment is ≤4 weeks 
before the final assessments visit at Week 52/WD, the assessment  should be cancelled and the 
subject should instead be invited to undergo the final assessme nts visit at Week 52 (the 
Week 52/WD visit is to be scheduled 52 weeks [±3 days] after Bas eline).
kA telephone contact will be made with the subject every 4 weeks  after the on-site visit (ie, at 
Weeks 8H, 16H, 22H, and every 4 weeks after Week 24 until Week 52/WD visit).
mCZP administration will be continued Q2W.
Change #22
Section 5.2 Schedule of stud y assessments, Table 5-3: table tit le 
Table 5‒3:  Schedule of alternative study assessment with other treatment 
(including biologics) - after subject discontinuation of the study treatment 
Has been changed to:
Table 5‒3:  Schedule of alternative study assessment with other treatment 
(including biologics) - after subject discontinuation of the 
double-blind study treatment REDACTED W
ms ms ofof
ek 0, Wk 0, W
a subjea subje
atatCOPYono
poprotpopro
WeekWeek
This document cannot 5.2 .2
e 5‒3e 5‒be 2S c2S cused to supportbe
and eand e
n will n will any e madmadmarketingect wect w
Week Week 
d to undto un
edulededuleauthorization k 52/Wk 52/W
f activactiv
Week Week 
whwapplication alt
the timhe tim
ein(a) in(a)nd ternternany extensions4 wee4 we
elled alled a
Week Week or variations TB. B. 
y thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 164 of 255Change #23
Additional text has been added for other treatment administratio n for Week 12, Week 24, and Q12W
Table  5‒3: Schedule of alternative study assessment with other treatment (including biologics) - 
after subject discontinuation of the double-blind study treatment 
Visit # 1
wdt2
wdt3
wdt
Week
Protocol Activity0 12 24 and Q12W
Continue assessments as at W24 every 12 weeks until as close as  possible to 
W52 of the original visit schedule. Subject will then be invite d to the final 
assessment visit at W52 ±4 weeks. 52/WD FUa
Other treatment administration Follow the regimen of the particular 
alternative treatment. REDACTED 
COPY This 
document 
cannot 
otbe 
used 
dto tsupport 
any 
marketing m
authorization 
application
ssiiio
and ble toble t
nal nal any yany
extensionsbiolobioltene
or 
variations 
on
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 165 of 255Has been changed to:
Table  5‒3: Schedule of alternative study assessment with other treatment (including biologics) - after 
subject discontinuation of the double-blind study treatment 
Visit # 1
wdt2
wdt3
wdt
Week
Protocol Activity0 12 24 and Q12W
Continue assessments as at W24 every 12 weeks until as close as  possible to 
W52 of the original visit schedule. Subject will then be invite d to the final 
assessment visit at W52 ±4 weeks. 52/WD FUa
Other treatment administration Follow the regimen of the particular 
alternative treatment. Telephone 
contact to be performed on the 
discretion of the investigator REDACTED 
COPY This 
document 
cannot 
be 
used sedto tsupport 
any 
marketing m
authorization 
application
ea sio
and s posss pos
o the fo the fany 
extensions 
onxtexxxx
orogog
variations 
on
gicgic
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 166 of 255Change #24
Section 5.2 Schedule of stud y assessments, Table 5-3: footnotes  have been reordered and 
changes to footnotes are noted.
Note: All weeks are ±3 days compared to Baseline. Week 0 of the  alternative schedule starts 
2 weeks after the last dos e of the study treatment.
bIf the last Q12W assessment for a subject who discontinues stud y treatment is ≤4 weeks 
before the final assessments visit at Week 52 the assessment sh ould be cancelled and the 
subject should instead be invited to undergo the final assessme nts visit at Week 52/WD (the 
Week 52 visit is to be scheduled 52 w eeks [±3 days] after Basel ine).
Have been changed to:
Note: All weeks are ±3 days compared to Baseline. Week 0 of the  alternative schedule starts 
2 weeks after the last dose of t he double-blind study treatment.
bSubjects will be encouraged to be in fasting condition at the t ime the subject shifts to 
alternative treatment, for Apo A 1, ApoB, and lipoprotein(a) ass essments.
cHbA1c will be measured at wdt Week 0.
dIf the last Q12W assessment for a subject who discontinues stud y treatment is ≤4 weeks 
before the final assessments visit at Week 52/WD, the assessmen t should be cancelled and 
the subject should instead be  invited to undergo the final asse ssments visit at Week 52/WD 
(the Week 52/WD visit is to be scheduled 52 weeks [±3 days] aft er Baseline).
Change #25
Section 5.2 Schedule  of study assessments
The following paragrap hs have been added:
At any time during the study course, but preferably not before Week 12, the Investigator may 
discontinue the double-blind study  treatment and start open-lab el treatment with either CZP 
(which will be provided free of ch arge by UCB) or an alternativ e drug (eg, other treatment 
[including biologics]).
The determination by the Investigator to switch a subject from double-blind study treatment to 
either open-label CZP or other tre atment will generally be done  after the subject has completed 
the assessments at a given scheduled study visit. That study vis it then becomes the wdt Week 0 
visit of the given alternative schedule of assessments. Since m any of the assessments required at 
the wdt Week 0 visit may have already been completed as part of  the originally scheduled study 
visit, only those not already done at that visit should be comp leted. Table 5‒4 outlines which 
additional study assessments would be required at wdt Week 0 fo r subjects switching to the 
open-label CZP alternative schedule, and Table 5‒5 shows this information for subjects 
switching to the other treatment alternative schedule.
It may be possible that an Investigator determines that a subje ct should switch to the alternative 
schedule with either open-label C ZP or another treatment withou t initiating the alternative 
treatment at the study visit wh en this determination is made. I n this case, the subject will come REDACTEDerg
d 52 wd 52 wCOPYsconsco
WD, thWD,
rgo tgo t
This documentisit,sit,
addiaddi
ocannotf the gthe g
wdt Wwdt W
t, oobementmentusedon bon b
bel Cbel Cto ]).)supportind stund st
d free ofreeany courseoursmarketing smentssmen
been beenauthorization he
the finhe fin
weeksweeksapplication ses
inues snues 
e asseassendthe she s
ssmssmany subsuextensions schescheorWD WDvariations e  
D( t hD( t hthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 167 of 255back another day shortly thereaf ter to initiate the treatment a nd to complete all assessments 
outlined on the relevant alternative schedule of assessments (se e Table 5‒4 orTable 5‒5 ) for the 
wdt Week 0 visit. It is important then to schedule the wdt Week  0 and the subsequent on-site 
visits accordingly in order to end up at Week 52 with the same visit date as originally planned for 
the regular double-blind study course.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 168 of 255Change #26
Section 5.2 Schedule  of study assessments
The following tables have been added:
Table 5‒4: Schedule of study assessments – additional assessments for wdt 0 visit required for subjects 
transitioning to open-label CZP 
Visit #a1/
BL234567 8 9
H10 11
H12 13
H14 15
H16 17
H18 19
H20 21
H22 23
H24 25
H26 27
Week
Protocol Activity0 1 24 6 8 10 12 14 
/H 16 18 
/H 20 22 
/H 24 26 
/H 28 30 
/H 32 34 
/H 36 38 
/H 40 42 
/H 44 46 
/H 48 50 
Vital signs X X X X X X X X X
Hematology/urine/ 
biochemistryX X X X X X X X X X X X X X X X X X X
CRP X X X X X X X X X X X X
Pregnancy testing XXX X X X X X X X X X X X X X X X X X X X X
PE X X X X X X X X X X X X X X X X X X
TB questionnaire  XXX X X X X X X X X X X X X X X X X X
BASMI & spinal 
mobilityX X X X X X X X X X X X
BASDAI X X X X X X X X X X X X
BASFI X X X X X X X X X X X X
SF-36 XXX X X X X X X X X X X X X X X X X
ASQoL XXX X X X X X X X X X X X X X X X X
MOS Sleep Scale XXX X X X X X X X X X X X X X X X X
EQ-5D XXX X X X X X X X X X X X X X X X X
MASES X X X X X X X X X X X X X X X X
Total and nocturnal 
spinal painX X X X X X X X X X X XREDACTED 
DDDXXEDDDCT
D
XX
CCTCTACT
XX XXDDAREDRRR
COPOPY PYOPXXOCOOOOThis 
document 
cannanannotnanan
ot otanannot
bebbe ebebbbbbb
used 
duXX
dddueduuuusu
toXXXtosupport 
ttportport
trt
XX
ppppppppup
Xs
anyXXy yyaya
marketing 
garkekXX
ggngggke
gmamaarm
authorization 
nnationation
nnna
n
XX
aaatza
X XXhhhorth
XXau
application /H/Holicatiocatitioooli
o
XX Xlililicapli
and d300
HH33dddnd
any 1ny
extensions sit reqt req
9ex
or 
variations 
on
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 169 of 255Table 5‒4: Schedule of study assessments – additional assessments for wdt 0 visit required for subjects 
transitioning to open-label CZP 
Visit #a1/
BL234567 8 9
H10 11
H12 13
H14 15
H16 17
H18 19
H20 21
H22 23
H24 25
H26 27
Week
Protocol Activity0 1 24 6 8 10 12 14 
/H 16 18 
/H 20 22 
/H 24 26 
/H 28 30 
/H 32 34 
/H 36 38 
/H 40 42 
/H 44 46 
/H 48 50 
Swollen and tender joint 
countsXXX X X X X X X X X X X X X X X X X X
PhGADA X X X X X X X X X X X X
PGADA X X X X X X X X X X X X
CZP plasma 
concentration/anti -CZP 
Abs/BiomarkerXXX X X X X X X X X X X X X X X X X X
IXRS X X X X X X X X X
Study drug 
administration sc
BASMI=Bath Ankylosing Spondyliti s Metrology Index; CRP=C reacti ve protein; CZP=certolizumab pegol; EQ ̻5D=EuroQoL Health Status Questionnaire 
(5dimensions); H=home; IXRS =Interactive Response System; MA SES=Maastricht Ankylosis Spondy litis Enthesitis Score; MOS=Medical Outcomes Study; 
PE=physical exam; PhGADA=Physician’s Global Assessment of Disea se Activity; PGADA=Patient’s Global Assessment of Disease Acti vity; 
sc=subcuta neously; SF ̻36=Short̻Form 36̻item Health Survey; TB=tuberculosis  REDACTED
DDACCTEDTED
DD DDDACT
D
ctive prtive p
ASES=ASES=
DiseDise
ACACC
COPYOPY OPXXOPOPOPOPOPCCThis 
document 
cannot 
be 
used 
to support 
any 
marketing =MaMa
ease Acase Ac
B=tubeB=tub
authorization 
tiontionnhhorizarizzatioatiotioh
za
rotein; otein
aastaas
hhho
application 
tiotiXXo
XXtioooapli
oa
andd X
ndd dddnda
any Xnyaaa
extensions 21
HHio
H3636
ioioonxte
io
XXex
or ror
variations 
onfor sfor sv
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 170 of 255Table 5‒5: Schedule of study assessments – additional assessments for wdt 0 visit required for subjects 
transitioning to alternative treatment  
Visit #a1/
BL23456 7 8 9
H10 11
H12 13
H14 15
H16 17
H18 19
H20 21
H22 23
H24 25
H26 27
Week
Protocol Activity0 1246810 12 14
/H16 18
/H20 22
/H24 26
/H28 30
/H32 34
/H36 38
/H40 42
/H44 46
/H48 50
Hematology/urine/ 
biochemistryX X X X X X X X X X X X X X X X X X X
CRP X X X X X X X X X X X X
PE X X X X X X X X X X X X X X X X X X
BASDAI X X X X X X X X X X X X
BASFI X X X X X X X X X X X X
Total and nocturnal 
spinal painX X X X X X X X X X X X
PhGADA X X X X X X X X X X X X
PGADA X X X X X X X X X X X X
CZP plasma 
concentration/ 
anti-CZP Abs/ 
BiomarkerXXX X X X X X X X X X X X X X X X X X
IXRS X X X X X X X X X
BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; BASF I=Bath Ankylosing Spondylitis Functional Index; CRP=C reactive p rotein; 
CZP=certolizumab pegol; H=home;  IXRS=Interactive Response Syste m; MOS=Medical Outcomes S tudy; PE=physical exam; PhGADA=Physician’s Global 
Assessment of Disease Activity; PGADA=Patient’s Global Assessme nt of Disease Activity; sc=subcutaneously  
aAdditional assessments to be perf ormed correspond to the assess ments to be performed at wdt Week 0. REDACTED 
EEDCTECTEXXEEDEDTEDDACTACTCTDAXXEDDDR
D
COPY OPYOPY
YCOPOPOPCOThis 
document 
cannot 
be 
used 
to supporty IyI
e RespResp
s GlobaGlob
espondspond
any nyy nyndex;ndexnynyny
marketing XXar
tinmamamaaaa
authorization
ationioXXon
X
rizazazzzarizautaXXhoautauauuau
application XXtilicatilicatXtititioati
X
pplicpliclicpp
XX
papppp
andandnd danaaaa
any XXanaaaaa
extensions 1
HHio366
iioionext
sioxexexxex
or 22ro
variations 
onfor sfor sv
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 171 of 255Change #27
Section 5.3 Schematic diagram, Figure 5-1
CZP 400mg loading dose has been added to the figure. 
Change #28
Section 5.3 Schematic diagram, Figure 5-2“Double -blind” and “other treatment” have been added to clarify the stu dy treatment.
Change #29
Section 6.2 Exlcusion criteria, e xclusion criterion 29, first s ubcriterion
29. Subjects with significant laboratory abnormalities, includin g but not limited to: 
 liver function tests >2.0xULN, if th e subject is not treated wi th MTX and >ULN if 
subject is on concomitant MTX treatment
Has been changed to:
29. Subjects with significant laboratory abnormalities, includin g but not limited to: 
 liver function tests >2.0xULN
Change #30
Section 6.3 Withdrawal criteria, paragraphs 1 and 3
If a subject is withdrawn from st udy treatment, the Investigato r should encourage the subject to 
continue participation in the st udy in accordance with the appr opriate alternative schedule of 
study assessments ( Table 5‒2 orTable 5‒3 ). The treatment that the subject receives following 
withdrawal of study medication is at the discretion of the Inve stigator. Open label CZP for 
treatment to be supplied to discont inued subjects will be made available as a treatment option 
according to the local requirement mandated in the region. UCB will provide this medication 
free of charge. Alternatively, the Investigator may treat the s ubject with other treatments 
(including biologics) as deemed appropriate by local regulation s. If the Investigator choses to 
withdraw subjects on the other therapy, the local guidelines on  initiation and monitoring of the 
particular treatment should be followed.
Although the subject may be withdrawn from the double-blind stu dy treatment at any time, every 
effort should be made to retain the subject in the study and en courage compliance of the subject 
with the scheduled study visits. For subjects who fail to retur n to study visit(s) or are considered 
lost to follow up, the Investigator should specifically communi cate (at least 1 phone call and 1 
written message to the subject), and document his/her effort (d ate and summary of the phone call 
and copy of the written message  in the source documents). In ca se the attempts to direct contact 
the subject fail, the Investigator is encouraged to gain inform ation about the wellbeing of the 
subject at the end of the regular visit schedule (Week 52) from  other sources in compliance with 
local regulations. All results of observations and communicatio n with the subject, including and REDACTED COPY ities, iities,
This documentefforffor
witwit
lcannotar trr tr
houghhough
rttbesubjesubje
eaeausedAlterlter
ologiclogictocal rcal r
rnarnasupport22
icationcation
ed to dd to d
requreqanydy idy 
ororTTmarketing ragrapagra
dy tready tre
ininauthorizationinclncapplication witwit
cludiludand ot lit l
ith Mth Many limitimextensions orententvariations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 172 of 255not limited to the relevant i nformation on his/her wellbeing, m ust be recorded in the source 
documents.
Have been changed to:
If a subject is withdrawn from the double-blind study treatment , the Investigator should 
encourage the subject to continue  participation in the study in  accordance with the appropriate 
alternative schedule of study assessments ( Table 5‒ 2orTable 5‒3 ). The treatment that the 
subject receives following withdrawal of study medication is at  the discretion of the Investigator, 
with open-label CZP available as a treatment option according t o the local requirement mandated 
in the region. UCB will provide  this medication free of charge.  Alternatively, the Investigator 
may treat the subject with other treatments (including biologic s) as deemed appropriate by local 
regulations. If the Investigator chooses to withdraw subjects o n the other therapy, the local 
guidelines on initiation and monitoring of the particular treat ment should be followed.
Although the subject may be withdrawn from the double-blind stu dy treatment at any time, every 
effort should be made to retain the subject in the study and en courage compliance of the subject 
with the scheduled study visits. For subjects who fail to retur n to study visit(s) or are considered 
lost to follow up, the Investigator should specifically communi cate (at least 1 phone call and 
1 written message to the subject ), and document his/her effort ( date and summary of the phone 
call and copy of the written message in the source documents). In case the attempts to direct 
contact the subject fail, the Investigator is encouraged to gai n information about the wellbeing of 
the subject at the end of the regular visit schedule (Week 52/W D) from other sources in 
compliance with local regulations. All results of observations and communication with the 
subject, including and not limited to the relevant information on his/her wellbeing, must be 
recorded in the source documents.  
Change #31
Section 7.1 Description of invest igational medicinal product(s) , paragraph 1
The IMP will be supplied under the responsibility of the UCB Cl inical Supply Unit. The 
frequency at which IMP will be  supplied to each individual cente r will be adapted to the 
recruitment capacity of that ce nter and to the expiry date of t he IMP and will be managed by the 
interactive response system (IXRS).
Has been changed to:
The IMP (double-blind study t reatment: CZP or placebo), will be  supplied under the 
responsibility of the UCB Clinical Supply Unit. The frequency a t which IMP will be supplied to 
each individual center will be ada pted to the recruitment capac ity of that center and to the expiry 
date of the IMP and will be manag ed by the interactive response  system (IXRS).REDACTEDs of os of o
elevanlevanCOPY cumcu
ged toged to
e (We (W
This document atetecannotibilitbilit
indivindiv
e of ofbedoubdoub
ttused nged ged 
blbltoe sye sysupport ndend
will bewill b
of that f that 
ysteystany stist
er ther tmarketing tigatigaauthorizationo g
Week 5eek 5
bservabserv
nt infont infoapplicationate (atate (a
t (date (date
nts). Ints). I
gain igain and comom
dy vidy vianymentmen
mplimpextensionssti
riate briate b
y,the lthe l
followollow
torigatgatvariations gator, ator, 
andatndatthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 173 of 255Change #32
Section 7.2.1 Treatment administration, paragraph 2
At on-site visit days (at Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 50), 
study treatments will be administered sc at the study site by d edicated, unblinded and adequately 
trained site personnel. The study treatment will be self-inject ed at home at Weeks 14, 18, 22, 26, 
30, 34, 38, 42, and 46. All subjects will receive training for self-injection at the study site on 
Weeks 10 and 12. During the training on Weeks 10 and 12 visits,  the study treatment will be self 
administered under the supervision of the unblinded study perso nnel.
Has been changed to:
At on-site visit days (at Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 50), the 
double-blind study treatments will  be administered sc at the st udy site by dedicated, unblinded, 
and adequately trained site personnel. The double-blind study t reatment will be self-injected at 
home at Weeks 14, 18, 22, 26, 30, 34, 38, 42, and 46. All subjec ts will receive training for self 
injection at the study site on Weeks 10 and 12. During the trai ning on Weeks 10 and 12 visits, 
the double-blind study treatment will be self-administered unde r the supervision of the unblinded 
study personnel.
Change #33
Section 7.8 Concomitant medication(s)/treatment(s)
Table 7‒1: Concomitant Medications (prior to Baseline and Study Visits)
Drug class Dose  Exclusion criteria Study Visits
SAARDsb:
SSZ and/or HCQ 
and/or MTX and/or 
LFN and/or AZAMaximum 
allowed:  
SSZ ≤3g daily  
HCQ ≤400mg 
daily  
MTX ≤25mg 
weekly AZA 
≤150mg/day  
LFN 
≤20mg/day (see exclusion 
criteria for 
washout 
requirements)  SAARD initiated and or any change 
in the dose regimen in the 28 days 
prior to the Baseline Visit.  
Use of LFN in the 6 months prior to 
the Baseline Visit unless a cholestyramine washout has been 
performed. In case of a 
cholestyramine washout, use 28 days 
prior to the Baseline Visit is 
acceptable.
 Changes in SAARD 
doses should not be 
made between Week 0
and Week 12 or within 
4weeks prior to 
Week 24 or Week 52 
visit.  
SAARD dose reduction 
to manage intolerance 
or safety issues is allowed at any time 
during the study at the 
Investigator’s 
discretion.
 
SAARDs:
AZA, cyclosporine, 
cyclophosphamide, 
mycophenolic acid, 
apremilastUp to 
maximum 
approved dose  Use within 28 days prior to the 
Baseline Visit  Changes in SAARD 
doses or initiation of a 
new SAARD should be 
avoided between 
Week 0 and Week 12 or 
within 4 weeks prior to 
Week 24 or Week 52 REDACTEDatmeatme
ions (ons 
ExclExclDA
RSSRRRRCOPY 
This document SASAen
umcannot be used to≤≤tosupport y
MTX ≤2TX ≤
weekweek
1any ilyl
00mg 00mgmarketing uss
yySAARDAAR
in thin t
prng
maauthorization nt(s)t(s)
(prio(prio
sion ionutapplication he se andn WeWe
supsupany l b
ceiveceive
ekextensions 48, an48, a
cated,ated,
be sbe sor variations e self self thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 174 of 255Table 7‒1: Concomitant Medications (prior to Baseline and Study Visits)
Drug class Dose  Exclusion criteria Study Visits
visit 
Anti-TNF therapies
IFX
ADA
ETN
GOLCZPAny dose  For IFX, ADA, and GOL, any use 
within the 3 months prior to the 
Baseline Visit.  
For CZP any exposure history.  
For ETN, use within the 28 days 
prior to the Baseline Visit.  
Only 1 previous biologic is allowed.  If biologic therapy is 
required the subject 
must be discontinued 
from study medication 
and should conduct the remaining visits 
according to 
Figure 5–2. 
Has been changed to:
Table 7‒1: Concomitant Medications (prior to Baseline and Study Visits)
Drug class Dose  Exclusion criteria Study Visits
SAARDsb:
SSZ and/or HCQ 
and/or MTX and/or 
LFN and/or AZAMaximum 
allowed:  
SSZ ≤3g daily  
HCQ ≤400mg 
daily  
MTX ≤25mg 
weekly 
AZA 
≤150mg/day  
LFN 
≤20mg/day  SAARD initiated and or any change 
in the dose regimen in the 28 days 
prior to the Baseline visit.  
 Changes in SAARD 
doses should not be 
made between Week 0
and Week 12 or within 
4weeks prior to 
Week 24 or Week 52
visit.  
SAARD dose reduction 
to manage intolerance 
or safety issues is 
allowed at any time 
during the study at the 
Investigator’s 
discretion.  
SAARDs:
cyclosporine, 
cyclophosphamide, 
mycophenolic acid, 
apremilastUp to 
maximum 
approved dose  Use within 28 days prior to the 
Baseline visit  Changes in SAARD 
doses or initiation of a 
new SAARD should be 
avoided between 
Week 0 and Week 12 or 
within 4 weeks prior to Week 24 or Week 52
visit 
Anti-TNF therapies
IFX
ADA
ETN
GOLCZPAny dose  Only 1 previous biologic is allowed.
For IFX, ADA, and GOL, any use 
within the 3 months prior to the 
Baseline visit.  
ForETN, use within the 28 days 
prior to the Baseline visit.  
For CZP any exposure history.  If biologic therapy is 
required the subject 
must be discontinued 
from study medication 
and should conduct the remaining visits 
according to 
Figure 5–2. REDACTED RCOPY inen
This document IFXFX
ADADumcanni-TNFTNFnnot nnbe used d, to tosupport to 
aximuxim
approapprotany amarketing maauthorization applicationchangchang
28 day28 day
sit.t.and aanyStudyStudaaaaextensionsto o FiFi
sor ts ts variations tion on 
uct thuct thonthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 175 of 255Change #34
Section 7.9.1 Maintenance of stud y treatment blind, paragraph 3
If the Investigator decides to discontinue the study treatment and initiate open-label treatment 
with CZP or other treatment (including biologics), efforts will  be made to ensure that the 
blinding of the previously assigned study treatment will be mai ntained. This is to ensure that in 
case open-label treatment with CZP is chosen by the Investigato r, the 3 loading doses of CZP 
400mg Q2W will be administered by dedicated study personnel wit hout disclosing to the subject 
the use of the PFS. After the last loading dose the subject can  self administer CZP until Week 52
of the regular visit schedule.
Has been changed to:
If the Investigator decides to discontinue the double-blind stu dy treatment and initiate open-label 
treatment with CZP or other treatment (including biologics), ef forts will be made to ensure that 
the blinding of the previously assigned double-blind study trea tment will be maintained. 
Therefore, if the open-label treatment with CZP is chosen by th e Investigator, the 3 loading 
doses of CZP 400mg Q2W will be administered by dedicated study personnel without disclosing 
to the subject the use of the PFS . After the last loading dose the subject can self administer CZP 
until Week 52/WD of the regular visit schedule.
Change #35
Section 7.10.1 Interactive Response System, paragraph 3
The IXRS will allocate kits of study medication at Week 1, 2, 4 , 6, 8, 12, 16, 20, 24, 28, 32, 36, 
40, 44, 48, and 50.
Has been changed to:
The IXRS will allocate kits of s tudy medication at Weeks 0, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 
40, 44, 48, and 50.
Change #36
Section 8.1 Screening visit (Week - 6 to Day -1): bullet point i tem 1 and paragraph 5
x Confirm inclusion/exclusion criteria
One rescreening of subjects with latent TB who are able to comp lete a minimum of 4 weeks of 
TB therapy within the Screening Period is permitted. In this ev ent, all Screening assessments 
must be repeated.
Has been changed to:x Confirm inclusion/exclusion criteria (to be performed within We eks -6 and Day -1 and 
confirmed between Days - 5 and -3 before Baseline)
One rescreen is permitted for subjects with LTB. In this event,  all Screening assessments must be 
repeated. Subjects are allowed t o start the IMP after at least 4 weeks of prophylactic TB 
treatment (if compliant with the local regulations on initiatio n of biologic therapy in subjects REDACTED em, pem, p
medicatmedicaCOPY 
This document HasHascannot reeree
erapyerapy
st be t bebe enineninused enini
nclusnclusto ningingsupport any marketing dy medy mauthorization paragarag
tion aion aapplication y py p
 subjecsubjeandestigastiga
perspersany mm
be mbe m
atotextensions d iinitianitia
mademadeor variations bject ject 
eekeek55thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 176 of 255with LTB) within the Screening Period. The subject is required to complete the full prophylactic 
treatment.
Change #37
Section 8.2 Baseline visit ( Week 0), bullet point item 3
x Blood samples will be collected for hematology and biochemistry  analyses
Has been changed to:
x Blood samples (subjects should be e ncouraged to be under fastin g conditions, the same 
condition [fasting or not fastin g] should be applied at Week 52 ) will be collected for 
hematology and biochemistry analyse s (biochemistry assessment w ill include the 
measurement of apolipoprotein (Apo) A1, ApoB, lipoprotein(a), a nd glycated hemoglobin 
[HbA1c])
Change #38
Section 8.3 Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 , 26, 28, 30, 32, 34, 36, 38, 40, 42, 
44, 46, 48, and 50 (all visits ±3 days relative to Baseline), b ulleted items 5, 8, and 28. 
x Physical examination (Weeks 2, 4, 8, 12, 16, 24, and 36), inclu ding weight at Week 24 and at 
completion at Week 52/WD
x MRI (SI joints only, Week 12 only)
x Contact IXRS to obtain next kit number (Week 1, 2, 4, 6, 8, 10,  12, 16, 20, 24, 28, 32, 36, 40, 
44, 48, and 50)
Have been changed to:
x Physical examination (Weeks 2, 4, 8, 12, 16, 24, and 36), inclu ding weight at Week 24 
x MRI (spine and SI joints; Week 12 only)
x Contact IXRS to register the visit and obtain next kit number, where applicable (Weeks 2, 4, 
6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 50)
Change #39
Section 8.5 Week 52/WD (±3 days)
8.5 Completion Visit (Week 52)/Early Withdrawal (±3 days) Has been changed to:
8.5 Week 52/WD (±3 days) REDACTED 6, ,
numbnumbCOPY22
aselinaselin
24, 24, 
This document .55
HaHacannot on 8.5n 8.5be 3939used ,to 2020supportints; Wnts; W
registeegiste
2anyeks 2eks 2marketing ber (Wer (authorization and 3and 3
(WWapplication 4, 26, 4, 26,
e), bue), buand any yextensionshe same sam
cted foted fo
ude thde th
catedatedor variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 177 of 255Change #40
Section 8.5 Completion Visit (Week 52)/Early Withdrawal (±3 day s), paragraph 1, bulleted 
items 2 and 10
Assessments at this visit include:
x Blood samples will be collected for hematology, biochemistry, a nd CRP
x MRI for spine and SI joints (at Week 52 Visit if previous MRI w as performed more than 
12 weeks prior to Week 52 visit)
Have been changed to:
A subject is regarded to have completed the study if s/he compl etes the Week 52/WD. 
Assessments at this visit include:
x Blood samples (subjects should be e ncouraged to be under fastin g conditions the same 
condition [fasting or not fastin g] at Baseline  should be applie d at Week 52) will be collected 
for hematology, biochemistry, and CRP (biochemistry assessment will include the 
measurement of apolipoprotein (Apo) A1, ApoB, lipoprotein(a), a nd HbA1c)
x MRI for spine and SI joints (at Week 52/WD visit if previous MR I was performed more than 
12 weeks prior to Week 52/WD visit)
Change #41
Section 8.6 FU visit (8 weeks after the Week 52/WD visit)
8.6 FU Visit (8 weeks after the Week 52/WD visit) 
Has been changed to:8.6 FU visit (8 weeks after the Week 52/WD visit [±3 days]) 
Change #42
Section 8.8 Alternative visit sch edules after subject discontin uation of study treatment and 
bullet points 2, 15 and 16. New bulle t points have been added f or telephone contact.
8.8 Alternative Visit schedules after subject discontinuation of study treatment 
Alternative schedules for asse ssment for subjects who discontin ue the study treatment are 
described in this section. Assessm ents are to be continued as a t Week 24 every 12 weeks until as 
close as possible to Week 52 (within ±3 days of the originally planned Week 52 visit) of the 
original visit schedule. Subject will then be invited to the fi nal assessment visit at Week 52.
The following assessments will be performed for subjects who ar e treated with open-label CZP 
after discontinuation of study treatment:
x Blood samples will be collected for hematology, biochemistry an alyses, urine will be 
collected for urinalysis at wdt Weeks 0, 12, 24 (and Q12W), 52 and FU and CRP at Week 0, 
12, 24 (and Q12W), 52, and FU (8 wee ks after Week 52 Visit)REDACTED  WeekWee
e Wee WeCOPY 
This documentorigirigi
ThTcannot ve ve
bed inbed in
se as pe as pbe e sche schused 15 a5 
ative tive toti
andansupport ive vive viany marketingeek ek 
the Wthe Wauthorization k 52/Wk 52/W
k5k5application(a), a(a), a
vious Mvious Mand Weee
nt wilnt wilanyditioditi
ek 52ek 52extensions /WD. WD.
ononor variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 178 of 255x CZP administration at wdt Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 (and Q12W), 52, 
and FU. Loading dose of CZP 400mg at Weeks 0, 2 and 4 must be a dministered by dedicated 
site-staff 
The following assessments will be applied for subjects who rece ive an alternative study 
assessment with other treatment (including biologics) after dis continuation of study treatment:
x Blood samples will be collected for hematology, biochemistry, a nd urine will be collected for 
urinalysis at wdt Week 0, CRP ana lyses will be performed at wdt  Weeks 0, 12, 52, and FU 
Has been changed to:
8.8 Alternative visit schedules after subject discontinuation of the double-blind 
study treatment 
The following assessments will be performed for subjects who ar e treated with open-label CZP 
after discontinuation of the doubl e-blind study treatment:
x Blood samples will be collected for hematology, biochemistry, a nd CRP analyses, and urine 
will be collected for urinalys is at wdt Weeks 0, 12, 24 (and Q1 2W), 52 and FU (8 weeks 
after Week 52 visit)
Note: Fasting blood samples will  be collected for hematology, b iochemistry, and CRP 
analyses at wdt Week 0 (biochemistry assessment will include th e measurement of 
apolipoprotein (Apo) A1, ApoB, lipoprotein(a), and HbA1c). At W eek 52, the biochemistry 
assessment will include the measurement of HbA1c. 
x CZP administration at wdt Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, and every 
2 weeks thereafter, until Week 52. Loading dose of CZP 400mg at Weeks 0, 2, and 4 must be 
administered by dedicated site-staff
x Telephone contact will occur every 4 weeks after the on-site vi sit at the discretion of the 
Investigator
The following assessments will be applied for subjects who rece ive an alternative study 
assessment with other treatment (including biologics) after dis continuation of the double-blind 
study treatment:
x Blood samples will be collected for hematology and biochemistry  analyses, and urine will be 
collected for urinalysis at wdt Week 0. C-reactive protein anal yses will be performed at wdt 
Weeks 0, 12, 52, and FU 
Note: Biochemistry assessment will include the measurement of H bA1c at wdt Week 0
x Telephone contact will occur every 4 weeks after the on-site vi sit at the discretion of the 
Investigator
Change #43
Section 9.1.2 ASAS20, 40, ASAS 5/6 response, and ASAS partial r emission, bulleted item 2
x Pain assessment (the average of t otal and nocturnal spinal pain  NRS scores)REDACTED(
of Hof H
2, 4, 62, 4, 6
 Load Loa
tafftaffCOPY hemhe
ent wient w
a), ana), a
b
This document Icannot BB
Telepheleph
InvInvbe BiocBiocusedr urinurin
12, 512, 5towillwilsupportatmenmen
lb elbany ll be ll be
ntmarketing ery 4 wry 4 authorizationnd Hbnd H
bA1c.A1c
6, 8, 16, 8, 1
ing dng dapplication 2W2W
tologyolog
ll inclul incl
bAandnd CRd CR
W), W),any RPRextensions ubleuble
ith opth opor variations for or 
FU U thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 179 of 255Has been changed to:
x Pain assessment (the total spinal pain NRS score)
Change #44
Section 9.1.3 ASAS-NSAID score, bulleted item 10
x Days per week: Number of days per week when the NSAID is taken.  This is collected in the 
categories described in the days with intake category listed ab ove. Each category corresponds 
to a score as follows (score in parentheses):
 Every day (7)
 ≥5 days/week (6)
 3 to 5 days/week (4)
 1 to 3 days/week (2)
 <1 day/week (0.5)
 No NSAID intake (0)
Has been changed to: 
x Days per week: Proportion of days per week when the NSAID is ta ken. This is collected in 
the categories described in the days with intake category liste d above. Each category 
corresponds to a score as follows (score in parentheses):
 Every day (7/7)
 ≥5 days/week (6/7)
 3 to 5 days/week (4/7)
 1 to 3 days/week (2/7)
 <1 day/week (0.5/7)
 No NSAID intake (0)
Change #45
Section 9.1.4 ASQoL, addition of Table 5-2 to paragraph 2REDACTEDeek week w
th intath inta
core incore inCOPY hh
This document cannotn 9.1.n 9.1.be 45used tointaintasupport 7)7)
5/7)5/7)
take akeany marketing authorization hen thhen th
ake cake ca
n paren pareapplication and any extensions orrespresvariations n the n the 
spospothereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 180 of 255Change #46
Section 9.1.5 BASDAI, paragraph 5
The BASDAI assessments per visit are described in the schedule of study assessments Table 5-1 .
Has been changed to:
The BASDAI assessments per visit are described in the schedule of study assessments Table 5-1 ,
Table 5‒2 , and Table 5‒3 .
Change #47
Section 9.1.6 BASFI, paragraph 2
The BASFI assessments per visit are described in Table 5‒1 .
Has been changed to:
The BASFI assessments per visit are described in Table 5‒1 ,Table 5‒2 , and Table 5‒3 .
Change #48
Section 9.1.7 BASMI, paragraph 2
The BASMI assessments per visit are described in Table 5‒1 .
Has been changed to:
The BASMI assessments per visit are described in Table 5‒1 andTable 5‒2 .
Change #49
Section 9.1.8 Enthesitis (MASES), paragraph 2
Enthesitis assessments per visit are described in Table 5‒1 .
Has been changed to:
Enthesitis assessments per  visit are described in Table 5‒1 and Table 5‒2 .
Change #50
Section 9.1.9 Extra-articular assessments
The evolution of associated nonmuscu loskeletal features includi ng inflammatory bowel disease, 
psoriasis and uveitis (including their severity) and flare rate  will be assessed as described 
Table 5‒1.
Has been changed to:
The evolution of associated nonmusculoskeletal features includi ng inflammatory bowel disease, 
psoriasis and uveitis (including their severity) and flare rate  will be assessed as described 
Table 5‒1and Table 5‒2 .REDACTEDed ined in
e descre descCOPY 
This documentThe he 
psopso
Tcannot #5#5
on 9.n 9.
evevbe 5050used memeoents entssupportvisitvisi
o:anySES)SES
tmarketing ribauthorization Tableable
ibed bed application and 5‒2‒2aaany extensions or variations 11,,thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 181 of 255Change #51
Section 9.1.10 Health status (EQ-5D), paragraph 2
This instrument is to be completed by the subject as described i n Table 5‒1 .
Has been changed to:
This instrument is to be completed by the subject as described in Table 5‒1 and Table 5‒2 .
Change #52
Section 9.1.11 MOS Sleep Scale, paragraph 2
Subjects will be asked to complete the MOS Sleep Scale as descr ibed in Table 5‒1 .
Has been changed to:
Subjects will be asked to complete the MOS Sleep Scale as descr ibed in Table 5‒1 and 
Table 5-2 .
Change #53
Section 9.1.12 MRI assessments
Magnetic Resonance Imaging according to the ASAS/Omeract defini tion is the presence of bone 
marrow oedema (BMO) or osteitis high ly suggestive of SpA that i s located in the typical 
anatomical areas (subchodral or periarticular bone marrow). The re must be either more than
1 BMO lesion on 1 slice or a lesion that is present on at least two consecutive slices (Rudwaleit 
et al, 2009d). In practice this is very similar to the SPARCC S IJ ≥2 definition of MRI that 
requires at least 2 BMO lesions to be present. A recent paper s howed that the sensitivity and 
specificity of the ASAS/Omeract and SPARCC SIJ score ≥2 definit ions of MRI positive were 
identical (sensitivity 0.80, specificity 0.76) (Weber et al, 20 14). The Berlin modification of the 
ASspiMRI-a is a scoring system with a concentration on short-ta u-inversion recovery (STIR) 
sequences without other fat saturation techniques (Braun and Ba raliakos, 2011, Lukas et al, 
2007; Braun and van der Heijde , and 2002; Braun et al, 2003). T his scoring method quantifies 
changes in 23 vertebral units  (VU) of the spine (from C2 to S1) . A VU is defined as the region 
between 2 virtual lines through the  middle of each vertebra. Ac tive inflammation is scored by 
grading the degree of BMO from 0 to 3 in 1 dimension on 1 or mo re consecutive slices that 
represent the highest level of inflammation in a particular VU.  Total spine ASspiMRI-a score in 
the Berlin modification can range from 0 to 69. In addition to the method mentioned above, 
MRIs may be evaluated using other reading criteria.
Magnetic resonance imaging of the spine and SI joints will be p erformed at Screening, Week 12 
(SI only), 52, or Withdrawal Visit if MRI was performed more th an 12 weeks prior to Early 
Withdrawal. MRIs will be assessed centrally and scoring will be  done by 2 independent readers, 
who are blinded to both the order of t he scans and to the treat ment group, using a previously 
reported scoring system.e ASe AS
suggessugge
cular cular 
hat is hat is
simsimCOPY SASA
This documentMagMag
(SI(SIcannotrlin min m
Is mays maybehe hihe husedal linl lin
egreegreetobralbrasupport ysteste
fat satufat sa
der Heder He
al ual uanyificitifici
em wmmarketing prpr
milar tomilar to
e presepres
and SPand S
tytauthorization AS/OmAS/Om
stive otive 
bone bone 
resereseapplication and in n Tany TablTabextensions 5‒15‒1or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 182 of 255Has been changed to:
Magnetic Resonance Imaging according to the ASAS/Omeract defini tion is the presence of bone 
marrow oedema (BMO) or osteitis high ly suggestive of SpA that i s located in the typical 
anatomical areas (subchondral or periarticular bone marrow). Th ere must be either more than 
1 BMO lesion on 1 slice or a lesion that is present on at least 2 consecutive slices (Rudwaleit et 
al, 2009d). In practice this is very similar to the SPARCC SIJ ≥2 definition of MRI that requires 
at least 2 BMO lesions to be present. A recent paper showed tha t the sensitivity and specificity of 
the ASAS/Omeract and SPARCC SIJ score ≥2 definiti ons of MRI positive were identical 
(sensitivity 0.80, specificity 0.76) (Weber et al, 2014). The B erlin modification of the 
ASspiMRI-a is a scoring system with a concentration on short-ta u-inversion recovery (STIR) 
sequences without other fat sat uration techniques (Braun and Ba raliakos, 2011; Lukas et al, 
2007; Braun and van der Heijde , 2002; Braun et al, 2003). This scoring method quantifies 
changes in 23 vertebral units  (VU) of the spine (from C2 to S1) . A VU is defined as the region 
between 2 virtual lines through the  middle of each vertebra. Ac tive inflammation is scored by 
grading the degree of BMO from 0 to 3 in 1 dimension on 1 or mo re consecutive slices that 
represent the highest level of inflammation in a particular VU.  Total spine ASspiMRI-a score in
the Berlin modification can range from 0 to 69. In addition to the method mentioned above, 
MRIs may be evaluated using other reading criteria.
Magnetic resonance imaging of the  spine and SI joints will be p erformed at Screening and at the 
Week 12 and at the Week 52/WD visits  if MRI was performed more t han 12 weeks prior to 
Week 52/WD. Magnetic resonance images will be assessed centrall y and scoring will be done by 
2 independent readers, who are blinded to both the order of the  scans and to the treatment group, 
using a previously reported scoring system.
Change #54
Section 9.1.13 PGADA (NRS), paragraph 2
The PGADA assessments per visit are described in Table 5‒1 .
Has been changed to:
The PGADA assessments per visit are described in Table 5‒1 ,Table 5‒2 , and Table 5‒3 .
Change #55
Section 9.1.14 PhGADA, paragraph 3
The PhGADA will be compl eted as described in Table 5‒1 .
Has been changed to:
The PhGADA will be compl eted as described in Table 5‒1 ,Table 5‒2 , and Table 5‒3 .REDACTEDll bell b
both thboth th
em.em.COPYnts wnts w
was pewas pe
eaea
This documentHas Has 
TTcanno9.1.9.1.
 PhGAPhGAbe 11used to support ments pents any visit visitmarketing paragraragauthorizationerforrfor
assessssess
he ordhe ordapplicatione methe met
ill be pll be p
rmermandonsns
spinspinanymmatimmat
secusecextensionsy (STy (ST
ukas ekas e
d quand quan
fined ned 
ior TITIvariations y of y of thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 183 of 255Change #56
Section 9.1.17 SF-36, paragraph 3
The SF-36 has been used and has shown to be responsive in axSpA  (Haibel et al, 2008) and also 
validating in van Tubergen et al. ( Manuscript validating the re sponse has been submitted to 
Rheumatology). The SF-36 will be adm inistered per visit as descr ibed in Table 5‒1 .
Has been changed to:
The SF-36 has been used and has shown to be responsive in axSpA  (Haibel et al, 2008) and is 
also validated (van Tubergen et al, 2015). The SF-36 will be ad ministered per visit as described 
inTable 5‒1 and Table 5-2 .
Change #57
Section 9.1.18 Spinal mobility, paragraph 2
Spinal mobility will be assessed as described in Table 5‒1 .
Has been changed to:
Spinal mobility will be assessed as described in Table 5‒1 and Table 5‒2 .
Change #58
Section 9.1.19 Swollen and tender  joint counts (44 joints evalua tion), paragraph 1
The following 44 joints are to be examined for swelling and ten derness by the Principal 
Investigator, another delegated physician, or an appropriately qualified medical professional 
(based on local requirements) who has had documented training o n how to perform these 
assessments correctly. Preferably the same assessor should eval uate the subject at each arthritis 
assessment. The individual with this delegated duty must be lis ted on Form 1572.
Has been changed to:
The following 44 joints are to be examined for swelling and ten derness by the Principal 
Investigator, another delegated physician, or an appropriately qualified medical professional 
(based on local requirements) who has had documented training o n how to perform these 
assessments correctly. Preferably the same assessor should eval uate the subject at each arthritis 
assessment.
Change #59
Section 9.1.19 Swollen and tender  joint counts (44 joints evalu ation), paragraph 6
The assessments per visit are described in Table 5‒1 .
Has been changed to:
The assessments per visit are described in Table 5‒1 and Table 5‒2 .REDACTED t count coun
aminedmine
iciaiciaCOPY 5‒5
This document haha
SecSecannot angeangebe t.tusedrequequ
orrecorrectoer der d
uirirsupport ts are ts are 
deledeleanyh thih thmarketing d fd f
an, or an, or 
has hadas had
the samthe sa
isiauthorization nts (4nts (4
for sfor sapplication and nd TaTand any extensions orescriscrvariations d is d is 
ibthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 184 of 255Change #60
Section 9.1.20 Total and nocturnal spinal pain NRS, paragraph 2
The pain NRS assessments per  visit are described in Table 5 ‒1.
Has been changed to:
The pain NRS assessments per  visit are described in Table 5‒1 ,Table 5‒2 , and Table 5‒3.
Change #61
Section 12.5 Laboratory m easurements, Table 12 –1
Apoliproproteins and lipoprote in(a) have been added to Table12- 1 and a repeat of “others” 
has been removed from the “others” column
Change #62
Section 12.6.1 Pregnancy testing
Pregnancy testing must be carried out for women of childbearing  potential and will consist of 
serum testing at Screening and FU and urine testing (dipstick) at Baseline and 
Week 52/Withdrawal FU.
Has been changed to:
Pregnancy testing must be carried out for women of childbearing  potential and will consist of 
serum testing at Screening and FU and urine testing (dipstick) at Baseline, at wdt Week 0 of the 
alternative study assessment (for subjects administering either  open-label CZP or alternative 
treatment), and at Week 52/WD.
Change #63
Section 12.6.3 Assessment and management of TB and TB risk fact ors, paragraph 13
Subjects who prematurely discontinue treatment for latent TB, or , in the opinion of the 
Investigator or Sponsor, are noncompliant with anti-TB therapy must discontinue further use of 
study medication and be immediately withdrawn. Once withdrawn f rom study treatment, 
subjects should return for the Study Completion/Withdrawal Visi t, complete all Early 
Withdrawal assessments, and compl ete a FU Visit (8 weeks after the Week 52/WD-visit).
Has been changed to:
Subjects who prematurely discontinue treatment for LTB, or, in the opinion of the Investigator or 
Sponsor, are noncompliant with anti-TB therapy must discontinue  further use of study 
medication and be immediately wit hdrawn. Once withdrawn from st udy treatment, subjects 
should return for the Week 52/WD visit, complete all Week 52/WD  assessments, and complete a 
FU visit (8 weeks after the Week 52/WD visit).REDACTED or womor wom
nd urinnd uri
bjecbjecCOPY hilhi
g (dipg (dip
This documentSubjSubj
SSpcannoawalwal
s beenbeenbeouldould
lalausedponon
ion anon a
drdrto aturtu
nsonsosupport ment anent a
urelyrelyany marketing ne ne
cts admts admauthorization p
men omen o
e testesapplication earing aring
stick) tick)and any extensions repeatepeator variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 185of 255Change #64
Section 12.6.3.2 Chest x -ray, paragraph 1
A plain posteroanterior chest x -ray (or, if done, computed axial tomography of the chest) must be 
done within 3 months prior to the Screening Visit. The chest x -ray must be clear of signs of TB 
infection (previous or current) before first study drug adminis tration. The chest x -ray will be 
repeated at Completion Week 52/ Withdrawal Visit (if chest x -ray was performed more than 
12weeks prior to Early Wi thdrawal Visit), only if the TB test was confirmed positive or any 
further evidence is suggestive of potential TB infection (eg, e xposure). Radiographic findings 
suggestive of inactive TB or active TB may include but are not limited to: apical fibrosis, pl eural 
thickening, pulmonary nodules, fibrotic scars, calcified granul omas, upper lobe infiltrates, 
cavitations and pleural effusions , calcified lung nodules, calc ified hilar lymph nodes, and 
pericardial calcification.
Has been changed to:
A plain posteroan terior chest x -ray (or, if done, computed axial tomography of the chest) must be 
done within 3 months prior to the S creening visit. The chest x -ray must be clear of signs of TB 
infection (previous or current) before first study drug adminis tration. The che st x-ray will be 
repeated at Week 52/WD visit (if chest x -ray was performed more than 12 weeks prior to 
Week 52/WD visit), only if the TB test was confirmed positive or any  further evidence is 
suggestive of potential TB i nfection (eg, exposure). Radiograph ic findings suggestive of inactive 
TB or active TB may include but are not limited to: apical fibr osis, pleural thickening, 
pulmonary nodules, fibrotic sca rs, calcified granulomas, upper lobe infiltrates, cavitations and 
pleural effusions, calcified lung n odules, calcified hilar lymph nodes, and pericardial 
calcification.
Change #65
Section 12.6.3.4 Tuberculosis questionnaire, paragraph 1
The questionnaire “ ” should be used as a 
source document. The questionn aire will be completed at Scre ening, Baseline, and every 
12weeks thereafter including a nd up to Week 36 and at Completion at Week 52/Early 
Withdrawal Visit. The questionnair e will assist with the identi fication of subjects who may 
require therapy for TB. A subject who answers “Yes” to the question “  
at Screening is excluded. A “Yes” response to any of the other questions within th e
questionnaire at Screening should t rigger further careful asses sment to determine if subject has 
latent or active TB (see Exclusion Criterion 16, Section 6.2). A “Yes” response to any of the 
questions during the study should trigger further assessments t o determine if the subject has 
either latent TB or active TB infection (see Appendix 18.12 ).
Has been changed to:
The questionnaire ” should be used as a 
source document. The questi onnaire will be completed at Screening, Baseline, and every 
12weeks thereafter including and up to Week 36 and including Week  52/WD visit. The REDACTEDed toed t
granugranu
 calcicalciCOPYed poed p
e). Rae). Ra
to:to:
This documentquesques
eitheitcannot at at
onnaionna
nt or nt or 
tiobet SctS cbe used . TT
y for Tfor T
usoThe Thesuppoquestiouesti
ncludicludtort anyqueque
amarketing estauthorizationadiodio
apicaapica
ulomaloma
ified hfied happlication mumu
ation. Ttion.
more more
sitive ositive
ograograandgraphgrap
must ustany hyhextensionssis
ltratesltrate
odes, ades, aors, pl, pvariations y
ngs ngs thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 186of 255questionnaire will assist with t he identification of subjects w ho may require therapy for TB. A 
subject who answers “Yes” to the question  
 at Screening 
is excluded. A “Yes” response to any of the other questions wit hin the questionnaire at Screening 
should trigger further careful assessment to determine if subject has LTB or a ctive TB (see 
Exclusion Criterion 16, Section 6.2). A “Yes” response to any of the questions during the study 
should trigger further assessmen ts to determine if the subject has either LTB or ac tive TB 
infection (see Appendix 18.12 ).
Change #66
Section 12.6.3.5 Tuberculosis management, paragraph 6
The subject should be transferred to the care of his/her physic ian and managed according to the 
best available standard of care. Subjects identified a s having converted to active TB during the 
study must be withdrawn and scheduled to return for the Withdra wal Visit as soon as possible 
but no later than the next schedu led study visit and complete a ll Early Withdrawal Visit 
assessments.
Has been changed t o:
The subject should be transferred to the care of his/her physic ian and managed according to the 
best available standard of care . Subjects identified as having converted to active TB during the 
study must be withdrawn and sch eduled to return for the Week 52 /WD visit as soon as possible 
but no later than the next schedu led study visit and complete a ll Week 52/WD visit assessments. 
Change #67
Section 13.2.1 Definition of sou rce data, paragraph 2 and bulle ted items 1 and 2
The following data will be recorded directly in the PC Tablet on site and will not appear in a 
source document as defined above:
x Patient outcome questionnaires: SF -36, EQ -5D-3L, OMERACT flare questionnaire, 
PGADA, WPS -RA and the socio -professional status
x Investigator’s assessments: PhGADA and the swollen and tender joint counts
Have been changed to:
The following data will be recorded directly in the electronic patient reported outcome (ePRO) 
Tablet on site and will not appear in a source document as defi ned above:
x Patient Reported Outcome questionnaires: SF -36, EQ -5D-3L, PGADA, BASDAI, BASFI, 
ASQoL, MOS Sleep Scale, Total and Nocturnal Spinal Pain Questio nnaireREDACTED fiedfied
return return 
y visity visitCOPY s/her ps/her
d asda
This documentxPPcannotllowinlowi
let onet onben chan chausedr’s as’s as
ananto RARAsupportd abab
uestionestio
A anAa nanyordedorde
bovbovmarketing rce datce da
dauthorization phyphy
s havihavi
for thfor th
t and cand application arlyrly
hysicysicandVisiVisi
ly WyWany gee
o activ acti
tatextensions ed acd acor variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 187 of 255Change #68
Section 13.3.1 Case report completion, paragraph 2
The following paragraph has been deleted:
The study will also use an electronic device (Site Tablet) to ca pture the PhGADA and joint 
counts (see Section 13.4).
Change #69
Section 13.4 Electronic reporting outcome, paragraph 2
This study will use an electronic Site Tablet having a large sc reen and intuitive fingertip data 
entry to ensure all questionnaire data are captured appropriate ly, completely and on time. Not 
only subjects’ data will be collected with the tablets, physici ans’ data (joint counts and 
PhGADA) will be entered directly.
Has been changed to:
This study will use an electronic Site Tablet having a large scr een and intuitive fingertip data 
entry to ensure all questionnaire data are captured appropriate ly, completely and on time. Only 
subjects’ data will be collected with the tablets; the data of both the physic ians (joint counts and 
PhGADA) and WPS will be entere d directly in the eCRF or collect ed on worksheets.
Change #70
Section 13.5.1 Subject Screening and Enrollment log/Subject Ide ntification Code list
Heading 13.5.1 has been deleted.
Change #71
Section 14.1 Definition of analysis sets, paragraph 3
The Safety Set (SS) will cons ist of all subjects in the RS who have received at least 1 dose of 
study medication.
Has been changed to:
The Safety Set (SS) will cons ist of all subjects who have recei ved at least 1 dose of study 
medication.
Change #72
Section 14.2 General statistical considerations, paragraph 2
The statistical analysis of the  primary efficacy variable and s elected secondary efficacy variables 
will account for multiplicity by using a fixed sequence testing  procedure. The predefined order 
of hypothesis testing, each at a 2-sided 0.05 significance leve l for the comparison between CZP 
200mg Q2W and placebo, will be perf ormed in the sequence shown below. After the first test, REDACTED and Ennd EnCOPYdata odata 
he eCRhe eC
This document ChaChacannot yy
tion.ion.beSet Setused angedngedto support of anaof ana
will coill coany marketingnroroauthorizationRF oRF o
ollmollapplication een anden an
tely, coely, c
of bothf both
ororand anyt cocoextensions fingertnger
and onnd on
ounounor variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 188 of 255each subsequent test is performed only if the previous test is significant in favor of CZP at the 
2-sided 0.05 level. Note that the fi rst test relates to the pri mary efficacy variab le while the others 
provide the sequence testing for secondary efficacy variables.
Has been changed to
The statistical analysis of the  primary efficacy variable and s elected secondary efficacy variables 
will account for multiplicity by using a fixed sequence testing  procedure. The predefined order 
of hypothesis testing, each at a 2-sided 0.05 significance leve l for the comparison between CZP 
200mg Q2W and placebo, will be perf ormed in the sequence shown below. After the first test, 
each subsequent test is performed only if the previous test is significant in favor of CZP at the 
2-sided 0.05 level. Note that the first test relates to the pri mary efficacy variable while the others 
provide the sequence testing for selected secondary efficacy va riables.
Change #73
Section 14.3 Planned efficacy analyses
The primary efficacy variable measurement for this study is bas ed on ASDAS-MI response at 
Week 52. The associated primary  outcome of the study will be de fined as a composite endpoint 
that is achieved if a subject fulfills the following 2 componen ts:
1. Remain in the study and on study treatment through 52 weeks2. Achieve an ASDAS-MI response at 52 weeks
For simplicity, this primary efficacy variable will be referred  to as ASDAS-MI response at 
Week 52. However, the composite de finition as described above wi ll apply when this endpoint is 
analyzed. The primary analysis for this endpoint will be based on logistic regression. The odds 
ratio of the ASDAS-MI responder ra tes at Week 52 will be estima ted and tested between 
treatment groups using a logistic regression model with factors  of treatment group, region, and 
MRI/CRP classification (MRI+/CRP+; MRI+/CRP-; MRI-/CRP+). If the  logistic regression 
model is unable to converge, then MRI/CRP classification may be  dropped from the model to 
facilitate convergence. The study design is likely to result in  some sites with a small number of 
enrolled subjects. The use of region as a stratification variab le and as a factor in the model is 
intended to combine study centers in similar geographic regions . The geographic regions to be 
used will be defined in the IXRS and in the SAP. Given the compo site endpoint definition 
described above, there will be  no missing data for the primary endpoint, as subjects that 
discontinue study treatment prior to Week 52 or who do not have  an ASDAS-MI status at 
Week 52 are considered nonresponders to study treatment.
As described in Section 6.3, subjects who discontinue study treatment will not necessarily  be 
withdrawn from the study. In an a ttempt to minimize missing dat a, efforts will be made to 
continue to collect safety and efficacy data on these subjects through study completion. An 
alternative analysis for ASDAS-MI at Week 52 will be performed in which the observed data at 
Week 52 will be used, regardless  of whether or not the subject is still on his/her randomized 
study treatment at that time. Despite efforts to continue to col lect data on all subjects (even if 
they discontinue study treatment), there may still be subjects with missing data at Week 52. Such 
subjects will be considered as nonresponders in accordance with  the composite endpoint REDACTEDweeksweek
iable wiable 
efinitioefinitio
his ehis eCOPYompoomp
throuthrou
This documentwithdwith
conconcannot2 are2 are
descriescr
drdbee stue stuusedned ed
ve, thve, th
ddtoe ste st
di ndisupport e, t t
he studhe stu
use ofuse o
studytudany/CR/CR
then hen marketingon
endpoendpo
tes at Wes at 
regressegres
RP+RPauthorizationugh 5ugh 5
ss
will bwill b
n as n as application ed on ed on
be definbe def
nents:nents
22and any extensionsZP 
hile thhile thorat tat tvariations CZP ZP 
test, test, thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 189 of 255definition outlined above. The same logistic regression model s pecified for the primary analysis 
will be used.
Subgroup analyses by age, gender, race, symptom duration, smoki ng history, HLA-B27 
genotype, anti-CZP Ab status, region, prior anti-TNF exposure, and MRI/CRP classification 
(MRI+/CRP+; MRI+/CRP-; MRI-/CRP+) will be performed for the pri mary variable.
Has been changed to:
The primary efficacy variable measurement for this study is bas ed on ASDAS-MI response at 
Week 52. The associated primary  outcome of the study will be de fined as a composite endpoint 
that is achieved if a subject fulfills the following 2 componen ts:
1. Remain in the study and on the double-blind study treatment t hrough 52 weeks 
2. Achieve an ASDAS-MI response at 52 weeks
For simplicity, this primary efficacy variable will be referred  to as ASDAS-MI response at 
Week 52. However, the composite de finition as described above wi ll apply when this endpoint is 
analyzed. The primary analysis for this endpoint will be based on logistic regression. The odds 
ratio of the ASDAS-MI responder ra tes at Week 52 will be estima ted and tested between 
treatment groups using a logistic regression model with factors  of treatment group, region, and 
MRI/CRP classification (MRI+/CRP+; MRI+/CRP-; MRI-/CRP+). If th e logistic regression 
model is unable to converge, then the MRI/CRP classification va riable may be dropped from the 
model to facilitate convergence. The study design is likely to result in some sites with a small 
number of enrolled subjects. The use of region as a stratificat ion variable and as a factor in the 
model is intended to combine study centers in similar geographi c regions. The geographic 
regions to be used will be define d in the IXRS and in the SAP. Given the composite endpoint 
definition described above, the re will be no missing data for t he primary endpoint, as subjects 
that discontinue the double-blind study treatment prior to Week  52 or who do not have an 
ASDAS MI status at Week 52 are considered nonresponders to the double-blind study treatment.
As described in Section 6.3, subjects who discontinue the double-blind study treatment wil l not 
necessarily be withdrawn from the study. In an attempt to minim ize missing data, efforts will be 
made to continue to collect safety and efficacy data on these s ubjects through study completion. 
Sensitivity analyses will be performed to evaluate the impact o f missing data on the analysis of 
the primary efficacy variable (see Section 14.8).
Subgroup analyses by age, gender, race, symptom duration, smoki ng history, HLA-B27 
genotype, anti-CZP Ab status, region, prior anti-TNF exposure, and MRI/CRP classification 
(MRI+/CRP+; MRI+/CRP-; MRI-/CRP+) will be performed for the pri mary efficacy variable. 
Subgroup analyses will be summarized using descriptive statisti cs only.
Change #74
Section 14.4 Secondary efficacy analyses
The changes from Baseline in BASDAI and BASFI at Week 12 and We ek 52 are specified as 
secondary efficacy variables. As these are continuous variables , missing data must be handled 
using a different approach from what is specified for the prima ry efficacy endpoint (a responder 
variable). REDACTED ignign
ion ion as as
ers in ers in 
he IXRhe IXR
ll be ll be COPY MRMR
classifclassi
n is ni s
This document ChChcannot CRPRP
roup aoup abe ntiti
RP+;RP+;used yses byses b
iCZCZtoy vay vasupport romom
ect safect sa
will be pill be 
ariaaranybjectbjec
m themt hmarketingno mno m
dy treatdy trea
considconsid
tstauthorization ficaca
likelylikely
a straa stra
similasimil
RS anRS anapplication ogg
mated mated
ors of trrs of t
/CRP/CRP
ationationdapplappl
gistigistianyASAS--MM
ly wlyextensions eksksorndpndpvariations e at at 
poipoithereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 190 of 255Investigators will be given discretion to discontinue study tre atment for subjects not responding 
in order to provide them with alterna tive therapy to treat the condition. Therefore, in many cases,
missing efficacy data due to stu dy treatment discontinuation sh ould be dependent on the 
observed efficacy scores,  but independent of unobserved data. T his would be consistent with a 
missing at random pattern of missingness. However, the possibil ity of discontinuation due to 
tolerability or other unobserved data cannot be completely disc ounted. Therefore, a missing not 
at random mechanism will be consider ed as the primary analysis method of continuous 
secondary efficacy variables, where reference-based imputation methods will be used. 
This approach will impute missing  data as well as data at time points following discontinuation 
of study treatment for both the CZP and placebo groups using an  imputation model developed 
based on data from the placebo g roup (Mallinckrodt, 2013). The estimand being evaluated in this 
case is a de-facto estimand that has been described as the diff erence in outcome improvement in 
all randomized subjects at the planned endpoint attributable to  the initially randomized 
medication (Mallinckrodt, 2012). This reference-based imputatio n procedure will be described in 
greater detail in the SAP. The fi nal model to be used on the im puted data will be an analysis of 
covariance (ANCOVA) model where response is the change from Bas eline, with Baseline score 
as a fixed-effect covariate  and treatment group, region, and MR I/CRP classification as fixed 
effect categorical factors. 
Additionally, change from Baselin e in SI joint SPARCC score at Week 12 is a continuous 
secondary efficacy variable. As with BASDAI and BASFI, a refere nce-based imputation 
approach will be used to account fo r missing data. However, it should be noted that, unlike 
BASDAI and BASFI, SPARCC score will not be measured at any time  points between Baseline 
and Week 12, meaning that those are the only 2 time points that  can be considered in the 
evaluation of SPARCC score at Week 12. Therefore, Week 12 repre sents the only time point at 
which the placebo treatment effect can be evaluated for the imp utation procedure. Comparisons 
between treatment groups will be made using an ANCOVA on the im puted data set. The model 
will include Baseline score, treatment group, region, and MRI/C RP classification. 
The ASAS40 response at Week 12 and Week 52 are responder second ary efficacy endpoints. As
a responder variable, ASAS40 will be analyzed using logistic re gression based on a model 
similar to the one described for the primary analysis. As with the primary efficacy endpoint, the 
ASAS40 will be treated as a compos ite endpoint when it is analy zed. Specifically, subjects will 
need to 1) achieve the relevant  response (ASAS40) and 2) remain  in the study and on their 
randomized study treatment through the time point being analyze d (Week 12 or Week 52).
The comparison of CZP 200mg Q2W to placebo as described above f or the ASAS40 response, 
BASDAI, and BASFI at Week 12 and Week 52 and for SI joint SPARC C score at Week 12 will 
be part of the fixed sequence testing procedure outlined in Sec tion 14.2.
Additionally, sensitivity ana lyses will be conducted on these s econdary efficacy endpoints. In 
particular, the assumptions related to missing data will be inv estigated further. These analyses 
are described in Section 14.8.
An additional secondary efficacy variable is the number of subj ects with relevant changes to
background medication. This variable will be based on whether o r not subjects take certain 
pre-specified background medications during the course of the s tudy and will be defined in the REDACTEDdata.data
not benot be
e onlye only
k 12. Tk 12. 
an ban bCOPYRCC RCC
nd BAnd BA
aHaH
This documentAddiAddi
partparcannoAI, anI, an
art of trt of t
ditiitibearisoariso
andandusede t
udy tredy tr
onontothe rthe supporS40 S40 
ibed fobed f
ed as ed asanyk 12 k 12
0w iwmarketingTh
be evabe eva
ade usinde us
ment grent gauthorizationASFISFI
HoweHowe
e mea mea
y 2 tim2 tim
herehereapplicationI/CRP/CRP
score ascore 
IaIandata ta 
aseliaselanyure wure 
wilwiextensionsdevelevel
evaluavalua
e impre impr
andomndomonuatnua
lolvariations atioatithereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 191 of 255SAP. The analysis for this variable will use the same logistic regression model described for the 
primary variable.
Has been changed to:
The changes from Baseline in BASDAI and BASFI at Week 12 and We ek 52 are specified as 
secondary efficacy variables. As these are continuous variables , missing data must be handled 
using a different approach from what is specified for the prima ry efficacy endpoint (a responder 
variable). In the current study, Investigators will be given di scretion to discontinue the double 
blind study treatment for subjects not responding in order to p rovide them with alternative 
therapy to treat the condition. T herefore, in many cases, missi ng efficacy data due to the 
double-blind study treatment di scontinuation should be dependen t on the observed efficacy 
scores, but independent of unobserved data. This would be consi stent with a missing at random 
(MAR) assumption. However, the  possibility of discontinuation d ue to tolerability or other 
unobserved data cannot be completely discounted. Therefore, a m issing not at random 
mechanism will be used for the ana lysis of continuous secondary efficacy variables.
A reference-based multiple imputation (MI) procedure will be us ed for this analysis, which will 
impute missing data as well as data at the time points followin g the discontinuation of the 
double-blind study treatment for  both the CZP and placebo group s. This procedure will use an 
imputation model developed based on available data from the pla cebo group, thereby assuming a 
placebo trajectory for missing data following study treatment d iscontinuation for subjects in both 
treatment groups (Mallinckrodt , 2013). The estimand being evalu ated in this case is the 
difference in the outcome of improvement in all randomized subj ects at the planned endpoint, 
attributable to the initially randomized medication. This is an  effectiveness estimand of the de 
facto hypothesis which has been referred to as “estimand 6” (Ma llinckrodt, 2012).
Additionally, change from Baselin e in SI joint SPARCC score at Week 12 is a continuous 
secondary efficacy variable. The  same MI procedure specified as  the main analysis approach for 
BASDAI and BASFI will be used to account for missing SPARCC dat a. However, it should be 
noted that, unlike BASDAI and BASFI, SPARCC score will not be m easured at any time points 
between Baseline and Week 12, meaning that those are the only 2 time points that can be 
considered in the evaluation of S PARCC score at Week 12. Compar isons between treatment 
groups will be made using an ANC OVA model on the imputed data s et. The model will include 
Baseline score, treatment group, region, and MRI/CRP classificat ion.  
The ASAS40 response at Week 12 and Week 52 are responder second ary efficacy endpoints. As 
a responder variable, ASAS40 will be analyzed using logistic re gression based on a model 
similar to the one described for the  primary analysis. As with the primary efficacy endpoint, the 
ASAS40 will be treated as a compos ite endpoint when it is analy zed. Specifically, subjects will 
need to 1) achieve the relevant  response (ASAS40) and 2) remain  in the study and on their 
randomized double-blind study treatment through the time point b eing analyzed (Week 12 or 
Week 52).
The comparison of CZP 200mg Q2W to placebo as described above f or the ASAS40 response, 
BASDAI, and BASFI at Week 12 and Week 52 and for SI joint SPARC C score at Week 12 will 
be part of the fixed sequence testing procedure outlined in Sec tion 14.2.REDACTEDn all ran all r
edicatidicati
ed to aed to a
in Sin SCOPY fromfro
y treaty treat
mandmand
This document andond
WeWecannot40 wi0 wi
d to 1)d to 1
domdombeva
he ohe ousedesponpon
ariabariabto tmemsupportion of on of
sing aning a
ment gentanyBABA
2, me2, m
SmarketingSI joinI join
me MI pe MI 
to accoo ac
ASFASauthorizationtm
d beinbein
andomandom
ion. Tion. T
as “esas “esapplicationthe dihe d
oups. Toups. 
the plahe pl
ment dment dand for thor thany ata
y variy varextensionshe
efficaeffica
sing aing a
bility oility 
at ratr aor variations r r 
le e thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 192 of 255Additionally, sensitivity ana lyses will be conducted on these s econdary efficacy endpoints. In 
particular, the assumptions related to missing data will be inv estigated further. These analyses 
are described in Section 14.8.
An additional secondary efficacy variable is the number of subj ects with relevant changes to 
background medication. This variable will be based on whether o r not subjects take certain 
pre-specified background medications during the course of the s tudy and will be defined in the 
SAP. The analysis for this variable will use the same logistic regression model described for the 
primary variable.
Change #75
Section 14.5 Other efficacy analyses, paragraph 1
Treatment group comparisons for CZP 200mg Q2W vs placebo will b e performed based on the 
change from Baseline in other selected efficacy variables. Thes e analyses will be performed 
using an ANCOVA model including Baseline score, treatment group , region, and MRI/CRP 
classification. The treatment  differences and corresponding 95%  confidence intervals will be 
calculated based on the adjusted means. Missing values or value s observed after discontinuing 
study treatment will be imputed using last observation carried forward (LOCF). The following 
variables will be analyzed in this manner:
Has been changed to:
Treatment group comparisons for C ZP 200mg Q2W versus placebo wi ll be performed based on 
the change from Baseline in other selected efficacy variables. These analyses will be performed 
using an ANCOVA model including Baseline score, treatment group , region, and MRI/CRP 
classification. The treatment  differences and corresponding 95%  confidence intervals will be 
calculated based on the adjusted means. Missing values or value s observed after discontinuing 
the double-blind study treatment will be imputed using last obs ervation carried forward (LOCF). 
The following variables will be analyzed in this manner:
Change #76
Section 14.6.1 Safety analyses, paragraph 2
Since subjects will be permitted to change background medicatio ns and because they may also 
discontinue study treatment and i nitiate a new treatment (inclu ding biologics) during the course 
of the study, special considerat ion will be given to how AEs ar e attributed to study treatment. 
This, along with other specialize d AE summaries, will be descri bed in greater detail in the SAP.
Has been changed to:
Since subjects will be permitted to change background medicatio ns and because they may also 
discontinue the double-blind study treatment and initiate a new  treatment (including biologics) 
during the course of the study, special consideration will be g iven to how AEs are attributed to 
the double-blind study treatment. This, along with other specia lized AE summaries, will be 
described in greater detail in the SAP.REDACTED 0mg Q0mg Q
ted effted ef
BaselBase
ncesncesCOPY n cac
This documentHas Has 
SinSincannotudyudy
alongalong
bbbee stue stu
ysysused fee
s will will
udydtoety ety support anye anaanmarketing linin
s and cand 
ans. Mns. M
will bewill b
alylauthorization Q2W v2W v
fficacyficacy
ne scne sapplicationconficonf
ues obues ob
ied fored foand seses
p, regi, reg
fidfidanyrformrfor
s wils wilextensions rmrmor variations the he thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 193 of 255Change #77
Section 14.6.2 Pharmacokinetic and immunogenicity variable anal ysis, paragraph 1
Certolizumab pegol plasma concentrations will be tabulated and summarized by treatment group 
(overall and by anti-CZP Ab level - above or below 2.4 units/mL within each treatment group) 
for each visit at which samples were taken using the geometric mean, geometric coefficient of 
variation, 95% confidence intervals (CIs), arithmetic mean, ari thmetic SD, minimum and 
maximum, geomean plasma concentration time curves with their 95 % CI will be plotted overall 
and by anti CZP Ab status.
Has been changed to:
Certolizumab pegol plasma concentrations will be tabulated and summarized by treatment group 
(overall and by anti-CZP Ab level - above or below 2.4 units/mL w ithin each treatment group) 
for each visit at which samples were taken using the geometric mean, geometric coefficient of 
variation, 95% confidence intervals (CIs), arithmetic mean, ari thmetic SD, minimum and 
maximum, geomean plasma concentration time curves with their 95 % CI will be plotted overall 
and by anti CZP Ab status. Individual plasma concentrations for  CZP and anti-CZP levels versus 
time will be produced on the same graph.
Change #78
Section 14.8 Handling of dropouts or missing data
For analysis purposes, the primary efficacy variable is defined  as a composite endpoint in which 
it is necessary to achieve ASDAS-MI at Week 52 and to remain on  randomized study treatment 
through Week 52 in order to be considered a responder (see Sect ion 14.3). Because this 
composite endpoint definition does not allow for a missing resp onse status, no formal method for 
handling missing data is neede d in the primary analysis. An add itional analysis (also described in 
Section 14.3) will be performed in which all observed data at Week 52 are u sed, including data 
collected for subjects who may have discontinued study treatmen t without being withdrawn from 
the study.
Analyses of other binary efficacy variables will be treated in the same way as the primary 
efficacy variable. That is, a subject will be considered a resp onder only if the response is 
achieved and if the subject is still on his/her randomized stud y treatment at the time when the 
variable is evaluated. For ASAS40 response at Week 12 and Week 52 (secondary efficacy 
endpoints included in the fixed se quence statistical testing pr ocedure), an additional analysis 
based on all collected data (as de scribed above for the primary  endpoint) will be performed. 
To account for missing data and data following discontinuation of study treatment for continuous 
secondary efficacy variables (change from Baseline in BASDAI an d BASFI at Week 12 and 
Week 52 and change from Baseline i n SI joint SPARCC score at We ek 12), the analysis method 
that will be used when considering statistical significance in the fixed sequence testing procedure 
will be referenced-based imputation where an ANCOVA model is us ed on the multiply imputed 
data (see Section 14.4).
Other analyses of continuous secondary efficacy data will be im plemented to evaluate sensitivity 
of results to the method of handling missing data and will incl ude the following:REDACTEDng dng d
cy varcy var
at Weat We
sideresidereCOPY 
This documentseconecon
WeWecannotn alln all
accouaccou
nddbeincluincluusedthe she s
aluatealuate
ddtoThat hat
sususupport ary effiry eff
t is, ti sany in
y havy havmarketing ed a rd a 
ot allowt allo
the prihe pr
n whin whauthorization atata
riable riable 
ek 52ek 52
reapplication CZPZPand% CI CI 
P anPa nany etet
D, minD, mi
wextensions treatmreatm
treatmreatm
tric ric or variations erall rall thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 194 of 255x ANCOVA based on all observed data (including from subjects who discontinued study 
treatment but continued in the study) where any remaining missi ng data is imputed using 
reference-based imputation methods
x mixed model for repeated measures (MMRM) with Baseline score as  a fixed effect covariate 
and treatment group, region, MRI /CRP classification, and visits  as fixed effect categorical 
factors, and Baseline by visit and treatment group by visit as interaction terms (where data 
following study treatment discont inuation are treated as missin g)
x LOCF
x Baseline observation carried forward (BOCF)
Additionally, “tipping point” sensitivity analyses will be conducted. These a nalyses will vary 
assumptions about average outcomes among the subjects in the CZ P treatment group who 
discontinue study treatment early through a series of delta adj ustments (O’Kelly, 2014). These 
assumptions may be severe and will include the possibility that  subjects with missing data in the 
CZP treatment group had worse outcomes than dropouts on the pla cebo arm. Such adjustments 
to the assumptions may be perfor med until a statistically signi ficant result in favor of CZP is no 
longer observed. The plausibility of the assumptions leading to  that change would then be 
considered. Further details on all of these sensitivity analyse s will be provided in the SAP.
Descriptive summaries based on observed case data will also be prepared. 
Additionally, algorithms for imputing missing or partial dates for safety evaluations will be 
detailed in the SAP.
Has been changed to:
For analysis purposes, the primary efficacy variable is defined  as a composite endpoint in which 
it is necessary to achieve ASDAS-MI at Week 52 and to remain on  randomized double-blind 
study treatment through Week 52 in order to be considered a res ponder (see Section 14.3).
Because this composite endpoint definition does not allow for a  missing response status, no 
formal method for handling missing data is needed in the primar y efficacy analysis. However, in 
order to assess the impact of various missing data assumptions on the analysis, additional 
sensitivity analyses of the primary efficacy variable will be p erformed as follows:
x Including observed data at Week 52: The observed data at Week 5 2 will be used and 
analyzed according to randomize d treatment, regardless of wheth er or not the subject is still 
on his/her randomized double-blind study treatment at that time . Despite efforts to continue 
to collect data on all subjects (even if they discontinue the d ouble-blind study treatment), 
there may still be subjects w ith missing data at Week 52. Such subjects will be considered as 
non-responders in accordance with the composite endpoint defini tion outlined above. The 
same logistic regression model sp ecified for the primary analys is will be used.
x MI: The MCMC method will be used t o impute intermittent missing  data. The resulting 
multiply imputed data sets will be monotone missing and will be  imputed using monotone 
regression (assuming a MAR pattern). Note that the MI procedure  will be done on the 
continuous ASDAS variable, which will be dichotomized for the l ogistic regression analysis. 
Ankylosing Spondylitis Disease Activity Score data collected fo llowing the discontinuation REDACTEDor por 
fficafficaCOPY ta willa will
papa
This documentss
xxcannotre mae ma
nonon-rer
samsambeect dect dusedcordiordi
randrandtorvedvedsupportof vaof va
the prihe p
ddddany t dt d
missingissinmarketingacy vaacy v
at Weat W
in orden ord
defindefiauthorization l a
artial drtial dapplicationnt ret r
 that chthat c
es will s will
also balso bandebo arbo a
resuresany KelKe
with mwith extensions yses wses w
nt grout grou
ellyllyor variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 195 of 255of double-blind study treatment will be treated as missing in t he original data set for this 
sensitivity analysis.
x Tipping point analysis: In this analysis, various assumptions w ill be made about average 
outcomes among the subsets of subjects who prematurely disconti nued double-blind study 
treatment. Various “delta adju stments” will be made to the assu med responses among 
missing data in each treatment arm with varying degrees of plau sibility (O’Kelly, 2014). The 
goal of the tipping point analysis is to identify assumptions a bout the missing data under 
which the conclusions change, ie, under which there is no longe r evidence of a treatment 
effect. Then, the plausibility of such assumptions would be dis cussed. Further details of this 
procedure will be described in the SAP.
x Observed case analysis: This analysis will only include the obs erved data for subjects still on 
the original double-blind study treatment. Data collected after  the discontinuation of 
double-blind study treatment a nd all other missing data will be  excluded from the analysis. 
The same logistic regression model specified for the primary ef ficacy analysis will be 
performed.
The sensitivity analyses of the secondary binary efficacy varia bles (ASAS40 at Weeks 12 and 
52) will be as follows:
x Including observed data at Week 52: As described for the primar y efficacy variable.
x MI: As described for the primary efficacy variable. Note that a s ASAS40 is a composite of 
4 different variables, the MI procedure will be performed on eac h of these components, and 
the ASAS40 response will be derived based on the multiply imput ed datasets.
x Reference-based MI: This procedure will impute missing data as well as data at the time 
points following the discontinuation of the double-blind study treatment for both the CZP 
and placebo groups. This procedure will use an imputation model  developed based on data 
from the placebo group (Mallinckrodt, 2013). The estimand being  evaluated in this case is 
the difference in the outcome of improvement in all randomized subjects at the planned 
endpoint, attributable to the initially randomized medication, which has been referred to as 
“estimand 6” (Mallinckrodt, 2012).
x Observed case analysis: As described for the primary efficacy v ariable.
The sensitivity analyses of secondary continuous efficacy variab les (the change from Baseline in 
BASDAI and BASFI at Weeks 12 and 52 a nd the change from Baselin e in the SI joint SPARCC 
score at Week 12) will be as follows:
x Including observed data at Wee k 52: As described for the primar y efficacy variable.
x MI: As described for the primary efficacy variable.
x Observed case analysis: As described for the primary efficacy v ariable.
x LOCF
Missing data for the other efficacy variables described in Sect ion 14.5 will be handled as 
follows:REDACTEDar
will will bebe
basedbased
ure wure w
tion tion COPYed foed fo
riablriabl
This document xxcannotcludinudin
MI: MI: beeek eek usednalyaly
BASFBAS
1212to lyseysesupportthth
ckrodtkrod
alysis:lysisanye oe o
he inie inimarketingwil
n of theof th
ure wilre wi
inckrodnckro
of iofauthorizationle. Noe. No
 perfoperfo
d on thd on th
ll iml imapplicationes (Aes (A
r the prthe pand yyanyd frd f
y analanalextensions r subjesubje
inuatinuati
fromfromorofofvariations ent nt 
ft hftthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 196 of 255x With imputation: Non-responder imputation for binary variables and LOCF for continuous 
variables (as described in Section 14.5)
x Observed case analysis: As described for the primary efficacy v ariable.
Additionally, algorithms for imputing missing or partial dates for safety evaluations will be 
detailed in the SAP.
Change #79
Section 14.10 Determination of sample size
Subjects will be randomized in a 1:1 ratio to the CZP 200mg Q2W  and placebo treatment 
groups. The expected response rates for ASDAS-MI at Week 52 are  40% and 20% for CZP and 
placebo, respectively. A to tal sample size of 300 (150 subjects  per treatment group) provides 
95% power to detect a statistical ly significant difference in t he ASDAS-MI response rate at 
Week 52 between CZP and placebo, using a 2-sided significance l evel of 0.05.
Has been changed to:
Subjects will be randomized in a 1:1 ratio to the CZP 200mg Q2W  and placebo treatment 
groups. The expected responder rates for ASDAS-MI at Week 52 ar e 40% and 20% for CZP and
placebo, respectively. A to tal sample size of 300 (150 subjects  per treatment group) provides 
95% power to detect a statistical ly significant difference in t he ASDAS-MI responder rate at 
Week 52 between CZP and placebo, using a 2-sided significance l evel of 0.05.
REDACTED diffdiff
a 2a 2--sidsidCOPYI at Wat
(150 su150 
fferefer
This document cannot be used to support any marketing authorization subjub
ence innce i
ded siged siapplication Q2W Q2W
Week 52eek 5
bjectjectandel of l of any MI resMI re
000extensions reatmeeatm
20% f0% f
grougrouor variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 197 of 255Change #80
Section 17 References
Callhoff J, Sieper J, Weiß A, Zink A, Listing J. Efficacy of TN Fα blockers in patients with 
ankylosing spondylitis and non-radiographic axial spondyloarthr itis: a meta-analysis. Ann 
Rheum Dis. 2015;
Has been changed to:
Callhoff J, Sieper J, Weiß A, Zink A, Listing J. Efficacy of TN Fα blockers in patients with 
ankylosing spondylitis and non-radiographic axial spondyloarthr itis: a meta-analysis. Ann 
Rheum Dis. 2015;74:1241-8.
Change #81
Section 17 References
Dougados M, van der Heijde D, Sieper J, et al. Efficacy of etan ercept in nonradiographic axial 
spondyloarthritis. The Symptomatic Efficacy and Effect on Objec tive Signs of Inflammation of 
Etanercept in Early Nonradiogr aphic Axial Spondyloarthritis. An n Rhuem. 2014;66:2091-102.
Has been changed to:
Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych W,  Citera G, et al. Efficacy of 
etanercept in nonradiographic axial spondyloarthritis. The symp tomatic efficacy and effect on 
objective signs of inflammation of etanercept in early nonradio graphic axial spondyloarthritis. 
Ann Rhuem. 2014;66:2091-102.
Change #82
Section 17 References
van Tubergen A, Black PM, Coteur G. Are Patient-Reported Outcom e Instruments for 
Ankylosing Spondylitis Fit-For-Purpose for the Axial Spondyloar thritis Patient? A Qualitative 
and Psychometric Analysis. Rheum. In press
Has been changed to:
van Tubergen A, Black PM, Coteur G. Are Patient-Reported Outcom e Instruments for 
Ankylosing Spondylitis Fit-For-Purpose for the Axial Spondyloart hritis Patient? A Qualitative 
and Psychometric Analysis. Rheum. 2015;54:1842-51.
Change #83
Section 17 References
Weber U, Ostergaard M, Lambert RG, Pedersen SJ, Chan SM, Zubler  V, et al. Candidate 
lesion- based criteria for defini ng a positive sacroiliac joint MRI in two cohorts of patients with 
axial spondyloarthritis. Ann Rheum Dis. 2014-205408. Doi: 10.11 36/annrheumdis-2014-205408,REDACTEDJ
oarthroarthr
cept inept inCOPY J, MaJ, M
This documentChanCha
Scannotychomchombeg Spg Spused ed d 
A, BA, Bto to:to:support , CC
Fitit--ForFo
alysis. alysis.any CoteuCotemarketing authorizationMaksymaksym
itis. Titis. T
n earlyn earlyapplicationep
ective ective
. Ann R. Ann and pt in nt in any extensions or nn nn variations h thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 198 of 255Has been changed to:
Weber U, Ostergaard M, Lambert RG, Pedersen SJ, Chan SM, Zubler  V, et al. Candidate lesion
based criteria for defining a pos itive sacroiliac joint MRI in two cohorts of patients with axial 
spondyloarthritis. Ann Rheum Dis. 2015;74:1976-82.
Change #84
Section 18.1 ASAS classification  criteria for axial SpA, footno te 3 (number 1)
1) age at onset <40 years
Has been changed to:
1) age at onset <45 years
Change #85
Sections 18.9 PGADA (NRS) and 18.11 Total spinal pain NRS and n octurnal spinal pain 
NRS; “Spondylitis” has been changed to “Spondyloarthritis”.
REDACTED COPY 
This document cannot be used to support any marketing authorization applicationS andS an
tis”.is”.and dany extensions or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 199 of 25518.14 Protocol Amendment 2 
Rationale for the amendment
This substantial amendment incl udes changes to clarify some of the study procedures, as well as 
to update Inclusion Criteria 5 a nd 6 concerning the Assessment of SpondyloArthritis 
International Society (ASAS) criteria, and to increase the numb er of participating sites and 
screened subjects. The rationale for the changes is as follows:
x Inclusion Criterion 5 about subjects having a documented diagno sis of adult-onset axial 
spondyloarthritis (axSpA) as defined by the specified ASAS crit eria has been updated in 
order to:  i.) clarify that the ASAS criteria are classificatio n criteria and are not intended to be 
used as diagnosis criteria a nd to avoid any misinterpretation, and ii.) remove the part “with at 
least 12 months symptom duration before Screening ” since this part has been added to the 
updated Inclusion Criterion 6. 
x Inclusion Criterion 6 about subjects having evidence of inflamm atory back pain as defined 
by the ASAS criteria has been upda ted to specify that subjects must have had back pain for at 
least 12 months before Screening. The reason is that the require ments for objective signs and 
symptoms of inflammation are clearly defined in Inclusion Crite rion 9. The initial Inclusion 
Criterion 6 was therefore a repetition of this requirement. The  updated version stresses the 
importance of having back pain as the lead symptom for axSpA fo r at least 12 months to 
ensure that the pain is chronic in nature.
x The number of participating site s and the number of screened su bjects have been increased 
from 95 to 120 and from 900 to 1200, respectively, in order to adjust for a higher screening 
failure rate, which was actually exceeding the expected rate of  67%.
x Other changes included the following:
 Text about chest x-ray at Scre ening has been updated to clarify  that the chest x-ray must 
be done at Screening unless a ches t x-ray (or a computed tomogr aphy of the chest) has 
been done within 3 months prior to the Screening visit.
 Text about study treatment administration at on-site visits has  been updated to clarify at 
which visits the subcutaneous (sc) injections will be administe red by dedicated, 
unblinded, and adequately trained site personnel or by self-inj ection of the subject under 
the supervision of the unblinded study personnel.
 Study contact information for Clinical Trial Biostatistician ha s been updated.
 Minor editorial changes have been made.
Modifications and changes
Global changes
The following changes were made:
x The study contact information for Clinical Trial Biostatisticia n has been updated.
x Inclusion Criteria  5 and 6 have been updated.REDACTEDe nume num
resperespe
ceedinceedin
owinowinCOPYptom ptom
This documentGlobGlob
TTcannoMinoMin
dificadificabe y cy
nornorsedrvisivisi
contcontoand and
ionionsupporttreatmreatm
e subcusubc
d adeda danynths nthsmarketing ng:g:
reenineenin
ss a chs a cauthorization mber ofber of
ectivelective
ng the g theapplicationremeem
CriteriCriter
t. The u The
for axSfor axandy
ust haust h
menmenany y backyb a cextensionsntendtend
he pare pa
en adden addord ind i
dedvariations l 
innthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 200of 255x The number of participating site s and screened subjects has bee n increased from 95 to 120 
and from 900 to 1200, respectively.
x Text about chest x -ray at Screening has been updated throughout the protocol to cl arify that 
the c hest x -ray must be done at Screening unless a chest x -ray (or a computed tomography of 
the chest) has been done within 3 months prior to the Screening  visit.
x Text about study treatment administration at on -site visits has been upda ted to clarify at 
which v isits the sc injections will be administered by dedicated, unbl inded, and adequately 
trained site personnel or by self -injection of the subject under the supervision of the 
unblinded study personnel.
x Other changes made in this amendment are to provide clar ification or are administrative in 
nature, including minor editorial changes to abbreviations.
Specific changes
This section displays the modifications in this amendment compa red with the Final Protocol 
Amendment 1 dated 15 Dec 2015. The changes are displa yed in order of appearance.
Change #1
Study Contact Information  
Clinical Trial Biostatistician  
Name: , MS
Address: 8010 Arco Corporate Drive
Raleigh, NC 27617
United States 
Phone:
Fax:
Has been changed to:
Clinical Trial Biostatistician  
Name: , MS
Address: 8010 Arco Corporate Drive
Raleigh, NC 27617
United States of America
Phone:
Fax:REDACTED SSD
porateporate
C 2761C 2761CTCOPY 
This document cannot anbedresdresused d
uto osostsupport statstataany keting 177
ke
markeauthorization ati
e DriveDrivhorapplication rderdeandwithwith
er oroany thextensions inistranistror variations ely ly thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 201 of 255Change #2
Section 1 Summary, paragraph 2
The study population will be subjects (≥18 years), with a documented diagnosis of adult -onset 
axSpA as meeting the Assessment of SpondyloArthritis Internatio nal Society ([ASAS], Sieper et 
al, 2009) criteria of at least 12 months’ symptom duration, and  with active disease defined by a 
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥4,  and spinal pain ≥4 on a 
0 to 10 Numerical Rating Scale (N RS). At Baseline, evidence of in flammatory disease will be 
confirmed either by presence of s acroiliitis on MRI (according to ASAS/Outcome Measures in 
Rheumatology Clinical Trials [OMERACT] criteria) or by elevated  CRP or by presence of both.
Has been changed to:
The study population will be subjects (≥18 years), with a docum ented diagnosis of adult -onset 
axSpA and who meet the Assessment of SpondyloArthritis Internat ional Society ([ASAS], 
Sieper et al, 2009) criteria for  axSpA, who have had back pain of at least 12 months’ symptom 
duration, and with active disease defined by a Bath Ankylosing Spondylitis Disease Activity 
Index (BASDAI) ≥4, and spinal pain ≥4 on a 0 to 10 Numerical Rating Scale (NRS). At 
Baseline, evidence of inflammatory disease will be confirmed ei ther by presence of sacroiliitis 
on MRI (according to ASAS/Outcome Measures in Rheumatology Clin ical Trials [OMERACT] 
criteria) or by elevated CRP or by presence of both.
Change #3
Section 1 Summary, paragraph 4
At on-site visit days (at Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 2 4, 28, 32, 36, 40, 44, 48, and 50), the 
double-blind study treatments will  be administered sc at the st udy site by dedicated, unblinded, 
and adequately trained site personnel. The double-blind study t reatment will be self-injected at 
home at Weeks 14, 18, 22, 26, 30, 34, 38, 42, and 46. All subje cts will receive training for self 
injection at the study site at Weeks 10 and 12. During the train ing at the Weeks 10 and 12 visits, 
the double-blind study treatment will be self administered unde r the supervision of the dedicated 
unblinded study personnel.
Has been changed to:
At on-site visit days (at Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 2 4, 28, 32, 36, 40, 44, 48, and 50), the 
double-blind study treatments will  be administered sc at the st udy site. At the Week 0, 2, 4, 6, 
and 8 visits, the administration must be done by dedicated, unb linded, and adequately trained site
personnel. At the Week 10 and 12 visits, the subject will recei ve training on self-injection and 
the study treatment will be self-administered under the supervi sion of the unblinded study 
personnel. At Weeks 16, 20, 24, 28, 32, 36, 40, 44, 48, and 50,  the study treatment administration 
should preferably be done by the unblinded study personnel, or alternatively by self-injection of 
the subject under the supervision of the unblinded study person nel. The double-blind study 
treatment will be self-injected at home at Weeks 14, 18, 22, 26,  30, 34, 38, 42, and 46.REDACTED 6, 8, 6, 8, 
e adme admCOPY 
This documentshouhou
thethecannot l. A. 
udy tredy tre
sonneonne
uldldbe th
At tAt tusedysy
tudy trudy t
he adhe atos (ats (asupport :
tWany k
ent wient wmarketing minismini
The doThe d
34, 38,4, 38
kss10 10authorization 10, 1210, 12
sttapplication atintin
either bther 
tology tologyanddylitdylit
ing ngany cici
12 m12 m
isiextensions ce 
sis of as of a
iety ety orof bof variations be e 
es ines inthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 202 of 255Change #4
Section 1 Summary, paragraph 16, first sentence
Approximately 900 subjects will be screened in order to have 30 0 subjects (150 subjects per 
treatment group) randomized into the study.
Has been changed to:
Approximately 1200 subjects will be screened in order to have 3 00 subjects (150 subjects per 
treatment group) randomized into the study.
Change #5
Section 4.4 Safety variables, paragraph 6
At Screening, all subjects will have an  Interferon-Gamma Release Assay (IGRA) test 
(QuantiFERON®TB test or Elispot®test, when the QuantiFERON test indicated is not available), 
and a chest x-ray read (or, i f done, computed tomography of the  chest) which must be reported 
consistent with standard clinical reporting practice by an expe rienced qualified TB specialist, 
radiologist, or a pulmonologist, who is specifically required t o look for signs of active TB or 
signs of past/inactive TB infection. The official report of the  imaging must specifically indicate 
the absence of findings suggestive of current active TB or prior  inactive TB. In addition to a 
physical examination done intermittently throughout the study, subjects will be evaluated at 
Screening, Baseline, and every 12 weeks thereafter up to and in cluding the Week 52/WD visit, 
for signs and symptoms of latent tuberculosis (LTB) or active T B infection and risk factors for 
exposure to TB using the TB questionnaire. 
Has been changed to:
At Screening, all subjects will have an  Interferon-Gamma Release Assay (IGRA) test 
(QuantiFERON®TB test or Elispot®test, when the QuantiFERON test indicated is not available), 
and a chest x-ray reading (or, if done, computed tomography of the chest) which must be 
reported consistent with standard clinical reporting practice b y an experienced qualified TB 
specialist, radiologist, or a pulmonologist, who is specificall y required to look for signs of active 
TB or signs of past/inactive TB infection. A chest x-ray will n ot be done at Screening if a chest 
x-ray (or computed tomography of the chest) was done within 3 mo nths prior to the Screening 
visit. The official report of the  imaging must specifically ind icate the absence of findings 
suggestive of current active TB or prior inactive TB. In additi on to a physical examination done 
intermittently throughout the study, subjects will be evaluated  at Screening, Baseline, and every 
12 weeks thereafter up to Week 36 and including the Week 52/WD visit, for signs and symptoms 
of latent tuberculosis (LTB) or active TB infection and risk fa ctors for exposure to TB using the 
TB questionnaire. 
Change #6
Section 5.1.1 Study periods , Period 2, paragraph 2
At on-site visit days (at Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 2 4, 28, 32, 36, 40, 44, 48, and 50), the 
double-blind study treatments will  be administered sc at the st udy site by dedicated, unblinded 
and adequately trained site personnel. The double-blind study t reatment will be self-injected at 
home at Weeks 14, 18, 22, 26, 30, 34, 38, 42, and 46. All subjec ts will receive training for REDACTEDaft
is (LTs (LT
re. re. 
nnCOPYTB oTB 
out theut th
ter uer u
This document ChaChcannot  thth
nt tubnt tub
questquestbe ly ty
herehereusedre
urrenurren
throthrotoeporeposupporpulmpulm
tive TBive T
omogrmogr
tanyard clard c
momomarketing Interfenterfe
test, wtest, 
one, cone, 
iauthorization e s
up to ap to a
TB) or B) or applicationed
ook foook fo
imaginimagi
prior inprior 
studytudyand) whwh
d quad quanydicatedicat
hichhicextensions GRA) RA)or variations r thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 203 of 255self-injection at the study site on Weeks 10 and 12. During the training on Weeks 10 and 12 
visits, the double-blind study treat ment will be self-administe red under the supervision of the 
unblinded study personnel. Concom itant medications permitted du ring the study should remain 
stable for at least 4 weeks prior to the Weeks 12, 24, and 52/W D assessments.
Has been changed to:
At on-site visit days (at Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 2 4, 28, 32, 36, 40, 44, 48, and 50), the 
double-blind study treatments will be administered sc at the st udy site. At the Week 0, 2, 4, 6, 
and 8 visits, the administration must be done by dedicated, unb linded, and adequately trained site 
personnel. At the Week 10 and 12 visits, the subject will recei ve training on self-injection and 
the study treatment will be self-administered under the supervi sion of the unblinded study 
personnel. At Weeks 16, 20, 24, 28, 32, 36, 40, 44, 48, and 50,  the study treatment administration 
should preferably be done by the unblinded study personnel, or alternatively by self-injection of 
the subject under the supervision of the unblinded study person nel. The double-blind study 
treatment will be self-injected at home at Weeks 14, 18, 22, 26 , 30, 34, 38, 42, and 46. 
Concomitant medications permitted during the study should remai n stable for at least 4 weeks 
prior to the Weeks 12, 24, and 52/WD assessments.
Change #7
Section 5.1.3 Planned number of subjects and site(s)
Approximately 900 subjects are exp ected to enter the Screening Period in order to have 
300 subjects randomized into the  Double-Blind Period. The end of  the study will be defined as 
the date of last subject last FU visit. It is planned to enroll  the subjects at approximately 95 sites.
Has been changed to:
Approximately 1200 subjects are ex pected to enter the Screening  Period in order to have 
300 subjects randomized into the  Double-Blind Period. The end of  the study will be defined as 
the date of last subject last FU visit. It is planned to enroll  the subjects at approximately 
120 sites.
Change #8
Section 5.2 Schedule of stud y assessments - Study Periods 1 to 3  (Screening until FU), 
Table 5-1: footnote j
jScreening chest x-ray (or comput ed tomography of the chest) mus t have occurred within 3 
months prior to Screening visit and will be repeated at Week 52/ WD visit only if the TB test 
was confirmed positive or any further evidence is suggestive of  potential TB infection (eg, 
exposure).
Has been changed to:
jA chest x-ray must be done at Screening unless a chest x-ray (o r computed tomography of the 
chest) has been done within 3 months prior to the Screening vis it. The chest x-ray will be 
repeated at Week 52/WD visit only if the TB test was confirmed p ositive or any further 
evidence is suggestive of potential TB infection (eg, exposure) .REDACTED nternter
lind Plind P
planneplannCOPY te(s)te(s)
r thert h
This documentHas Has 
jjcannotpp
confironfir
posurposurbech
rior rior usednoteote
hest xhest to ule ole 
ejejsupport  of sofany sismarketing ected tocted t
Doubleouble
it. It it. Itauthorization e Scree Scr
Perioderiod
ned to ed to application andstableableany ublub
8, 42,8, 42
fextensionstio
d studyd stud
nt admnt adm
by selfy sel
blele--bboron an avariations he he 
6, , 
ned sed sthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 204 of 255Change #9
Section 5.2 Schedule of stud y assessments - Study Periods 1 to 3  (Screening until FU), 
Table 5-1: footnote q
qAt on-site visit days (Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 24,  28, 32, 36, 40, 44, 48, and 50), the 
double-blind study treatments will  be administered sc at the st udy site by dedicated, unblinded 
and adequately trained site personnel. The double-blind study t reatment will be self-injected at 
home at Weeks 14, 18, 22, 26, 30, 34, 38, 42, and 46. From Week  52 onwards, after completion 
of all onsite assessments and procedures, the subject may recei ve open-label CZP at the 
discretion of the Investigator.  
Has been changed to:
qAt on-site visit days (Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 24,  28, 32, 36, 40, 44, 48, and 50), the 
double-blind study treatments will be administered sc at the stu dy site. At the Week 0, 2, 4, 6, 
and 8 visits, the administration must be done by dedicated, unb linded, and adequately trained 
site personnel. At the Week 10 and 12 visits, the subject will receive training on self-injection 
and the study treatment will be self-administered under the sup ervision of the unblinded study 
personnel. At Weeks 16, 20, 24, 28, 32, 36, 40, 44, 48, and 50,  the study treatment 
administration should preferably be done by the unblinded study  personnel, or alternatively by 
self-injection of the subject under the supervision of the unbl inded study personnel. The 
double-blind study treatment will be self-injected at home at W eeks 14, 18, 22, 26, 30, 34, 38, 
42, and 46. From Week 52 onwards, after completion of all onsite  assessments and procedures, 
the subject may receive open-label CZP at the discretion of the  Investigator.
Change #10
Section 6.1 Inclusion criteria, Inclusion Criteria 5 and 6
5. Subjects must have a documented diagnosis of adult-onset axSp A as defined by the specified 
ASAS criteria (not including family history and good response t o NSAIDs; see 
Appendix 18.1) with at least 12 months symptom duration before Sc reening.
6. Subjects must have eviden ce of inflammatory back pain as defi ned by the ASAS criteria.
Have been changed to:
5. Subjects must have a documented diagnosis of adult-onset axSp A and meet the ASAS 
criteria for axSpA (not including family history and good respo nse to NSAIDs; see 
Appendix 18.1).
6. Subjects must have had back pa in for at least 12 months befor e Screening.
Change #11
Section 7.2.1 Treatment administration, paragraph 2
At on-site visit days (at Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 2 4, 28, 32, 36, 40, 44, 48, and 50), the 
double-blind study treatments will be administered sc at the stu dy site by dedicated, unblinded, 
and adequately trained site personnel. The double-blind study t reatment will be self-injected at 
home at Weeks 14, 18, 22, 26, 30, 34, 38, 42, and 46. All subjec ts will receive training for 
self-injection at the study site on Weeks 10 and 12. During the training on Weeks 10 and 12 mpmp
the dithe d
usiousioCOPYf thef th
d at hoat h
pletioleti
This document haha
SecSeccannotbjectsects
angeangebe dixxused t hah
axSpaxSp
1818tohavehavesupportvidencdenc
to:o:anyst 12st 12marketingon Crion Cr
ed diagd dia
familyamilauthorization om
ion ofon of
iscretiscretiapplicationvis
, the stthe s
study pstudy 
unblindunblin
me atme aande traitrai
sionsionanynd adnd a
inininextensions 4, 48, , 48,
he Whe Wor variations at at 
etion etion thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 205 of 255visits, the double-blind study treat ment will be self-administe red under the supervision of the 
unblinded study personnel.
Has been changed to:
At on-site visit days (at Weeks 0, 2, 4, 6, 8, 10, 12, 16, 20, 2 4, 28, 32, 36, 40, 44, 48, and 50), the 
double-blind study treatments will  be administered sc at the st udy site. $WWKH:HHN
DQGYLVLWVWKHDGPLQLVWUDWLRQPXVWEHGRQHE\GHGLFDWHG XQEOLQGHGDQG
DGHTXDWHO\WUDLQHGVLWHSHUVRQQHO$WWKH:HHNDQGYLVLWV WKHVXEMHFW
ZLOOUHFHLYHWUDLQLQJRQVHOILQMHFWLRQDQGWKHVWXG\WUHDWPHQW ZLOOEHVHOI
DGPLQLVWHUHGXQGHUWKHVXSHUYLVLRQRIWKHXQEOLQGHGVWXG\SHUVR QQHO At Weeks 
16, 20, 24, 28, 32, 36, 40, 44, 48, and 50, the study treatment  administration should preferably be 
done by the unblinded study personnel, or alternatively by self -injection of the subject under the 
supervision of the unblinded study personnel. The double-blind study treatment will be self-
injected at home at Weeks 14, 18, 22, 26, 30, 34, 38, 42, and 46 .
Change #12
Section 8.1 Screening visit (Week -6 to Day -1), bullet 8
x Chest x-ray (must occur within 3 months prior to Screening visi t)
Has been changed to:
x Chest x-ray to be done at Screening (unless a chest x-ray or com puted tomography of the 
chest has been done within 3 months prior to the Screening visi t)
Change #13
Section 12.6.3.2 Chest x-ray
A plain posteroanterior chest x-r ay (or, if done, computed axia l tomography of the chest) must be 
done within 3 months prior to the Scr eening visit. The chest x- ray must be clear of signs of TB 
infection (previous or current) before first study drug adminis tration. The chest x-ray will be 
repeated at Week 52/WD visit (if chest x-ray was performed more  than 12 weeks prior to 
Week 52/WD visit), only if the TB test was confirmed positive or  any further evidence is 
suggestive of potential TB i nfection (eg, exposure). Radiograph ic findings suggestive of inactive 
TB or active TB may include but are not limited to: apical fibro sis, pleural thickening, 
pulmonary nodules, fibrotic sca rs, calcified granulomas, upper lobe infiltrates, cavitations and 
pleural effusions, calcified lung nodules, calcified hilar lymp h nodes, and pericardial 
calcification.
The chest x-ray (or, if done, Computed Axial Tomography of the Chest) must be negative for TB 
infection as determined by a  qualified radiologist and/ or pulm onary physician. Any new 
clinically significant findings post-Baseline during physical e xam or on chest x-ray must be
documented in the source doc uments and CRF as an AE.
Has been changed to:
A plain posteroanterior chest x-r ay must be done at Screening u nless a chest x-ray (or a 
computed tomography of the chest) has been done within 3 months  prior to the Screening visit.
The chest x-ray must be clear of signs of TB infection (previou s or current) before first study REDACTEDss ass ac
rior torior toCOPY Scrc
h
This documentinfecnfec
clinclin
dcannotationtion
chestchest
ctitibeusionusio
nnusedmayma
dulesdulestotial tial
ay iay isupportnt)t)
 visit visit 
nly if tnly if 
al TBlT Banyhe She S
) befobefomarketing y (or, iy (or, 
ScrScauthorization hest xest x
o the Sthe Sapplication ning viing vand any extensionsAt At 
ld prefd pre
subjesubje
ent went wor VV
WWvariations QGG
HFWHFW
VHOVHOthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 206 of 255drug administration. The chest x -ray will be repeated at Week 5 2/WD visit (if chest x-ray was 
performed more than 12 weeks prior to Week 52/WD visit), only if t he TB test was confirmed 
positive or any further evidence is suggestive of potential TB infection (eg, exposure). 
Radiographic findings suggestive of inactive TB or active TB ma y include but are not limited to: 
apical fibrosis, pleural thickening, pulmonary nodules, fibroti c scars, calcified granulomas, upper 
lobe infiltrates, cavitations and pleural effusions, calcified lung nodules, calcified hilar lymph 
nodes, and pericardial calcification.
The chest x-ray (or, if done, the computed tomography of the ch est) must be negative for TB 
infection as determined by a  qualified radiologist and/ or pulm onary physician. Any new 
clinically significant findings post-Baseline during physical e xam or on chest x-ray must be 
documented in the source doc uments and CRF as an AE.
COPY 
This document cannot be used to support any marketing authorization application and any extensionsmust mustor bbvariations TB B thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 207 of 25518.15 Protocol Amendment 3 
Rationale for the amendment
This substantial amendment includes changes to clarify the stud y details regarding the additional 
2 years of long-term, open-label C ZP treatment that will be prov ided to eligible subjects at the 
completion of the Week 52 visit. This period of the study has b een named the Safety-Follow Up 
Extension (SFE) Period and the prot ocol has been updated throug hout accordingly (eg, a new 
Schedule of Study Assessments has  been added and eligibility cr iteria, guidance for study drug 
administration and concomitant medication usage have been updat ed).
Additional changes include:
x allowing female subjects who beco me pregnant while participatin g in the AS0006 study the 
option to enroll in a separate, observational, pregnancy follow -up study sponsored by UCB.
x removal of the 40% cap on IXRS randomization to each of the 3 c linical subgroups for 
MRI/CRP classifications: (MRI+/CRP+, MRI+/CRP-, or MRI-/CRP+) i n order to reflect the 
real world situation. 
x to clarify that ca ses of potential Hy’s Law, defined as ≥3xULN ALT or AST with co existing 
≥2xULN total bilirubin in the absence of ≥2xULN ALP, with no al ternative explanation for 
the biochemical abnormality, must ALWAYS be reported to UCB as an AE of interest 
(ie, without waiting for any additional etiologic investigations  to have been concluded).
x minor typographical errors have been corrected throughout the p rotocol. Additional specific 
changes are listed below.
Modifications and changes
Global changes
The following changes were made throughout the protocol:
Specific changes
Change #1
The study acronym (C-AXSPAND) was added to the title page.
Change #2
The fax number for SAE reporting in the USA and Canada has been  updated.
Serious Adverse Event reportin g (24h) and safety related issues
Fax Europe and Rest of the World: +32 2 386 24 21
USA and Canada: +1 800 880 6949 or +1 866 890 3175
E-Mail DS_ICT@ucb.comREDACTEDrrecterrecteCOPYe repe rep
gic invgic inv
This document mecannotxot otbe SSeused ber foer futo support AXSPAXSany marketing througthrouauthorizationvestiesti
d throd throapplication ULN ALLN A
with nwith 
orted torted t
igaigaand RP+P+anycal sual s
+) in+) iextensions S0006 0006 
ponsoronsoor variations rug ug thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 208 of 255Change #3
List of abbreviations
The following terms were revised or added:
ICH International Council for Harmonisation
SFE Safety Follow-Up Extension
SFE-SS Safety Follow-Up Extension-Safety Set
Change #4
Section 1 SummaryParagraph 1, first sentence:
AS0006 is a randomized, double-blind, parallel-group, placebo-c ontrolled study, consisting of 
52 weeks of treatment with certolizumab pegol (CZP) and a Follow -Up (FU) Period of 8 weeks 
after the Week 52 visit.
Has been changed to:
The C-axSpAnd study (AS0006) is a randomized, double-blind, par allel-group, placebo-
controlled study, consisting of 52 weeks of treatment with certo lizumab pegol (CZP) and a 
Follow-Up (FU) Period of 8 weeks after the Week 52 visit.
And paragraphs 6 and 7:
Subjects whose disease activity cannot be controlled by study m edication and changes in 
background therapy (including and not limited to analgesics, NS AIDs, and slow-acting 
antirheumatic drugs [SAARDs]) will be permitted to withdraw fro m the double-blind study drug. 
Subjects will either transition to open-label CZP treatment off ered by UCB or to other treatment 
(including biologics) at the discretion of the Investigator unt il the assessment of the primary 
endpoint at Week 52. At the comp letion of the Week 52 visit, an d in accordance with the local 
regulatory requirements, CZP will be provided for a maximum dur ation of 2 years or until 
marketing authorization is gran ted for CZP (if applicable), whi chever comes first.  
All subjects, including those withdrawn from double-blind study  treatment, will have a FU visit 
8 weeks after their final Week 52 visit. 
Have been changed to:
Subjects whose disease activity cannot be controlled by study m edication and changes in 
background therapy (including and not limited to analgesics, NS AIDs, and slow-acting 
antirheumatic drugs [SAARDs]) will be permitted to withdraw fro m the double-blind study drug.
Subjects will either transition to open-label CZP treatment off ered by UCB or to other treatment 
(including biologics) at the discretion of the Investigator unt il the assessment of the primary 
endpoint at Week 52. At the comp letion of the Week 52 visit ass essments, subjects on double-
blind study treatment may receive open-label CZP treatment for an additional 2 years in an open-
label, Safety Follow-Up Extension (SFE) Period. Subjects who wi thdrew from double-blind 
study treatment and transitioned to open-label CZP treatment ar e also eligible to participate in 
the SFE Period after completing the Week 52 visit assessments. Subjects on alternative 
treatments are not eligible to participate in the SFE Period.REDACTED e conte cont
t limitt limit
ll be pl be COPYnt witnt wi
kk52 v52 
This document ubjbj
(incl(incl
enencannotoundund
heumheum
bjectjectbehosehos
ttused angedngedtofinafinasupports grangran
g those those
al Walany mplmp
will bwill 
ntemarketingpermperm
label Clabel
ion of ton of
pletioletiauthorization visitisi
trolledrolled
ted toed to
iiapplication ind, pand, p
h certolcerto
ittand any stustu
FU) PFU) extensions udyudyor variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 209 of 255All subjects not participating in the SFE Period after study co mpletion at Week 52, including 
those withdrawn from the study prematurely, will have a FU visi t 8 weeks after their Week 52
visit. 
And paragraphs 15, 16, and 17:
Safety variables to be assessed are adverse events (AEs), vital  signs, physical examination, and 
measurements of laboratory parameters. In addition, subjects wi ll be evaluated at Screening, 
Baseline, and at every 12 wee ks thereafter up to Week 36 and in cluding Week 52/Withdrawal 
(WD) for signs and symptoms of latent or active tuberculosis (T B) infection and risk factors for 
exposure to TB using the TB questionnaire.
Approximately 1200 subjects will be screened in order to have 3 00 subjects (150 subjects per 
treatment group) randomized into the study. Randomization will be stratified by presence of 
sacroiliitis on MRI and elevated CR P to ensure balanced treatme nt allocation across 
3 subgroups: MRI+/CRP+; MRI+/CRP- ; MRI-/CRP+. For each subject, the study will last a 
maximum of 66 weeks and will consist of 3 periods: 
x Screening Period lasting up to 6 weeks
x Double-Blind, Placebo-Controlled Period for 52 weeks
x FU Period 8 weeks after the Week 52/WD visit.
The estimated recruitment period is up to 15 months. The first subject first visit is planned in 
Quarter 3 2015. A completed subject is one who completes the We ek 52 visit. 
Have been changed to:
Safety variables to be assessed are adverse events (AEs), vital  signs, physical examination, and 
measurements of laboratory parameters. In addition, subjects wi ll be evaluated at Screening, 
Baseline, and at every 12 wee ks thereafter up to Week 36 and in cluding Week 52/Withdrawal 
(WD) (for subjects not participating in the SFE Period) for sign s and symptoms of latent or 
active tuberculosis (TB) infection and risk factors for exposur e to TB using the TB 
questionnaire.
Approximately 1200 subjects will be screened in order to have 3 00 subjects (150 subjects per 
treatment group) randomized into the study. Randomization will be stratified by presence of 
sacroiliitis on MRI and elevated CR P to ensure balanced treatme nt allocation across 
3 subgroups: MRI+/CRP+; MRI+/CRP-; MRI-/CRP+. 
For each subject, the study will consist of 3 periods and will l ast a maximum of 66 weeks: 
x Screening Period lasting up to 6 weeks
x Double-Blind, Placebo-Controlled Period for 52 weeks
x FU Period 8 weeks after the Week 52/WD visit (for subjects not p articipating in the SFE 
Period).
For subjects participating in the SFE Period, the study will ex tend up to a maximum of 
104 additional weeks.
The estimated recruitment period is up to 15 months. The first subject first visit is planned in 
Quarter 3 2015. The end of the study  will be defined as the dat e of the last subject’s last visit, who cwho c
dversedverse
terstersCOPY nths. nths. 
This document xxcannot reeninreenin
DouDoubeubjecubjeused RI I
MRI+/RI+/
ttod
andandsupport ubjects bjects
domizomizanyon aon amarketing e eve
s. In adIn ad
reafter eafter
ngngin tin 
andauthorizationThe The 
ompleomple
evenvenapplication fiand anyhe stuhe stextensions subjecubjec
y yprespres
n acroacro
tor variations al l 
rs fors fothereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 210 of 255defined as the FU visit 8 weeks after the Week 52/WD visit for subjects not participating in the 
SFE Period, or the last visit of the SFE Period. 
Change #5
Section 2.5 Rationale 
Paragraph 2:
To address the unmet need for tre atment options for nr-axSpA, A S0006 will be conducted 
focusing on subjects who do not meet the mNY classification cri teria for AS 
(see Appendix 18.2). Data suggest that patients with objective si gns of inflammation and high 
disease activity are likely to run a chronic disease course and  unlikely to be well managed on 
conventional therapy (Rudwaleit ACR 2013). Furthermore, studies  where anti-TNFs have been 
withdrawn in nr-axSpA patients show that patients flare quickly  and hence the disease is unlikely 
to go into spontaneous remission. However, there are no long-ter m prospective studies to assess 
how patients meeting the ASAS c lassification criteria respond t o conventional therapies. With 
the conduct of this 52-week study comparing CZP to placebo in c ombination with standard of 
care, a better understanding should be gained of how a long-ter m anti-TNF therapy compares to 
standard of care in patients meeting the ASAS criteria with obj ective signs of inflammation. 
Moreover, patients whose diseas e cannot be managed under the bl inded study treatment 
conditions will be able to disc ontinue the double-blind study t reatment and transition to either 
open-label CZP or other therapies.
Has been changed to:
To address the unmet need for tre atment options for nr-axSpA, A S0006 will be conducted 
focusing on subjects who do not meet the mNY classification cri teria for AS 
(see Appendix 18.2). Data suggest that patients with objective si gns of inflammation and high 
disease activity are likely to run a chronic disease course and unlikely to be well managed on 
conventional therapy (Rudwaleit ACR 2013). Furthermore, studies  where anti-TNFs have been 
withdrawn in nr-axSpA patients show that patients flare quickly  and hence the disease is unlikely 
to go into spontaneous remission. However, there are no long-te rm prospective studies to assess 
how patients meeting the ASAS c lassification criteria respond t o conventional therapies. With 
the conduct of the 52-week blinded study period comparing CZP t o placebo in combination with 
standard of care, a better unde rstanding should be gained of ho w a long-term anti-TNF therapy 
compares to standard of care in patients meeting the ASAS crite ria with objective signs of 
inflammation. Moreover, patients whose disease cannot be manage d under the blinded study 
treatment conditions will be able to discontinue the double-bli nd study treatment and transition 
to either open-label CZP or other therapies.
And a new 3rdparagraph has been added: 
The addition of the SFE Period w ill allow collection of long-te rm safety data from eligible 
subjects on open-label CZP for up to 2 years. During the SFE Pe riod, CZP will be provided by 
the Sponsor. The treating investigator is requested to apply ro utine, standard of care according to 
local standard medical practice and investigator clinical judgme nt. REDACTED optionoptio
the mthe m
hat phat pCOPYnd stnd s
This documentThe The 
subsubcannotopeope
a nea nebe ondnd
penpenused darar
MoreMore
ditiditito ett
rd ord osupportASASASA
week bleek b
tter uter uany shsh
ion. Hion. H
Smarketingpatienpatien
onic dionic d
ACR 20CR 2
how howauthorization ns forns for
NY cNY c
tapplication ntnt
ective sctive
the blithe bl
udy tredy trandbininatat
tii--TNTany tiviv
tionaliona
tioiextensionsanagednage
NFs hFs h
e diseadisea
ve sve sord hid hivariations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 211 of 255Change #6
Section 5.1 Study description
Paragraph 1: 
Study AS0006 is a 52-week, multicenter, randomized, double-blin d, parallel-group, 
placebo-controlled clinical study to evaluate the efficacy and safety of CZP in adult subjects with
active axSpA without x-ray evidence of AS and with objective si gns of inflammation (sacroiliitis 
on MRI and/or elevated CRP) and w ho have had an inadequate resp onse to, have a 
contraindication to, or are i ntolerant to NSAIDs. 
Has been changed to:
Study AS0006 is a 52-week, multicenter, randomized, double-blin d, parallel-group, 
placebo-controlled clinical study to evaluate the efficacy and safety of CZP in adult subjects with
active axSpA without x-ray evidence of AS and with objective si gns of inflammation (sacroiliitis 
on MRI and/or elevated CRP) and w ho have had an inadequate resp onse to, have a 
contraindication to, or are intolerant to NSAIDs. At the comple tion of the Week 52 visit 
assessments, eligible subjects may receive open-label CZP treat ment for an additional 2 years in 
an open-label, SFE Period. 
Change #7
Section 5.1.1 Study periodsThe subsection describing the Follow-Up Period (Period 3):
Period 3 (Follow-Up Period):
All subjects, including those withdrawn from the double-blind s tudy treatment, will have a FU 
visit 8 weeks after the Week 52/WD visit.
Has been changed to:
Period 3 (Follow-Up Period):
All subjects not participating in the SFE Period after Week 52,  including those withdrawn from 
the study prematurely, will have a  FU visit 8 weeks after the Week 52/WD visit.
And a new subsection describing th e SFE Period has been added:
Safety Follow-Up Extension (SFE) Period: Week 52 to Week 156, op en-label. 
At the completion of the Week 52 visit assessments, subjects on  double-blind study treatment 
may receive open-label CZP treatment for an additional 2 years.  Subjects who withdrew from 
double-blind study treatment and transitioned to open-label CZP  treatment are also eligible to 
participate in the SFE Period a fter completing the Week 52 visi t assessments. Subjects on 
alternative treatments are not eligible to participate in the S FE Period. 
Eligible subjects are allowed to roll-over to the SFE-Period up  to 3 months after completion of 
the Week 52 assessments.
In order to maintain the blind for subjects completing double-b lind treatment, their study 
treatment will be administered sc at the study site by unblinde d, dedicated study personnel on 
Weeks 52, 54, and 56. Subjects who withdrew from double-blind s tudy treatment and REDACTED PerioPerio
awn frawn fr
vivCOPY 
This document artirt
alteraltercannotceiveeive
lee--blibli
ticipicipbempletmpletused Up EUp E
iitotiontionsupporting inng in
will hawill h
ndndany tmarketingfrom om
isit.sit.authorization od (Ped (Pe
mt hmt happlicationment fment and se e 
of thef the
ffanyflamflam
to, hto, hextensions oup, up, 
n adun adu
mmmmor variations h
iitis tis thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 212 of 255transitioned to open-label CZP treatment do not need to visit t he site at Week 54 and Week 56, 
and should continue their open-lab el CZP treatment regimen.
For the remainder of the SFE Per iod, CZP can be administered at  the site by dedicated study 
personnel, or by self-injection of the subject under the superv ision of the dedicated study 
personnel, or subjects may self-admi nister their study treatmen t Q2W at home. 
Starting at Week 64, all subjects  are to visit the site approxim ately every 12 weeks for
assessments. 
The last dosing visit will be at Week 154. The final study asse ssments are performed at 
Week 156/SFE-WD.
Change #8
Section 5.1.2 Study duration per subject
For each subject, the study will last a maximum of 66 weeks, as  follows:
x Up to 6 weeks in the Screening Period
x 52 weeks in the Double-Blind Period
x A FU visit 8 weeks after the Week 52/WD visit
The estimated recruitment period is up to 15 months. The first subject first visit is planned in 
Quarter 3 of 2015. A completed subj ect is one who completes the  Week 52/WD visit. Subjects 
will either transition to open-label  CZP treatment offered by U CB or to other treatment 
(including biologics) at the discretion of the Investigator unt il the assessment of the primary 
endpoint at Week 52/WD. At the completion of the Week 52/WD visi t, and in accordance with 
the local regulatory requirements, CZP will be provided for a m aximum duration of 2 years or 
until marketing authorization is granted for CZP (if applicable ), whichever comes first.
Has been changed to:
For each subject, the first 3 periods of the study will last a maximum of 66 weeks, as follows:
x Up to 6 weeks in the Screening Period
x 52 weeks in the Double-Blind Period
x A FU visit 8 weeks after the Week 52/WD visit (for subjects not  participating in the SFE 
Period).
For subjects participating in the SFE Period, the study will ex tend up to a maximum of 
104 additional weeks.
The estimated recruitment period is up to 15 months. The first subject first visit is planned in 
Quarter 3 of 2015. The end of the study will be d efined as the date of the last subject’s last visit, 
defined as the FU visit 8 weeks after the Week 52/WD visit for subjects not participating in the 
SFE Period, or the last visit of the SFE Period  REDACTEDwh
ment ment
the Invthe Inv
pletionpletion
ZP wZP wCOPY hs. Thhs. T
ho cho c
This documentQuarQuar
dedecannotditionition
e estimestibets pats pausedweeweeto eekseksupportScreenScree
oubleoubleanyriodsriodsmarketing will bill b
ed for Cd for authorization he 
complompl
offereoffere
vestigvestig
n of thn of t
bebapplication e firstfirstand any extensions or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 213 of 255Change #9
Section 5.2 Schedule of study assessments
The Schedule of assessments is shown in Table 5-1 for subjects who complete the study on either 
CZP 200mg Q2W or placebo.
In order to optimize the treatment the Investigator may adjust the background medication in 
accordance with the specifications described in Table 7‒1 .
At any time during the study course, but preferably not before Week 12, the Investigator may 
discontinue the double-blind study  treatment and start open-lab el treatment with either CZP 
(which will be provided free of ch arge by UCB) or an alternativ e drug (eg, other treatment 
[including biologics]). Table 5‒2 shows the schedule of assessm ents for subjects receiving 
open-label treatment with CZP and Table 5‒3 shows the schedule of assessments for subjects 
receiving an alternative treatment (not CZP). 
Has been changed to:
The Schedule of assessments is shown in Table 5-1 for subjects who complete 52 weeks of 
treatment on either CZP 200mg Q2W or placebo.
In order to optimize the treatment the Investigator may adjust the background medication in 
accordance with the specifications described in Table 7-1 .
At any time during the study course, but preferably not before Week 12, the Investigator may 
discontinue the double-blind study  treatment and start open-lab el treatment with either CZP 
(which will be provided free of ch arge by UCB) or an alternativ e drug (eg, other treatment 
[including biologics]). Table 5-2 shows the schedule of assess ments for subjects receiving 
open-label treatment with CZP and Table 5-3 shows the schedule of assessments for subjects 
receiving an alternative treatment (not CZP).
Table 5-6 shows the schedule of assessments for subjects participating in  the SFE Period.
Change #10
The title of Table 5-1:
Table 5‒1: Schedule of study assessment - –Study Periods 1 to 3 (Screening until FU)
Has been changed to:
Table 5‒1: Schedule of study assessments - –Screening through Week 52 and FU 
And the visit number, 29, has been  removed from the column of a ssessments to be 
performed at the Follow-Up Visit.
And the following note has been added under the table:
Note: At the completion of the  Week 52 visit, subjects may rece ive open-label CZP treatment for 
an additional 2 years in the SFE Period.
And footnote b under Table 5-1:
bFU: 8 weeks after Week 52/WD visit. REDACTEDab
t and st and 
y UCBy UCB
ws the ss the 
TableTable
ttCOPYy ay 
le 7le 7--1
bly nly n
This document Andnd
NoNocannot visvi
rmedmed
d thdt hbe isitisitused ed td 
SchSchto to:to:support ule of ule of any marketing  55--33
t CZP)CZP)
assessmssessauthorization not beot be
start ostart o
B) or aB) or a
schedched
3application ho 
ust the bst the
.nd o comcomany extensionsatmenatme
receivreceiv
ents fonts foorCZPCZPvariations may may thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 214 of 255Has been changed to:
bFU: 8 weeks after Week 52/WD visit for subjects not participati ng in the SFE. 
And footnote k under Table 5-1:
k.TB test: IGRA test (QuantiFERON test [or Elispot test when the QuantiFERON indicated is 
not available]). The TB test will be repeated at Week 52 (or at  WD visit if medically indicated) 
for subjects with previously negative TB test result. Subjects who tested positive for TB should 
be encouraged to complete a FU  visit (8 weeks after the Week 52/ WD visit) and follow-up
information of suspected and confi rmed TB cases should be provi ded to UCB at least after 3, 9, 
and 12 months of the start date of anti-TB treatment.
Has been changed to:
kTB test: IGRA test (QuantiFERON test [or Elispot test when the QuantiFERON indicated is not 
available]). The TB test will be  repeated at Week 52 (or at WD v isit if medically indicated) for 
subjects with previously negative TB test result. Subjects who tested positive for TB should be 
encouraged to complete a FU visit (8 weeks after the Week 52/WD visit for subjects not 
participating in the SFE) a nd follow-up information of suspecte d and confirmed TB cases should 
be provided to UCB at least after 3, 9, and 12 months of the sta rt date of anti-TB treatment.
Change #11
Table 5‒2: Schedule of alternative study asse ssment with CZP - after subjec t 
discontinuation of the double blind study treatment
The following note has been added under the table:
Note: At the completion of the W eek 52 visit, subjects who tran sitioned to open-label CZP 
treatment after withdrawal from  the Double-Blind Period are eli gible to participate in the SFE 
Period.
And footnote a of Table 5-2:
aFU: 8 weeks after Week 52/WD visit.
Has been changed to:
aFU: 8 weeks after Week 52/WD vi sit for subjects not participati ng in the SFE Period.
Change #12
Table 5‒3: Schedule of alternative study a ssessment with other treatment ( including 
biologics) - after subject discontinuation of the double-blind s tudy treatment
Pregnancy testing has been added  to the table with the following  footnote g:
gPregnancy testing must be carried out for women of childbearing  potential and will be a serum 
test at the FU visit and a urine test (dipstick) at wdt Week 0 and Week 52/WD visit.
Change #13
A Schedule of assessments for the SFE Period (Table 5-6) has be en added:REDACTEDreatmreat
der theder th
52 52 vivi
e Doe DoCOPY sessmsessm
m
This documentPrePre
testtestcannot s) ) 
gnancnanc
egnbe afafused ScScto er support WeeWeeany 2/WD2/WDmarketing isi
oubleoubleauthorizationmentment
mentent
e table tabl
it, sut, suapplicationand and 
art dart date
wand osios
visit fvisit f
canydicaldica
itive tive extensions RON iRON i
allallorer 3er variations ld 
r3 ,3thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 215 of 255Table 5‒6:  Schedule of study assessments - Safety Follow-Up Extension Period  
Visit # 29 30 31 32 33 34 35 36 37 38 39 40
Overall Study Week/SFE Week
Protocol Activity52/0a54/2 56/4 64/12 76/24 88/36 100/48 112/60 124/72 136/84 148/96 156/104/WD  
Informed consentbX   
AEs X X X X X X X X X X X 
IXRScX X X X X X XX  XX  XX
Study drug loading dose 
administration scd XX X         
Study drug dispensationeX X X X XXXXX
AEs=adverse events; CZP=certolizumab pegol; FU=Follow-Up; IXRS= Interactive Response System; SFE=Safety Follow-Up Extension; WD =Withdrawal; 
aAssessments performed at the Week 52 Visit for subjects who com pleted the previous Double- Blind Period are in Table 5‒1; A ssessments performed at the 
Week 52 Visit for subjects who tr ansitioned to open-label CZP t reatment after withdrawal from the Double- Blind Period are in Table 5‒2.
bA separate informed consent form will be obtained from subjects  consenting to particip ate in the SFE Period.
cContact IXRS to register the vis it and obtain next kit number, where applicable, or to indicate t hat the subject has complete d the SFE Period or withdrawn from 
the study.
dAt Weeks 52, 54, and 56, study t reatment administration should be performed at the site by unbli nded study personnel in order t o keep the blind (see 
Section 7.2.1).
eStarting at Week 52 for subjects completing open- label CZP treatment and the Week 52 visit, dispense the assigne d study medication to the subject for use at 
home, as appropriate.
REDACTED er wer w
ting to ing to 
pplicabpplica
be perbe per
COPY 
Y ResponRespo
reviousevious
withwith
YYYThis 
document 
cannot 
be 
used 
to support 
any 
marketing rformorm
atment ament
authorizations DouDou
hdrawadrawa
participartici
ble, or ble, or
meme
appse Syste Sys
blb
plication 
atiXX
atattatpp
and Xnd
any nnnnyan
extensions 1313sionsex
or 88o
variations vaaaa
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 216 of 255Change #14
A new schematic diagram for the SFE Period (Figure 5-3) has bee n added:
Figure 5-3: Schematic diagram for subjects completing the double-blind study treatment and rolling over to the 
SFE Period 
             
  W0/BL    W52/SFE-W0    W156/SFE-W104 
  randomized treatment (CZP or PBO)        
 SCR Double-Blind Period   Open-Label SFE Period     
             
             
             
BL=Baseline; CZP=certolizumab pego l; FU=Follow-Up; SFE=Safety E xtension; PBO=placebo; SCR=Screening; SFE=safety Follow-Up Exte nsion; W=week
Note: Subjects who complete either double-blind treatment or ope n-label CZP-treatment and all assessments at Week 52 are eligibl e to roll-over to the SFE 
Period. Subjects who complete alternative treatment must finish  the study at Week 52 and be sch eduled for the final FU visit ( 8 weeks after the Week 52 visit).REDACTED afetyafety
COPY OPPPThis 
document 
cannot 
be 
used 
to support 
anynish tnish
marketing ExtensExten
openpen--lal
theth
authorization 
application PeriodPeriod
nap
and a
any 
extensionsent ant a
or anan
variations 
thereof. 11
UCB 17 Dec 2108
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 217 of 255Change #15
Section 5.4 Rationale for stud y design and selection of dose
Paragraph 2:
In accordance with prescribing information for CZP, 3 loading do ses of 400mg Q2W should be 
administered upon initiation of t herapy. Thus all subjects who transition to open-label CZP 
within the AS0006 study from the Double-Blind Period will recei ve this loading dose prior to the 
maintenance dose of 200mg Q2W. It is recognized that some subje cts would have been on active 
CZP prior to transition to open-label CZP. However, this dosing  approach is justified in all 
transitioning subjects as there  will be no change in benefit-ri sk due to administration of loading 
dose and the blinding will be maintained in the study, preservi ng the data integrity.
Has been changed to:
In accordance with prescribing information for CZP, 3 loading do ses of 400mg Q2W should be 
administered upon initiation of t herapy. Thus all subjects who withdraw from double-blind 
treatment prior to Week 52 and transition to open-label CZP wit hin the AS0006 study will 
receive this loading dose prior to the maintenance dose of 200m g Q2W. It is recognized that 
some subjects would have been on active CZP prior to transition  to open-label CZP. However, 
this dosing approach is justified in all transitioning subjects  as there will be no change in benefit-
risk due to administration of loading dose and the blinding wil l be maintained in the study, 
preserving the data integrity.
Change #16
Section 6.3 Withdrawal criteria 
Criterion 4:
4. There is confirmation of a pregnancy during the study, as ev idenced by a positive pregnancy 
test.
Has been changed to:
4. There is confirmation of a pregnancy during the study, as ev idenced by a positive pregnancy 
test (see Section 12.1.6 for more information regarding pregnan cies).
Change #17
A new subsection has been added:
Section 6.4 Eligibility for the SFE Period
To be eligible to participate in the SFE Period, subjects on do uble-blind study treatment and 
subjects who withdrew from double-blind study treatment and tra nsitioned to open-label CZP 
treatment must complete all of the Week 52 visit assessments. S ubjects on alternative treatments 
are not eligible to participate in the SFE Period. 
Eligible subjects are allowed to roll-over to the SFE-Period up  to 3 months after completion of 
the Week 52 assessments.
Prior to initiating the SFE asse ssments, all subjects will be a sked to read and sign a separate 
informed consent form.REDACTED COPY bjej
blindinblindi
This documenttreatmreatm
arearecannot elligibigi
jects ects be4 Eli4 Elused tion hion hto supportof a prf a pr
6 for mfor many marketing ncy durcy duauthorization applicationg Q2Wg Q2W
on to oon to 
s as theas th
ng willg wiland w fw 
the Ahe A
WWany0mg0m
fromfromextensionsof loof l
y.
mgmgor all all
loaoavariations the the 
activeactive
lthereof. 
UCB 17 Dec 2108
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 218 of 255Questions concerning the eligibi lity of a subject to continue p articipation in the study should be 
made in consultation with the Medical Monitor.
Change #18
Section 7.2.1 Treatment administration
Paragraph 1, first sentence:
A pharmacy manual will be provided to each site containing inst ructions regarding drug 
preparation and dosing. The injecti on schedule is described in Section 7.2.2.
Has been changed to:
A pharmacy manual will be provided to each site containing inst ructions regarding drug 
preparation and dosing. The injection schedule through Week 52 is presented in Figure 7‒1. The 
injection schedule for the SFE Period is presented in Figure 7‒ 2.
And new paragraphs 4, 5, and 6 were added
During the SFE Period, CZP will be administered sc by dedicated  unblinded study personnel at 
the study site on Weeks 52, 54, and 56 for subjects completing double-blind treatment in order to 
maintain the blind. Subjects who complete the Week 52 visit on p lacebo treatment will receive 
loading doses of CZP 400mg at these visits. Subjects who comple te the Week 52 visit on CZP 
treatment will receive 1 injection of CZP 200mg and 1 injection of placebo at these visits to 
continue their previous CZP treatment regimen.
Subjects who withdrew from double-blind study treatment and tra nsitioned to open-label CZP 
treatment do not need to visit the site at Week 54 and Week 56,  and should continue their 
open-label CZP treatment regimen.
For the remainder of the SFE Per iod, CZP can be administered at  the site by dedicated study 
personnel, or by self-injection of the subject under the superv ision of the dedicated study 
personnel, or subjects may self-admi nister their study treatmen t Q2W at home. 
Change #19
The title of the figure:
Figure 7-1: Injection scheduleHas been changed to:
Figure 7-1: Injection sc hedule through Week 52
Change #20An injection schedule for the OLE Period (Figure 7-2)  has been added:REDACTED study study 
WeekWeek
CCCOPYwhwh
and 1nd 1 i
This document cannot #20#20be AAusedged ted t
InInto ctio
tsupport ion son sany marketing CZP caZP ca
e subje subj
dminisminauthorization injj
y treatmtreatm
k 54 an54 aapplicationu
doubledouble
on plaon pla
complcomp
jectioectioand nblinblinany extensions ng drug dru
in Figun Figor variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 219 of 255Figure 7‒2:  Injection schedule for the SFE Period
CZP=Certolizumab pegol; FU=follo w-up; H=home; SFE=Safety Follow -Up Extension; W=week
* Subjects who complete either double-blind treatment or open-l abel CZP-treatment and all asse ssments at Week 52 are eligible t o roll-over to the SFE Period. 
Subjects who complete alternative treatment must finish the stu dy at Week 52 and be scheduled f or the final FU visit (8 weeks a fter the Week 52 visit).
** Subjects rolling over from open-label CZP-treatment to the S FE Period can self-administer their study medication at home fr om Weeks 2 to 10.
*** Subjects will complete the study assessments at Week 52 acc ording to the protocol and be invited for the final FU visit 8 w eeks after Week 52.W 5 0  HHHHHHHHH
week and before SFE-W 0 2 4 6 - 10 12 14-22 24 26-34 36 38-46 48 50-58 60 62-70 72 74-82 84 86-94 96 98-102 104
● ● ●●●●●●●●●●●●●●●●●●
○○
○ ● ●●●●●●●●●●●●●●●●●●
●●
● ●●●●●●●●●●●●●●●●
according to the 
assigned treatment regimenCZP        
200 mg
Placebo●
○Safety Follow-up Extension Double-blinded
●
●W52*
open other 
treatment***● open CZP 
200 mg● **
REDAFollowFollow
belbelCC
DACCCCCCCCCCCCCTTTTTTTTTTTTTEEEEEEEEEEEEEDDDDDDDDDDDDD 
YY
CCCCCCCCCCCCCOOOOOPPPYYY This 
document 
cannot 
be 
used 
to support 
any aamarketing UpUp
CZPCZP--tretre
y at Wey at W
FE PerE Pe
accordccor
autpEpE
uthoooooooooooorrrrrrrrrrrrriiiiiiiiiiiiizzzzzzzzzzzzzaaaaaaaaaaaaatttttttttttttiiiiiiiiiiiiiooooooooooooonnnnnnnnnnn pplication 
cationcctiotiooncapli
apppppp
anandd ddana
any ann
●nnnynyanan
extensions
ionnsexte●
nsnsssionsnstetenee
ororooror oo
variations v822arariaararvva
thereof. 11
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 220 of 255Change # 21
Section 7.4 Labeling
Clinical drug supplies will be labeled in accordance with the c urrent International Conference on 
Harmonisation (ICH) guidelines  on Good Clinical Practice (GCP) and GMP and will include any 
locally required statements. If necessary, labels will be trans lated into the local language. Details 
on Labeling will be provided in the Pharmacy manual.
Has been changed to:
Clinical drug supplies will be labeled in accordance with the c urrent International Council for 
Harmonisation (ICH) guidelines  on Good Clinical Practice (GCP) and GMP and will include any 
locally required statements. If necessary, labels will be transl ated into the local language. Details 
on Labeling will be provided in the Pharmacy manual.
Change #22
7.8.1 Permitted concomitant treatments for axSpA (medications an d therapies)
Paragraph 12
If the Investigator discontinues the double-blind study treatme nt and initiates therapy with CZP, 
UCB will supply the subject with the CZP. UCB is offering CZP i n accordance with the local 
regulatory requirements for a maximum duration of 2 years or unt il marketing authorization is 
granted for CZP (if applicable), whichever comes first. If the decision is made to start a different 
treatment (including biologics), UCB will not be supplying the medication. 
Has been changed to:
If the Investigator discontinues the double-blind study treatme nt and initiates therapy with CZP, 
UCB will supply the subject with the CZP. If the decision is ma de to start a different treatment 
(including biologics), UCB will not be supplying the medication . 
Change #23
A new subsection has been added: 
Section 7.8.3 Concomitant medicati on(s)/treatments during the SF E Period
At the completion of the Week 52 visit assessments, subjects on  double-blind study treatment 
may receive open-label CZP treatment for an additional 2 years (SFE Period). During this time, 
CZP will be provided by the Sponsor. Concomitant medication usag e during the SFE Period is at 
the discretion of the Investigator.
Change #24
Section 7.9 Blinding
Paragraph 1, first sentence:
Due to differences in presentation and viscosity between CZP an d placebo, special precautions 
will be taken in order to ensure blinding of the study. REDACTEDmes
ot be sot be 
doubledouble
CCCOPYfferiffer
of 2f 2ye
s firss firs
This document ectc
ParParcannot ge #2ge #2
tiontionbep
ion oion ousedenn--lala
rovidrovidtoof thof th
bbsupport addad
mitant itan
heheany ddeddedmarketing e-blibl
CZP. IfZP. If
t be supbe suauthorization ea
rst. If tst. If t
supplyupply
linlinapplication ent andent an
g CZPg CZP
ars orrs orands andandany dtdextensionsll incll inc
anguagnguaorcil fcil fvariations fthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 221 of 255Has been changed to:
Due to differences in presentation and viscosity between CZP an d placebo, special precautions 
will be taken in order to ensure blinding during the Double-Bli nd Period of the study. 
Change #25
Section 7.9.1 Maintenance of study treatment blind
A 4th paragraph has been added:
For the SFE Period, in order to maintain the blind for subjects  completing the Double-Blind 
Period, study treatment will be administered sc by unblinded st udy staff at the study site on 
Weeks 52, 54, and 56. Subjects who completed the Week 52 visit o n placebo treatment will 
receive loading doses of CZP 400mg at these visits. Subjects wh o completed the Week 52 visit 
on CZP treatment will receive 1 injection of CZP 200mg and 1 inj ection of placebo at these 
visits to continue their previous CZP treatment regimen. 
Change #26
Section 7.10.2  Randomization
The following sentence
The IXRS will be designed to ens ure that at least 20% and no mo re than 40% of the randomized 
subjects belong to 1 of the 3 clinical subgroups above.
Has been changed to:
The IXRS will be designed to ens ure that at least 20% of the ra ndomized subjects belong to each 
of the 3 clinical subgroups above.
Change #27
Section 8 Study procedures by visit
Paragraphs 2 and 3:
During the study the Investigator will assess the subjects over  the entire study period of 
approximately 66 weeks including a FU Period of 8 weeks after t he final Week 52/WD visit. 
Visit windows of ±3 days on either side of the scheduled visit are permitted; however, the 
Investigator should try to keep the subjects on the original dos ing schedule. The window of 
±3 days is relative to Baseline and is applicable for all subseq uent visits. Changes to the dosing 
schedule outside of the 3-day wi ndow must be discussed with the  Medical Monitor and may 
result in subject withdrawal. 
Has been changed to:
During the first 3 periods of the study the Investigator will a ssess the subjects over the entire 
study period of approximately 66 weeks including a FU Period of  8 weeks after the 
Week 52/WD visit. Visit windows of ±3 days on either side of the  scheduled visit are permitted; 
however, the Investigator should try to keep the subjects on th e original dosing schedule. The 
window of ±3 days is relative to B aseline and is applicable for all subsequent visits. Changes to 
the dosing schedule outside of the 3-day window must be discusse d with the Medical Monitor 
and may result in subject withdrawal. REDACTED at at leat leCOPY0% an% an
bove.bove.
This documentDuriDuri
stustucannotsusubb
s beenbeenbeutsidtsid
bjebjeuseduld tuld t
ative tative 
ddto3 da3 d
trytrysupportstigattigat
ks inclus incl
daysdayany tortmarketing visitisitauthorization east 20ast 20application d no md no mand any extensionssite ote 
ment wment w
e WeeWee
placebacebor nn
ononvariations nd dthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 222 of 255Change #28
Section 8.5 Week 52/WD (±3 days)
The last bullet:
x Contact IXRS to indicate that subject has completed or withdraw n from the study
Has been changed to:
x Contact IXRS to indicate that s ubject has rolled over to the SF E Period or withdrawn from 
the study
Change #29
A new subsection 8.6 has been adde d and subsequent subsections were renumbered 
accordingly:
Section 8.6 SFE Period (Week 52 to Week 156) 
All eligible subjects must complete the Week 52 visit assessmen ts.
Eligible subjects are allowed to roll-over to the SFE-Period up  to 3 months after completion of 
the Week 52 assessments.
Prior to rolling over to the SFE Period, subjects will be asked to read and sign a separate 
informed consent form.
Telephone contacts are upon the discretion of the Investigator.  Starting at Week 56, and at the 
discretion of the Investigator, i t is recommended to contact th e subject by phone at least once in 
between the on-site visits.
Starting at Week 64, all subjects  are to visit the site approxim ately every 12 weeks for
assessments performed according to local standard medical pract ice, as needed, including:
x Document AEs (Note: any [possible] drug-related AE must be foll owed-up, at least by 
phone.) 
x Contact IXRS 
 to register the visit and obtain next kit number at Weeks 54 an d 56 for subjects receiving 
loading doses of study drug administration at the study site
 to register the visit and obtain next kit number for subjects r eceiving study drug 
administration at the study site approximately Q12W during the remainder of the study
 to indicate that subject has completed the SFE Period or withdr awn from the study 
(Week156/WD)
Change #30
Section 8.6 FU visit (8 weeks afte r the Week 52/WD visit [±3 da ys])
Has been renumbered section  8.7 and a new paragraph has been ad ded:
Subjects not participating in the SFE Period will attend a FU v isit 8 weeks after the 
Week 52/WD visit (±3 days). REDACTEDf the f the 
mendedended
to vto vCOPYl be abe a
This documentChanCha
SScannotto into in
((WWbeminisniused ster thter th
istrstrtoes oes osupport visit avisit a
of sfany marketingvisit thisit th
local stocal s
ossiblessiblauthorization InvestInvest
d to cd to c
happlicationo 3o 3mom
sked toked tand any extensions umbembeor variations rom om thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 223 of 255Change #31
Section 12.1.6 Pregnancy
Paragraph 1: 
If an Investigator is notified that a subject has become pregna nt after the first intake of any IMP, the 
Investigator must immediately notify UCB’s Drug Safety (DS) dep artment by providin g the completed 
Pregnancy Report and Outcome form (for contact details see Seri ous Adverse Event reporting 
information at the beginning of this protocol). The subject sho uld be withdrawn from the study as soon as 
the pregnancy is known (by positive pregnancy test), and the fo llowing should be completed:
x The subject should return for an Early Withdrawal Visit.
x The subject should immediately stop the intake of the IMP or be  down-titrated as instructed at the 
Early Withdrawal Visit. 
x A FU visit should be scheduled 8 weeks after the Week 52/WD vis it.
Has been changed to:
If an Investigator is notified that a subject has become pregna nt after the first intake of any IMP, 
the Investigator must immediately notify UCB’s Drug Safety (DS)  department by providing the 
completed Pregnancy Report and Outcome form (for contact detail s see Serious Adverse Event 
reporting information at the beginning of this protocol). The s ubject should be withdrawn from 
the study as soon as the pregnancy is known (by positive pregna ncy test), and the following 
should be completed:
x The subject should return for an Early Withdrawal Visit.
x The subject should immediately stop the intake of the IMP. 
x A FU visit should be scheduled 8 weeks after the Week 52/WD vis it.
And the following paragraph has been added:
Should a subject become pregnant while participating in the stu dy, the subject may be offered the 
option to enroll in a separate observational pregnancy follow-u p study sponsored by UCB and 
conducted independently from study AS0006. If the study is avai lable locally, the AS0006 
Principle Investigator will be provided with the locally approv ed information about the 
observational pregnancy follow-up study to inform the subject a t the time the pregnancy is 
reported. Participation in this separate study will be voluntar y and will not impact therapeutic 
management of the subject nor interfere with termination and fo llow-up procedures as described 
in study protocol AS0006.
Change #32
Section 12.3 Adverse events of interest
A new paragraph 2 has been added:
Note : Potential Hy’s Law, defined as ≥3xULN ALT or AST with co existing ≥2xULN total 
bilirubin in the absence of ≥2xULN ALP, with no alternative exp lanation for the biochemical 
abnormality, must ALWAYS be reported to UCB as an AE of interes t (ie, without waiting for 
any additional etiologic invest igations to have been concluded) . Follow-up information should REDACTED y py p
rly Wirly Wi
stop stop COPYr conr con
tocol).ocol
posipos
This documentSectiSecti
AAcannoty propro
ange #ange bent ofnt o
totousedegnagna
icipatcipat
fftotor wor w
nannansupportegg
rate obate ob
ntly froly fro
willwilany nant nant marketingthe ithe i
 weekweek
as bes beauthorization . ThT
sitive ptive 
ithdrathdra
iiapplicationafter tafter 
y (DS) y (DS)
act detct de
The sheand any extensions nstrucstrucor variations oon asoon asthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 224 of 255then be reported if an alternati ve etiology is identified durin g investigation and monitoring of the 
subject.
Change #33
Section 12.5 Laboratory measurements
The title of Table 12‒1: L aboratory measurements
Have been changed to:
Table 12‒1 Laboratory measurements up to W eek 52 (including the FU visit ( 8 weeks 
after the Week 52/WD visit)
And new paragraph 3 has bee n added bene ath the table:
For subjects participating in the SFE Period after Week 52, it is recommended that laboratory 
assessments be performed at the lo cal laboratory at the discret ion of the Investigator according to 
local standard medical practice to evaluate potential AEs.
Change #34
Section 12.6.1 Pregnancy testing
A new paragraph 2 has been added:
For subjects participating in the SFE Period after Week 52, it is recommended that pregnancy 
testing be performed according to local standard medical practi ce.
Change #35
Section 12.6.2 Physical assessments
Paragraph 1:
Physical examination will be perform ed at Screening, Baseline, Weeks 2, 4, 8, 12, 16, 24, 36, 
52/WD, and at the FU visit (8 weeks after the Week 52/WD visit).  Physical examination findings 
will be recorded in the CRF only at Screening. Clinically impor tant abnormal changes in 
subsequent physical examinations will be recorded as AEs. Physi cal examinations must be 
documented in source documentation.
Have been changed to:
Physical examination will be perform ed at Screening, Baseline, Weeks 2, 4, 8, 12, 16, 24, 36, 
52/WD, and at the FU visit (8 weeks after the Week 52/WD visit f or subjects not participating in 
the SFE Period). It is recomme nded that physical examinations b e performed according to local 
standard medical practice for subjects participating in the SFE  Period after Week 52,
And paragraph 4:
In addition the TB signs and sympt oms will be assessed at Scree ning, Baseline, Weeks 2, 4, 8, 
12, 16, 24, 36, completion at Week 52/WD visit and FU (8 weeks a fter the Week 52/WD visit).
Has been changed to:
In addition, the TB signs and sym ptoms will be assessed at Scre ening, Baseline, Weeks 2, 4, 8, 
12, 16, 24, 36, completion at Week 52/WD visit and FU (8 weeks a fter the Week 52/WD visit for 
subjects not participating in the SFE Period).REDACTEDrd mrd m
ntsntsCOPY WeekWee
meme
This document ndnd
In aIn a
1annot PePe
ard merd me
d pad pabe d at
erioderiodusedinationatio
t thet thetod tod tosupportinationati
ocumeocum
to:o:any eee
nlnly aty a
onmarketing rmed amed 
eks afeks aauthorizationk 5252
edical dical application 2, it2i tand anyvestvesextensions d thatthat
stigstigor eeeevariations eks eksthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 225 of 255Change #36
Section 12.6.3 Assessment and management of TB and TB risk facto rs
Paragraphs 10-13:
Active TB/NTMB
Subjects who develop active TB or NTMB infection during the stu dy (conversion demonstrated 
by IGRA) must be immediately discontinued from study medication , and a withdrawal visit must 
be scheduled as soon as possib le, but not later than the next r egular visit. The subject should be 
encouraged to keep the FU visit (8 weeks after the Week 52/WD v isit). The TB must be 
documented as an SAE. Treatment  for TB should be started based on local guidelines.
Note that subjects with histor y of or active NTMB infection are  excluded from the study 
regardless of prior or current therapy.
Confirmed active TB is an SAE and an adverse event of special i nterest (AESI) and must be 
captured on an SAE report form  and provided to the Sponsor in a ccordance with SAE reporting 
requirements. As with all SAEs, periodic follow-up reports shou ld be completed as per protocol 
requirement until such time as the TB infection resolves. 
Subjects who prematurely discontinue treatment for LTB, or, in the opinion of the Investigator or 
Sponsor, are noncompliant with anti-TB therapy must discontinue  further use of study 
medication and be immediately wit hdrawn. Once withdrawn from st udy treatment, subjects 
should return for the Week 52/WD visit, complete all Week 52/WD assessments, and complete a 
FU visit (8 weeks after the Week 52/WD visit).
Have been changed to:
Active TB/NTMB
Subjects who develop active TB or NTMB infection during the stu dy (conversion demonstrated 
by IGRA) must be immediately discontinued from study medication , and a withdrawal visit must 
be scheduled as soon as possib le, but not later than the next r egular visit. The subject should be 
encouraged to keep the FU visit (8 weeks after the Week 52/WD vi sit for subjects not 
participating in the OLE Period) . The TB must be documented as an SAE. Treatment for TB 
should be started based on local guidelines.
Note that subjects with histor y of or active NTMB infection are excluded from the study 
regardless of prior or current therapy.
Confirmed active TB is an SAE and an adverse event of special i nterest (AESI) and must be 
captured on an SAE report form  and provided to the Sponsor in a ccordance with SAE reporting 
requirements. As with all SAE s, periodic follow-up reports shou ld be completed as per protocol 
requirement until such time as the TB infection resolves. 
Subjects who prematurely discontinue treatment for LTB, or, in the opinion of the Investigator or 
Sponsor, are noncompliant with anti-TB therapy must discontinue  further use of study 
medication and be immediately wit hdrawn. Once withdrawn from st udy treatment, subjects not
participating in the OLE Per iod should return for the Week 52/WD  visit, complete all 
Week 52/WD assessments, and complete a FU visit (8 weeks after t he Week 52/WD visit).REDACTEDpleteplete
visit).visit).COPYTBT
ust diust di
e withwith
ea
This documentequiequi
SuSucannoted on d on 
uiremeirem
uireuirbeactiactiusedts ww
prior orior to withwithsupport visivis
E PerioPeri
ed on ld onanyble, buble, b
sit (itmarketing NTMBNTM
iscontsconauthorizationhdrawhdraw
all Wall Wapplication be
r, in th, in th
scontinconti
wnnddancdanc
e coe coanyAESIAES
ceceextensions es.s.
the stuhe stuor variations must must 
ld beld bethereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 226 of 255Change #37
Section 12.6.3.1 Tuberculosis assessments
Paragraph 1, first sentence:
During conduct of the study the TB assessment by IGRA will be p erformed at Screening and 
should be repeated at Week 52/WD for all subjects. 
Has been changed to:
During conduct of the study the TB assessment by IGRA will be p erformed at Screening and 
should be repeated at Week 52/WD  for all subjects not participat ing in the SFE Period. It is 
recommended that TB testing be performed according to local sta ndard medical practice during 
the SFE Period. 
Change #38
Section 12.6.3.2 Chest x-rayParagraph 1:
A plain posteroanterior chest x-r ay must be done at Screening u nless a chest x-ray (or a 
computed tomography of the chest) has been done within 3 months  prior to the Screening visit. 
The chest x-ray must be clear of signs of TB infection (previou s or current) before first study 
drug administration. The chest x -ray will be repeated at Week 5 2/WD visit (if chest x-ray was 
performed more than 12 weeks prior to Week 52/WD visit), only if the TB test was confirmed 
positive or any further evidence is suggestive of potential TB infection (eg, exposure). 
Radiographic findings suggestive of inactive TB or active TB may  include but are not limited to: 
apical fibrosis, pleural thickening, pulmonary nodules, fibroti c scars, calcified granulomas, upper 
lobe infiltrates, cavitations and pleural effusions, calcified lung nodules, calcified hilar lymph 
nodes, and pericardial calcification.
Has been changed to:
A plain posteroanterior chest x-r ay must be done at Screening u nless a chest x-ray (or a 
computed tomography of the chest) has been done within 3 months  prior to the Screening visit. 
The chest x-ray must be clear of signs of TB infection (previou s or current) before first study 
drug administration. For subjects not participating in the SFE Period the chest x-ray will be 
repeated at Week 52/WD visit (if chest x-ray was performed more  than 12 weeks prior to 
Week 52/WD visit), only if the TB test was confirmed positive or  any further evidence is 
suggestive of potential TB infe ction (eg, exposure). It is reco mmended that the chest x-ray be 
repeated for subjects participating in the SFE Period, if the T B test was confirmed positive or 
any further evidence is sugges tive of potential TB infection (e g, exposure). Radiographic 
findings suggestive of inactive TB or active TB may include but  are not limited to: apical 
fibrosis, pleural thickening, pulmonary nodules, fibrotic scars , calcified granulomas, upper lobe 
infiltrates, cavitations and pleural effusions, calcified lung nodules, calcified hilar lymph nodes, 
and pericardial calcification.REDACTED52/W52/
ve of pve of p
ctive Tctive 
lmonalmona
ral eral eCOPYon (pon (p
ated aated a
WW
This documentndnd
fibrofibro
inincannod forfor
furtherurther
dingsingsbeof pof p
rsrsusedk 5252
vivisit)sit
popoto . FoF
2/W2/Wsupportt
the chthe c
be cleare cle
For sorany xx--rayray
hmarketingar
effusioffusioauthorizationat Wt W
WD visD vis
potenpoten
TB orTB or
ry noy noapplication unless nless
monthmonth
reviouseviou
WeeWeand any extensionsd. It. It
acticeacticeor ana
It isti svariations and ndthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 227 of 255Change #39
Section 12.6.3.3 QuantiFERON or Elispot testing
At Screening all subjects will hav e an IGRA test (QuantiFERON t ube test or Elispot, if 
QuantiFERON test indicated is not available). The TB test will be repeated at completion at 
Week 52/WD. Results of the tests will be reported as positive, negative, or indeterminate.
Has been changed to:
At Screening all subjects will have an IGRA test (QuantiFERON t ube test or Elispot, if 
QuantiFERON test indicated is not available). The TB test will be repeated at completion at 
Week 52/WD for subjects not participating in the SFE Period. It  is recommended that TB testing 
be performed according to local s tandard medical practice durin g the SFE Period. Results of the 
tests will be reported as posi tive, negative, or indeterminate.
Change #40
Section 12.6.4 Vital signs
Paragraph 2:
Vital signs, including temperature will be measured at all on-s ite visits including the FU visit 
(8 weeks after the Week 52/WD visit) with the exception of the W eek 1 visit (respiration rate 
will be measured at Screening and Baseline only unless the subj ect has an AE).
Has been changed to:
Vital signs, including temperature will be measured at all on-s ite visits including the FU visit 
(8 weeks after the Week 52/WD visit) with the exception of the W eek 1 visit (respiration rate 
will be measured at Screening and Baseline only unless the subj ect has an AE). It is 
recommended that vital signs be measured according to local sta ndard medical practice during 
the SFE Period. 
Change #41
Section 14.1 Definition of analysis sets
A new paragraph 6 was added:
The SFE Safety Set (SFE-SS) will be defined as all subjects who  continued into the SFE Period 
and who received at least 1 dose of CZP in the SFE Period.
Change #42
Section 14.5 Other efficacy analyses
Paragraph 1, first sentence:
Treatment group comparisons for C ZP 200mg Q2W versus placebo wi ll be performed based on 
the change from Baseline in other selected efficacy variables. 
Has been changed to:
Double-Blind Period treatment group comparisons for CZP 200mg Q 2W versus placebo will be 
performed based on the change from Baseline in other selected e fficacy variables.REDACTED measumeasu
with twith t
BaselinBaselin
susCOPYptiontio
unless nles
This documentTreaTrea
ththcannot14.514.5
ragraagrabe 2
55usedd at d attot (SFt (S
llsupportanaana
was addas ad
FEFEany alyalymarketingne one o
ured acred acauthorization  th
sured aured a
the exhe ex
oonnapplication site vissite v
of the Wf the 
he suhe suand any extensionshat TBat TB
d. ResuResuorn atn avariations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 228 of 255Change #43
Section 14.6 Planned safety and other analyses
The following text was added:
The Safety Set (SS) will be used for analysis of safety data fr om the Double-Blind Period as well 
as the combined Double-Blind and SFE Period (as applicable), and  the SFE-SS will be used for 
analysis of safety data from the SFE Period.
Change #44
Section 14.9 Planned interim  analysis and data monitoring
A new paragraph 1 was added:
An interim analysis is planned a fter the completion of the Doub le-Blind Period of the last subject 
at Week 52. At this time, the database from the Double-Blind Pe riod will be locked, the 
treatment codes will be made available to relevant UCB personne l, and an interim study report 
will be written. The Investigat ors and subjects will remain bli nd to the assigned CZP dose 
regimen of the Double-Blind Peri od. After the completion of the  SFE Period of the last subject, 
the database will be locked, and a final study report will be w ritten. From the Week 52 Visit 
onward, subjects will be treated with open-label CZP until the last dosing visit of the study 
(SFE Week 104).
REDACTED COPY unun
This document cannot be used to support any marketing authorization applicationSFE SFE
itten. Ftten. 
the lasthe lasanda
he asse ass
EPEPanye loe l
n inten int
iextensions od of td of t
lococor variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 229 of 25518.16 Protocol Amendment 4 
Rationale for the amendment
The purpose of this substantial amendment is to add an alternat ive primary efficacy variable for 
Canada and any other country where applicable or where requeste d by Regulatory Authorities. In 
response to feedback from the Canadian Health Authorities, the primary efficacy variable for 
Canada (and any other country whe re applicable or where request ed by Regulatory Authorities) 
will be the ASAS40 response at  Week 12. For these geographies, the ASDAS-MI at Week 52 
was moved to the list of secondary efficacy variables. In addit ion, the following 3 efficacy 
variables have been added to the  bottom of the testing hierarch y lists for all countries:
x Change from Baseline in ASQoL at Week 52 (elevated from “other”  to “secondary” efficacy 
variable) 
x Change from Baseline in nocturnal spinal pain [NRS] at Week 52 (elevated from “other” to 
“secondary” efficacy variable )
x Number of subjects with AU or new AU flares through Week 52 (ne w variable)   
Specific changes to the lists of efficacy variables, the hierar chical testing procedure, and 
statistical analyses are described in detail below.
Other changes in this amendment include replacement of the curre nt assay for measuring 
anti-CZP (anti-drug antibodies) in plasma samples (a validated screening enzyme-linked 
immunosorbent assay (ELISA) method based on a double-antigen sa ndwich [bridge] format) 
with new methods in order to align with current regulatory guid elines. This change is being made 
across the CZP development program. In the current version of t he AS0006 protocol, an ADAb 
level >2.4 units/mL is defined as positive according to the bio analytical method and testing 
strategy. The updated strategy for immunogenicity testing will take a tiered approach consisting 
of initial screening for ADAb positive samples in subjects rand omized to CZP or placebo, using 
a population-specific cutpoint resulting in a 5% false positive  rate. Samples scored positively in 
the screening assay will be c onfirmed using a confirmatory assa y with a population-specific 
confirmatory cutpoint resulting in a 1% false positive rate. Ch aracterization of confirmed 
positive samples will consis t of determination of the titer, an d for a subset of samples, 
assessment of the neutralizing potential using a cell-based neu tralizing antibody assay. 
An additional change to the amendment is to correctly describe the version of the MOS Sleep 
Scale used in the study. Refere nces to the older 6-point scale,  which was not used, were updated 
to reflect the newer 5-point s cale, and a copy of the 6-point s cale questionnaire in Appendix 18.8
was replaced with the correct 5-point scale questionnaire.
Additional minor changes to the prot ocol include correction of t he order of presentation of the 
subsections for secondary and other efficacy variables, and cor rections of minor typographical 
errors. Specific changes are listed below.REDACTEDd on ad on 
urrenturrent
In theIn the
sitive sitive 
mmCOPY ment ofment o
es (a es (a 
This documentubseubs
erroerrocannotlaceace
ditionationa
secsecbee nen
ed wedusedangng
the stuhe stu
ewewto ge tge tsupportltinging
nsist onsist o
tralizitralizianynfirmnfirm
gi ngimarketingaccacc
munogeunoge
ive samve sam
ultingultingauthorizationvalidvalid
a douba doub
t regut regu
e currecurre
corcorapplication cal testal tes
f the cuthe cand 2 (new(newany ateateextensions ndary”dary
ted fedor yyvariations ) ) 
2 2 
ythereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 230 of 255Modifications and changes
Specific changes
Change #1Section 1 Summary
Paragraph 13:
The primary efficacy variable is Ankylosing Spondylitis Disease  Activity Score major 
improvement (ASDAS-MI) response at Week 52. The secondary effica cy variables are 
ASAS 40% (ASAS40) response at Weeks 12 and 52, change from Baselin e in Bath Ankylosing 
Spondylitis Functional Index (BASFI) at Weeks 12 and 52, change  from Baseline in BASDAI at 
Weeks 12 and 52, change from Baseline in SI joint Spondyloarthr itis Research Consortium of 
Canada (SPARCC) score at W eek 12, and the number of subjects wit hout relevant changes to 
background medication.
Has been changed to:
The primary efficacy variable is Ankylosing Spondylitis Disease  Activity Score major 
improvement (ASDAS-MI) response at Week 52. The secondary effica cy variables are 
ASAS 40% (ASAS40) response at Weeks 12 and 52, change from Baselin e in Bath Ankylosing 
Spondylitis Functional Index (BASFI) at Weeks 12 and 52, change  from Baseline in BASDAI at 
Weeks 12 and 52, change from Baseline in SI joint Spondyloarthr itis Research Consortium of 
Canada (SPARCC) score at W eek 12, the number of subjects without  relevant changes to 
background medication, change from Baseline in Ankylosing Spond ylitis Quality of Life 
(ASQoL ) at Week 52, change from Baseline in nocturnal spinal p ain (NRS) at Week 52, and the 
number of subjects with anterior uveitis (AU) or new AU flares through Week 52.
And a new paragraph 14 has been added:
For Canada (and any other country where applicable or where req uested by Regulatory 
Authorities), the primary efficacy variable is the ASAS40 respo nse at Week 12. The secondary 
efficacy variables are ASAS40 response at Week 52, ASDAS-MI at W eek 52, change from 
Baseline in BASFI at Weeks 12 and 52, change from Baseline in B ASDAI at Weeks 12 and 52, 
change from Baseline in SI joint SPARCC score at Week 12, the nu mber of subjects without 
relevant changes to background medication, change from Baseline  in ASQoL at Week 52, 
change from Baseline in nocturna l spinal pain (NRS) at Week 52,  and the number of subjects 
with AU or new AU flares through Week 52.
Change #2
Section 3.3 Other objectives
The other objectives of the study are to assess the effect of C ZP on the following: 
x Spinal mobility
x Total and nocturnal spinal pain (NRS)mbermber
eline inline in
seline seline
itis (Aitis (ACOPYchch
and 5and 
int Spnt Sp
o
This documentThe he 
xxcannot #2#2
ion 3.3on 3.3
ototbe 22usedselinelin
ew AUw Atobacba
nenesupport S404
eeks 12eks 1
in SI jn SI 
ackgckanycy vcy v
0 res0 resmarketing AUAU
added:dded
y whery wh
varvaauthorizationpondypond
of subf sub
n Ankn Ank
e in noin no
U) orU) oapplicationActiActi
ary effiry eff
ge frome from
52, cha2, ch
yloland tivivany extensionsAnkynky
in BAn BA
ConsoConso
levantevantor kyloylovariations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 231 of 255Has been changed to:
The other objectives of the study are to assess the effect of C ZP on the following: 
x Spinal mobility
x Total spinal pain (NRS)
Change #3
Section 4.1.1 Primary efficacy variable
x ASDAS-MI at Week 52
Has been changed to:
x ASDAS-MI at Week 52
The primary efficacy variable for Canada (and any other country  where applicable or where 
requested by Regulatory Authorities) is the ASAS40 response at Week 12.
Change #4
The subsection for “other effica cy variables” was moved down an d the header was 
corrected from Section 4.1.2 to Section 4.1.3.
Section 4.1.3 Other efficacy variablesAnd the following variables were removed from the list of other  efficacy variables:
x Nocturnal spinal pain (NRS) 
x Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) 
Change #5
The subsection for “secondary efficacy var iables” was moved up and the header was 
corrected from Section 4.1.3 to Section 4.1.2.
Section 4.1.2 Secondary efficacy variables
And the following variables were  added to the list of secondary  efficacy variables:
x Change from Baseline in ASQoL at Week 52
x Change from Baseline in ASQoL at timepoints other than Week 52
x Change from Baseline in nocturnal spinal pain (NRS) at Week 52
x Number of subjects with AU or new AU flares through Week 52 
And a new paragraph has been added:
For Canada (and any other country where applicable or where req uested by Regulatory 
Authorities), the secondary efficacy variables are:
x ASAS40 response at Week 52
x ASDAS-MI at Week 52 
x Change from Baseline in BASFI at Weeks 12 and 52REDACTEDfromfrom
sing Sping SCOPY mtm
This document ndnd
ForFor
Acannot umbermber
d a nd a nbee froe frousedom Bam Batoaselasesupport fficfic
iables ables
elilinenany SS
cacycacmarketing p
fficacyficac
SectiSecauthorization the lihe li
pondyondyapplication own anwn aand 11anyplicpli
2.2.extensions cabcabor variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 232 of 255x Change from Baseline in BASDAI at Weeks 12 and 52
x Change from Baseline in SI joint SPARCC score at Week 12
x Number of subjects without relevant changes to background medic ation
x Change from Baseline in ASQoL at Week 52
x Change from Baseline in ASQoL at timepoints other than Week 52
x Change from Baseline in nocturnal spinal pain (NRS) at Week 52
x Number of subjects with AU or new AU flares through Week 52 
Change #6
Section 4.3 Immunological variables
Anti-CZP antibody (anti-CZP Ab) concentrations will be assessed  at Baseline and Weeks 1, 2, 4, 
12, 24, 36, 52/WD, and the FU visit (8 weeks after the Week 52/W D visit). In addition, the 
anti-CZP Ab concentrations will be assessed in subjects who wit hdraw from study drug and 
transition to open-label CZP. 
The number and percent of subjects with anti-CZP Ab concentrati ons above 2.4 units/mL will be 
reported as follows: 
x Number and percentage of subjects with anti-CZP Ab >2.4 units/m L at the time of each visit
x Number and percentage of subjects with anti-CZP Ab >2.4 units/mL  at any visit during 
treatment (not including posttreatment withdrawal or FU visits)
x Number and percentage of subjects with anti-CZP Ab >2.4 units/mL  at any visit including 
posttreatment withdrawal or FU visits
Has been changed to:
Anti-CZP antibody/anti-drug antibody (anti-CZP Ab/ADAb) concent rations will be assessed at 
Baseline and Weeks 1, 2, 4, 12, 24, 36, 52/WD, and the FU visit  (8 weeks after the Week 52/WD 
visit). In addition, the anti-CZP Ab concentrations will be ass essed in subjects who withdraw 
from study drug and transition to open-label CZP. 
Determination of ADAb will be done using a validated screening,  confirmation and titration 
ADAb bridging assay, with potenti al further characterization by  a neutralizing antibody assay. 
The immunogenicity data will be processed according to dedicate d Bioanalytical Analysis plans.
Change #7
Section 9.1.11 MOS Sleep Scale
Paragraph 2, second sentence:
The frequency with which each problem has been experienced duri ng the previous 4 weeks is 
rated on a 6- point scale ranging from “none o f the time” to “all of the time ,” except sleep 
quantity, which is reported in hours. REDACTED antiantiC
nt withnt with
cts witcts wi
visvisCOPY CZPCZP
This documentParagPara
TTcannot e #7#7
tion 9ion 9be ogegusedAA
g assaassa
genicenictoADAADAsupport 121
ti-CZPCZP
ransitioansiti
banyntibontib
2, 242, 2marketing ith h 
sitsts
ododauthorizationAb Ab 
CZP ACZP 
hdrawhdraw
hantantapplication ntrationtratio
>2and isitsi
aw froaw froanyline line
t). Int). extensions eaor variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 233 of 255Has been changed to:
The frequency with which each problem has been experienced duri ng the previous 4 weeks is 
rated on a 5-point s cale ranging from “none of the time” to “all of the time,” exce pt sleep 
quantity, which is reported in hours. 
Change #8
Section 10  Assessment of pharmacok inetics, exploratory biomark ers, and 
pharmacogenomics variables
Paragraph 2
These plasma samples may be used for possible analyses of explor atory biomarkers, selected 
from the following list: MMP-3, BMP-2, -4 and -7, WNT1, WISP, Gr emlin, DKK1, Sclerostin, 
Hedgehog proteins (Shh, Ihh, Dhh), Collagen turnover/cleavage p roducts, collagen type X, 
VEGF, citrullinated vimentin fragments, cytokines: IL13, IL17 A  and F, IL23, IL34, (TGF- β, 
M-CSF, GM-CSF, CSF-1, sCSF1r levels. The results of the analyse s of CZP and its constituent 
moieties from alternative methods may be reported separately.
Has been changed to:
These plasma samples may be used for possible analyses of explo ratory biomarkers which might 
include, but are not limited to:  MMP-3, BMP-2, -4 and -7, WNT1, WISP, Gremlin, DKK1, 
Sclerostin, Hedgehog proteins (Shh, Ihh, Dhh), Collagen turnove r/cleavage products, collagen 
type X, VEGF, citrullinated vimentin fragments, cytokines: IL13 , IL17 A and F, IL23, IL34, 
(TGF- β, M -CSF, GM-CSF, CSF-1, sCSF1r levels. The results of the analyses  of CZP and its 
constituent moieties from alte rnative methods may be reported s eparately.
Change #9
Section 11 ASSESSMENT OF IMMUNOGENICITY VARIABLES
Plasma samples for the measurement of anti-CZP antibodies will be taken at Baseline and 
Weeks 1, 2, 4, 12, 24, 36, 52/WD, and the FU visit (8 weeks after  the Week 52/WD visit). 
The number and percent of subjects with anti-CZP concentrations  above 2.4 units/mL will be 
reported as follows: 
x At the time of each visit 
x At any visit during treatment (not  including posttreatment with drawal or FU visits)
x At any visit including posttreatment withdrawal or FU visits
The sampling, handling, and shipment of samples will be perform ed as detailed in the Laboratory 
Manual.
Has been changed to:
Plasma samples for the measurement of anti-CZP antibodies and p otentially neutralizing 
antibodies will be taken at Baseline and Weeks 1, 2, 4, 12, 24, 3 6, 52/WD, and the FU visit 
(8 weeks after the Week 52/WD visit). 
The sampling, handling, and shipment of samples will be perform ed as detailed in the Laboratory 
Manual.REDACTEDnts, cnts, 
r lever leve
ethodsethodCOPYsee
and and --7
CollagCollag
c
This document HasHascannot yy
ampliampli
nual.nual.bevisitvisiused it durt durtoeachachsupportof subf sub
vanyWD, aWD, 
jmarketing MUNOMUNO
ment oent oauthorizationgen tugen t
ytokintokin
els. Ths. Th
s maymayapplication fe x p l o rexplo
7, WN, WN
urand f CfCanyL23,L23
CZP CZP extensions rs, seles, sele
KK1, SK1, S
ollagenlagen
3I3or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 234 of 255Change #10
Section 14.1 Definition of analysis sets
Paragraph 4:
The Full Analysis Set (FAS) wil l consist of all subjects in the  RS who have received at least 
1 dose of study medication and who have a valid Baseline efficac y measurement for ASDAS. 
Has been changed to:
The Full Analysis Set (FAS) will consist of all subjects in the  RS who have received at least 
1 dose of study medication. 
Change #11
Section 14.2 General statistical considerations
All efficacy analyses will be pe rformed using the FAS. The PPS will be used for a sensitivity 
analysis on the primary endpoint only. 
The statistical analysis of the  primary efficacy variable and s elected secondary efficacy variables 
will account for multiplicity by using a fixed sequence testing  procedure. The predefined order 
of hypothesis testing, each at a 2-sided 0.05 significance level  for the comparison between 
CZP 200mg Q2W and placebo, will be p erformed in the sequence sho wn below. After the first 
test, each subsequent test is performed only if the previous te st is significant in favor of CZP at 
the 2-sided 0.05 level. Note that the first test relates to the  primary efficacy variable while the 
others provide the sequence testing for selected secondary effi cacy variables.
1. ASDAS-MI response at Week 52 
2. ASAS40 response at Week 12 
3. Change from Baseline in BASDAI at Week 12
4. Change from Baseline in BASFI at Week 12 
5. ASAS40 response at Week 52
6. Change from Baseline in BASDAI at Week 52
7. Change from Baseline in BASFI at Week 52
8. Change from Baseline in SI joint SPARCC score at Week 12
Variables evaluated over time will be summarized using imputed and observed case values. 
Further details on data summari zation will be provided in the S AP.
Has been changed to:
All efficacy analyses will be pe rformed using the FAS. The PPS will be used for a sensitivity 
analysis on the primary endpoint only. 
The statistical analysis of the  primary efficacy variable and s elected secondary efficacy variables 
will account for multiplicity by using a fixed sequence testing  procedure. The predefined order 
of hypothesis testing, each at a 2-sided 0.05 significance leve l for the comparison between 
CZP 200mg Q2W and placebo, will be p erformed in the sequence sho wn below. After the first 
test, each subsequent test is performed only if the previous te st is significant in favor of CZP atREDACTEDelateelat
ected sected sCOPYn the n the
e prev prev
eses
This documentAll eAll e
anancannodetadeta
s beenbeenbevalualu
ailailusedm Bam Ba
uaatoaselasesupport eekek
ine in Bne in 
elinelinany ASFAS
k 52k5marketing AI at WAI at 
SFI aFIauthorizationviousous
s to thto th
secondecondapplicationed sd s
proceduroced
el for tel for 
sequenequen
st estand secsecanysed fsed extensions for easavariations ast stthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 235 of 255the 2-sided 0.05 level. Note that the first test relates to the  primary efficacy variable while the 
others provide the sequence testing for selected secondary effi cacy variables.
1. ASDAS-MI response at Week 52 
2. ASAS40 response at Week 12 
3. Change from Baseline in BASDAI at Week 12
4. Change from Baseline in BASFI at Week 12 
5. ASAS40 response at Week 52
6. Change from Baseline in BASDAI at Week 52
7. Change from Baseline in BASFI at Week 52
8. Change from Baseline in SI joint SPARCC score at Week 12
9. Change from Baseline in ASQoL at Week 52
10. Change from Baseline in nocturnal spinal pain (NRS) at Week 52
11. Number of subjects with AU or new AU flares through Week 52
Hierarchical testing of efficacy variables for Canada and any o ther country where applicable:  
1. ASAS40 response at Week 12 
2. ASDAS-MI response at Week 52  
3. Change from Baseline in BASDAI at Week 12
4. Change from Baseline in BASFI at Week 12 
5. ASAS40 response at Week 52
6. Change from Baseline in BASDAI at Week 52
7. Change from Baseline in BASFI at Week 52
8. Change from Baseline in SI joint SPARCC score at Week 12
9. Change from Baseline in ASQoL at Week 52
10. Change from Baseline in nocturnal spinal pain (NRS) at Week 52
11. Number of subjects with AU or new AU flares through Week 52
Variables evaluated over time will be summarized using imputed and observed case values. 
Further details on data summari zation will be provided in the S AP.
Change #12
Section 14.3 Planned efficacy analyses
A new paragraph 4 has been added
For Canada (and any other country where applicable or where req uested by Regulatory 
Authorities), the primary efficacy variable measurement is the ASAS40 response at Week 12.REDACTED AI at WAI at W
ataCOPY ada anada a
CO
This document urtrt
ChaChcannot berbe
ables ebles e
ther her be er of er ofused BaBa
om Bom Boaselasesupporte in BAin B
eline line inin
ianyASDASD
Amarketing We
t WeekWeek
DAauthorization nd ad an
eek eek application ek 52k 52
any anyand 22any extensions or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 236 of 255Analysis of the ASAS40 response at Week 12 will be performed as  described above for 
ASDAS-MI response at Week 52. Simil ar to the ASADAS-MI efficacy  endpoint, the ASAS40 
will be treated as a composite endpoint when it is analyzed. Sp ecifically, subjects will need 
to: 1) achieve the relevant response (ASAS40); and 2) remain in t he study and on their 
randomized double-blind study treatment through Week 12.
Paragraph 5 has been revised:
Subgroup analyses by age, gender, race, symptom duration, smoki ng history, HLA-B27 
genotype, anti-CZP Ab status, region, prior anti-TNF exposure, and MRI/CRP classification 
(MRI+/CRP+; MRI+/CRP-; MRI-/CRP+) will be performed for the prim ary efficacy variable. 
Subgroup analyses will be summarized using descriptive statisti cs only.
Has been changed to:
Subgroup analyses by age, gender, race, symptom duration, smoki ng history, HLA-B27 
genotype, anti-CZP Ab (ADAb) status, region, prior anti-TNF exp osure, Baseline SPARCC 
score ≥5, and MRI/CRP classification (MRI+/CRP+; MRI+/CRP -; MRI-/CRP+) will be 
performed for the primary efficacy variable. Subgroup analyses will be summarized using 
descriptive statistics only.
Change #13
Section 14.4 Secondary efficacy analyses
The changes from Baseline in BASDAI and BASFI at Week 12 and We ek 52 are specified as 
secondary efficacy variables. As these are continuous variables , missing data must be handled 
using a different approach from what is specified for the prima ry efficacy endpoint (a responder 
variable). In the current study, Investigators will be given di scretion to discontinue the 
double-blind study treatment for subjects not responding in ord er to provide them with 
alternative therapy to treat t he condition. Therefore, in many cases, missing efficacy data due to 
the double-blind study treatment discontinuation should be depe ndent on the observed efficacy 
scores, but independent of unobserved data. This would be consi stent with a missing at random
(MAR) assumption. However, the  possibility of discontinuation d ue to tolerability or other 
unobserved data cannot be completely discounted. Therefore, a m issing not at random 
mechanism will be used for the a nalysis of continuous secondary  efficacy variables.
A reference-based multiple imputation (MI) procedure will be us ed for this analysis, which will 
impute missing data as well as data at the time points followin g the discontinuation of the 
double-blind study treatment for bot h the CZP and placebo group s. This procedure will use an 
imputation model developed based on available data from the pla cebo group, thereby assuming a 
placebo trajectory for missing data following study treatment d iscontinuation for subjects in both 
treatment groups (Mallinckrodt, 2013). The estimand being evalua ted in this case is the 
difference in the outcome of improvement in all randomized subj ects at the planned endpoint, 
attributable to the initially randomized medication. This is an  effectiveness estimand of the de 
facto hyp othesis which has been referred to as “estimand 6” (Mallinckrod t, 2012).
Additionally, change from Baselin e in SI joint SPARCC score at Week 12 is a continuous 
secondary efficacy variable. The  same MI procedure specified as  the main analysis approach for 
BASDAI and BASFI will be used to account for missing SPARCC dat a. However, it should be 
noted that, unlike BASDAI and BASFI, SPARCC score will not be m easured at any time points REDACTEDBASFBAS
contincontin
specifspeci
tigatortigato
bjectbjecCOPY FIFI
This documentdiffediffe
attrattcannot on mn 
bo trajo tra
atmentmenbe d stst
momoused d mm
g datadata
studtudomulmulsupport ver,er
be come co
ed for ed for
ianybservbser
, thethmarketing rs ws 
cts not s not 
tion. Tion. T
discontdiscon
veauthorization I at Wat W
nuousuous
ified fied ff
wilwilapplication ill bll bandMRIRI--//
be beany y, y,
BaselBase
CRCextensions var
, HLHLorriabriabvariations on on thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 237 of 255between Baseline and Week 12, meaning that those are the only 2  time points that can be 
considered in the evaluation of S PARCC score at Week 12. Compar isons between treatment 
groups will be made using an ana lysis of covariance (ANCOVA) mo del on the imputed data set. 
The model will include Baseline score, treatment group, region,  and MRI/CRP classification. 
The ASAS40 response at Week 12 and Week 52 are responder second ary efficacy endpoints.  As 
a responder variable, ASAS40 will be analyzed using logistic re gression based on a model 
similar to the one described for the primary analysis. As with the primary efficacy endpoint, the 
ASAS40 will be treated as a compos ite endpoint when it is analy zed. Specifically, subjects will 
need to 1) achieve the relevant  response (ASAS40) and 2) remain  in the study and on their 
randomized double-blind study treatment through the time point being analyzed (Week 12 or 
Week 52).
The comparison of CZP 200mg Q2W to placebo as described above f or the ASAS40 response, 
BASDAI, and BASFI at Week 12 and Week 52 and for SI joint SPARC C score at Week 12 will 
be part of the fixed sequence testing procedure outlined in Sec tion 14.2.
Additionally, sensitivity ana lyses will be conducted on these s econdary efficacy endpoints. In 
particular, the assumptions related to missing data will be inv estigated further. These analyses 
are described in Section 14.8.
An additional secondary efficacy variable is the number of subj ects with relevant changes to 
background medication. This variable will be based on whether o r not subjects take certain 
pre-specified background medications during the course of the s tudy and will be defined in the 
SAP. The analysis for this variable will use the same logistic regression model described for the 
primary variable. 
Has been changed to:
The changes from Baseline in BASDAI and BASFI at Week 12 and We ek 52, change from 
Baseline in ASQoL at Week 52, and change from Baseline in noctu rnal spinal pain at 
Week 52are specified as secondary efficacy variables. As these a re continuous variables, missing 
data must be handled using a differ ent approach from what is sp ecified for the primary efficacy 
endpoint (a responder variable). I n the current study, Investig ators will be given discretion to 
discontinue the double-blind study treatment for subjects not r esponding in order to provide them 
with alternative therapy to tre at the condition. Therefore, in many cases, missing efficacy data 
due to the double-blind study tre atment discontinuation should be dependent on the observed 
efficacy scores, but independent of unobserved data. This would  be consistent with a missing at 
random (MAR) assumption. However, the possibility of discontinu ation due to tolerability or 
other unobserved data cannot be completely discounted. Therefor e, a missing not at random 
mechanism will be used for the a nalysis of continuous secondary  efficacy variables.
A reference-based multiple imputation (MI) procedure will be use d for this analysis, which will 
impute missing data as well as data at the time points followin g the discontinuation of the 
double-blind study treatment for  both the CZP and placebo group s. This procedure will use an 
imputation model developed based on available data from the pla cebo group, thereby assuming a 
placebo trajectory for missing data following study treatment d iscontinuation for subjects in both 
treatment groups (Mallinckrodt , 2013). The estimand being evalu ated in this case is the 
difference in the outcome of improvement in all randomized subj ects at the planned endpoint, REDACTEDthe che 
the sathe saCOPYmber mber
ed on ed on
coco
This document  rere
impimp
ddcannotobsobs
anismanism
eferferbeARAR
servserused blbl
s, but , but 
R) aR) ato rapp
blindlindsupportiableable)
blind blind
py to py to any aryary
differdiffer
)marketing AI andAI and
nd chand cha
ry effye fauthorizationn whwh
ourse ourse o
ame lome lapplicationigatedgated
of subjef subj
hethhethand ary eary e
dany cocoextensionseek 1ek 1
ASAS4SAS4
ore oreor eir eir 
22variations he he 
s will will thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 238 of 255attributable to the initially randomized medication. This is an  effectiveness estimand of the de 
facto hypothesis which has been referred to as “estimand 6” (Ma llinckrodt, 2012).
Additionally, change from Baselin e in SI joint SPARCC score at Week 12 is a continuous 
secondary efficacy variable. The  same MI procedure specified as  the main analysis approach for 
BASDAI and BASFI will be used to account for missing SPARCC dat a. However, it should be 
noted that, unlike BASDAI and BASFI, SPARCC score will not be m easured at any time points 
between Baseline and Week 12, meaning that those are the only 2  time points that can be 
considered in the evaluation of S PARCC score at Week 12. Compar isons between treatment 
groups will be made using an ana lysis of covariance (ANCOVA) mo del on the imputed data set. 
The model will include Baseline score, treatment group, region,  and MRI/CRP classification. 
The ASAS40 response at Week 12 and Week 52 are responder seconda ry efficacy endpoints. 
(For Canada and any other country where applicable or where req uested by Regulatory 
Authorities, the ASAS40 response at Week 12 is the primary effi cacy variable; the ASAS40 
response at Week 52 and the ASDAS-MI response at Week 52 are se condary efficacy variables). 
As a responder variable, ASAS40 will be analyzed using logistic  regression based on a model 
similar to the one described for the primary analysis. 
The number of subjects with new  onset post-Baseline AU or new A U flares through Week 52 is 
a categorical secondary efficacy endpoint for all regions. Subj ects with a new event at one or 
more visits post-Baseline will be  classified as having had a fl are, subjects without new events at 
all visits post-Baseline will be  classified as not having had a  flare. As a dichotomous outcome 
variable, treatment groups will be compared for differences usi ng logistic regression based on a 
model similar to the one descri bed for the primary analysis.
The comparison of CZP 200mg Q2W to placebo as described above f or the ASAS40 response, 
BASDAI, and BASFI at Week 12 and Week 52, for SI joint SPARCC s core at Week 12, for 
ASQoL at Week 52, nocturnal pain score at Week 52, and number o f subjects with AU or new 
AU flares through Week 52 will be pa rt of the fixed sequence te sting procedure outlined in 
Section 14.2.
Additionally, sensitivity ana lyses will be conducted on these s econdary efficacy endpoints. In 
particular, the assumptions related to missing data will be inv estigated further. These analyses 
are described in Section 14.8.
An additional secondary efficacy variable is the number of subj ects with relevant changes to 
background medication. This variable will be based on whether o r not subjects take certain 
pre-specified background medications during the course of the s tudy and will be defined in the 
SAP. The analysis for this variable will use the same logistic regression model described for the 
primary variable. 
Change #14
Section 14.5 Other efficacy analyses
Paragraph 2: 
The following variables were removed from the list of other eff icacy variables
x Nocturnal spinal pain (NRS) 
x Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) REDACTEDfor difor d
primaprima
W to plato pl
nd Wnd WCOPY ons.ons
ng hadng ha
avingaving
This documentChanha
SeSecannothe ane an
ary varry va
angangbeed bd b
anaanaused conon
medicatedicat
bacbacto ndarndasupportalysalys
ons relans rel
on 14.n 14.any yses sesmarketingWeek 5Week 
core atcore a
e part opartauthorizationad 
g hadg had
ifferenfferen
ary anary an
ceboceboapplication new AUew A
ubjectsubjec
a flaa flaandressioessioany blebl
dary edary extensionsificatfica
cy endy end
Regulategula
le; te; todatdat
titivariations nt nt 
tatathereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 239 of 255Change #15
Section 14.6.2  Pharmacokinetic and immunogenicity variable ana lysis
Certolizumab pegol plasma concentrations will be tabulated and summarized by treatment group 
(overall and by anti-CZP Ab level - above or below 2.4 units/mL within each treatment group) 
for each visit at which samples were taken using the geometric m ean, geometric coefficient of 
variation, 95% CIs, arithmetic mea n, arithmetic SD, minimum and  maximum, geomean plasma 
concentration time curves wit h their 95% CI will be plotted ove rall and by anti-CZP Ab status. 
Individual plasma concentrations for CZP and anti-CZP levels ve rsus time will be produced on 
the same graph.
The number and percent of subj ects with titer above 2.4 units/m L will be presented for each visit, 
at any visit during treatment (not  including posttreatment with drawal or FU visits) and at any 
visit including posttreatment withdrawal or FU visits. For the subjects with at least 
1 anti-CZP Ab titer above 2.4 units /mL, the first timepoint of oc currence of the titer above 
2.4 units/mL will also be displayed.
In addition, safety and efficacy profiles by anti-CZP Ab level will be investigated.
Has been changed to:
Certolizumab pegol plasma concentrations will be tabulated and summarized by treatment group 
for each visit at which samples were taken using the geometric mean, geometric coefficient of 
variation, 95% CIs, arithmetic mea n, arithmetic SD, minimum and  maximum. Individual plasma 
concentrations for CZP and anti-CZP levels versus time will be produced on the same graph.
Immunogenicity will be assessed through listing of individual re sults by subject and summary 
tables. Immunogenicity data will be correlated with PK and effi cacy readout. In addition, 
immunogenicity will be correlated with possible safety findings .
Change #16
Section 14.8 Handling of dropouts or missing data
For analysis purposes, the primary efficacy variable is defined  as a composite endpoint in which 
it is necessary to achieve ASDAS-MI at Week 52 and to remain on  randomized double-blind 
study treatment through Week 52 in order to be considered a res ponder (see Section 14.3). 
Because this composite endpoint definition does not allow for a  missing response status, no 
formal method for handling missing data is needed in the primar y efficacy analysis. However, in 
order to assess the impact of various missing data assumptions on the analysis, additional 
sensitivity analyses of the primary efficacy variable will be p erformed as follows:
x Including observed data at Week 52: The observed data at Week 5 2 will be used and 
analyzed according to randomized treatment, regardless of wheth er or not the subject is still 
on his/her randomized double-blind study treatment at that time . Despite efforts to continue 
to collect data on all subjects (even if they discontinue the d ouble-blind study treatment), 
there may still be subjects w ith missing data at Week 52. Such subjects will be considered as 
non-responders in accordance with the composite endpoint defini tion outlined above. The 
same logistic regression model sp ecified for the primary analys is will be used.
x MI: The Markov Chain Monte Carlo (MCMC) method will be used to i mpute intermittent 
missing data. The resulting multiply imputed data sets will be monotone missing and will be c Sc S
versuversu
gh listigh list
correlcorrel
withwithCOPYbulabula
the geothe g
SD, SD
This document ocannot y ay 
ncludincludi
analanalbe ess
analanalusedpop
for hfor h
s thes thetoositeositsupporprimprim
e ASDe ASD
gh Wegh Wanyopoopo
marmamarketing lateate
h possibpossi
outouauthorization omom
minimmini
us tims tim
ting ofng of
ted wed wapplication be be
ed and d and
metrimetrand e invinanyof thof thextensions d for ed for e
its) anits) an
at leasleas
hhor variations us. s. 
ed ond onthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 240 of 255imputed using monotone regression (assuming a MAR pattern). Not e that the MI procedure 
will be done on the continuous ASDAS  variable, which will be dic hotomized for the logistic 
regression analysis. Ankylosing Spondylitis Disease Activity Sc ore data collected following 
the discontinuation of double-blind study treatment will be tre ated as missing in the original 
data set for this sensitivity analysis.
x Tipping point analysis: In this analysis, various assumptions w ill be made about average 
outcomes among the subsets of subjects who prematurely disconti nued double-blind study 
treatment. Various “delta adjustments” will be made to the assu med responses among 
missing data in each treatment arm with varying degrees of plau sibility (O’Kelly, 2014). The 
goal of the tipping point analysis is to identify assumptions a bout the missing data under 
which the conclusions change, ie, under which there is no longe r evidence of a treatment 
effect. Then, the plausibility of such assumptions would be dis cussed. Further details of this 
procedure will be described in the SAP.
x Observed case analysis: This analysis will only include the obs erved data for subjects still on 
the original double-blind study treatment. Data collected after  the discontinuation of 
double-blind study treatment a nd all other missing data will be  excluded from the analysis. 
The same logistic regression model specified for the primary ef ficacy analysis will be 
performed.
The sensitivity analyses of the secondary binary efficacy varia bles (ASAS40 at Weeks 12 and 
52) will be as follows:
x Including observed data at Week 52: As described for the primar y efficacy variable.
x MI: As described for the primary efficacy variable. Note that a s ASAS40 is a composite of 
4 different variables, the MI procedure will be performed on eac h of these components, and 
the ASAS40 response will be derived based on the multiply imput ed datasets.
x Reference-based MI: This procedure will impute missing data as well as data at the time 
points following the discontinuation of the double-blind study treatment for both the CZP 
and placebo groups. This procedure will use an imputation model  developed based on data 
from the placebo group (Mallinckrodt, 2013). The estimand being  evaluated in this case is 
the difference in the outcome of improvement in all randomized subjects at the planned 
endpoint, attributable to the initially randomized medication, which has been referred to as 
“estimand 6” (Mallinckrodt, 2012). 
x Observed case analysis: As described for the primary efficacy v ariable.
The sensitivity analyses of secondary continuous efficacy varia bles (the change from Baseline in 
BASDAI and BASFI at Weeks 12 and 52 a nd the change from Baselin e in the SI joint SPARCC 
score at Week 12) will be as follows:
x Including observed data at Week 52: As described for the primar y efficacy variable.
x MI: As described for the primary efficacy variable.
x Observed case analysis: As described for the primary efficacy v ariable.
x LOCFREDACTED s descs desc
fficacfficac
cedurcedur
iiCOPY fficacyficacy
This document oror
xxcannositivitiv
DAI aDAI a
re ate atbe d c
vitvitused” (M(M
casecasetoutabutab
MalMalsupports ps p
up (Map (M
he outce out
able bleanyinuainu
proceprocemarketingre wie wi
ved based bas
cedurecedur
uatiuatauthorization y vy
cribedribed
cy variy vari
willwillapplicatione excex
ry efficy eff
variavariaande discdisc
xclxclany data fdata extensionsta una un
a treattreat
her deher deo14)14)
ddvariations y y
)T)thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 241 of 255Missing data for the other efficacy variables described in Sect ion 14.5 will be handled as 
follows:
x With imputation: Non-responder imputation for binary variables and LOCF for continuous 
variables (as described in Section 14.5) 
x Observed case analysis: As described for the primary efficacy v ariable.
Additionally, algorithms for imputing missing or partial dates for safety evaluations will be 
detailed in the SAP.
Has been changed to: 
For analysis purposes, the primary efficacy variable is defined  as a composite endpoint in which 
it is necessary to achieve ASDAS-MI at Week 52 and to remain on  randomized double-blind 
study treatment through Week 52 in order to be considered a res ponder (see Section 14.3). 
Because this composite endpoint definition does not allow for a  missing response status, no 
formal method for handling missing data is needed in the primar y efficacy analysis. However, in 
order to assess the impact of various missing data assumptions on the analysis, additional 
sensitivity analyses of the primary efficacy variable will be p erformed as follows:
x Including observed data at Week 52: The observed data at Week 52  will be used and 
analyzed according to randomize d treatment, regardless of wheth er or not the subject is still 
on his/her randomized double-blind study treatment at that time . Despite efforts to continue 
to collect data on all subjects (even if they discontinue the d ouble-blind study treatment), 
there may still be subjects w ith missing data at Week 52. Such subjects will be considered as 
non-responders in accordance with the composite endpoint defini tion outlined above. The 
same logistic regression model sp ecified for the primary analys is will be used.
x MI: The Markov Chain Monte Carlo (MCMC) method will be used to i mpute intermittent 
missing data. The resulting multiply imputed data sets will be monotone missing and will be 
imputed using monotone regression (assuming a MAR pattern). Not e that the MI procedure 
will be done on the continuous ASDAS  variable, which will be di chotomized for the logistic 
regression analysis. Ankylosing Spondylitis Disease Activity Sc ore data collected following 
the discontinuation of double-blind study treatment will be trea ted as missing in the original 
data set for this sensitivity analysis.
x Tipping point analysis: In this analysis, various assumptions w ill be made about average 
outcomes among the subsets of subjects who prematurely disconti nued double-blind study 
treatment. Various “delta adju stments” will be made to the assu med responses among 
missing data in each treatment arm with varying degrees of plau sibility (O’Kelly, 2014). The 
goal of the tipping point analysis is to identify assumptions a bout the missing data under 
which the conclusions change, ie, under which there is no longe r evidence of a treatment 
effect. Then, the plausibility of such assumptions would be dis cussed. Further details of this 
procedure will be described in the SAP.
x Observed case analysis: This analysis will only include the obs erved data for subjects still on 
the original double-blind study treatment. Data collected after  the discontinuation of 
double-blind study treatment and a ll other missing data will be excluded from the analysis. 
The same logistic regression model specified for the primary ef ficacy analysis will be 
performed.discdis
data adata a
he come com
ecifiedecifie
arlarCOPYgardlegardl
atmenatmen
sconsco
This documentecannotsing ng 
oal ofal of
whicwhicbeent. Vent. V
gd agdusedt anan
amonmon
VaVato nalynalsupportkylokylo
f doubf dou
nsitivinsitivianyuous uous
losinosmarketing loo(MC(MC
tiply imiply i
essionssion
Aauthorizationnt at at
ontinuentinue
at Wet We
mposimposi
d for for applicationormedormed
at Weeat We
ss of wss of 
tt h att h aand cacyac
e anae ana
ddanyesponespo
cy anyaextensions point ioint 
dodoubub
SectioSectio
onor variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 242 of 255Sensitivity analyses of the primary efficacy variable for Canad a (and any other country where 
applicable or where requested by Regulatory Authorities), ASAS4 0 response at Week 12, will 
mirror the approach describe d above for ASDAS-MI at Week 52. 
The sensitivity analyses of the secondary binary efficacy varia bles (ASAS40 at Week 52) will be 
as follows:
x Including observed data at Week 52: As described for the primary  efficacy variable.
x MI: As described for the primary efficacy variable. Note that a s ASAS40 is a composite of 
4 different variables, the MI procedure will be performed on eac h of these components, and 
the ASAS40 response will be derived based on the multiply imput ed datasets.
x Reference-based MI: This procedure will impute missing data as well as data at the time 
points following the discontinuation of the double-blind study treatment for both the CZP 
and placebo groups. This procedure will use an imputation model  developed based on data 
from the placebo group (Mallinckrodt, 2013). The estimand being  evaluated in this case is 
the difference in the outcome of improvement in all randomized subjects at the planned 
endpoint, attributable to the initially randomized medication, which has been referred to as 
“estimand 6” (Mallinckrodt, 2012). 
x Observed case analysis: As described for the primary efficacy v ariable.
For the secondary efficacy variable “number of s ubjects with AU or new AU flares through 
Week 52,” missing values should only occur in the unlikely case  that a subject does not have any 
post-Baseline AU assessments performed. Therefore, sensitivity analyses for this variable will 
focus on analyses adjusting for exposure time at risk such as e vent rate, incidence rate, and 
confidence interval.
The sensitivity analyses of secondary continuous efficacy varia bles (the change from Baseline in 
BASDAI and BASFI at Weeks 12 and 52, a nd the change from Baseli ne in the SI joint SPARCC 
score at Week 12, change from Baseline in ASQoL at Week 52, and  change from Baseline in 
nocturnal spine pain at Week 52) will be as follows:
x Including observed data at Week 52: As described for the primar y efficacy variable.
x MI: As described for the primary efficacy variable.
x Observed case analysis: As described for the primary efficacy v ariable.
x LOCF
Missing data for the other efficacy variables described in Sect ion 14.5 will be handled as 
follows:
x With imputation: Non-responder imputation for binary variables and LOCF for continuous 
variables (as described in Section 14.5) 
x Observed case analysis: As described for the primary efficacy v ariable.
Additionally, algorithms for imputing missing or partial dates for safety evaluations will be 
detailed in the SAP.REDACTEDn thn th
TherefTheref
e time time
ycycCOPYmarymar
ubjectubjec
he uhe u
This documentWcannotdatdat
ws:s:
WiWibe ata fata fused se ane ato analanasupportata at Wa at 
for thefor theany52) w52) w
Wmarketing continuontinu
and 52,nd 52
aselinaselin
iauthorizationts ws w
unlikeunlike
fore, sfore, s
at risat risapplicationwhichic
fficacyfficac
withwithandsubjeubje
ichchany opop
aluatealuat
textensions a at theat the
or botor bot
pedpedornts, nts,variations te of e of 
anathereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 243 of 255Change #17
Section 14.10 Determination of sample size
A new Paragraph 2 has been added
With Protocol Amendment 4, ASAS40 response at Week 12 was eleva ted to be the primary 
efficacy variable for Canada (and any other country where appli cable or where requested by 
Regulatory Authorities); however, the study was fully enrolled at the time of this amendment. 
The expected responder rates f or ASAS40 response at Week 12 are  also 40% for CZP and 20% 
for placebo, which are identical to the assumed response rates cited for ASDAS-MI at Week 52. 
Therefore, the planned total sample size of 300 would provide 9 5% power for this variable, as 
well.
Change #18
Section 18.8 MOS Sleep Scale Questionnaire
The copy of the 6-point scale questionnaire in Appendix 18.8, wh ich was not used in this study, 
was replaced with the correct 5-point scale questionnaire.
REDACTED COPY 
This document cannot be used to support any marketing authorization application andwas was any nonextensionsriabriabor eeee
bleblevariations 20% 20% 
ek 5ek 5thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 244of 25518.17  Protocol Amendment 5  
Rationale for the amendment
The purpose of this substantial amendment is to gain additional  information about the longer -
term dise ase progress and the effects of CZP treatment in patients with nr-axSpA. To support 
this, several PROs, a lab assessment, and an additional SI join t MRI will be taken at Week 
156/SFE -WD as updated in Table 5‒6. The visit windows for the SFE Period were also clarified.
Additional changes include: 
x An update to other efficacy variables to include the Week 156/S FE-WD timepoint. SFE-
WD added to Week 156 instances when needed to distinguish from Week 52/WD.
x An update to Table 5‒5to remove collection of samples for CZP plasma co ncentration, 
anti-CZP antibodies, and Biomarkers as this is not done for subjects  on alternative 
treatments.
x An update to the subheadings in Section 4.2.2, Section 4.2.3, a nd Section 4.3 to clarify 
categorization of variables .
x An update to Section 4.4 subh eadings to clarify safety variables.
x An update of ASDAS -MD to ASDAS -LD (Machado et al, 2018).
x Minor editorial and administrative changes have been made throu ghout the protocol.
Modifications and changes
Specific changes
Change #1
Study Contact Information  
Clinical Trial Biostatistician  
Name: , MS
Address: 8010 Arco Corporate Drive
Raleigh, NC 27617
United States of America
Phone:
Fax:
Has been changed to:
Clinical Trial Biostatistician  
Name: ,PhD
Address: Alfred-Nobel-Str 10
40789 Monheim  REDACTED gCOPYMachMach
es haes ha
This document Has as
ClCcannotFax:Fax:t
nnnn
s bebebe one:ne:bused usto suppor80180po
sutort any anyamarketing authorizationave beave beapplication variabvariab
ado et ado etandand Sand any SeSextensionsoin
2/WD2/WD
a coa concn
on altn altornt.nt.Svariations d.d.thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 245of 255Germany 
Phone:
Fax:
Change #2
List of abbreviations
The following terms were added or modified:
ASDAS-LD Ankylosing Spondylitis Disease Activity Score low disease
TEAE treatment-emergent adverse event
SFE-FAS Safety Follow-Up Full Analysis Set
Change #3
Section 2.5 Rationale
The addition of the SFE Period will allow collection of long -term safety data from eligible 
subjects on open -label CZP for up to 2 years. During the SFE Period, CZP will be  provided by 
the Sponsor. The treating investigator is requested to apply ro utine, s tandard of care according to 
local standard medical practice and investigator clinical judgm ent. 
Has been changed to:
The addition of the SFE Period will allow collection of long -term safety data from eligible 
subjects on open -label CZP for up to 2 years. In addition, MRI assessment of SI joint structural 
damage and laboratory assessment for CRP will be performed, and data f rom other selected 
efficacy variables will be collected at the end of the SFE Peri od. During the SFE Period, CZP 
will be provided by t he Sponsor. The treating Investigator is requested to apply rou tine, standard 
of care according to local standard medical practice and Invest igator clinical judgment. 
Change #4
Section 4.1.3 Other efficacy variables
The following variables will be analyz ed at scheduled time points through Week 52:
Has been changed to:
The following variables will be a nalyzed at scheduled time poin ts through Week 52 and at Week 
156 for selected variables:
Change #5
Section 4.1.3 Other efficacy variables, bullets 5, 6, 10, and 11
x Change from BASMI linearREDACTED r c
ow coow co
o 2 yeo 2 ye
ororCOPYthe the
to appto a
cliniclini
This document 566cannot n cc
followfollow
 forforbe g
chachaused herer
g varivarito r efre fsupport anydard mdardmarketingears.ars.
CRP wCRP w
at the eat the 
The trThe tauthorization pplp
ical jucal ju
ollectillecti
InInapplication term saterm s
SFE PerFE Pe
ly rouy rouand any extensions ns
s
xtor rr variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 246 of 255x ASDAS disease activity (Ankylosing Spondylitis Disease Activity  Score inactive disease 
[ASDAS-ID], Ankylosing Spondylitis Disease Activity Score moder ate disease 
[ASDAS-MD], Ankylosing Spondylitis Disease Activity Score high disease activity 
[ASDAS-HD], Ankylosing Spondylitis Disease Activity Score very high disease activity 
[ASDAS-vHD]) and clinical improvement (Ankylosing Spondylitis D isease Activity Score 
clinically important improvement [ASDAS-CII], ASDAS-MI)
x Change from Baseline in SI joint SPARCC score at Week 52 and ank ylosing spine MRI 
acuity (ASspiMRI-a) in the B erlin modification at Week 12 and W eek 52
x Proportion of subjects with SI joint SPARCC score <2 at Week 12 and Week 52
Has been changed to:
x Change from Baseline in BASMI linear
x ASDAS disease activity (Ankylosing Spondylitis Disease Activity  Score inactive disease 
[ASDAS-ID], Ankylosing Spondylitis Disease Activity Score low d isease [ASDAS-LD; 
Machado et al, 2018], Ankylosing Spondylitis Disease Activity S core high disease activity 
[ASDAS-HD], Ankylosing Spondylitis Disease Activity Score very high disease activity 
[ASDAS-vHD]) and clinical improvement (Ankylosing Spondylitis D isease Activity Score 
clinically important improvement [ASDAS-CII], ASDAS-MI)
x Change from Baseline in SI joi nt SPARCC score at Week 52 and We ek 156 and ankylosing 
spine MRI acuity (ASspiMRI-a) in the Berlin modification at Wee k 12 and Week 52
x Proportion of subjects with SI joint SPARCC score <2 at Week 12,  Week 52, and Week 156
Change #6
The following text was moved fro m Section 4.4 Safety variables to Section 12 Assessment of 
Safety:
Safety variables to be assessed are physical examinations, AEs,  vital signs, and measurements of 
laboratory parameters. 
Adverse events will be solicite d at every visit, and recorded a nd coded according to the latest 
version of the Medical Dictionary for Regulatory Activities (Me dDRA®) criteria.
Physical examination findings will be recorded in the CRF only at Screening. Clinically 
important abnormal changes in subsequent physical examinations will be recorded as AEs at all 
visits from Baseline to the FU visit.
Clinical laboratory values (hematology, biochemistry, urinalysi s) will be collected and assessed 
at Screening, Baseline, Weeks 2, 4, 8, 12, 24, 36, at the end of  study completion at Week 52/WD 
visit and at the FU visit (8 weeks after the Week 52/WD visit).  In addition, clinical laboratory 
values will be collected and a ssessed at study visits during th e administration of open-label CZP 
in subjects who withdraw from the double-blind study treatment.
Furthermore, CRP will be coll ected and assessed either in a bli nded or open manner at 
Screening, 3 to 5 days before Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and REDACTEDrlin rlin
PARCARCCOPYASDAS
core acore a
mm
This documentat Sct Sc
visviscannotom Bm B
nical lical beabnoabno
BBused edicdi
minatiminatitob
ical icalsupport seded
e solie solany d areda rmarketing om Seom Sauthorizationat Wt W
modificodifi
CC scoCC scoapplicationore verre ve
pondylpondy
ASAS--MIM
Weekeeanddisedis
Scorecoreanyore inore i
seasseaextensions or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 247 of 255at the end of study completion a t Week 52/WD visit and at the F U visit (8 weeks after the 
Week 52/WD visit).
At Screening, all subjects will have an  IGRA test (QuantiFERON®TB test or Elispot®test, when 
the QuantiFERON test indicated i s not available), and a chest x -ray reading (or, if done, 
computed tomography of the chest) which must be reported consis tent with standard clinical 
reporting practice by an experi enced qualified TB specialist, r adiologist, or a pulmonologist, who 
is specifically required to look for signs of active TB or sign s of past/inactive TB infection. A 
chest x-ray will not be done at Screening if a chest x-ray (or computed tomography of the chest) 
was done within 3 months prior to the Screening visit. The offic ial report of the imaging must 
specifically indicate the absence of findings suggestive of cur rent active TB or prior inactive TB. 
In addition to a physical examination done intermittently throu ghout the study, subjects will be 
evaluated at Screening, Baseli ne, and every 12 weeks thereafter  up to Week 36 and including the 
Week 52/WD visit, for signs and symptoms of LTB or active TB in fection and risk factors for 
exposure to TB using the TB questionnaire.
Change #7
The following section was added:
Section 4.4.1 Secondary safety variables
Assessment time points for safety variables are specified in Table 5 ‒1and Table 5 ‒6. The 
secondary safety variables are as follows:
x Incidence of treatment-emergent adverse events (TEAEs)
x Incidence of serious adverse events (SAEs)
x Adverse events leading to withdrawal from investigational medic inal product (IMP)
Change #8
The following section was added:Section 4.4.2 Other safety variables
Other safety variables are assessed as specified in Table 5 ‒1and Table 5 ‒6,and are as follows:
x Change from Baseline in vital signs (blood pressure, temperatur e, and pulse rate)
x Change from Baseline in clinical laboratory values (hematology,  biochemistry, and 
urinalysis)
Physical examination findings considered clinically significant  changes since the physical 
examination completed at the Screening Visit will be recorded a s AEs.
Change #9
Section 5.1.1 Study periods e spe sp
verse verse 
nts (Snts (COPY pecipec
This documentPhysPhys
exexcannotange ange 
urinalurinalbee frofrousedriableable
omomto r sasasupport was adwas a
safetafeany marketingSAESAE
rawal fawal authorization ified ified 
eventevent
EEapplication and any extensionsinactnac
bjectsbjects
6 and iand i
nd risd risomumu
titivariations o 
chest)hest)
ussthereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 248 of 255Starting at Week 64, all subjects  are to visit the site approxim ately every 12 weeks for
assessments. 
The last dosing visit will be at Week 154. The final study asse ssments are performed at 
Week 156.
Has been changed to:
Starting at Week 64, all subjects are to visit the site approxim ately every 12 weeks (±2 weeks) 
for assessments. 
The last dosing visit will be at Week 154. The final study asse ssments are performed at 
Week 156/SFE-WD.
Change #10
Table 5 ‒5Schedule of study assessments –additional assessments for wdt 0 visit required 
for subjects transitioning to alternative treatment 
The CZP-plasma concentration/anti-CZP Abs/Biomarker row was rem oved. The table list of 
abbreviations was updated.
Change #11
Table 5 ‒6Schedule of study assessments –Safety Follow-Up Extension Period
At Week 156 (Visit 40), the following assessments were added: bl ood sample for CRP, 
BASDAI, BASFI, ASQoL, total and nocturnal spinal pain, PGADA, a nd MRI SI joints. The 
table list of abbreviations was updated.
The column header for Visit 40 was updated to 156/104/SFE-WD. T he table list of abbreviations 
was updated.
Change #12
Figure 5 ‒3: Schematic diagram for subjects completing the double-blind st udy treatment
and rolling over to the SFE Period
The label for Week156 was updated to W156/SFE-W104/SFE-WD. The schematic list of
abbreviations was also updated.
Change #13
Section 8.6 SFE Period  (Week 52 to Week 156):
Starting at Week 64, all subjects  are to visit the site approxim ately every 12 weeks for
assessments performed according to local standard medical pract ice, as needed, including:
x Document AEs (Note: any [possible] drug-related AE must be foll owed-up, at least by 
phone.) REDACTED ––SafeSafe
assessassess
d noctud noctu
ededCOPY 
This documentChanha
SeSecannot ioio
angangbe r W
ons wons wusedr to  to 
WeeWeetomaticati
ththsupport ic dicdany marketingurnarn
as updas updauthorization fety Foty F
smentsment
nalnalapplicationaas rems remand orany r wdtwdtextensions or variations )thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 249 of 255x Contact IXRS 
 to register the visit and obtai n next kit number at Weeks 54 an d 56 for subjects receiving 
loading doses of study drug administration at the study site 
 to register the visit and obtain next kit number for subjects r eceiving study drug 
administration at the study site approximately Q12W during the remainder of the study
 to indicate that subject has completed the SFE Period or withdr awn from the study 
(Week156/WD)
Has been changed to:
Starting at Week 64, all subjects  are to visit the site approxim ately every 12 weeks (±2 weeks) 
for assessments performed according to local standard medical pr actice, as needed, including:
x Document AEs (Note: any [possible] drug-related AE must be foll owed-up, at least by 
phone.) 
x Contact IXRS 
 to register the visit and obtai n next kit number at Weeks 54 an d 56 for subjects receiving 
loading doses of study drug administration at the study site 
 to register the visit and obtain next kit number for subjects r eceiving study drug 
administration at the study site approximately Q12W during the remainder of the study
 to indicate that the subject has withdrawn from the study, if a pplicable
At Week 156/SFE-WD (±1 week), all subjects are to visit the sit e for the following assessments:
x Blood sample for CRP
x BASDAI
x BASFI
x ASQoL
x Total and nocturnal spinal pain
x PGADA
x MRI SI joints
x AEs
x Contact IXRS to indicate that the  subject has completed the SFE  Period (Week 156/SFE-
WD)
Change #14
Section 9.1.1 ASDAS
The variables related to ASDAS disease activity are defined as follows:
x ASDAS-Inactive Disease (ASDAS-ID): ASDAS <1.3REDACTED drawn drawn 
subjecsubjecCOPY ber fober fo
ately ately
This document cannot ontactntac
WD)WD)be used ntsntsto support l spinalspinaany marketing authorizationy Q12Q12
n fromfrom
cts ares areapplication s 54 an54 a
dy site dy site
r subjesubj
Wand any uuextensions s (±2 w(±2 w
ded, inded, in
up, up,or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 250 of 255x ASDAS-Moderate Disease (ASDAS- MD): ASDAS ≥1.3, <2.1
x ASDAS-High Disease Activity (ASDAS- HD): ASDAS ≥2.1, ≤3.5
x ASDAS-very High Disease Activity (ASDAS-vHD): ASDAS >3.5
Has been changed to:
The variables related to ASDAS disease activity are defined as follows:
x ASDAS-Inactive Disease (ASDAS-ID): ASDAS <1.3
x ASDAS-Low Disease (ASDAS- LD): ASDAS ≥1.3, <2.1
x ASDAS-High Disease Activity (ASDAS- HD): ASDAS ≥2.1, ≤3.5
x ASDAS-very High Disease Activity (ASDAS-vHD): ASDAS >3.5
Change #15
Section 9.1.1 ASDAS
The ASDAS will be calculated at Screening, Baseline, Weeks 2, 4,  8, 12, 16, 20, 24, 28, 32 36, 
40, 44, 48, and 52/WD.
Has been changed to:
The ASDAS will be calculated at Screening, Baseline, Weeks 2, 4 , 8, 12, 16, 20, 24, 28, 32 36, 
40, 44, 48, 52/WD, and Week 156/SFE-WD.
Change #16
Section 9.1.2 ASAS20, 40, ASAS 5/6 response, and ASAS partial r emission:
The ASAS variables will be calculated at Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 
and 52/WD.
Has been changed to:
The ASDAS will be calculated at Screening, Baseline, Weeks 2, 4 , 8, 12, 16, 20, 24, 28, 32 36, 
40, 44, 48, 52/WD, and Week 156/SFE-WD.
Change #17
Section 9.1.4 ASQoL
The ASQoL assessments per visit are described in Table 5 ‒1 and Table 5 ‒2.
Has been changed to:
The ASQoL assessments per visit are described in Table 5 ‒1, Table 5 ‒2, and Table 5 ‒6.REDACTED BaseBase
WD.D.COPY 
This documentThe AThe 
HHcannote #17#17
tion 9ion 9be 77usedWD, aD, ato e caca
ansupport alcualcanylculalculmarketing 5/6 re5/6 r
ateauthorization eline, Wline, Wapplication s 2, 4, s 2, 4,and any extensions or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 251 of 255Change #18
Section 9.1.5 BASDAI
The BASDAI assessments per visit are described in the schedule of study assessments Table 5 ‒
1, Table 5 ‒2, and Table 5 ‒3.
Has been changed to:
The BASDAI assessments per visit are described in the schedule of study assessments Table 5 ‒
1, Table 5 ‒2,Table 5 ‒3, and Table 5 ‒6.
Change #19
Section 9.1.6 BASFI
The BASFI assessments per visit are described in Table 5 ‒1, Table 5 ‒2, and Table 5 ‒3.
Has been changed to:
The BASFI assessments per visit are described in Table 5 ‒1, Table 5 ‒2,Table 5 ‒3, and Table 5 ‒
6.
Change #20
Section 9.1.12 MRI assessments
Magnetic resonance imaging of the spine and SI joints will be p erformed at Screening and at the 
Week 12 and at the Week 52/WD visi ts if MRI was performed more than 12 weeks prior to 
Week 52/WD. Magnetic resonance images will be assessed centrall y and scoring will be done by 
2 independent readers, who are blinded to both the order of the  scans and to the treatment group, 
using a previously reported scoring system.
Has been changed to:
Magnetic resonance imaging of the  spine and SI joints will be p erformed at Screening and at the 
Week 12 and at the Week 52/WD visi ts if MRI was performed more t han 12 weeks prior to 
Week 52/WD. A further MRI of the SI joints will be performed at  Week 156/SFE-WD. 
Magnetic resonance images will be  assessed centrally and scorin g will be done by 2 independent 
readers, who are blinded to both the order of the scans and to the treatment group, using a 
previously reported scoring system.
Change #21
Section 9.1.13 PGADA (NRS)
The PGADA assessments per visit are described in Table 5 ‒1, Table 5 ‒2, and Table 5 ‒3.
Has been changed to:
The PGADA assessments per visit are described in Table 5 ‒1, Table 5 ‒2,Table 5 ‒3, and 
Table 5 ‒6.REDACTED ne andne and
sits if sits if 
imaimaCOPY 
This document haha
SecSecannot angeangebereporepousedance nce
are blare bltourtheurth
ei mimsupport ging ofing o
eek 52ek 5
her Merany marketing MM
ages wiges w
ded to bed to
ng systg sysauthorization d SI joSI jo
MRI RI application blee55‒‒and anynd nd TTextensions Tor variations 55‒‒thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 252 of 255Change #22
Section 9.1.20 Total and nocturnal spinal pain NRS
The pain NRS assessments per  visit are described in Table 5 ‒1, Table 5 ‒2, and Table 5 ‒3.
Has been changed to:
The pain NRS assessments per  visit are described in Table 5 ‒1, Table 5 ‒2,Table 5 ‒3, and 
Table 5 ‒6.
Change #23
Section 12.5 Laboratory measurements
For subjects participating in the SFE Period after Week 52, it is recommended that laboratory 
assessments be performed at the lo cal laboratory at the discret ion of the Investigator according to 
local standard medical practice to evaluate potential AEs.
Has been changed to:
For subjects participating in the SFE Period after Week 52, it is recommended that laboratory 
assessments be performed at the lo cal laboratory at the discret ion of the Investigator according to 
local standard medical practice to evaluate potential AEs. At W eek 156/SFE-WD, a blood 
sample will be taken for CRP mea surement and analyzed at the ce ntral laboratory.
Change #24
Section 14.1 Definition of analysis sets
The following analysis set was added:
The SFE Full Analysis Set (SFE-FAS) will be defined as all subj ects in the FAS, who continued 
into the SFE Period and who received at least 1 dose of CZP in the SFE Period.
Change #25
Section 14.2 General statistical considerations
All efficacy analyses will be pe rformed using the FAS. The PPS will be used for a sensitivity 
analysis on the primary endpoint only.
Has been changed to:
All efficacy analyses will be pe rformed using the FAS. The PPS will be used for a sensitivity 
analysis on the primary endpoint only. Analysis of efficacy var iables in the SFE Period will be 
performed on the SFE-FAS.REDACTEDentient
and aand aCOPYeek 5eek 
at the at the
tialtial
This documentHas as 
AllAlcannotacyacy
sis onis on
sb ebebe ya nyaused GeneGento support (SFS
who reho reany ddd
FEFE-FFmarketing setssets
ded:ded:authorization disdis
l AEs.AEs.
analyznalyzapplication 2, it is 2, it is
screscreandthe Inhe Inany endedendedextensions or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 253 of 255Change #26
Section 17 References
The following reference was added:
Machado PM, Landewé R, van der Heijde D, Assessment of Spondylo Arthritis international Society 
(ASAS). Letter. Ankylosing Spondylitis Disease Activity Score ( ASDAS): 2018 update of the 
nomenclature for disease activity states. Ann Rheum Dis. 2018;7 7:1539-40.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 254 of 25519 DECLARATION AND SIGNATURE OF INVESTIGATOR 
I confirm that I have carefully read and understood this protoc ol and agree to conduct this 
clinical study as outlined in this protocol, according to curre nt Good Clinical Practice and local 
laws and requirements.
I will ensure that all subinvestigators and other staff members  read and understand all aspects of 
this protocol.
I have received and read all study-related information provided  to me.
The objectives and content of thi s protocol as well as the resu lts deriving from it will be treated 
confidentially, and will not be made available to third parties  without prior authorization by 
UCB.
All rights of publication of the results reside with UCB, unles s other agreements were made in a 
separate contract.
Investigator:
Printed name Date/Signature
REDACTED COPY Date/SDate/SPY
This document cannot be used to support any marketing authorizationSignaignapplication atutppand any extensionsbe 
zation zation
ents wnts wortreatrevariations thereof. 
UCB 17 Dec 2018
Clinical Study Protocol Certolizumab Pegol AS0006
Confidential Page 255 of 25520 SPONSOR DECLARATION 
I confirm that I have carefully read and understand this protoc ol and agree to conduct this 
clinical study as outlined in this protocol and according to cu rrent Good Clinical Practice.
COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
Approval Signatures
Name: as0006-protocol-amend-5
Version: 1. 0
Document Number: CLIN-000128521
Title: AS0006 Protocol Amendment 5
Approved Date: 18 Dec 2018
Document Approvals
Approval
Verdict: ApprovedName: Capacity: ClinicalDate of Signature: 18-Dec-2018 14:18:05 GMT+0000
ApprovalVerdict: ApprovedName: Capacity: ClinicalDate of Signature: 18-Dec-2018 14:30:20 GMT+0000
ApprovalVerdict: ApprovedName: 
Capacity: Clinical
Date of Signature: 18-Dec-2018 16:02:22 GMT+0000DACTED 
REDADAOPYYAppApp
COOOCO
This document cannot be used to supppport ppany marketing mamanp
uthorization n
oriNam
Ca
aututapplication provalovaaand any extensions or variations thereof. 